
<html lang="en"     class="pb-page"  data-request-id="522952d2-3e76-4ff4-96a4-9eb30d3470f5"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;issue:issue:10.1021/jmcmar.2018.61.issue-22;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:ACHS website Group;article:article:10.1021/acs.jmedchem.8b01262;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="Discovery and Preclinical Characterization of 5-[4,6-Bis({3-oxa-8-azabicyclo[3.2.1]octan-8-yl})-1,3,5-triazin-2-yl]-4-(difluoromethyl)pyridin-2-amine (PQR620), a Highly Potent and Selective mTORC1/2 Inhibitor for Cancer and Neurological Disorders" /></meta><meta name="dc.Creator" content="Denise  Rageot" /></meta><meta name="dc.Creator" content="Thomas  Bohnacker" /></meta><meta name="dc.Creator" content="Anna  Melone" /></meta><meta name="dc.Creator" content="Jean-Baptiste  Langlois" /></meta><meta name="dc.Creator" content="Chiara  Borsari" /></meta><meta name="dc.Creator" content="Petra  Hillmann" /></meta><meta name="dc.Creator" content="Alexander M.  Sele" /></meta><meta name="dc.Creator" content="Florent  Beaufils" /></meta><meta name="dc.Creator" content="Marketa  Zvelebil" /></meta><meta name="dc.Creator" content="Paul  Hebeisen" /></meta><meta name="dc.Creator" content="Wolfgang  Löscher" /></meta><meta name="dc.Creator" content="John  Burke" /></meta><meta name="dc.Creator" content="Doriano  Fabbro" /></meta><meta name="dc.Creator" content="Matthias P.  Wymann" /></meta><meta name="dc.Description" content="Mechanistic target of rapamycin (mTOR) promotes cell proliferation, growth, and survival and is overactivated in many tumors and central nervous system disorders. PQR620 (3) is a novel, potent, sel..." /></meta><meta name="Description" content="Mechanistic target of rapamycin (mTOR) promotes cell proliferation, growth, and survival and is overactivated in many tumors and central nervous system disorders. PQR620 (3) is a novel, potent, sel..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="October 25, 2018" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.8b01262" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="Copyright © 2018 American Chemical Society" /></meta><meta name="citation_fulltext_world_readable" content=""/></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.8b01262" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.8b01262" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.8b01262" /></link>
        
    
    

<title>Discovery and Preclinical Characterization of 5-[4,6-Bis({3-oxa-8-azabicyclo[3.2.1]octan-8-yl})-1,3,5-triazin-2-yl]-4-(difluoromethyl)pyridin-2-amine (PQR620), a Highly Potent and Selective mTORC1/2 Inhibitor for Cancer and Neurological Disorders | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.8b01262" /></meta><meta property="og:title" content="Discovery and Preclinical Characterization of 5-[4,6-Bis({3-oxa-8-azabicyclo[3.2.1]octan-8-yl})-1,3,5-triazin-2-yl]-4-(difluoromethyl)pyridin-2-amine (PQR620), a Highly Potent and Selective mTORC1/2 Inhibitor for Cancer and Neurological Disorders" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b01262/20181119/images/large/jm-2018-012622_0013.jpeg" /></meta><meta property="og:description" content="Mechanistic target of rapamycin (mTOR) promotes cell proliferation, growth, and survival and is overactivated in many tumors and central nervous system disorders. PQR620 (3) is a novel, potent, selective, and brain penetrable inhibitor of mTORC1/2 kinase. PQR620 (3) showed excellent selectivity for mTOR over PI3K and protein kinases and efficiently prevented cancer cell growth in a 66 cancer cell line panel. In C57BL/6J and Sprague–Dawley mice, maximum concentration (Cmax) in plasma and brain was reached after 30 min, with a half-life (t1/2) &gt; 5 h. In an ovarian carcinoma mouse xenograft model (OVCAR-3), daily dosing of PQR620 (3) inhibited tumor growth significantly. Moreover, PQR620 (3) attenuated epileptic seizures in a tuberous sclerosis complex (TSC) mouse model. In conclusion, PQR620 (3) inhibits mTOR kinase potently and selectively, shows antitumor effects in vitro and in vivo, and promises advantages in CNS indications due to its brain/plasma distribution ratio." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.8b01262"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.8b01262">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.8b01262&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.8b01262&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.8b01262&amp;href=/doi/10.1021/acs.jmedchem.8b01262" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2018</span><span class="cit-fg-volume">, 61</span><span class="cit-fg-issue">, 22</span><span class="cit-fg-pageRange">, 10084-10105</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/61/22" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.8b01200" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/acs.jmedchem.8b01281" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Discovery and Preclinical Characterization of 5-[4,6-Bis({3-oxa-8-azabicyclo[3.2.1]octan-8-yl})-1,3,5-triazin-2-yl]-4-(difluoromethyl)pyridin-2-amine (PQR620), a Highly Potent and Selective mTORC1/2 Inhibitor for Cancer and Neurological Disorders</span></h1><ul class="loa"><li><span><span class="hlFld-ContribAuthor">Denise Rageot</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Denise Rageot</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Biomedicine, University of Basel, Mattenstrasse 28, 4058 Basel, Switzerland</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Denise++Rageot">Denise Rageot</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-2833-5481" title="Orcid link">http://orcid.org/0000-0002-2833-5481</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Thomas Bohnacker</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Thomas Bohnacker</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Biomedicine, University of Basel, Mattenstrasse 28, 4058 Basel, Switzerland</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Thomas++Bohnacker">Thomas Bohnacker</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Anna Melone</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Anna Melone</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Biomedicine, University of Basel, Mattenstrasse 28, 4058 Basel, Switzerland</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Anna++Melone">Anna Melone</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Jean-Baptiste Langlois</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Jean-Baptiste Langlois</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Biomedicine, University of Basel, Mattenstrasse 28, 4058 Basel, Switzerland</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Jean-Baptiste++Langlois">Jean-Baptiste Langlois</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Chiara Borsari</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Chiara Borsari</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Biomedicine, University of Basel, Mattenstrasse 28, 4058 Basel, Switzerland</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Chiara++Borsari">Chiara Borsari</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-4688-8362" title="Orcid link">http://orcid.org/0000-0002-4688-8362</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Petra Hillmann</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Petra Hillmann</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">PIQUR Therapeutics AG, Hochbergerstrasse 60, 4057 Basel, Switzerland</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Petra++Hillmann">Petra Hillmann</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Alexander M. Sele</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Alexander M. Sele</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Biomedicine, University of Basel, Mattenstrasse 28, 4058 Basel, Switzerland</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Alexander+M.++Sele">Alexander M. Sele</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-4903-7934" title="Orcid link">http://orcid.org/0000-0002-4903-7934</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Florent Beaufils</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Florent Beaufils</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Biomedicine, University of Basel, Mattenstrasse 28, 4058 Basel, Switzerland</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Florent++Beaufils">Florent Beaufils</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Marketa Zvelebil</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Marketa Zvelebil</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Biomedicine, University of Basel, Mattenstrasse 28, 4058 Basel, Switzerland</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Marketa++Zvelebil">Marketa Zvelebil</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Paul Hebeisen</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Paul Hebeisen</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">PIQUR Therapeutics AG, Hochbergerstrasse 60, 4057 Basel, Switzerland</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Paul++Hebeisen">Paul Hebeisen</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Wolfgang Löscher</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Wolfgang Löscher</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Pharmacology, Toxicology, and Pharmacy, University of Veterinary Medicine Hannover, and Center for Systems Neuroscience, 30559 Hannover, Germany</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Wolfgang++L%C3%B6scher">Wolfgang Löscher</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">John Burke</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">John Burke</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Biochemistry and Microbiology, University of Victoria, Victoria, British Columbia V8W 2Y2, Canada</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=John++Burke">John Burke</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-7904-9859" title="Orcid link">http://orcid.org/0000-0001-7904-9859</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Doriano Fabbro</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Doriano Fabbro</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">PIQUR Therapeutics AG, Hochbergerstrasse 60, 4057 Basel, Switzerland</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Doriano++Fabbro">Doriano Fabbro</a></span></div></div></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor">Matthias P. Wymann</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Matthias P. Wymann</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Biomedicine, University of Basel, Mattenstrasse 28, 4058 Basel, Switzerland</div></div><span class="conrtib-corresp"><strong>*</strong>Phone: +41 61 207 5046. Fax: +41 61 207 3566. E-mail: <a href="/cdn-cgi/l/email-protection#d4b9b5a0a0bcbdb5a7faa3adb9b5baba94a1babdb6b5a7fab7bc"><span class="__cf_email__" data-cfemail="dab7bbaeaeb2b3bba9f4ada3b7bbb4b49aafb4b3b8bba9f4b9b2">[email protected]</span></a></span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Matthias+P.++Wymann">Matthias P. Wymann</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-3349-4281" title="Orcid link">http://orcid.org/0000-0003-3349-4281</a></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.8b01262&amp;href=/doi/10.1021%2Facs.jmedchem.8b01262" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2018</span></span><span class="cit-volume">, 61</span><span class="cit-issue">, 22</span><span class="cit-pageRange">, 10084–10105</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">October 25, 2018</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>9 August 2018</li><li><span class="item_label"><b>Published</b> online</span>25 October 2018</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 21 November 2018</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.8b01262" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.8b01262</a></div><div class="article_header-article-copyright"><strong>Copyright © 2018 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/page/rightslinkno.jsp">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"><a href="/page/policy/authorchoice/index.html"><img src="/pb-assets/images/programsLogos/OA_Icons_Ac-1612971054130.svg" alt="ACS AuthorChoice" /></img><span>ACS AuthorChoice</span></a><span class="article_header-cc-by-nc text">with CC-BY-NC-ND<a href="/page/policy/authorchoice_ccbyncnd_termsofuse.html" title="License">license</a></span></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.8b01262"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">4029</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">33</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.8b01262" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Discovery and Preclinical Characterization of 5-[4,6-Bis({3-oxa-8-azabicyclo[3.2.1]octan-8-yl})-1,3,5-triazin-2-yl]-4-(difluoromethyl)pyridin-2-amine (PQR620), a Highly Potent and Selective mTORC1/2 Inhibitor for Cancer and Neurological Disorders&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Denise&quot;,&quot;last_name&quot;:&quot;Rageot&quot;},{&quot;first_name&quot;:&quot;Thomas&quot;,&quot;last_name&quot;:&quot;Bohnacker&quot;},{&quot;first_name&quot;:&quot;Anna&quot;,&quot;last_name&quot;:&quot;Melone&quot;},{&quot;first_name&quot;:&quot;Jean-Baptiste&quot;,&quot;last_name&quot;:&quot;Langlois&quot;},{&quot;first_name&quot;:&quot;Chiara&quot;,&quot;last_name&quot;:&quot;Borsari&quot;},{&quot;first_name&quot;:&quot;Petra&quot;,&quot;last_name&quot;:&quot;Hillmann&quot;},{&quot;first_name&quot;:&quot;Alexander&quot;,&quot;last_name&quot;:&quot;M. Sele&quot;},{&quot;first_name&quot;:&quot;Florent&quot;,&quot;last_name&quot;:&quot;Beaufils&quot;},{&quot;first_name&quot;:&quot;Marketa&quot;,&quot;last_name&quot;:&quot;Zvelebil&quot;},{&quot;first_name&quot;:&quot;Paul&quot;,&quot;last_name&quot;:&quot;Hebeisen&quot;},{&quot;first_name&quot;:&quot;Wolfgang&quot;,&quot;last_name&quot;:&quot;Löscher&quot;},{&quot;first_name&quot;:&quot;John&quot;,&quot;last_name&quot;:&quot;Burke&quot;},{&quot;first_name&quot;:&quot;Doriano&quot;,&quot;last_name&quot;:&quot;Fabbro&quot;},{&quot;first_name&quot;:&quot;Matthias&quot;,&quot;last_name&quot;:&quot;P. Wymann&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2018&quot;,&quot;month&quot;:&quot;10&quot;,&quot;day&quot;:&quot;25&quot;,&quot;issue&quot;:&quot;22&quot;,&quot;volume&quot;:&quot;61&quot;,&quot;pages&quot;:&quot;10084-10105&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.8b01262&quot;},&quot;abstract&quot;:&quot;Mechanistic target of rapamycin (mTOR) promotes cell proliferation, growth, and survival and is overactivated in many tumors and central nervous system disorders. PQR620 (3) is a novel, potent, selective, and brain penetrable inhibitor of mTORC1/2 kinase. PQR620 (3) showed excellent selectivity for mTOR over PI3K and protein kinases and efficiently prevented cancer cell growth in a 66 cancer cell line panel. In C57BL/6J and Sprague–Dawley mice, maximum concentration (Cmax) in plasma and brain was reached after 30 min, with a half-life (t1/2) &gt; 5 h. In an ovarian carcinoma mouse xenograft model (OVCAR-3), daily dosing of PQR620 (3) inhibited tumor growth significantly. Moreover, PQR620 (3) attenuated epileptic seizures in a tuberous sclerosis complex (TSC) mouse model. In conclusion, PQR620 (3) inhibits mTOR kinase potently and selectively, shows antitumor effects in vitro and in vivo, and promises advantages in CNS indications due to its brain/plasma distribution ratio.&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.8b01262&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.8b01262" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.8b01262&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.8b01262" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.8b01262&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.8b01262" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.8b01262&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.8b01262&amp;href=/doi/10.1021/acs.jmedchem.8b01262" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.8b01262" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.8b01262" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (4 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.8b01262&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.8b01262%26sid%3Dliteratum%253Aachs%26pmid%3D30359003%26genre%3Darticle%26aulast%3DRageot%26date%3D2018%26atitle%3DDiscovery%2Band%2BPreclinical%2BCharacterization%2Bof%2B5-%255B4%252C6-Bis%2528%257B3-oxa-8-azabicyclo%255B3.2.1%255Doctan-8-yl%257D%2529-1%252C3%252C5-triazin-2-yl%255D-4-%2528difluoromethyl%2529pyridin-2-amine%2B%2528PQR620%2529%252C%2Ba%2BHighly%2BPotent%2Band%2BSelective%2BmTORC1%252F2%2BInhibitor%2Bfor%2BCancer%2Band%2BNeurological%2BDisorders%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D61%26issue%3D22%26spage%3D10084%26epage%3D10105%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (3)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=292464" title="Rodent models">Rodent models</a>,</li><li><a href="/action/doSearch?ConceptID=292528" title="Inhibitors">Inhibitors</a>,</li><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a>,</li><li><a href="/action/doSearch?ConceptID=292462" title="Central nervous system">Central nervous system</a>,</li><li><a href="/action/doSearch?ConceptID=291711" title="Selectivity">Selectivity</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/61/22" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/jmcmar.2018.61.issue-22/20181121/jmcmar.2018.61.issue-22.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b01262/20181119/images/medium/jm-2018-012622_0013.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b01262/20181119/images/large/jm-2018-012622_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01262&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">Mechanistic target of rapamycin (mTOR) promotes cell proliferation, growth, and survival and is overactivated in many tumors and central nervous system disorders. PQR620 (<b>3</b>) is a novel, potent, selective, and brain penetrable inhibitor of mTORC1/2 kinase. PQR620 (<b>3</b>) showed excellent selectivity for mTOR over PI3K and protein kinases and efficiently prevented cancer cell growth in a 66 cancer cell line panel. In C57BL/6J and Sprague–Dawley mice, maximum concentration (<i>C</i><sub>max</sub>) in plasma and brain was reached after 30 min, with a half-life (<i>t</i><sub>1/2</sub>) > 5 h. In an ovarian carcinoma mouse xenograft model (OVCAR-3), daily dosing of PQR620 (<b>3</b>) inhibited tumor growth significantly. Moreover, PQR620 (<b>3</b>) attenuated epileptic seizures in a tuberous sclerosis complex (TSC) mouse model. In conclusion, PQR620 (<b>3</b>) inhibits mTOR kinase potently and selectively, shows antitumor effects in vitro and in vivo, and promises advantages in CNS indications due to its brain/plasma distribution ratio.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_26668" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_26668" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The mechanistic target of rapamycin (mTOR, earlier mammalian TOR) operates downstream of phosphoinositide 3-kinase (PI3K) and protein kinase B (PKB/Akt). The PI3K/mTOR pathway is a key regulator of metabolism, cell growth, proliferation, and survival and is frequently overactivated in cancer and neurodegenerative disease.<a onclick="showRef(event, 'ref1 ref2'); return false;" href="javascript:void(0);" class="ref ref1 ref2">(1,2)</a> The mTOR kinase is part of two main TOR complexes (TORC1 and TORC2). TORC1 integrates signals from cell surface receptors, energy status, stress, and availability of oxygen and amino acids. Cell surface receptors activate PI3K to produce PtdIns(3,4,5)<i>P</i><sub>3</sub>, which serves as a docking site for PKB/Akt and 3-phosphoinositide-dependent protein kinase 1 (PDK1). PKB/Akt is phosphorylated by PDK1 on Thr308 and by mTOR kinase integrated in TORC2 in the hydrophobic motif on Ser473.<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a> Fully activated, PKB/Akt phosphorylates tuberous sclerosis 2 (TSC2, tuberin) in the tuberous sclerosis complex (TSC) and blocks its GTPase-activating protein (GAP) activity, which leads to the accumulation of GTP-loaded Rheb-GTPase (homologue enriched in brain) and assembly of active TORC1 on endomembranes.<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> TORC2 is linked to PI3K activation by the Sin1 PH domain, as the Sin1-PtdIns(3,4,5)<i>P</i><sub>3</sub> interaction unlocks TORC2 kinase activity after membrane translocation.<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a> The phosphorylation of S6 kinase (S6K) by TORC1 is key to control cellular protein and lipid synthesis. TORC1 activity also impacts lysosome dynamics and autophagy, and TORC2 promotes metabolic activity, cell cycle, and cytoskeletal rearrangements.<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a></div><div class="NLM_p">Rapamycin (sirolimus), its more soluble rapamycin-derivative (rapalog) RAD001 (everolimus), as well as CCI-779 (temsirolimus)<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> block TORC1 specifically by the formation of a TORC1/rapalog/FK506 binding protein 12 (FKBP12) complex.<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a> Rapamycin has a long history as an immunosuppressive agent in organ transplant recipients,<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a> and rapalogs have been exploited to prevent restenosis based on their anti-inflammatory and antiproliferative effects.<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a></div><div class="NLM_p">In 2007, temsirolimus (CCI-779) was approved for the treatment of renal cell carcinoma (RCC), followed by a phase III trial of everolimus in an advanced stage of the disease.<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> Everolimus has been approved for advanced pancreatic, lung, and gastrointestinal neuroendocrine tumors, mantle cell lymphoma, endometrial cancer, noncancerous kidney tumors in patients with TSC, pediatric subependymal giant cell astrocytoma (SEGA), and advanced ER+/HER2-negative breast cancer.<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a></div><div class="NLM_p">In spite of the clinical success of rapalogs in the above indications, overall response rates to rapalogs as a single agent in major solid tumors have been modest.<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> Reasons for this are: (i) adverse effects of rapamycin due to its immune-suppressive action, limiting the maximal tolerated dose, but also (ii) the attenuation of drug action by a rapamycin-mediated suppression of a negative feedback loop, where TORC1 activates S6K and Grb10 to negatively control PI3K activation by receptors for insulin and growth factors. In the presence of rapalogs, TORC1 is thus inhibited, but class IA PI3Ks are overactivated, resulting in a TORC2-dependent increase in PKB/Akt activity.<a onclick="showRef(event, 'ref1 ref2'); return false;" href="javascript:void(0);" class="ref ref1 ref2">(1,2)</a> Compounds targeting both TORC1 and TORC2 are therefore expected to provide a more efficient block of growth factor and PI3K downstream signaling.</div><div class="NLM_p">ATP-competitive inhibitors have therefore been developed to target TORC1 and TORC2 protein kinase activities.<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> Sapanisertib (INK128 (<b>73</b>), MLN0128, TAK-228)<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> is in multiple clinical trials including advanced solid tumors, non-Hodgkin’s lymphoma, breast cancer, multiple myeloma, and Waldenstrom’s macroglobulinaemia, while CC-223 (<b>77</b>)<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> is being explored in malignancies such as non-Hodgkin’s lymphoma, multiple myeloma, and diffuse large B-cell and follicular lymphoma. Vistusertib [AZD2014 (<b>78</b>)]<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> is currently evaluated in a range of advanced tumors and has progressed to phase II clinical trials as a single agent in nonresponders to chemotherapy with mutated TSC (for more studies see <a href="http://clinicaltrials.gov" class="extLink">clinicaltrials.gov</a>). Moreover, preclinically characterized chemical probes with different potency and selectivity for TOR kinase, such as Torin1, PP242 (<b>75</b>), Ku-0063794, WAY-600, WYE-687, WYE-354, Palomid 529, and more have been described (for a review see ref <a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a>.).</div><div class="NLM_p">The overactivation of the mTOR pathway is not only important in malignant cancer but also promotes the development of hyperplastic lesions. In autosomal-dominant tuberous sclerosis complex (TSC), mutations in either TSC1 (hamartin) or TSC2 (tuberin) lead to a loss of control of mTOR signaling and the formation of initially benign hamartomas. These occur in multiple organs such as skin, heart, kidneys, lung, and brain. Some form of impaired CNS function is frequent in TSC and includes epileptic seizures in ∼90% patients, which dominates TSC morbidity to a high degree.<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a></div><div class="NLM_p">Rapalogs have recently been explored to alleviate epileptic seizures triggered by loss-of-function mutations in the mTOR pathway. In a mouse model where TSC1 was selectively eliminated in neurons, sirolimus (rapamycin) and everolimus (RAD001) significantly improved the survival of neuronal-specific Tsc1 null mice and attenuated TORC1 downstream signaling.<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> A similar action of rapalogs could be achieved in TSC patients,<a onclick="showRef(event, 'ref18 ref19'); return false;" href="javascript:void(0);" class="ref ref18 ref19">(18,19)</a> finally culminating in the approval of everolimus for TSC-associated seizures in April 2018. Rapalogs are, however, not generally effective in the whole TSC population, as resistance and considerable adverse side effects lead to treatment termination and dose reduction.<a onclick="showRef(event, 'ref18 ref20'); return false;" href="javascript:void(0);" class="ref ref18 ref20">(18,20)</a></div><div class="NLM_p">Targeting mTOR has also been proposed to be beneficial in Alzheimer’s disease,<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> Huntington’s disease,<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> and Parkinson’s disease,<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> mostly based on the observation that inhibition of mTOR promoted removal of toxic protein complexes by the induction of autophagy. As rapalogs display limited brain permeability, there is a lack of molecules targeting mTOR in the CNS.</div><div class="NLM_p">We have recently reported on PQR309 (<b>1</b>),<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> a pan-PI3K/mTOR inhibitor with excellent brain penetration and oral bioavailability, which is currently in phase II clinical trials for the treatment of lymphoma and solid tumors. This compound served as a starting point for the development and rational design of selective and highly brain penetrable mTOR kinase inhibitors. By introducing substituents with specific steric demands and defined electronic properties, we were able to derive a compound class with increased affinity for mTOR and much reduced binding of PI3K (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>). From this series, we developed the highly selective and potent ATP-competitive mTOR inhibitor PQR620 (<b>3</b>), targeting TORC1 and TORC2.</div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b01262/20181119/images/medium/jm-2018-012622_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b01262/20181119/images/large/jm-2018-012622_0001.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Schematic design and optimization cascade leading to the mTOR kinase-selective ATP-binding site inhibitor PQR620 (<b>3</b>). Binding affinity for mTOR kinase was increased by the substitution of the trifluoromethyl group in PQR309 (<b>1</b>) with a difluoromethyl group in compound <b>2</b>. The introduction of substituted morpholino groups was then explored to reduce PI3K binding, resulting in PQR620 (<b>3</b>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b01262/20181119/images/large/jm-2018-012622_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01262&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_07118" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_07118" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The transition from a pan-PI3K to an mTOR inhibitor was initiated by the elucidation of the binding mode of PQR309 (<b>1</b>) in the ATP-binding pocket of PI3K and mTOR kinases, where PQR309 (<b>1</b>) showed a 6-fold selectivity for PI3Kα over mTOR kinase (<i>K</i><sub>i</sub> for PI3Kα was 15.6 nM and <i>K</i><sub>i</sub> for mTOR was 93.4 nM). The binding mode of PQR309 (<b>1</b>) in PI3Kγ involves a hydrogen bond interaction in the hinge region between the backbone amide of Val882 and the morpholine oxygen atom. Additional interactions occur between Asp836 and Asp841 and the 2-aminopyridine moiety in the affinity pocket.<a onclick="showRef(event, 'ref23 ref24'); return false;" href="javascript:void(0);" class="ref ref23 ref24">(23,24)</a> An analogous binding mode of PQR309 (<b>1</b>) is assumed in mTOR, involving residues Val2240 and Asp2190/2357.</div><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i4" class="anchor-spacer"></div><h3 class="article-section__title" id="_i4"> Optimization of mTOR Affinity</h3><div class="NLM_p">To assess the influence of the trifluoromethyl moiety at the C4-position of the aminopyridine (R-substituent), toward selective mTOR inhibition, we prepared a series of compounds replacing the trifluoromethyl moiety with various substituents and tested them in cellular and enzymatic assays (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>). Physicochemical properties, such as clogP and PSA, were calculated for all studied compounds (see Supporting Information, <a href="/doi/suppl/10.1021/acs.jmedchem.8b01262/suppl_file/jm8b01262_si_001.pdf" class="ext-link">Table S9</a>). Substitutions on the heteroaromatic ring (compounds <b>1</b>, <b>2</b>, and <b>4</b>–<b>9</b>) had a major impact on the balance between hydrophilicity and lipophilicity (clogP variations from 1.08 to 2.72).</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. SAR Study of Selected R-Substituted Triazine Core Compounds</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b01262/20181119/images/medium/jm-2018-012622_0010.gif" alt="" id="fx1" /></img><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="2" align="center" char=".">IC<sub>50</sub> [nM]<a class="ref internalNav" href="#t1fn1" aria-label="a">a</a></th><th class="rowsep1 colsep0" colspan="2" align="center" char="."><i>K</i><sub>i</sub> [nM]<a class="ref internalNav" href="#t1fn2" aria-label="b">b</a></th><th class="rowsep1 colsep0" align="center" char=".">ratio <i>K</i><sub>i</sub></th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center">R</th><th class="colsep0 rowsep0" align="center"><i>M</i><sub>n</sub></th><th class="colsep0 rowsep0" align="center" char=".">pPKB/Akt</th><th class="colsep0 rowsep0" align="center" char=".">pS6</th><th class="colsep0 rowsep0" align="center" char=".">p110α</th><th class="colsep0 rowsep0" align="center" char=".">mTOR</th><th class="colsep0 rowsep0" align="center" char=".">p110α/mTOR</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>4</b><a class="ref internalNav" href="#t1fn3" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">M<sub>0</sub></td><td class="colsep0 rowsep0" align="char" char=".">404</td><td class="colsep0 rowsep0" align="char" char=".">382</td><td class="colsep0 rowsep0" align="char" char=".">94.0</td><td class="colsep0 rowsep0" align="char" char=".">46.1</td><td class="colsep0 rowsep0" align="char" char=".">2.0</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>5</b><a class="ref internalNav" href="#t1fn4" aria-label="d">d</a></td><td class="colsep0 rowsep0" align="left">CH<sub>3</sub></td><td class="colsep0 rowsep0" align="left">M<sub>0</sub></td><td class="colsep0 rowsep0" align="char" char=".">401</td><td class="colsep0 rowsep0" align="char" char=".">939</td><td class="colsep0 rowsep0" align="char" char=".">61.2</td><td class="colsep0 rowsep0" align="char" char=".">609</td><td class="colsep0 rowsep0" align="char" char=".">0.10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">PQR309 (<b>1</b>)<a class="ref internalNav" href="#t1fn3" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="left">CF<sub>3</sub></td><td class="colsep0 rowsep0" align="left">M<sub>0</sub></td><td class="colsep0 rowsep0" align="char" char=".">178</td><td class="colsep0 rowsep0" align="char" char=".">194</td><td class="colsep0 rowsep0" align="char" char=".">15.6</td><td class="colsep0 rowsep0" align="char" char=".">93.4</td><td class="colsep0 rowsep0" align="char" char=".">0.17</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>2</b></td><td class="colsep0 rowsep0" align="left">CHF<sub>2</sub></td><td class="colsep0 rowsep0" align="left">M<sub>0</sub></td><td class="colsep0 rowsep0" align="char" char=".">102</td><td class="colsep0 rowsep0" align="char" char=".">118</td><td class="colsep0 rowsep0" align="char" char=".">11.5</td><td class="colsep0 rowsep0" align="char" char=".">6.9</td><td class="colsep0 rowsep0" align="char" char=".">1.7</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>6</b></td><td class="colsep0 rowsep0" align="left">CH<sub>2</sub>F</td><td class="colsep0 rowsep0" align="left">M<sub>0</sub></td><td class="colsep0 rowsep0" align="char" char=".">397</td><td class="colsep0 rowsep0" align="char" char=".">218</td><td class="colsep0 rowsep0" align="char" char=".">68.6</td><td class="colsep0 rowsep0" align="char" char=".">54.3</td><td class="colsep0 rowsep0" align="char" char=".">1.3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>7</b></td><td class="colsep0 rowsep0" align="left">CH<sub>2</sub>OH</td><td class="colsep0 rowsep0" align="left">M<sub>0</sub></td><td class="colsep0 rowsep0" align="char" char=".">341</td><td class="colsep0 rowsep0" align="char" char=".">528</td><td class="colsep0 rowsep0" align="char" char=".">81.3</td><td class="colsep0 rowsep0" align="char" char=".">74.5</td><td class="colsep0 rowsep0" align="char" char=".">1.1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>8</b></td><td class="colsep0 rowsep0" align="left">CH(OCH<sub>3</sub>)<sub>2</sub></td><td class="colsep0 rowsep0" align="left">M<sub>0</sub></td><td class="colsep0 rowsep0" align="char" char=".">1198</td><td class="colsep0 rowsep0" align="char" char=".">2109</td><td class="colsep0 rowsep0" align="char" char=".">129</td><td class="colsep0 rowsep0" align="char" char=".">474</td><td class="colsep0 rowsep0" align="char" char=".">0.27</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>9</b></td><td class="colsep0 rowsep0" align="left">OCH<sub>3</sub></td><td class="colsep0 rowsep0" align="left">M<sub>0</sub></td><td class="colsep0 rowsep0" align="char" char=".">1848</td><td class="colsep0 rowsep0" align="char" char=".">1918</td><td class="colsep0 rowsep0" align="char" char=".">693</td><td class="colsep0 rowsep0" align="char" char=".">483</td><td class="colsep0 rowsep0" align="char" char=".">1.4</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>10</b></td><td class="colsep0 rowsep0" align="left">CHF<sub>2</sub></td><td class="colsep0 rowsep0" align="left">M<sub>1</sub></td><td class="colsep0 rowsep0" align="char" char=".">147</td><td class="colsep0 rowsep0" align="char" char=".">138</td><td class="colsep0 rowsep0" align="char" char=".">20.8</td><td class="colsep0 rowsep0" align="char" char=".">9.6</td><td class="colsep0 rowsep0" align="char" char=".">2.1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>11</b></td><td class="colsep0 rowsep0" align="left">CHF<sub>2</sub></td><td class="colsep0 rowsep0" align="left">M<sub>2</sub></td><td class="colsep0 rowsep0" align="char" char=".">144</td><td class="colsep0 rowsep0" align="char" char=".">112</td><td class="colsep0 rowsep0" align="char" char=".">23.7</td><td class="colsep0 rowsep0" align="char" char=".">3.4</td><td class="colsep0 rowsep0" align="char" char=".">7.0</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>12</b></td><td class="colsep0 rowsep0" align="left">CHF<sub>2</sub></td><td class="colsep0 rowsep0" align="left">M<sub>3</sub></td><td class="colsep0 rowsep0" align="char" char=".">156</td><td class="colsep0 rowsep0" align="char" char=".">113</td><td class="colsep0 rowsep0" align="char" char=".">25.8</td><td class="colsep0 rowsep0" align="char" char=".">11.2</td><td class="colsep0 rowsep0" align="char" char=".">2.3</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup><sup>a</sup></sup><p class="last">Phosphorylation of PKB/Akt on Ser473 and ribosomal protein S6 on Ser235/236 were analyzed in A2058 cells exposed to the indicated inhibitors and subsequent detection of phosphoproteins in an in-cell Western assay.<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a></p></div><div class="footnote" id="t1fn2"><sup><sup>b</sup></sup><p class="last">Compounds were tested in vitro for binding to the catalytic subunit of PI3Kα (p110α) and mTOR using a commercially available time-resolved FRET (TR-FRET) displacement assay (LanthaScreen). Means of <i>K</i><sub>i</sub>s are shown. Standard errors of the mean (SEM) are depicted in Supporting Information, <a href="/doi/suppl/10.1021/acs.jmedchem.8b01262/suppl_file/jm8b01262_si_001.pdf" class="ext-link">Table S9</a>.</p></div><div class="footnote" id="t1fn3"><sup><sup>c</sup></sup><p class="last">Extended from ref <a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a>.</p></div><div class="footnote" id="t1fn4"><sup><sup>d</sup></sup><p class="last">Derived from ref <a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a>.</p></div></div></div><div class="NLM_p">Among this bismorpholino-substituted triazine series, compound <b>2</b> with a difluoromethyl substituent (R = CHF<sub>2</sub>) was found to be the most potent compound in vitro (<i>K</i><sub>i</sub> for mTOR of 6.9 nM) and in cells (IC<sub>50</sub> for phosphorylated PKB = 102 nM, for phosphorylated S6, IC<sub>50</sub> = 118 nM). In general, the affinity toward mTOR increased as a function of R in the order: CH<sub>3</sub> ≈ CH(OCH<sub>3</sub>)<sub>2</sub> ≈ OCH<sub>3</sub> < CF<sub>3</sub> ≈ CH<sub>2</sub>OH ≈ CH<sub>2</sub>F ≈ H < CHF<sub>2</sub>. For compound <b>2</b> the cellular data displayed both efficient inhibition of TORC1 upstream of ribosomal protein S6 kinase (see IC<sub>50</sub> value for pS6 in <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>), and TORC2 activity upstream of PKB phosphorylation (see IC<sub>50</sub> for pPKB in <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>). The low mTOR affinities of compounds <b>8</b> and <b>9</b> can only in part be attributed to bulky substituents as the affinity differences in CF<sub>3</sub>-, CHF<sub>2</sub>-, CH<sub>2</sub>F, and CH<sub>3</sub>-substituted compounds point to an importance of the dipole moment of CHF<sub>2</sub> group in R in mTOR, but less so in PI3Kα.</div><div class="NLM_p">The CHF<sub>2</sub> group was recently proposed to act as a lipophilic hydrogen donor<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> and has as such two possible conformational interaction modes in PI3K and mTOR: as depicted in <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>A, the proton of the CHF<sub>2</sub>-group could (i) interact with a triazine core nitrogen in an intramolecular fashion, or (ii) form interactions with Asp836 in PI3Kγ or Glu2190 in mTOR (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>B). An intramolecular proton–nitrogen interaction with the core does not disturb the overall orientation of the inhibitor, although in class I PI3K the CHF<sub>2</sub> group is in close proximity to a methionine (Met804 in PI3Kγ, distance ca. 3.3 Å), while mTOR presents an isoleucine (Ile2163, >7 Å) at this position. Turned toward Glu2190 (mTOR) or Asp836 (PI3Kγ), the CHF<sub>2</sub> group appears to be closer to the negative side chain in mTOR than in PI3Kγ. This, and the slightly more hydrophobic nature of the pocket in mTOR (see Ile2163), is likely to enforce a CHF<sub>2</sub> proton–Glu2190 hydrogen bond and thus explains the pronounced increase in mTOR affinity for CHF<sub>2</sub>-substituted compounds.</div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b01262/20181119/images/medium/jm-2018-012622_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b01262/20181119/images/large/jm-2018-012622_0002.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Predicted interactions of compound <b>2</b> with the catalytic core of PI3Kγ (gray) and mTOR kinase (teal). Displayed are amino acids in close contact with the inhibitor; three-digit numbers refer to PI3Kγ, four-digit codes to mTOR kinase. Labeled spheres: N, nitrogen atom of the hinge region Val (882/2240); S, sulfur atom of Met804; F and H, difluoromethyl group. (A) One morpholine group (left) of <b>2</b> interacts with the nitrogen atom of the hinge region Val. Here the hydrogen atom of the difluoromethyl group is oriented to form an intramolecular interaction with the triazine core. (B) The hinge region valine interaction is oriented toward the back, and the hydrogen atom of the difluoromethyl group is well positioned to form an interaction with Glu2190 of mTOR. (A,B) Compound <b>2</b> in PI3Kγ was modeled based on a PQR309 (<b>1</b>)–PI3Kγ complex<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5OQ4">5OQ4</a>; resolution of 2.7 Å), and the mTOR–compound <b>2</b> complex was derived from a 3.6 Å resolution structure of PI103 bound to mTOR (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4JT6">4JT6</a>) by docking as described in ref <a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a>. A comparative listing of amino acid residues depicted here across PI3K isoforms can be found in Supporting Information, <a href="/doi/suppl/10.1021/acs.jmedchem.8b01262/suppl_file/jm8b01262_si_001.pdf" class="ext-link">Table S1</a>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b01262/20181119/images/large/jm-2018-012622_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01262&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i6" class="anchor-spacer"></div><h3 class="article-section__title" id="_i6"> Increasing Selectivity for mTOR, Dialing Out PI3K</h3><div class="NLM_p">As many of the above R-substituents maintained low <i>K</i><sub>i</sub> values for PI3Kα (see PQR309 (<b>1</b>), <b>2</b>, <b>5</b>, and <b>6</b>; <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>), we introduced various morpholine derivatives as <i>M</i><sub>n</sub> substituents, such as (<i>R</i>)-3-methylmorpholine (M<sub>1</sub>), 8-oxa-3-azabicyclo[3.2.1]octane (M<sub>2</sub>), and 3-oxa-8-azabicyclo[3.2.1]octane (M<sub>3</sub>, <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>). Morpholine derivatives M<sub>1</sub>, M<sub>2</sub>, and M<sub>3</sub> with increased steric demands were examined to determine whether the interaction in the hinge region of mTOR occurs with the oxygen atom of the morpholine M<sub>0</sub> or of the substituted morpholine (M<sub>1–3</sub>). The effect of various substitution of morpholines on mTOR versus PI3K selectivity has been reported for pyrazolopyrimidines,<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> showing a profound loss in PI3Kα activity leading to a >1000-fold selectivity for mTOR over PI3Kα when morpholine M<sub>0</sub> was replaced with the 2,6- or 3,5-ethylene bridged morpholine (M<sub>2</sub> and M<sub>3</sub>). Likewise, the introduction of (<i>R</i>)-3-methylmorpholine (M<sub>1</sub>) improved the selectivity for mTOR.</div><div class="NLM_p">Consequently, we prepared analogues of compound <b>2</b> (with R = CHF<sub>2</sub>) with selected substituted morpholines. Among <i>M</i><sub>n</sub> substituents, morpholine M<sub>2</sub> showed the highest affinity and selectivity for mTOR in <b>11</b> (<i>K</i><sub>i</sub> for mTOR = 3.4 nM, and ratio of <i>K</i><sub>i</sub> of p110α/mTOR ∼7). Inhibitors <b>10</b>, <b>11</b>, and <b>12</b> with substituents <i>M</i><sub>n</sub> = M<sub>1</sub>, M<sub>2</sub>, and M<sub>3</sub>, respectively, proved to be all excellent inhibitors for mTOR and PI3K in vitro and in cells (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>). These results underline that the increase in mTOR activity is dominated by the 4-(difluoromethyl)pyridin-2-amine group rather than from substitutions of one morpholine group. Compounds <b>10</b>–<b>12</b> maintain most likely affinity for PI3K as they all bear one unsubstituted morpholine (M<sub>0</sub>), which is able to bind to the hinge region of the ATP-binding site of PI3K. The bulky morpholines (M<sub>1–3</sub>) would then be solvent exposed and have a negligible effect on PI3K or mTOR binding.</div><div class="NLM_p">These observations prompted us to focus our SAR study on symmetrically substituted triazines (<a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>). Introduction of methyl groups, methylene, or ethylene bridges into morpholine groups (see <b>13</b>–<b>17</b>) did not significantly affect the clogP. Bulky alkylic substitutions on the morpholine yielded, however, more lipophilic compounds (compounds <b>18</b>–<b>24</b> and <b>26</b>; see Supporting Information, <a href="/doi/suppl/10.1021/acs.jmedchem.8b01262/suppl_file/jm8b01262_si_001.pdf" class="ext-link">Table S9</a>). Many of these compounds showed excellent mTOR activity in vitro (<i>K</i><sub>i</sub> ≤ 30 nM for PQR620 (<b>3</b>), <b>13</b>–<b>15</b>, <b>18</b>–<b>19</b>, <b>21</b>, and <b>24</b>–<b>25</b>). The affinity for mTOR was reduced when both, the C2- and C6-morpholine positions were substituted with a methyl-group (<i>K</i><sub>i</sub> of 650 nM for compound <b>22</b>), whereas methyl-substitution at both the C3- and C5-position showed only a minor effect on mTOR binding. Excellent in vitro (>100-fold) selectivity for mTOR versus PI3Kα were obtained for compounds PQR620 (<b>3</b>, M<sub>3</sub>), <b>15</b> (M<sub>4</sub>), <b>20</b> (M<sub>9</sub>), and <b>26</b> (M<sub>15</sub>); good selectivity (>70-fold) for compounds <b>14</b> (M<sub>2</sub>), <b>23</b> (M<sub>12</sub>), and <b>25</b> (M<sub>14</sub>).</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. SAR of Symmetrically Substituted 4-(Difluoromethyl)-5-(1,3,5-triazin-2-yl)pyridine-2-amines</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b01262/20181119/images/medium/jm-2018-012622_0011.gif" alt="" id="fx2" /></img><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="2" align="center" char=".">IC<sub>50</sub> [nM]<a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></th><th class="rowsep1 colsep0" colspan="2" align="center" char="."><i>K</i><sub>i</sub> [nM]<a class="ref internalNav" href="#t2fn2" aria-label="b">b</a></th><th class="rowsep1 colsep0" align="center" char=".">ratio <i>K</i><sub>i</sub></th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center"><i>M</i><sub>n</sub></th><th class="colsep0 rowsep0" align="center" char=".">pPKB</th><th class="colsep0 rowsep0" align="center" char=".">pS6</th><th class="colsep0 rowsep0" align="center" char=".">p110α</th><th class="colsep0 rowsep0" align="center" char=".">mTOR</th><th class="colsep0 rowsep0" align="center" char=".">p110α/mTOR</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>13</b></td><td class="colsep0 rowsep0" align="left">M<sub>1</sub></td><td class="colsep0 rowsep0" align="char" char=".">364</td><td class="colsep0 rowsep0" align="char" char=".">310</td><td class="colsep0 rowsep0" align="char" char=".">633</td><td class="colsep0 rowsep0" align="char" char=".">12.6</td><td class="colsep0 rowsep0" align="char" char=".">50</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>14</b></td><td class="colsep0 rowsep0" align="left">M<sub>2</sub></td><td class="colsep0 rowsep0" align="char" char=".">630</td><td class="colsep0 rowsep0" align="char" char=".">301</td><td class="colsep0 rowsep0" align="char" char=".">1297</td><td class="colsep0 rowsep0" align="char" char=".">13.9</td><td class="colsep0 rowsep0" align="char" char=".">93</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">PQR620 (<b>3</b>)</td><td class="colsep0 rowsep0" align="left">M<sub>3</sub></td><td class="colsep0 rowsep0" align="char" char=".">190</td><td class="colsep0 rowsep0" align="char" char=".">85.2</td><td class="colsep0 rowsep0" align="char" char=".">4203</td><td class="colsep0 rowsep0" align="char" char=".">10.8</td><td class="colsep0 rowsep0" align="char" char=".">389</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>15</b></td><td class="colsep0 rowsep0" align="left">M<sub>4</sub></td><td class="colsep0 rowsep0" align="char" char=".">4037</td><td class="colsep0 rowsep0" align="char" char=".">1565</td><td class="colsep0 rowsep0" align="char" char=".">>20000</td><td class="colsep0 rowsep0" align="char" char=".">18.5</td><td class="colsep0 rowsep0" align="char" char=".">>1000</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>16</b></td><td class="colsep0 rowsep0" align="left">M<sub>5</sub></td><td class="colsep0 rowsep0" align="char" char=".">17685</td><td class="colsep0 rowsep0" align="char" char=".">12572</td><td class="colsep0 rowsep0" align="char" char=".">4632</td><td class="colsep0 rowsep0" align="char" char=".">308</td><td class="colsep0 rowsep0" align="char" char=".">15</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>17</b></td><td class="colsep0 rowsep0" align="left">M<sub>6</sub></td><td class="colsep0 rowsep0" align="char" char=".">17851</td><td class="colsep0 rowsep0" align="char" char=".">5768</td><td class="colsep0 rowsep0" align="char" char=".">>20000</td><td class="colsep0 rowsep0" align="char" char=".">551</td><td class="colsep0 rowsep0" align="char" char=".">49</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>18</b></td><td class="colsep0 rowsep0" align="left">M<sub>7</sub></td><td class="colsep0 rowsep0" align="char" char=".">354</td><td class="colsep0 rowsep0" align="char" char=".">209</td><td class="colsep0 rowsep0" align="char" char=".">32.2</td><td class="colsep0 rowsep0" align="char" char=".">13.6</td><td class="colsep0 rowsep0" align="char" char=".">2.4</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>19</b></td><td class="colsep0 rowsep0" align="left">M<sub>8</sub></td><td class="colsep0 rowsep0" align="char" char=".">252</td><td class="colsep0 rowsep0" align="char" char=".">160</td><td class="colsep0 rowsep0" align="char" char=".">141</td><td class="colsep0 rowsep0" align="char" char=".">3.5</td><td class="colsep0 rowsep0" align="char" char=".">40</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>20</b></td><td class="colsep0 rowsep0" align="left">M<sub>9</sub></td><td class="colsep0 rowsep0" align="char" char=".">3570</td><td class="colsep0 rowsep0" align="char" char=".">1189</td><td class="colsep0 rowsep0" align="char" char=".">>20000</td><td class="colsep0 rowsep0" align="char" char=".">79.9</td><td class="colsep0 rowsep0" align="char" char=".">>250</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>21</b></td><td class="colsep0 rowsep0" align="left">M<sub>10</sub></td><td class="colsep0 rowsep0" align="char" char=".">379</td><td class="colsep0 rowsep0" align="char" char=".">294</td><td class="colsep0 rowsep0" align="char" char=".">64.0</td><td class="colsep0 rowsep0" align="char" char=".">21.1</td><td class="colsep0 rowsep0" align="char" char=".">3.0</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>22</b></td><td class="colsep0 rowsep0" align="left">M<sub>11</sub></td><td class="colsep0 rowsep0" align="char" char=".">20872</td><td class="colsep0 rowsep0" align="char" char=".">10380</td><td class="colsep0 rowsep0" align="char" char=".">15364</td><td class="colsep0 rowsep0" align="char" char=".">650</td><td class="colsep0 rowsep0" align="char" char=".">24</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>23</b></td><td class="colsep0 rowsep0" align="left">M<sub>12</sub></td><td class="colsep0 rowsep0" align="char" char=".">4815</td><td class="colsep0 rowsep0" align="char" char=".">2329</td><td class="colsep0 rowsep0" align="char" char=".">8787</td><td class="colsep0 rowsep0" align="char" char=".">73.4</td><td class="colsep0 rowsep0" align="char" char=".">120</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>24</b></td><td class="colsep0 rowsep0" align="left">M<sub>13</sub></td><td class="colsep0 rowsep0" align="char" char=".">942</td><td class="colsep0 rowsep0" align="char" char=".">526</td><td class="colsep0 rowsep0" align="char" char=".">632</td><td class="colsep0 rowsep0" align="char" char=".">32.8</td><td class="colsep0 rowsep0" align="char" char=".">19</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>25</b></td><td class="colsep0 rowsep0" align="left">M<sub>14</sub></td><td class="colsep0 rowsep0" align="char" char=".">357</td><td class="colsep0 rowsep0" align="char" char=".">275</td><td class="colsep0 rowsep0" align="char" char=".">2379</td><td class="colsep0 rowsep0" align="char" char=".">31.0</td><td class="colsep0 rowsep0" align="char" char=".">77</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>26</b></td><td class="colsep0 rowsep0" align="left">M<sub>15</sub></td><td class="colsep0 rowsep0" align="char" char=".">1212</td><td class="colsep0 rowsep0" align="char" char=".">1298</td><td class="colsep0 rowsep0" align="char" char=".">>20000</td><td class="colsep0 rowsep0" align="char" char=".">60.2</td><td class="colsep0 rowsep0" align="char" char=".">>330</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup><sup>a</sup></sup><p class="last">Phosphorylation of PKB/Akt on Ser473 and ribosomal protein S6 on Ser235/236 were analyzed in A2058 cells exposed to the indicated inhibitors and subsequent detection of phosphoproteins in an <i>in-cell</i> Western assay.<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a></p></div><div class="footnote" id="t2fn2"><sup><sup>b</sup></sup><p class="last">Compounds were tested in vitro for binding to the catalytic subunit of PI3Kα (p110α) and mTOR using a commercially available time-resolved FRET (TR-FRET) displacement assay (LanthaScreen). Means of <i>K</i><sub>i</sub>s are shown. SEMs are depicted in Supporting Information, <a href="/doi/suppl/10.1021/acs.jmedchem.8b01262/suppl_file/jm8b01262_si_001.pdf" class="ext-link">Table S9</a>.</p></div></div></div><div class="NLM_p">Compounds containing 3,5-dimethylmorpholines (M<sub>8</sub>, M<sub>9</sub>, and M<sub>10</sub>) showed relevant differences in cellular potency and in selectivity for mTOR versus PI3Kα. Whereas compound <b>20</b> (M<sub>9</sub>) showed good selectivity (<i>K</i><sub>i</sub> of p110α/mTOR > 250) and no inhibition of mTOR/PI3K in cells, its enantiomer <b>21</b> (M<sub>10</sub>) was much less selective (<i>K</i><sub>i</sub> of p110α/mTOR ∼3) and was slightly more active in cells. The enantiomeric pair <b>15</b> and <b>16</b> (M<sub>4</sub> and M<sub>5</sub>) showed poor potency in cellular assays (IC<sub>50</sub> > 1000 nM), although a remarkable difference in affinity for mTOR between them (<i>K</i><sub>i</sub> = 18.5 nM for <b>15</b> vs <i>K</i><sub>i</sub> = 308 nM for <b>16</b>).</div><div class="NLM_p last">Generally, the symmetrically substituted derivatives in <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a> displayed reduced cellular activities as compared to unsymmetrically substituted analogues (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>, compounds <b>10</b>–<b>12</b>), with the exception of the selected compound PQR620 (<b>3</b>). Compound PQR620 (<b>3</b>) was the most potent in biochemical and cellular assays (<i>K</i><sub>i</sub> for mTOR = 10.8 nM; IC<sub>50</sub> for pPKB = 190 nM and IC<sub>50</sub> for pS6 = 85.2 nM) and very selective for mTOR versus PI3K (389-fold selectivity).</div></div><div id="sec2_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i8" class="anchor-spacer"></div><h3 class="article-section__title" id="_i8"> Elucidation of Binding Modes to PI3K and mTOR</h3><div class="NLM_p">Computational modeling studies were used to elucidate the binding mode of PQR620 (<b>3</b>) and ultimately provided structural features defining the compounds high selectivity toward mTOR versus PI3K. Exploiting the 2.7 Å resolution X-ray structure of PQR309 (<b>1</b>) in PI3Kγ (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5OQ4">5OQ4</a>), we substituted the inhibitor for PQR620 (<b>3</b>). Energy minimization calculations of the resulting PI3Kγ–ligand complex maintained important interactions such as hydrogen bonds between the aminopyridine and Asp836/964 as well the one between one morpholine oxygen atom and the backbone amine of Val882 (as present in the parental structure with PQR309 (<b>1</b>)). In PQR620 (<b>3</b>), the ethylene bridge of the morpholine pointing toward Val882 can take two main conformations, with the bridge oriented toward Met953 (“bridge-up”, <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>A,B) or toward Ile881 (“bridge-down”, <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>C). The bridge-up conformation induces steric clashes within a region of the ATP-binding pocket that has previously been identified as very rigid in PI3Kγ and is defined by residues Tyr867, Phe961, and Ile963.<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a></div><figure id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b01262/20181119/images/medium/jm-2018-012622_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b01262/20181119/images/large/jm-2018-012622_0003.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Steric clashes of PQR620 (<b>3</b>) docked into PI3Kγ (light gray). Two opposite conformations of the ethylene bridges of the morpholines of PQR620 (<b>3</b>) that allow the morpholine oxygen to form a hydrogen bond with the hinge Val882 nitrogen (N) are shown. (A) In the “bridge-up” conformation, the ethylene bridge of PQR620 (<b>3</b>) (yellow) points toward Met953 and is flanked by a rigid part of PI3Kγ,<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> represented by Tyr867, Phe961, and Ile963 (colored in brown). (B) When the surface of PI3Kγ is depicted as a mesh and PQR620 (<b>3</b>) as space filling model (atom size set to 0.9 times of van der Waals radii), steric clashes become visible as penetrations of the PI3Kγ surface mesh. (C) In the “bridge-down” conformation (pink), steric clashes imposed by the ethylene bridges in PQR620 (<b>3</b>) occur with the backbone of Ile881 and Glu880 and side chains of Ile831 and Ile881. As for <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>, the models were derived from coordinates of a PQR309 (<b>1</b>)–PI3Kγ complex<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5OQ4">5OQ4</a>; resolution of 2.7 Å). A comparative listing of amino acid residues depicted here across PI3K isoforms can be found in Supporting Information, <a href="/doi/suppl/10.1021/acs.jmedchem.8b01262/suppl_file/jm8b01262_si_001.pdf" class="ext-link">Table S2</a>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b01262/20181119/images/large/jm-2018-012622_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01262&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The “bridge-down” conformation of PQR620 (<b>3</b>) generates steric clashes with the backbone of Ile881 and Glu880 and side chains of Ile831 and Ile881. All these steric clashes can only be minimized when the distance between the Val882 and the morpholine O atom is significantly increased to >3.5 Å, as compared to a 2.5 Å distance in the PQR309 (<b>1</b>)–PI3Kγ complex, and therefore no longer represents a strong hydrogen bond. Steric clashes, and as a consequence the weakening of the essential hydrogen bond to the PI3K hinge region explain the reduced affinity of PQR620 (<b>3</b>) for PI3K.</div><div class="NLM_p">Analogous computational modeling studies were performed for a PQR620 (<b>3</b>)<b>−</b>mTOR kinase complex starting with the 3.6 Å resolution structure of the PI103–mTOR complex (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4JT6">4JT6</a>). After a ligand exchange, the oxygen atom of one bridged morpholine of PQR620 (<b>3</b>) forms a hydrogen bond with the hinge region Val2240 backbone nitrogen and the 2-amino moiety interacts with Asp2195/2357 side chains in the affinity binding pocket of mTOR. The binding pocket of mTOR is deeper due to the presence of the flexible Leu2354 replacing the rigid Phe961 in PI3Kγ (see <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>). As a result, an ethylene-bridged morpholine (M<sub>3</sub>) can be easily accommodated in the pocket pointing toward Val2240. Although these modeling efforts suggest some preference for the “bridge-up” conformation in mTOR, the low resolution of the mTOR template structure prevents a precise placement of the ethylene bridge in the morpholine pointed toward Val2240 (Supporting Information, <a href="/doi/suppl/10.1021/acs.jmedchem.8b01262/suppl_file/jm8b01262_si_001.pdf" class="ext-link">Figure S1</a>).</div><div class="NLM_p">Glu2190 in mTOR can be superimposed with Asp836 of PI3Kγ, but Glu2190 has a different vector allowing it to interact with the 2-amino moiety (3.1 Å) and the dipole of the CHF<sub>2</sub> group (3.4 Å). This view is supported by biological data pointing to an important role of the CHF<sub>2</sub> substituent in the selectivity of mTOR binding. The combination of the Glu2190 CHF<sub>2</sub> group dipole interaction in mTOR and the steric clashes in PI3K explain the enhanced binding affinity for mTOR and the reduced affinity of PQR620 (<b>3</b>) for PI3K as compared to PQR309 (<b>1</b>).</div><div class="NLM_p">To ascertain the choice for a lead compound, the SAR study was extended to pyrimidine core analogues of PQR620 (<b>3</b>) (<a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>). Therefore, we prepared BKM120 (<b>27</b>), its regioisomer <b>29</b>,<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> and the corresponding 4-(difluoromethyl)pyridin-2-amine analogues <b>28</b> and <b>30</b>. Replacement of trifluoromethyl by difluoromethyl as R-substituent improved mTOR binding by a factor of 5–20 for pyrimidine analogues in vitro (<a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>), validating the CHF<sub>2</sub>–dipole mTOR interactions discussed above. Still, both pyrimidine core regioisomers <b>28</b> and <b>30</b> showed reduced potency compared to their triazine analogue <b>2</b> (compare <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>).</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. SAR Study of Selected Pyrimidine Core Compounds</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b01262/20181119/images/medium/jm-2018-012622_0012.gif" alt="" id="fx3" /></img><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="2" align="center" char=".">IC<sub>50</sub> [nM]<a class="ref internalNav" href="#t3fn1" aria-label="a">a</a></th><th class="rowsep1 colsep0" colspan="2" align="center" char="."><i>K</i><sub><i>i</i></sub> [nM]<a class="ref internalNav" href="#t3fn3" aria-label="b">b</a></th><th class="rowsep1 colsep0" align="center" char=".">ratio of <i>K</i><sub>i</sub>s</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center">R</th><th class="colsep0 rowsep0" align="center"><i>M</i><sub>n</sub></th><th class="colsep0 rowsep0" align="center">X</th><th class="colsep0 rowsep0" align="center">Y</th><th class="colsep0 rowsep0" align="center" char=".">pPKB/Akt</th><th class="colsep0 rowsep0" align="center" char=".">pS6</th><th class="colsep0 rowsep0" align="center" char=".">p110α</th><th class="colsep0 rowsep0" align="center" char=".">mTOR</th><th class="colsep0 rowsep0" align="center" char=".">p110α/mTOR</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">BKM120 (<b>27</b>)</td><td class="colsep0 rowsep0" align="left">CF<sub>3</sub></td><td class="colsep0 rowsep0" align="left">M<sub>0</sub></td><td class="colsep0 rowsep0" align="left">N</td><td class="colsep0 rowsep0" align="left">CH</td><td class="colsep0 rowsep0" align="char" char=".">416</td><td class="colsep0 rowsep0" align="char" char=".">553</td><td class="colsep0 rowsep0" align="char" char=".">20</td><td class="colsep0 rowsep0" align="char" char=".">199</td><td class="colsep0 rowsep0" align="char" char=".">0.10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>28</b></td><td class="colsep0 rowsep0" align="left">CHF<sub>2</sub></td><td class="colsep0 rowsep0" align="left">M<sub>0</sub></td><td class="colsep0 rowsep0" align="left">N</td><td class="colsep0 rowsep0" align="left">CH</td><td class="colsep0 rowsep0" align="char" char=".">207</td><td class="colsep0 rowsep0" align="char" char=".">184</td><td class="colsep0 rowsep0" align="char" char=".">18</td><td class="colsep0 rowsep0" align="char" char=".">35</td><td class="colsep0 rowsep0" align="char" char=".">0.51</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>29</b><a class="ref internalNav" href="#t3fn2" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="left">CF<sub>3</sub></td><td class="colsep0 rowsep0" align="left">M<sub>0</sub></td><td class="colsep0 rowsep0" align="left">CH</td><td class="colsep0 rowsep0" align="left">N</td><td class="colsep0 rowsep0" align="char" char=".">729</td><td class="colsep0 rowsep0" align="char" char=".">926</td><td class="colsep0 rowsep0" align="char" char=".">41</td><td class="colsep0 rowsep0" align="char" char=".">911</td><td class="colsep0 rowsep0" align="char" char=".">0.045</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>30</b></td><td class="colsep0 rowsep0" align="left">CHF<sub>2</sub></td><td class="colsep0 rowsep0" align="left">M<sub>0</sub></td><td class="colsep0 rowsep0" align="left">CH</td><td class="colsep0 rowsep0" align="left">N</td><td class="colsep0 rowsep0" align="char" char=".">243</td><td class="colsep0 rowsep0" align="char" char=".">256</td><td class="colsep0 rowsep0" align="char" char=".">29</td><td class="colsep0 rowsep0" align="char" char=".">42</td><td class="colsep0 rowsep0" align="char" char=".">0.69</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>31</b></td><td class="colsep0 rowsep0" align="left">CF<sub>3</sub></td><td class="colsep0 rowsep0" align="left">M<sub>3</sub></td><td class="colsep0 rowsep0" align="left">N</td><td class="colsep0 rowsep0" align="left">CH</td><td class="colsep0 rowsep0" align="char" char=".">520</td><td class="colsep0 rowsep0" align="char" char=".">318</td><td class="colsep0 rowsep0" align="char" char=".">2190</td><td class="colsep0 rowsep0" align="char" char=".">30</td><td class="colsep0 rowsep0" align="char" char=".">73.0</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>32</b></td><td class="colsep0 rowsep0" align="left">CHF<sub>2</sub></td><td class="colsep0 rowsep0" align="left">M<sub>3</sub></td><td class="colsep0 rowsep0" align="left">N</td><td class="colsep0 rowsep0" align="left">CH</td><td class="colsep0 rowsep0" align="char" char=".">287</td><td class="colsep0 rowsep0" align="char" char=".">164</td><td class="colsep0 rowsep0" align="char" char=".">2090</td><td class="colsep0 rowsep0" align="char" char=".">12</td><td class="colsep0 rowsep0" align="char" char=".">174</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>33</b></td><td class="colsep0 rowsep0" align="left">CF<sub>3</sub></td><td class="colsep0 rowsep0" align="left">M<sub>3</sub></td><td class="colsep0 rowsep0" align="left">CH</td><td class="colsep0 rowsep0" align="left">N</td><td class="colsep0 rowsep0" align="char" char=".">3318</td><td class="colsep0 rowsep0" align="char" char=".">1944</td><td class="colsep0 rowsep0" align="char" char=".">5668</td><td class="colsep0 rowsep0" align="char" char=".">435</td><td class="colsep0 rowsep0" align="char" char=".">13.0</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>34</b></td><td class="colsep0 rowsep0" align="left">CHF<sub>2</sub></td><td class="colsep0 rowsep0" align="left">M<sub>3</sub></td><td class="colsep0 rowsep0" align="left">CH</td><td class="colsep0 rowsep0" align="left">N</td><td class="colsep0 rowsep0" align="char" char=".">650</td><td class="colsep0 rowsep0" align="char" char=".">395</td><td class="colsep0 rowsep0" align="char" char=".">2230</td><td class="colsep0 rowsep0" align="char" char=".">60</td><td class="colsep0 rowsep0" align="char" char=".">37.2</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t3fn1"><div class="footnote" id="t3fn1"><sup><sup>a</sup></sup><p class="last">Phosphorylation of PKB/Akt on Ser473 and ribosomal protein S6 on Ser235/236 were analyzed in A2058 cells exposed to the indicated inhibitors and subsequent detection of phosphoproteins in an in-cell Western assay.<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a></p></div><div class="footnote" id="t3fn3"><sup><sup>b</sup></sup><p class="last">Compounds were tested in vitro for binding to the catalytic subunit of PI3Kα (p110α) and mTOR using a commercially available time-resolved FRET (TR-FRET) displacement assay (LanthaScreen). Means of <i>K</i><sub>i</sub>s are shown.</p></div><div class="footnote" id="t3fn2"><sup><sup>c</sup></sup><p class="last">Compound is referred to as BKM120-R1 (regio-isomer of BKM120) in ref <a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a>. SEMs are depicted in Supporting Information, <a href="/doi/suppl/10.1021/acs.jmedchem.8b01262/suppl_file/jm8b01262_si_001.pdf" class="ext-link">Table S9</a>.</p></div></div></div><div class="NLM_p last">Pyrimidine core derivatives of PQR620 (<b>3</b>), such as compounds <b>32</b> and <b>34</b>, displayed higher selectivity for mTOR as compared to their CF<sub>3</sub>-substituted analogues (<b>31</b> and <b>33</b>). The pyrimidine core compounds bearing substituted morpholines were inactive toward PI3K, but triazine-based PQR620 (<b>3</b>) surpassed its pyrimidine analogue <b>32</b> regarding selectivity and potency toward mTOR in vitro and in cells.</div></div><div id="sec2_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i10" class="anchor-spacer"></div><h3 class="article-section__title" id="_i10"> Chemical Synthesis</h3><div class="NLM_p">Triazine analogues described above and substituted with two unsubstituted morpholines (M<sub>0</sub>) (PQR309 (<b>1</b>), <b>2</b>, <b>4</b>–<b>9</b>) or with one morpholine M<sub>0</sub> and a M<sub>1–3</sub> morpholine (compounds <b>10</b>–<b>12</b>) were prepared according to the synthetic route A depicted in <a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a> starting from commercially available 4-(4,6-dichloro-1,3,5-triazin-2-yl)morpholine (<b>35</b>). Morpholine derivatives were introduced as <i>M</i><sub>n</sub> substituents by nucleophilic aromatic substitution reaction (for intermediates <b>37</b>–<b>39</b>, with <i>M</i><sub>n</sub> ≠ M<sub>0</sub>) and a subsequent palladium catalyzed Suzuki coupling between the desired organoboronic ester and cholorotriazine intermediate <b>36</b>–<b>39</b> gave the inhibitors PQR309 (<b>1</b>), <b>2</b>, and <b>4</b>–<b>12</b>. The synthetic strategy B was used to prepare di-<i>M</i><sub>n</sub>-substituted triazines (PQR620 (<b>3</b>) and compounds <b>13</b>–<b>26</b>) and route C to synthesize pyrimidine core analogues (compound <b>28</b>–<b>34</b>). All three synthetic routes only differ by the reaction conditions used. Overall, this strategy represents a robust and modular synthetic route giving access to a broad variety of compounds.</div><figure id="sch1" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b01262/20181119/images/medium/jm-2018-012622_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b01262/20181119/images/large/jm-2018-012622_0009.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of Trisubstituted Compounds with Triazine and Pyrimidine Core<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b01262/20181119/images/large/jm-2018-012622_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01262&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (i) morpholine derivative (<i>M</i><sub>n</sub>-H), DIPEA, EtOH, 0 °C → rt, o/n (for <b>37</b>–<b>39</b>); (ii) 2-aminopyridine-5-boronic acid pinacol ester or 2-amino-4-methyl-pyridine-5-boronic acid pinacol ester, Pd(dppf)Cl<sub>2</sub> (cat.), Na<sub>2</sub>CO<sub>3</sub>, 1,2-dimethoxyethane/H<sub>2</sub>O, 90 °C, 16 h (for <b>4</b>, <b>5</b>); (iii) (1) boronic ester <b>72</b>, Pd(OAc)<sub>2</sub>/PPh<sub>3</sub> (cat.), K<sub>2</sub>CO<sub>3</sub>, THF/H<sub>2</sub>O, 55 °C, 2 h, (2) HCl, H<sub>2</sub>O, 55 °C, 16 h (for PQR309); (iv) boronic ester <b>64</b>, XPhosPdG2 (cat.), K<sub>3</sub>PO<sub>4</sub>, dioxane/H<sub>2</sub>O, 95 °C, o/n (for <b>10</b>, <b>11</b>, <b>12</b>, <b>14</b>, <b>17</b>, <b>18</b>, <b>23</b>, <b>24</b>, PQR620); (v) boronic ester generated in situ, XPhosPdG2 (cat.), K<sub>3</sub>PO<sub>4</sub>, dioxane/H<sub>2</sub>O, 95 °C, 3.5 h, (2) TFA, CH<sub>2</sub>Cl<sub>2</sub>, add. at 0 °C, rt, 6 h (for <b>8</b>); (vi) (1) boronic ester <b>64</b> or <b>72</b> or boronic ester generated in situ, XPhosPdG2 (cat.), K<sub>3</sub>PO<sub>4</sub>, dioxane/H<sub>2</sub>O, 95 °C, 3–16 h, (2) HCl, dioxane/H<sub>2</sub>O, 60 °C, 3–16 h (for <b>2</b>, <b>6</b>, <b>7</b>, <b>13</b>, <b>15</b>, <b>16</b>, <b>19</b>–<b>22</b>, <b>25</b>, <b>26</b>, <b>28</b>, <b>30</b>–<b>34</b>; for <b>9</b> the reaction was carried out in ethanol at 80 °C); (vii) <i>M</i><sub>n</sub>-H, DIPEA, CH<sub>2</sub>Cl<sub>2</sub>, 0 °C → rt, o/n (for <b>41</b>–<b>47</b>, <b>52</b>, <b>53</b>, <b>55</b>); (viii) <i>M</i><sub>n</sub>-H, DIPEA, THF, add at 0 °C, 70 °C, o/n (for <b>48</b>–<b>51</b>, <b>54</b>); (ix) morpholine derivative (<i>M</i><sub>n</sub>-H), DIPEA, EtOH, Δ, o/n (for <b>57</b>–<b>60</b>); (x) (1) boronic ester <b>72</b>, Pd(OAc)<sub>2</sub>/PPh<sub>3</sub> (cat.), K<sub>2</sub>CO<sub>3</sub>, dioxane/H<sub>2</sub>O, 80 °C, 16 h, (2) HCl, H<sub>2</sub>O, 60 °C, 18 h (for BKM120, <b>29</b><a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a>).</p></p></figure></div><div id="sec2_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i12" class="anchor-spacer"></div><h3 class="article-section__title" id="_i12"> Enzymatic and Cellular Profiling, Determination of Selectivity, and in Vitro ADME</h3><div class="NLM_p">Because of its superior activity and mTOR selectivity PQR620 (<b>3</b>) was chosen for further characterization. DiscoverX KINOME<i>scan</i> assays confirmed PQR620 (<b>3</b>)’s excellent mTOR selectivity: PQR620 (<b>3</b>) was ∼3700-fold more potent for mTOR as compared to class I and class III PI3K isoforms and did not inhibit PI4Kβ even at excessive concentrations (<a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a>). The selectivity of PQR620 (<b>3</b>) for mTOR over PI3K thus exceeds competitor compounds such as INK128 (<b>73</b>) (∼40×), CC223 (<b>77</b>) (∼80×), and AZD2104 (<b>78</b>) (∼230×) and is closely followed by SB2602 (<b>74</b>) with a selectivity of ∼3100-fold.</div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. mTOR and Lipid Kinase Binding Constants of PQR620 (<b>3</b>) and Reference Compounds</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="center" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="8" align="center">kinases</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="7" align="center">inhibitor binding constants<a class="ref internalNav" href="#t4fn1" aria-label="a">a</a><i>K</i><sub>d</sub>, [nM]</th><th class="rowsep1 colsep0" align="center">fold selectivity</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center">mTOR</th><th class="colsep0 rowsep0" align="center">PI3Kα</th><th class="colsep0 rowsep0" align="center">PI3Kβ</th><th class="colsep0 rowsep0" align="center">PI3Kδ</th><th class="colsep0 rowsep0" align="center">PI3Kγ</th><th class="colsep0 rowsep0" align="center">PI4Kβ</th><th class="colsep0 rowsep0" align="center">VPS34</th><th class="colsep0 rowsep0" align="center">PI3Kx/mTOR<a class="ref internalNav" href="#t4fn3" aria-label="c">c</a></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="center">PQR620 (<b>3</b>)<a class="ref internalNav" href="#t4fn4" aria-label="d">d</a></td><td class="colsep0 rowsep0" align="center">0.27</td><td class="colsep0 rowsep0" align="center"><b>1000</b></td><td class="colsep0 rowsep0" align="center">22000</td><td class="colsep0 rowsep0" align="center">23000</td><td class="colsep0 rowsep0" align="center">18000</td><td class="colsep0 rowsep0" align="center">>30000</td><td class="colsep0 rowsep0" align="center">2750</td><td class="colsep0 rowsep0" align="center">∼3700×</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="center">INK128 (<b>73</b>)</td><td class="colsep0 rowsep0" align="center">0.092</td><td class="colsep0 rowsep0" align="center">15</td><td class="colsep0 rowsep0" align="center">81</td><td class="colsep0 rowsep0" align="center">30</td><td class="colsep0 rowsep0" align="center"><b>3.7</b></td><td class="colsep0 rowsep0" align="center">n.d.</td><td class="colsep0 rowsep0" align="center">8200</td><td class="colsep0 rowsep0" align="center">∼40×</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="center">SB2602 (<b>74</b>)</td><td class="colsep0 rowsep0" align="center">0.85</td><td class="colsep0 rowsep0" align="center">2700</td><td class="colsep0 rowsep0" align="center">20000</td><td class="colsep0 rowsep0" align="center">>30000</td><td class="colsep0 rowsep0" align="center">22000</td><td class="colsep0 rowsep0" align="center">>30000</td><td class="colsep0 rowsep0" align="center">8300</td><td class="colsep0 rowsep0" align="center">∼3100×</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="center">PP242 (<b>75</b>)<a class="ref internalNav" href="#t4fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="center">3</td><td class="colsep0 rowsep0" align="center">150</td><td class="colsep0 rowsep0" align="center">120</td><td class="colsep0 rowsep0" align="center"><b>31</b></td><td class="colsep0 rowsep0" align="center">42</td><td class="colsep0 rowsep0" align="center">940</td><td class="colsep0 rowsep0" align="center">nd</td><td class="colsep0 rowsep0" align="center">∼10×</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="center">CC223 (<b>77</b>)</td><td class="colsep0 rowsep0" align="center">28</td><td class="colsep0 rowsep0" align="center"><b>2300</b></td><td class="colsep0 rowsep0" align="center">18000</td><td class="colsep0 rowsep0" align="center">6200</td><td class="colsep0 rowsep0" align="center">7100</td><td class="colsep0 rowsep0" align="center">39</td><td class="colsep0 rowsep0" align="center">2500</td><td class="colsep0 rowsep0" align="center">∼80×</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="center">AZD2014 (<b>78</b>)</td><td class="colsep0 rowsep0" align="center">0.14</td><td class="colsep0 rowsep0" align="center"><b>33</b></td><td class="colsep0 rowsep0" align="center">3300</td><td class="colsep0 rowsep0" align="center">1500</td><td class="colsep0 rowsep0" align="center">8400</td><td class="colsep0 rowsep0" align="center">>30000</td><td class="colsep0 rowsep0" align="center">23000</td><td class="colsep0 rowsep0" align="center">∼230×</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t4fn1"><div class="footnote" id="t4fn1"><sup><sup>a</sup></sup><p class="last">Dissociation constants (<i>K</i><sub>d</sub>) were determined using ScanMax technology (DiscoveRx) with 11-point 3-fold serial dilutions of the indicated compounds. <i>K</i><sub>d</sub> is the mean value from experiments performed in duplicate and were calculated from standard dose response curves using the Hill equation (<i>n</i> ≥ 2).</p></div><div class="footnote" id="t4fn2"><sup><sup>b</sup></sup><p class="last">Dissociation constants (<i>K</i><sub>d</sub>) of PP242 (<b>75</b>) are reprinted from ref <a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a>. with the consent of DiscoverX Corporation. nd: not determined.</p></div><div class="footnote" id="t4fn3"><sup><sup>c</sup></sup><p class="last">Fold selectivity: ratio of <i>K</i><sub>d</sub> of most sensitive class I PI3K isoform (displayed in bold type) over <i>K</i><sub>d</sub> for mTOR.</p></div><div class="footnote" id="t4fn4"><sup><sup>d</sup></sup><p class="last">A preliminary data set has been compared with rapamycin and everolimus (<i>K</i><sub>d</sub>s for the FKBP12 site were 0.6 and 2 nM, respectively) in ref <a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a>. Standard deviations are reported in Supporting Information, <a href="/doi/suppl/10.1021/acs.jmedchem.8b01262/suppl_file/jm8b01262_si_001.pdf" class="ext-link">Table S3</a>, except for cited values of PP242.</p></div></div></div><div class="NLM_p">Moreover, compound PQR620 (<b>3</b>) showed negligible off-target effects when screened against a DiscoverX <i>scan</i>MAX kinase assay panel containing a set of 456 diverse wild-type kinases (Supporting Information, <a href="/doi/suppl/10.1021/acs.jmedchem.8b01262/suppl_file/jm8b01262_si_001.pdf" class="ext-link">Figure S2</a>). At a concentration of 10 μM, PQR620 (<b>3</b>) and SB2602 (<b>74</b>) reached outstanding selectivity scores (S(10) of 0.005 and 0.003, respectively; Supporting Information, <a href="/doi/suppl/10.1021/acs.jmedchem.8b01262/suppl_file/jm8b01262_si_001.pdf" class="ext-link">Table S4</a>), while values of INK128 (<b>73</b>) and PP242 (<b>75</b>) exceeded 0.1 for S(10) [S(10) = number of hits/number of tested kinases (at a threshold of 10% of control; see Supporting Information, <a href="/doi/suppl/10.1021/acs.jmedchem.8b01262/suppl_file/jm8b01262_si_001.pdf" class="ext-link">Table S4</a>)].</div><div class="NLM_p last">The in vitro pharmacology profile of PQR620 (<b>3</b>) at 10 μM was determined in a panel of assays covering a broad range of targets including receptors, ion channels, transporters, enzymes, and second messengers. No off-target binding activities were identified and PQR620 (<b>3</b>) showed excellent selectivity versus unrelated receptors and ion channels including hERG (Supporting Information, <a href="/doi/suppl/10.1021/acs.jmedchem.8b01262/suppl_file/jm8b01262_si_001.pdf" class="ext-link">Figure S3</a>). Detectable signals for COX1 and PDE4D2 inhibition remained below 50% (Supporting Information, <a href="/doi/suppl/10.1021/acs.jmedchem.8b01262/suppl_file/jm8b01262_si_001.pdf" class="ext-link">Figure S4</a>).</div></div><div id="sec2_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i14" class="anchor-spacer"></div><h3 class="article-section__title" id="_i14"> Cellular Activities</h3><div class="NLM_p">Compound PQR620 (<b>3</b>) was tested in vitro across a panel of tumor cell lines including glioblastoma (A-172, T98G, and “U-87 MG”), neuroblastoma (SK-N-AS and SK-N-FI) and malignant melanoma (A375, COLO 829, and RPMI-7951) cancer cell lines (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a> and Supporting Information, <a href="/doi/suppl/10.1021/acs.jmedchem.8b01262/suppl_file/jm8b01262_si_001.pdf" class="ext-link">Table S6</a>). Growth inhibitory activity was evaluated after an exposure time of 72 h with inhibitor concentrations ranging from 10<sup>–9</sup> to 10<sup>–5</sup> M. Compound PQR620 (<b>3</b>) showed potency across these cell lines with a mean IC<sub>50</sub> value of 0.92 μM for growth inhibition. An analysis of the most frequently mutated cancer genes in the cell panel did not yield a significant and relevant association of mutations and susceptibility to the mTOR inhibitor (Supporting Information, <a href="/doi/suppl/10.1021/acs.jmedchem.8b01262/suppl_file/jm8b01262_si_001.pdf" class="ext-link">Figure S6</a>).</div><figure id="fig4" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b01262/20181119/images/medium/jm-2018-012622_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b01262/20181119/images/large/jm-2018-012622_0004.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Waterfall plot representing the potency of PQR620 (<b>3</b>) in a full NTRC (Netherlands Translational Research Center BV) Oncolines cell panel of 66 cancer cell lines. Concentrations of half-maximal growth inhibition (IC<sub>50</sub>) for PQR620 (<b>3</b>) were obtained from dose–response growth curves, and individual IC<sub>50</sub> values of a cell line was related to the mean IC<sub>50</sub> of all cells lines; cell lines were sorted by lowest to highest sensitivity for PQR620 (<b>3</b>) from left (SK-N-FI) to right (A-498). Individual cell lines and values (IC<sub>50</sub> and GI<sub>50</sub>) are given in Supporting Information, <a href="/doi/suppl/10.1021/acs.jmedchem.8b01262/suppl_file/jm8b01262_si_001.pdf" class="ext-link">Table S6</a>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b01262/20181119/images/large/jm-2018-012622_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01262&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">When compared with other mTOR kinase inhibitors such as PP242 (<b>75</b>), SB2602 (<b>74</b>), and the PI3K inhibitor GDC0941 (<b>76</b>), PQR620 (<b>3</b>) shows a very similar potential to prevent cell growth and proliferation in two reference cell lines A2058 and SKOV3 (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>). INK128 (<b>73</b>) is more potent but exceeds the expected ca. 3-fold difference defined by its in vitro potency for mTOR by far, which could indicate that PI3K inhibition (<a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a>) or other off target kinase actions (Supporting Information, <a href="/doi/suppl/10.1021/acs.jmedchem.8b01262/suppl_file/jm8b01262_si_001.pdf" class="ext-link">Figure S2</a>) contribute to its antiproliferative potential.</div><figure id="fig5" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b01262/20181119/images/medium/jm-2018-012622_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b01262/20181119/images/large/jm-2018-012622_0005.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Proliferation, cell cycle, and cellular signaling. A2058 (A) and SKOV3 (B) cells were exposed to indicated inhibitors for 72 h; cell numbers are shown as % of DMSO controls. The dashed line indicates cell numbers at <i>t</i> = 0 h, as % of cells of DMSO control at 72 h (<i>n</i> = 9, three independent experiments (ie); rapamycin and GDC0941 (<b>76</b>) <i>n</i> = 6; 2 ie; each data point measured at least in triplicate, mean ± SEM. Cell cycle distribution of (C) A2058 and (D) SKOV3 cells after 24 h exposure to (C) 5 μM or (D) 2 μM of drugs or DMSO. After Hoechst33342 staining, cell cycle profiles were determined by FACS. Quantification and statistics are provided in Supporting Information, <a href="/doi/suppl/10.1021/acs.jmedchem.8b01262/suppl_file/jm8b01262_si_001.pdf" class="ext-link">Figure S5</a>. (E) A2058 and (F) SKOV3 cells were incubated for 1 h with compounds and then subjected to in cell western detection of phosphorylation of PKB/Akt and S6. Phospho-protein signals are presented as % of DMSO controls (<i>n</i> = 3, mean ± SEM); immunoblots of phospho-PKB/Akt, S6, S6K, and 4E-BP1 are in Supporting Information, <a href="/doi/suppl/10.1021/acs.jmedchem.8b01262/suppl_file/jm8b01262_si_001.pdf" class="ext-link">Figure S5</a>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b01262/20181119/images/large/jm-2018-012622_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01262&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Because of a loss of PTEN (phosphatase and tensin homologue) and an activating B-Raf mutation A2058 cells are rather resistant to PI3K inhibition,<a onclick="showRef(event, 'ref23 ref30'); return false;" href="javascript:void(0);" class="ref ref23 ref30">(23,30)</a> while growth of SKOV3 cells is promoted by a constitutively activated PI3Kα, rendering these cells more sensitive to PI3K and mTOR kinase inhibitors. Even for excessive concentrations of rapamycin (10 μM), no attenuation of cell proliferation could be observed, indicating that the inhibition of mTORC1 is insufficient to block proliferation of A2058 and SKOV3. Cell cycle analysis revealed that all tested PI3K and mTOR kinase inhibitors accumulated cells in G1, diminishing cell numbers in S and G2/M cell cycle phases (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a> and Supporting Information, <a href="/doi/suppl/10.1021/acs.jmedchem.8b01262/suppl_file/jm8b01262_si_001.pdf" class="ext-link">Figure S5</a>). Moreover, at 10 μM PQR620 (<b>3</b>) did not show cytotoxicity in 65 of 66 cell lines of the NTCR panel, a typical feature for the blockage of the PI3K/mTOR pathway.<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a></div><div class="NLM_p last">Growth inhibition goes hand in hand with the inhibition of mTORC1 and mTORC2 targets, where PQR620 (<b>3</b>), INK128 (7<b>3</b>), PP242 (<b>75</b>), SB2602 (<b>74</b>), and GDC0941 (<b>76</b>) efficiently block the phosphorylation of S6, S6K, 4E-BP1, and PKB/Akt (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a> and Supporting Information, <a href="/doi/suppl/10.1021/acs.jmedchem.8b01262/suppl_file/jm8b01262_si_001.pdf" class="ext-link">Figure S5</a>). As observed earlier for PI3K inhibitors,<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> the mTOR inhibitors also yield half-maximal growth inhibition only when mTOR targets are close to 90% inhibited. While rapamycin is highly efficient to block phosphorylation of mTORC1 targets such as S6K (and therefore S6) and 4E-BP1, it leads to an increase of pPKB/Akt in A2058 and SKOV3 cells. This corresponds to a previously reported feedback loop, where rapalog-dependent mTORC1 and S6K inactivation enforces surface receptor to PI3K signaling,<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a> which explains the reduced antiproliferative activity of rapalogs as compared to mTOR kinase inhibitors.</div></div><div id="sec2_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i15" class="anchor-spacer"></div><h3 class="article-section__title" id="_i15"> Metabolic Stability</h3><div class="NLM_p">To predict the metabolic stability of PQR620 (<b>3</b>), the compound was incubated in vitro with microsomes and hepatocytes from different animal species. Compound PQR620 (<b>3</b>) was found to be very stable in rat liver microsomes (no metabolites detected), whereas it was moderately metabolized in mouse liver microsomes (∼70% remaining PQR620 (<b>3</b>) after a 30 min incubation, <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a></a>). Similarly, compound PQR620 (<b>3</b>) was more stable in rat hepatocytes (RH) than in mouse hepatocytes (MH) (CL<sub>hep</sub> = 1.850 μL/min/10<sup>6</sup> cells for RH and CL<sub>hep</sub> = 2.671 μL/min/10<sup>6</sup> cells for MH).</div><div class="NLM_table-wrap" id="tbl5"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 5. Stability of Compound PQR620 (<b>3</b>)</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="char" char="±" /></col><col align="char" char="±" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" colspan="2" align="center" char="±"> </th><th class="rowsep1 colsep0" colspan="4" align="center" char=".">hepatocyte</th></tr><tr valign="top" class="colsep0"><th class="rowsep1 colsep0" colspan="2" align="left" char="±">microsome stability,<a class="ref internalNav" href="#t5fn1" aria-label="a">a</a> [% remaining after 30 min]</th><th class="rowsep1 colsep0" colspan="2" align="center" char=".">-clearance [μL/min/10<sup>6</sup> cells]<a class="ref internalNav" href="#t5fn2" aria-label="b">b</a></th><th class="rowsep1 colsep0" colspan="2" align="center" char=".">-stability <i>t</i><sub>1/2</sub> [min]<a class="ref internalNav" href="#t5fn2" aria-label="b">b</a></th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center" char="±">rat</th><th class="colsep0 rowsep0" align="center" char="±">mouse</th><th class="colsep0 rowsep0" align="center" char=".">rat</th><th class="colsep0 rowsep0" align="center" char=".">mouse</th><th class="colsep0 rowsep0" align="center" char=".">rat</th><th class="colsep0 rowsep0" align="center" char=".">mouse</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char="±">108 ± 3.3</td><td class="colsep0 rowsep0" align="char" char="±">70.2 ± 0.33</td><td class="colsep0 rowsep0" align="char" char=".">1.85</td><td class="colsep0 rowsep0" align="char" char=".">2.67</td><td class="colsep0 rowsep0" align="char" char=".">468.4</td><td class="colsep0 rowsep0" align="char" char=".">324.4</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t5fn1"><div class="footnote" id="t5fn1"><sup><sup>a</sup></sup><p class="last">Experiments were carried out by Aphad Srl with rat and mouse liver microsomes (Xenotech). Each experiment performed <i>n</i> = 2.</p></div><div class="footnote" id="t5fn2"><sup><sup>b</sup></sup><p class="last">Experiments were carried out by Pharmacelsus GmbH using cryopreserved hepatocytes.</p></div></div></div><div class="NLM_p">In addition, PQR620 (<b>3</b>) showed moderate passive permeability (52.23 ± 7.35 nm/s) in a PAMPA assay (parallel artificial membrane permeability assay), suggesting nonlimiting cellular permeability. As a further indicator for bioavailability the thermodynamic solubility was assessed over a range of pH, as well as in fasted and fed state simulated intestinal fluids (FaSSIF and FeSSIF). The solubility of compound PQR620 (<b>3</b>) was 20.0 ± 6.5 mM at pH 1.2, 33.7 ± 4.3 μM at pH 6.8, and reached 335 ± 148 μM in FeSSIF buffer (<a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">Table <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">6</a></a>). Overall, PQR620 (<b>3</b>) displays good ADME properties and promising physicochemical characteristics, such as the experimental log <i>D</i> value (3.47 in PBS buffer pH 7.4), the partition coefficient clogP (3.06), and molecular weight (445.47). Moreover, the CNS MPO score, an algorithm used to estimate blood–brain barrier permeability, was 3.8 for PQR620 (<b>3</b>), which suggests good penetration to the brain.</div><div class="NLM_table-wrap" id="tbl6"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 6. Physicochemical Properties of Compound PQR620 (<b>3</b>)</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="char" char="±" /></col><col align="char" char="±" /></col><col align="char" char="±" /></col><col align="char" char="±" /></col><col align="char" char="±" /></col><col align="char" char="±" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center" char="±"> </th><th class="rowsep1 colsep0" colspan="5" align="center" char="±">thermodynamic solubility, [μM]</th><th class="colsep0 rowsep0" align="center" char="."> </th><th class="colsep0 rowsep0" align="left" char="."> </th><th class="colsep0 rowsep0" align="left" char="."> </th><th class="colsep0 rowsep0" align="left" char="."> </th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="left" char="±">permeability <i>P</i><sub>app</sub> [nm/s]</th><th class="colsep0 rowsep0" align="center" char="±">pH 1.2</th><th class="colsep0 rowsep0" align="center" char="±">pH 4.5</th><th class="colsep0 rowsep0" align="center" char="±">pH 6.8</th><th class="colsep0 rowsep0" align="center" char="±">FaSSIF<a class="ref internalNav" href="#t6fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center" char="±">FeSSIF<a class="ref internalNav" href="#t6fn2" aria-label="b">b</a></th><th class="colsep0 rowsep0" align="center" char=".">log <i>D</i> pH 7.4</th><th class="colsep0 rowsep0" align="left" char=".">clogP<a class="ref internalNav" href="#t6fn3" aria-label="c">c</a></th><th class="colsep0 rowsep0" align="left" char=".">mol wt [g/mol]</th><th class="colsep0 rowsep0" align="left" char=".">CNS MPO score</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char="±">52.23 ± 7.35</td><td class="colsep0 rowsep0" align="char" char="±">19967 ± 6487</td><td class="colsep0 rowsep0" align="char" char="±">78.2 ± 15.5</td><td class="colsep0 rowsep0" align="char" char="±">33.7 ± 4.3</td><td class="colsep0 rowsep0" align="char" char="±">66.0 ± 3.2</td><td class="colsep0 rowsep0" align="char" char="±">335 ± 148</td><td class="colsep0 rowsep0" align="char" char=".">3.47</td><td class="colsep0 rowsep0" align="char" char=".">3.06</td><td class="colsep0 rowsep0" align="char" char=".">445.47</td><td class="colsep0 rowsep0" align="char" char=".">3.8</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t6fn1"><div class="footnote" id="t6fn1"><sup><sup>a</sup></sup><p class="last">FaSSIF: fasted simulated intestinal fluid.</p></div><div class="footnote" id="t6fn2"><sup><sup>b</sup></sup><p class="last">FeSSIF: fed simulated intestinal fluid.</p></div><div class="footnote" id="t6fn3"><sup><sup>c</sup></sup><p class="last">clogP values were calculated using MarvinSketch. Solubility assays were performed by Aphad Analytical Solutions.</p></div></div></div></div><div id="sec2_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i18" class="anchor-spacer"></div><h3 class="article-section__title" id="_i18"> In Vivo Pharmacokinetic and Pharmacodynamic Evaluation</h3><div class="NLM_p">Compound PQR620 (<b>3</b>) was then profiled in vivo in rats and mice to evaluate PK and PD. After a single oral dose of PQR620 (<b>3</b>) (10 mg/kg) given to healthy female Sprague–Dawley (SD) rats, PQR620 (<b>3</b>) concentrations in plasma and brain were monitored over time (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>): the maximal concentration (<i>C</i><sub>max</sub>) of PQR620 (<b>3</b>) was reached in plasma and brain after 30 min (1355  and 1310 ng/g, respectively). After 8 h, the total exposure AUC<sub>0–8</sub> was 409 μg·h/mL in plasma and 404 μg·h/mL in brain. A comparison with SB2602 (<b>74</b>) showed that its plasma <i>C</i><sub>max</sub> exceeded the one of PQR620 (<b>3</b>), while plasma AUC levels were relatively comparable. Brain levels of PQR620 (<b>3</b>) were maintained at ca. 900 ng/g for >8 h, for SB2602 (<b>74</b>) they dropped to ca. 170 ng/g after 4 h. PQR620 (<b>3</b>) displayed approximately a ∼1:1 distribution in brain/plasma, while brain access of SB2602 (<b>74</b>) was limited (brain/plasma levels ∼1:5.6; <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>).</div><figure id="fig6" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b01262/20181119/images/medium/jm-2018-012622_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b01262/20181119/images/large/jm-2018-012622_0006.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. PK and PD in female Sprague–Dawley rats (left panels) and male C57BL/6JRj mice (right panels). (A,B) Plasma and brain levels (broken lines) of indicated drugs determined after a single dose po of 10 mg/kg in rats, and 50 mg/kg in mice.* (C,D) Brain/plasma ratio over time calculated from values above. Plasma (E,F) insulin and (G,H) glucose levels measured in animals above. All experiments depicted as mean ± SEM (<i>n</i> = 3); error bars are omitted where smaller than symbols. *PQR620 data in (B) was compared to rapamycin and everolimus in ref <a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b01262/20181119/images/large/jm-2018-012622_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01262&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Dosed at 50 mg/kg in mice, a single oral application of PQR620 (<b>3</b>) yielded a <i>C</i><sub>max</sub> of 4835 ng/g in plasma and 7706 ng/g in brain (see Supporting Information, <a href="/doi/suppl/10.1021/acs.jmedchem.8b01262/suppl_file/jm8b01262_si_001.pdf" class="ext-link">Table S7</a>), confirming the excellent brain penetration of PQR620 (<b>3</b>) (brain/plasma levels ∼1.6:1). A brain tissue binding assay revealed an <i>f</i><sub>u</sub> (fraction unbound) value of 3%, which matches the levels of compounds with established brain activity in the same assay (see diazepam; <i>f</i><sub>u</sub> ∼4%, Supporting Information, <a href="/doi/suppl/10.1021/acs.jmedchem.8b01262/suppl_file/jm8b01262_si_001.pdf" class="ext-link">Table S8A</a>). Brain penetration data are also in accordance with MDCK permeability assays, which document a rapid, passive diffusion, independent of P-gp (P-glycoprotein 1, MDR1) transport (see Supporting Information, <a href="/doi/suppl/10.1021/acs.jmedchem.8b01262/suppl_file/jm8b01262_si_001.pdf" class="ext-link">Table S8B</a>).</div><div class="NLM_p last">As reported earlier, inhibitors targeting PI3Kα trigger an acute peak of plasma insulin.<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> PQR620 (<b>3</b>) and SB2602 (<b>74</b>) did not lead to an increase of plasma insulin concentrations in rats and mice as compared to background levels, while the pan-PI3K inhibitor PQR309 (<b>1</b>) at the same dose produced a prominent insulin peak. In rats, glucose levels could not be distinguished from background after PQR620 (<b>3</b>) administration, while PQR309 (<b>1</b>) led to a slow glucose increase, which even extends beyond the 8 h measurements presented here.<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> In contrast, an elevated dose and exposure of PQR620 (<b>3</b>) in mice caused an elevation of glucose plasma levels that were delayed in comparison to the increase triggered by PQR309 (<b>1</b>). While PQR309 (<b>1</b>) response pattern with a glucose and insulin increase can be explained by the induction of insulin resistance by suppression of GLUT4 in muscle and adipocytes, the glucose increase triggered by mTOR kinase inhibitors is less well-defined. It was proposed that mTOR kinase inhibitors acutely cause hyperglycemia via TORC2-mediated regulation of glycolysis in skeletal muscle.<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> PQR620 (<b>3</b>) displayed a good exposure after oral dosing and excellent brain permeability, which makes this compound suitable as potential agent for CNS cancer indications and neurological diseases.</div></div><div id="sec2_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i19" class="anchor-spacer"></div><h3 class="article-section__title" id="_i19"> Evaluation of in Vivo Efficacy</h3><div class="NLM_p">The in vivo efficacy of compound PQR620 (<b>3</b>) was preclinically evaluated in a xenograft tumor model (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>). Compound PQR620 (<b>3</b>) showed very good tolerability in mice (MTD ∼ 150 mg/kg) and was well tolerated in a 14-day toxicological study in rats, where the MTD was defined to be ∼30 mg/kg. PQR620 (<b>3</b>) was efficacious in an OVCAR-3 human ovarian cancer xenograft model, where BALB/C nude mice were inoculated subcutaneously with cisplatin resistant OVCAR-3 cells. Compound PQR620 (<b>3</b>) and PQR309 (<b>1</b>) at 50 mg/kg were well tolerated in tumor bearing mice and did not cause a significant body weight loss, except for an outlier in the PQR620 (<b>3</b>) treatment group (1 out of 8 mice) where one mouse lost >10% of its weight (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>). Tumor growth and terminal tumor weight were attenuated by treatment with compounds PQR620 (<b>3</b>) and PQR309 (<b>1</b>) by >50%. This demonstrates that mTOR kinase inhibition can be equivalent to the inhibition of upstream PI3K in some settings.</div><figure id="fig7" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b01262/20181119/images/medium/jm-2018-012622_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b01262/20181119/images/large/jm-2018-012622_0007.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. OVCAR-3 human ovarian cancer xenograft model in BALB/c nude mice: tumor cells were subcutaneously inoculated at day 0, and daily oral application of the indicated agents was started at day 17 (28 × QD). (A) Body weight was determined at the depicted time points. Body weight loss of >10% was observed in one mouse (of 8) in the PQR620 (<b>3</b>) treatment group. (B) The tumor size was measured and calculated as described in the <a class="ref internalNav" href="#sec4" aria-label="Experimental Section">Experimental Section</a>. (C) The tumor weight was determined at day 45 after inoculation. Statistics: (*<i>p</i> < 0.05; <sup>$</sup><i>p</i> < 0.001; <sup>$$</sup><i>p</i> < 0.0001; <i>n</i> = 8; (A,B) Two-Way ANOVA with Bonferroni or Dunnett’s correction for multicomparisons, mean ± SEM; (C) mean ± SD, One-Way ANOVA with Tukey’s correction for multicomparisons.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b01262/20181119/images/large/jm-2018-012622_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01262&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i20" class="anchor-spacer"></div><h3 class="article-section__title" id="_i20"> Attenuation of Neurological Disease</h3><div class="NLM_p">It has been previously reported that Tsc1GFAP conditional knockout mice (Tsc1<sup>flox/flox</sup> × GFAP-Cre) with targeted disruption of the Tsc1 gene in glial fibrillary acidic protein containing cells (mostly neurons) show a high incidence of spontaneous postnatal epilepsy. Treatment with rapamycin reduced the number of seizures and mortality.<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a></div><div class="NLM_p">Here we evaluated the capacity of PQR620 (<b>3</b>) and PQR309 (<b>1</b>) to rescue the neuronal loss of function Tsc1 phenotype: mice treated with vehicle (postnatal days 21–55) suffered robust electrographic seizures, while a daily treatment of PQR620 (<b>3</b>) (100 mg/kg, po) eliminated seizures almost completely (<a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>). The reduction of seizures by PQR309 (<b>1</b>) did not reach significance. It is tempting to speculate PQR309’s (<b>1</b>) capacity to inhibit mTOR was insufficient and that targeting of class I PI3Ks cannot remedy the TSC phenotype. It is possible, however, that it is PQR309’s (<b>1</b>) short half-life in mice that contributes to diminish its effectiveness. The protective effect of PQR620 (<b>3</b>) demonstrates clearly that targeting TORC1 and TORC2 mTOR kinase activity efficiently counteracts TSC-dependent overactivation of the mTOR pathway and thereby caused epileptic seizures.</div><figure id="fig8" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b01262/20181119/images/medium/jm-2018-012622_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b01262/20181119/images/large/jm-2018-012622_0008.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Effects of mTOR and PI3K inhibition on frequency of electrographic seizures caused by neuron-specific elimination of TSC1.<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a> (A) Tsc1<sup>GFAP</sup> conditional knockout mice were treated from postnatal days 21–53 with vehicle, PQR620 (<b>3</b>) (100 mg/kg), or PQR309 (<b>1</b>) (50 mg/kg). In three observation intervals, EEG traces were recorded, and the number of seizures were determined (depicted as seizure count/48 h; mean ± SEM, <i>n</i> = 30–48. Two-Way ANOVA test with Dunnet’s multiple comparison related to vehicle control; *<i>p</i> = 0.032; **<i>p</i> = 0.0021; ***<i>p</i> = 0.0002). (B) Body weights averaged over the whole observation time in the three treatment groups (mean ± SEM, <i>n</i> ≥ 13).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b01262/20181119/images/large/jm-2018-012622_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01262&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i21">Conclusions</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_53782" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_53782" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">In summary, we demonstrated that lead compound PQR620 (<b>3</b>) potently inhibits mTORC1/2 in vitro and in vivo. A >1000-fold selectivity toward mTOR over PI3Kα in binding assays is obtained by the introduction of a difluoromethyl-substituent and sterically demanding 3,5-ethylene bridged morpholines. PQR620 (<b>3</b>) exhibits excellent selectivity over a wide panel of protein and lipid kinases, as well as excellent selectivity versus unrelated receptor enzymes and ion channels. PQR620 (<b>3</b>) demonstrates its potency to inhibit cancer cell line proliferation with a potential comparable to pan-PI3K inhibition. The physicochemical properties (log <i>D</i>, solubility, liver microsomal stability (<i>t</i><sub>1/2</sub>), and apparent permeability) of compound PQR620 (<b>3</b>) resulted in a good exposure in both plasma and brain following oral administration. PQR620 (<b>3</b>) shows significant antitumor effects in a xenograft mouse model, is well tolerated in rats and mice, and lacks some of the adverse mechanism-based side effects of pan-PI3K inhibitors. The almost complete elimination of seizures in the mouse TSC null model above, and a significantly increased seizure threshold in a mouse model of chronic epilepsy<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> demonstrate the efficiency of PQR620 (<b>3</b>) in the CNS. The excellent brain/plasma partitioning promises a therapeutic potential in a wider range of neurodegenerative diseases and epilepsy with a reduced impact on host defense responses as compared to competitor compounds that require higher plasma levels to reach mTOR inhibition in brain tissue. Altogether, the preclinical data support a further development of this compound.</div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i22">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_53657" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_53657" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec4_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i23" class="anchor-spacer"></div><h3 class="article-section__title" id="_i23"> General Information</h3><div class="NLM_p">Reagents were purchased at the highest commercial quality from Acros, Sigma-Aldrich, or Fluorochem and used without further purification. Solvents were purchased from Acros Organics in AcroSeal bottles over molecular sieves. Cross coupling reactions were carried out under nitrogen atmosphere in anhydrous solvents, and glassware was oven-dried prior to use. Thin layer chromatography (TLC) plates were purchased from Merck KGaA (Polygram SIL/UV254, 0.2 mm silica with fluorescence indicator) and UV light (254 nm) was used to visualize the compounds. Column chromatographic purifications were performed on Merck KGaA silica gel (pore size 60 Å, 230–400 mesh particle size). Alternatively, flash chromatography was performed with Isco CombiFlash Companion systems using prepacked silica gel columns (40–60 μm particle size RediSep). <sup>1</sup>H and <sup>13</sup>C NMR spectra were recorded on a Bruker Avance 400 spectrometer. NMR spectra were obtained in deuterated solvents, such as CDCl<sub>3</sub>, (CD<sub>3</sub>)<sub>2</sub>SO, or CD<sub>3</sub>OD. The chemical shift (δ values) are reported in ppm and corrected to the signal of the deuterated solvents (7.26 ppm (<sup>1</sup>H NMR) and 77.16 ppm (<sup>13</sup>C NMR) for CDCl<sub>3</sub>, 2.50 ppm (<sup>1</sup>H NMR) and 39.52 ppm (<sup>13</sup>C NMR) for (CD<sub>3</sub>)<sub>2</sub>SO, and 3.31 ppm (<sup>1</sup>H NMR) and 49.00 ppm (<sup>13</sup>C NMR) for CD<sub>3</sub>OD). Coupling constants, when given, are reported in hertz (Hz). High resolution mass spectra (HRMS) were recorded on a Thermo Fisher Scientific LTQ Orbitrap XL (ESI-MS) spectrometer. MALDI-ToF mass spectra were obtained on a Voyager-De Pro measured in <i>m</i>/<i>z</i>. The chromatographic purity of final compounds was determined by high performance liquid chromatography (HPLC) analyses on an Ultimate 3000SD System from ThermoFisher with LPG-3400SD pump system, ACC-3000 autosampler and column oven, and DAD-3000 diode array detector. An Acclaim-120 C18 reversed-phase column from ThermoFisher was used as stationary phase. Gradient elution (5:95 for 0.2 min, 5:95 → 100:0 over 10 min, 100:0 for 3 min) of the mobile phase consisting of CH<sub>3</sub>CN/MeOH:H<sub>2</sub>O<sub>(10:90)</sub> was used at a flow rate of 0.5 mL/min at 40 °C. The purity of all final compounds was >95%.</div><div id="sec4_1_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i24" class="anchor-spacer"></div><h4 class="article-section__title" id="_i24"> General Procedure 1</h4><div class="NLM_p last">The free amine or the corresponding HCl salt (2.0–2.3 equiv) was dissolved in CH<sub>2</sub>Cl<sub>2</sub> (approximately 1 mL/0.8 mmol) and <i>N</i>,<i>N</i>-diisopropylamine (2.2–6.0 equiv) was added. The resulting solution was cooled to 0 °C and then added dropwise to a solution of cyanuric chloride (1.0 equiv) in CH<sub>2</sub>Cl<sub>2</sub> (approximately 1 mL/0.4 mmol) at 0 °C. The resulting reaction mixture was stirred overnight, while it was allowed to warm up to room temperature. Additional CH<sub>2</sub>Cl<sub>2</sub> (approximately 1 mL/0.5 mmol) was added, and the organic layer was washed with an aq satd solution of NaHSO<sub>4</sub> (2×). The organic layer was dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and filtered, and the solvent was evaporated under reduced pressure. The crude product was purified by column chromatography on silica gel.</div></div><div id="sec4_1_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i25" class="anchor-spacer"></div><h4 class="article-section__title" id="_i25"> General Procedure 2</h4><div class="NLM_p last">To a solution of the amine or the corresponding HCl salt (2.0–2.1 equiv) and <i>N</i>,<i>N</i>-diisopropylethylamine (4.0–4.2 equiv) in tetrahydrofuran (approximately 1 mL/0.1 mmol), cyanuric chloride (1.0 equiv) was added at 0 °C. The resulting mixture was stirred at reflux overnight. The mixture was then allowed to cool down to room temperature, washed with aq satd NaHSO<sub>4</sub> (2×), dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, and filtered, and the solvent was evaporated under reduced pressure. The crude product was purified by column chromatography on silica gel.</div></div><div id="sec4_1_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i26" class="anchor-spacer"></div><h4 class="article-section__title" id="_i26"> General Procedure 3</h4><div class="NLM_p last">To a solution of the morpholine derivative (1.1 equiv) and <i>N</i>,<i>N</i>-diisopropylethylamine (2.0–2.1 equiv) in ethanol (approximately 1 mL/0.2 mmol) at 0 °C, 4-(4,6-dichloro-1,3,5-triazin-2-yl)morpholine (<b>35</b>, 1.0 equiv) was added portionwise. The resulting mixture was stirred at room temperature overnight. The solvent was then removed under reduced pressure, and the residue was purified by column chromatography on silica gel.</div></div><div id="sec4_1_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i27" class="anchor-spacer"></div><h4 class="article-section__title" id="_i27"> General Procedure 4</h4><div class="NLM_p last">Monochlorotriazine derivative (1.0 equiv), boronic acid pinacol ester <b>64</b> (1.0–1.2 equiv), K<sub>3</sub>PO<sub>4</sub> (2.0 equiv), and chloro(2-dicyclohexylphosphino-2′,4′,6′-triisopropyl-1,1′-biphenyl)[2-(2′-amino-1,1′-biphenyl)]-palladium(II) (XPhos Pd G2, 0.05 equiv) were charged in a flask. Under nitrogen atmosphere, 1,4-dioxane (approximately 1 mL/0.2 mmol) and deionized H<sub>2</sub>O (approximately 1 mL/0.4 mmol) were added, and the resulting mixture was placed into an oil bath preheated at 95 °C and stirred at this temperature overnight. Deionized H<sub>2</sub>O was added and the aqueous layer was extracted with CH<sub>2</sub>Cl<sub>2</sub> (3×). The combined organic layers were dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and filtered, and the solvent was evaporated under reduced pressure. The crude product was purified by column chromatography on silica gel.</div></div><div id="sec4_1_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i28" class="anchor-spacer"></div><h4 class="article-section__title" id="_i28"> General Procedure <b>5</b></h4><div class="NLM_p last">Monochlorotriazine derivative (1.0 equiv), boronic acid pinacol ester <b>64</b> or <b>72</b> (1.0–1.1 equiv), K<sub>3</sub>PO<sub>4</sub> (2.0 equiv), and chloro(2-dicyclohexylphosphino-2′,4′,6′-triisopropyl-1,1′-biphenyl)[2-(2′-amino-1,1′-biphenyl)]palladium(II) (XPhos Pd G2, 0.05 equiv) were charged in a flask. Under nitrogen atmosphere, 1,4-dioxane (approximately 1 mL/0.2 mmol) and deionized H<sub>2</sub>O (approximately 1 mL/0.4 mmol) were added and the resulting mixture was placed into an oil bath preheated at 95 °C and stirred at this temperature for 2–5 h. After this time, the reaction mixture was allowed to cool down to room temperature, a 3 M aq HCl-solution (>10 equiv) was added, and the resulting mixture was stirred at 60 °C for 3–15 h. The pH was adjusted to 10 by addition of a 2 M aq NaOH solution, and the aqueous layer was then extracted with EtOAc (3×). The combined organic layers were dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and filtered, and the solvent was evaporated under reduced pressure. The crude product was purified by column chromatography on silica gel.</div></div><div id="sec4_1_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i29" class="anchor-spacer"></div><h4 class="article-section__title" id="_i29"> General Procedure 6</h4><div class="NLM_p last">Step 1: Bis(pinacolato)diboron (1.5 equiv), KOAc (3.0 equiv), [1,1′-bis(diphenylphosphino)-ferrocene]dichloropalladium(II) (Pd(dppf)Cl<sub>2</sub>, 0.10 equiv), and the respective bromo derivative (1.0 equiv) were dissolved in abs dioxane (approximately 1 mL/0.1 mmol) under nitrogen atmosphere. The resulting mixture was stirred at 95 °C for 6–8 h. The mixture was allowed to cool down to room temperature. Step 2: 4,4′-(6-Chloro-1,3,5-triazine-2,4-diyl)dimorpholine (<b>36</b>, 1.1 equiv), chloro(2-dicyclo-hexylphosphino-2′,4′,6′-triisopropyl-1,1′-biphenyl)[2-(2′-amino-1,1′-biphenyl)]palladium(II) (XPhos Pd G2, 0.05 equiv), and K<sub>3</sub>PO<sub>4</sub> (2.0 equiv) were added. The resulting reaction mixture was placed in a preheated oil bath at 95 °C and stirred for 3–16 h. Then the mixture was allowed to cool down to room temperature, deionized H<sub>2</sub>O was added, and the mixture was extracted with CH<sub>2</sub>Cl<sub>2</sub> (3×). The combined organic layers were washed with brine (2×), dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered, and reduced to dryness under reduced pressure. Step 3: The above residue was dissolved in dioxane (approximately 1 mL/0.1 mmol) and an aqueqous solution of HCl (3 M, 10–15 equiv) was added. The reaction mixture was stirred at 60 °C for 2 h. The mixture was diluted with deionized H<sub>2</sub>O and washed with EtOAc (1×). The aqueous layer was basified to pH = 10 and then extracted with EtOAc (3×). The combined organic layers were dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and filtered, and the solvent was evaporated under reduced pressure. The crude product was purified by column chromatography on silica gel.</div></div><div id="sec4_1_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i30" class="anchor-spacer"></div><h4 class="article-section__title" id="_i30"> General Procedure 7</h4><div class="NLM_p last">To a solution of di-<i>tert</i>-butyl dicarbonate (2.5–3.0 equiv) in tetrahydrofuran (approximately 1 mL/0.4 mmol), the respective amine was added (1.0 equiv) at 0 °C. Then, 4-(dimethylamino)pyridine (0.30 equiv) was added and the resulting mixture was stirred overnight, while it was allowed to warm up to room temperature. The solvent was evaporated under reduced pressure. The residue was dissolved in CH<sub>2</sub>Cl<sub>2</sub>, and the resulting organic layer was washed with an aq satd NH<sub>4</sub>Cl solution, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, and filtered. The solvent was evaporated under reduced pressure, and the crude product was purified by column chromatography on silica gel.</div></div><div id="sec4_1_8" class="NLM_sec NLM_sec_level_3"><div id="ac_i31" class="anchor-spacer"></div><h4 class="article-section__title" id="_i31"> 5-[4,6-Bis(morpholin-4-yl)-1,3,5-triazin-2-yl]-4-(trifluoromethyl)pyridin-2-amine (PQR309 (<b>1</b>))</h4><div class="NLM_p last"><b>1</b> was prepared according to the literature.<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a></div></div><div id="sec4_1_9" class="NLM_sec NLM_sec_level_3"><div id="ac_i32" class="anchor-spacer"></div><h4 class="article-section__title" id="_i32"> 5-[4,6-Bis(morpholin-4-yl)-1,3,5-triazin-2-yl]-4-(difluoromethyl)pyridin-2-amine (<b>2</b>)</h4><div class="NLM_p last"><b>2</b> was prepared according to general procedure 5 from intermediate <b>36</b> (355 mg, 1.24 mmol, 1.0 equiv) and boronic ester <b>64</b> (422 mg, 1.30 mmol, 1.0 equiv). Purification by column chromatography on silica gel (cyclohexane/EtOAc 1:0 →1:3) gave compound <b>2</b> (225 mg, 572 μmol, 46%) as a colorless solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 9.02 (s, 1 H), 7.65 (t, <sup>2</sup><i>J</i><sub>H,F</sub> = 55 Hz, 1 H), 6.84 (s, 1 H), 4.85 (br s, 2 H), 3.90–3.78 (m, 8 H), 3.78–3.71 (m, 8 H). <sup>13</sup>C{<sup>1</sup>H} NMR (101 MHz, (CD<sub>3</sub>)<sub>2</sub>SO): δ 168.9 (s, 1 C), 164.1 (s, 2 C), 161.6 (s, 1 C), 152.1 (s, 1 C), 142.1 (t, <sup>2</sup><i>J</i><sub>C,F</sub> = 22 Hz, 1 C), 118.2 (t, <sup>3</sup><i>J</i><sub>C,F</sub> = 4.4 Hz, 1 C), 111.8 (t, <sup>1</sup><i>J</i><sub>C,F</sub> = 237 Hz, 1 C), 103.1 (t, <sup>3</sup><i>J</i><sub>C,F</sub> = 8.4 Hz, 1 C), 66.0 (s, 4 C), 43.3 (s, 4 C). ESI-HRMS (<i>m</i>/<i>z</i>): [M + H]<sup>+</sup> calcd for C<sub>17</sub>H<sub>22</sub>F<sub>2</sub>N<sub>7</sub>O<sub>2</sub> 394.1798, found 394.1787. HPLC: <i>t</i><sub>R</sub> = 7.18 min (96.5% purity).</div></div><div id="sec4_1_10" class="NLM_sec NLM_sec_level_3"><div id="ac_i33" class="anchor-spacer"></div><h4 class="article-section__title" id="_i33"> 5-[4,6-Bis({3-oxa-8-azabicyclo[3.2.1]octan-8-yl})-1,3,5-triazin-2-yl]-4-(difluoromethyl)pyridin-2-amine <b>(</b>PQR620 (<b>3</b>))</h4><div class="NLM_p last"><b>3</b> was prepared according to general procedure 4 from intermediate <b>43</b> (396 mg, 1.17 mmol, 1.0 equiv) and boronic acid pinacol ester <b>64</b> (420 mg, 1.29 mmol, 1.1 equiv). Purification by column chromatography on silica gel (cyclohexane/EtOAc 1:0 → 2:3) gave compound PQR620 (<b>3</b>) (375 mg, 842 μmol, 72%) as a colorless solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 9.04 (s, 1 H), 7.71 (t, <sup>2</sup><i>J</i><sub>H,F</sub> = 55 Hz, 1 H), 6.83 (s, 1 H), 4.83 (br s, 2 H), 4.75–4.60 (m, 4 H), 3.83–3.72 (m, 4 H), 3.70–3.58 (m, 4 H), 2.14–1.92 (m, 8 H). <sup>13</sup>C{<sup>1</sup>H} NMR (101 MHz, CDCl<sub>3</sub>): δ 169.8 (s, 1 C), 163.3 (s, 2 C), 160.2 (s, 1 C), 152.5 (s, 1 C), 143.7 (t, <sup>2</sup><i>J</i><sub>C,F</sub> = 22 Hz, 1 C), 121.5 (t, <sup>3</sup><i>J</i><sub>C,F</sub> = 4.9 Hz, 1 C), 111.5 (t, <sup>1</sup><i>J</i><sub>C,F</sub> = 238 Hz, 1 C), 104.1 (t, <sup>3</sup><i>J</i><sub>C,F</sub> = 8.0 Hz, 1 C), 72.0 (s, 2 C), 71.7 (s, 2 C), 55.0 (s, 2 C), 54.6 (s, 2 C), 27.1 (s, 2 C), 27.0 (s, 2 C). ESI-HRMS (<i>m</i>/<i>z</i>): [M + H]<sup>+</sup> calcd for C<sub>21</sub>H<sub>26</sub>F<sub>2</sub>N<sub>7</sub>O<sub>2</sub> 446.2111, found 446.2101. HPLC: <i>t</i><sub>R</sub> = 8.15 min (99.4% purity).</div></div><div id="sec4_1_11" class="NLM_sec NLM_sec_level_3"><div id="ac_i34" class="anchor-spacer"></div><h4 class="article-section__title" id="_i34"> 5-[4,6-Bis(morpholin-4-yl)-1,3,5-triazin-2-yl]pyridin-2-amine (<b>4</b>) and 5-[4,6-Bis(morpholin-4-yl)-1,3,5-triazin-2-yl]-4-methylpyridin-2-amine (<b>5</b>)</h4><div class="NLM_p last"><b>4</b> and <b>5</b> were prepared according to the literature.<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a></div></div><div id="sec4_1_12" class="NLM_sec NLM_sec_level_3"><div id="ac_i35" class="anchor-spacer"></div><h4 class="article-section__title" id="_i35"> 5-[4,6-Bis(morpholin-4-yl)-1,3,5-triazin-2-yl]-4-(fluoromethyl)pyridin-2-amine (<b>6</b>)</h4><div class="NLM_p last"><b>6</b> was prepared according to general procedure 6 from intermediate <b>36</b> (71.0 mg, 248 μmol, 1.1 equiv) and <i>N</i>′-(5-bromo-4-(fluoromethyl)pyridin-2-yl)-<i>N</i>,<i>N</i>-dimethylformimidamide (<b>67</b>, 58.6 mg, 225 μmol, 1.0 equiv). Purification by column chromatography on silica gel (cyclohexane/EtOAc 1:0 →1:3) gave compound <b>6</b> (34.3 mg, 91.4 μmol, 41%) as a colorless solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 9.07 (s, 1 H), 6.75 (s, 1 H), 5.89 (d, <sup>2</sup><i>J</i><sub>H,F</sub> = 49 Hz, 2 H), 4.78 (br s, 2 H), 3.90–3.79 (m, 8 H), 3.79–3.71 (m, 8 H). <sup>13</sup>C{<sup>1</sup>H} NMR (101 MHz, CDCl<sub>3</sub>): δ 170.0 (s, 1 C), 164.8 (s, 2 C), 160.3 (d, <sup>4</sup><i>J</i><sub>C,F</sub> = 3.0 Hz, 1 C), 151.8 (s, 1 C), 149.5 (d, <sup>2</sup><i>J</i><sub>C,F</sub> = 17 Hz, 1 C), 120.2 (d, <sup>3</sup><i>J</i><sub>C,F</sub> = 4.0 Hz, 1 C), 130.2 (d, <sup>3</sup><i>J</i><sub>C,F</sub> = 19 Hz, 1 C), 82.9 (d, <sup>1</sup><i>J</i><sub>C,F</sub> = 172 Hz, 1 C), 66.9 (s, 4 C), 43.8 (br s, 4 C). ESI-HRMS (<i>m</i>/<i>z</i>): [M + H]<sup>+</sup> calcd for C<sub>17</sub>H<sub>23</sub>FN<sub>7</sub>O<sub>2</sub> 376.1892, found 376.1882. HPLC: <i>t</i><sub>R</sub> = 7.06 min (95.9% purity).</div></div><div id="sec4_1_13" class="NLM_sec NLM_sec_level_3"><div id="ac_i36" class="anchor-spacer"></div><h4 class="article-section__title" id="_i36"> {2-Amino-5-[4,6-bis(morpholin-4-yl)-1,3,5-triazin-2-yl]pyridin-4-yl}methanol (<b>7</b>)</h4><div class="NLM_p last"><b>7</b> was prepared according to general procedure 6 from intermediate <b>36</b> (421 mg, 1.47 mmol, 1.1 equiv) and <i>N</i>′-[5-bromo-4-{[<i>tert</i>-butyl(dimethyl)silyl]oxymethyl]-2-pyridyl}-<i>N</i>,<i>N</i>-dimethyl-formamidine (<b>68</b>, 500 mg, 1.34 mmol, 1.0 equiv). Purification by column chromatography on silica gel (CH<sub>2</sub>Cl<sub>2</sub>/CH<sub>3</sub>OH 1:0 → 9:1) gave compound <b>7</b> (163 mg, 437 μmol, 33%) as a colorless solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 9.08 (s, 1 H), 6.45 (s, 1 H), 4.81 (br s, 2 H), 4.62 (s, 2 H), 3.87–3.80 (m, 8 H), 3.80–3.72 (m, 8 H). <sup>13</sup>C{<sup>1</sup>H} NMR (101 MHz, CDCl<sub>3</sub>): δ 170.3 (s, 1 C), 164.4 (s, 2 C), 160.2 (s, 1 C), 152.9 (s, 1 C), 151.1 (s, 1 C), 122.1 (s, 1 C), 108.4 (s, 1 C), 66.7 (s, 4 C), 64.4 (s, 1 C), 43.8 (s, 4 C). ESI-HRMS (<i>m</i>/<i>z</i>): [M + H]<sup>+</sup> calcd for C<sub>17</sub>H<sub>24</sub>N<sub>7</sub>O<sub>3</sub> 374.1935, found 374.1948. HPLC: <i>t</i><sub>R</sub> = 5.59 min (99.9% purity).</div></div><div id="sec4_1_14" class="NLM_sec NLM_sec_level_3"><div id="ac_i37" class="anchor-spacer"></div><h4 class="article-section__title" id="_i37"> 5-[4,6-Bis(morpholin-4-yl)-1,3,5-triazin-2-yl]-4-(dimethoxymethyl)pyridin-2-amine (<b>8</b>)</h4><div class="NLM_p last"><b>8</b> was prepared from intermediate <b>36</b> (211 mg, 738 μmol, 1.1 equiv) and <i>tert</i>-butyl <i>N</i>-[5-bromo-4-(dimethoxymethyl)pyridin-2-yl]-<i>N</i>-[(<i>tert</i>-butoxy)carbonyl]carbamate (<b>70</b>, 301 mg, 673 μmol, 1.0 equiv) following steps 1 and 2 of general procedure 6. Step 3<i>.</i>: The residue was dissolved in CH<sub>2</sub>Cl<sub>2</sub> (5 mL), and trifluoroacetic acid (500 μL, 6.53 mmol, 9.7 equiv) was added at 0 °C. The reaction mixture was stirred at room temperature for 6 h. Then the reaction was quenched with 2 M aq NaOH-solution and diluted with CH<sub>2</sub>Cl<sub>2</sub>. The organic layer was separated, and the aqueous layer was extracted with CH<sub>2</sub>Cl<sub>2</sub> (2×). The combined organic layers were dried over Na<sub>2</sub>SO<sub>4</sub> and filtered, and the solvent was evaporated under reduced pressure. Purification by column chromatography on silica gel (cyclohexane/EtOAc 1:0 →0:1) gave compound <b>8</b> (32.0 mg, 76.7 μmol, 11%) as a yellowish solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.70 (s, 1 H), 6.81 (s, 1 H), 6.41 (s, 1 H), 4.70 (br s, 2 H), 3.95–3.80 (m, 8 H), 3.78–3.67 (m, 8 H), 3.32 (s, 6 H). <sup>13</sup>C{<sup>1</sup>H} NMR (101 MHz, CDCl<sub>3</sub>): δ 171.3 (s, 1 C), 164.9 (s, 2 C), 159.6 (s, 1 C), 151.7 (s, 1 C), 147.7 (s, 1 C), 123.3 (s, 1 C), 105.6 (s, 1 C), 99.8 (s, 1 C), 67.0 (s, 4 C), 54.0 (s, 2 C), 43.8 (s, 4 C). ESI-HRMS (<i>m</i>/<i>z</i>): [M + H]<sup>+</sup> calcd for C<sub>19</sub>H<sub>28</sub>N<sub>7</sub>O<sub>4</sub> 418.2197, found 418.2188. HPLC: <i>t</i><sub>R</sub> = 6.41 min (96.1% purity).</div></div><div id="sec4_1_15" class="NLM_sec NLM_sec_level_3"><div id="ac_i38" class="anchor-spacer"></div><h4 class="article-section__title" id="_i38"> 5-[4,6-Bis(morpholin-4-yl)-1,3,5-triazin-2-yl]-4-methoxypyridin-2-amine (<b>9</b>)</h4><div class="NLM_p last">Step 1: <i>tert</i>-Butyl <i>N</i>-(5-bromo-4-methoxypyridin-2-yl)-<i>N</i>-[(<i>tert</i>-butoxy)carbonyl]carbamate (<b>71</b>, 910 mg, 2.26 mmol, 1.0 equiv), tetrahydroxydiboron (607 mg, 6.77 mmol, 3.0 equiv), KOAc (665 mg, 6.77 mmol, 3.0 equiv), 2-dicyclohexylphosphino-2′,4′,6′-triisopropylbiphenyl (XPhos, 108 mg, 226 μmol, 0.10 equiv), and chloro(2-dicyclohexylphosphino-2′,4′,6′-triisopropyl-1,1′-biphenyl)[2-(2′-amino-1,1′-biphenyl)]palladium(II) (XPhos Pd G2, 89.0 mg, 113 mmol, 0.05 equiv) were charged in a flask, and abs ethanol (23 mL) was added under nitrogen atmosphere. The resulting mixture was heated at 80 °C for 1 h. Step 2: The mixture was allowed to cool down to room temperature and intermediate <b>36</b> (643 mg, 2.26 mmol, 1.0 equiv) was added, followed by K<sub>3</sub>PO<sub>4</sub> (1.44 g, 6.77 mmol, 3.0 equiv). The resulting reaction mixture was stirred at 80 °C for 3.5 h. An aq satd NH<sub>4</sub>Cl solution was added to quench the reaction, and the mixture was extracted with EtOAc (3×). The combined organic layers were washed with brine (2×), dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered, and reduced to dryness under reduced pressure. Step 3<i>:</i> The above residue was dissolved in dioxane (2 mL), and a 3 M aq HCl solution (3.0 mL, 12.0 mmol, 5.3 equiv) was added. The reaction mixture was stirred at 60 °C for 2 h. The mixture was then diluted with deionized H<sub>2</sub>O, basified to pH = 10, and extracted with CH<sub>2</sub>Cl<sub>2</sub> (3×). The combined organic layers were dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered, and reduced to dryness under reduced pressure. Purification by column chromatography on silica gel (CH<sub>2</sub>Cl<sub>2</sub>/CH<sub>3</sub>OH 1:0 → 95:5) gave compound <b>9</b> (336 mg, 900 μmol, 40%) as a colorless solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.65 (s, 1 H), 6.01 (s, 1 H), 4.75 (br s, 2 H), 3.91–3.78 (m, 11 H), 3.78–3.69 (m, 8 H). <sup>13</sup>C{<sup>1</sup>H} NMR (101 MHz, CDCl<sub>3</sub>): δ 169.8 (s, 1 C), 166.7 (s, 1 C), 165.0 (s, 2 C), 161.3 (s, 1 C), 152.2 (s, 1 C), 115.4 (s, 1 C), 90.2 (s, 1 C), 67.0 (s, 4 C), 55.6 (s, 1 C), 43.7 (s, 4 C). ESI-HRMS (<i>m</i>/<i>z</i>): [M + H]<sup>+</sup> calcd for C<sub>17</sub>H<sub>24</sub>N<sub>7</sub>O<sub>3</sub> 374.1935, found 374.1924. HPLC: <i>t</i><sub>R</sub> = 5.67 min (>95.0% purity).</div></div><div id="sec4_1_16" class="NLM_sec NLM_sec_level_3"><div id="ac_i39" class="anchor-spacer"></div><h4 class="article-section__title" id="_i39"> 4-(Difluoromethyl)-5-{4-[(3<i>R</i>)-3-methylmorpholin-4-yl]-6-(morpholin-4-yl)-1,3,5-triazin-2-yl}pyridin-2-amine (<b>10</b>)</h4><div class="NLM_p last"><b>10</b> was prepared according to general procedure 4 from intermediate <b>37</b> (250 mg, 833 μmol, 1.0 equiv) and boronic acid pinacol ester <b>64</b> (298 mg, 917 μmol, 1.1 equiv). Purification by column chromatography on silica gel (cyclohexane/EtOAc 1:0 → 1:3) gave compound <b>10</b> (248 mg, 609 μmol, 73%) as a colorless solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 9.03 (s, 1 H), 7.68 (t, <sup>2</sup><i>J</i><sub>H,F</sub> = 55 Hz, 1 H), 6.84 (s, 1 H), 4.84 (br s, 2 H), 4.79–4.67 (m, 1 H), 4.46–4.43 (m, 1 H), 3.97 (dd, <i>J</i><sub>H,H</sub> = 11, 3.6 Hz, 1 H), 3.90–3.63 (m, 10 H), 3.52 (td, <i>J</i><sub>H,H</sub> = 12, 2.8 Hz, 1 H), 3.28 (td, <i>J</i><sub>H,H</sub> = 13, 3.5 Hz, 1 H), 1.32 (d, <sup>3</sup><i>J</i><sub>H,H</sub> = 6.9 Hz, 3 H). <sup>13</sup>C{<sup>1</sup>H} NMR (101 MHz, CDCl<sub>3</sub>): δ 169.3 (s, 1 C), 164.8 (s, 1 C), 164.4 (s, 1 C), 160.3 (s, 1 C), 152.4 (s, 1 C), 143.6 (t, <sup>2</sup><i>J</i><sub>C,F</sub> = 22 Hz, 1 C), 121.4 (t, <sup>3</sup><i>J</i><sub>C,F</sub> = 4.7 Hz, 1 C), 111.4 (t, <sup>1</sup><i>J</i><sub>C,F</sub> = 239 Hz, 1 C), 104.1 (t, <sup>3</sup><i>J</i><sub>C,F</sub> = 7.8 Hz, 1 C), 71.1 (s, 1 C), 67.1 (s, 1 C), 66.9 (br s, 2 C), 46.5 (s, 1 C), 43.7 (br s, 2 C), 38.6 (s, 1 C), 14.4 (s, 1 C). ESI-HRMS (<i>m</i>/<i>z</i>): [M + H]<sup>+</sup> calcd for C<sub>18</sub>H<sub>24</sub>F<sub>2</sub>N<sub>7</sub>O<sub>2</sub> 408.1954, found 408.1948. HPLC: <i>t</i><sub>R</sub> = 7.73 min (99.9% purity).</div></div><div id="sec4_1_17" class="NLM_sec NLM_sec_level_3"><div id="ac_i40" class="anchor-spacer"></div><h4 class="article-section__title" id="_i40"> 4-(Difluoromethyl)-5-[4-(morpholin-4-yl)-6-{8-oxa-3-azabicyclo[3.2.1]octan-3-yl}-1,3,5-triazin-2-yl]pyridin-2-amine (<b>11</b>)</h4><div class="NLM_p last"><b>11</b> was prepared according to general procedure 4 from intermediate <b>38</b> (93.0 mg, 299 μmol, 1.0 equiv) and boronic acid pinacol ester <b>64</b> (99.0 mg, 305 μmol, 1.0 equiv). Purification by column chromatography on silica gel (CH<sub>2</sub>Cl<sub>2</sub>/CH<sub>3</sub>OH 40:1) gave compound <b>11</b> (39.1 mg, 93.2 μmol, 31%) as a colorless solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 9.02 (s, 1 H), 7.67 (t, <sup>2</sup><i>J</i><sub>H,F</sub> = 55 Hz, 1 H), 6.83 (s, 1 H), 4.84 (br s, 2 H), 4.50–4.26 (m, 4 H), 3.91–3.68 (m, 8 H), 3.29–3.13 (m, 2 H), 1.99–1.89 (m, 2 H), 1.82–1.72 (m, 2 H). <sup>13</sup>C{<sup>1</sup>H} NMR (101 MHz, CDCl<sub>3</sub>): δ 169.1 (s, 1 C), 165.9 (s, 1 C), 164.7 (s, 1 C), 160.2 (s, 1 C), 152.5 (s, 1 C), 143.7 (t, <sup>2</sup><i>J</i><sub>C,F</sub> = 22 Hz, 1 C), 121.6 (t, <sup>3</sup><i>J</i><sub>C,F</sub> = 3.7 Hz, 1 C), 111.4 (t, <sup>1</sup><i>J</i><sub>C,F</sub> = 238 Hz, 1 C), 104.1 (t, <sup>3</sup><i>J</i><sub>C,F</sub> = 7.5 Hz, 1 C), 74.0 (br s, 2 C), 66.9 (s, 2 C), 49.5 (s, 1 C), 49.2 (s, 1 C), 43.8 (br s, 2 C), 27.8 (br s, 2 C). ESI-HRMS (<i>m</i>/<i>z</i>): [M + H]<sup>+</sup> calcd for C<sub>19</sub>H<sub>24</sub>F<sub>2</sub>N<sub>7</sub>O<sub>2</sub> 420.1954, found 420.1945. HPLC: <i>t</i><sub>R</sub> = 7.34 min (99.6% purity).</div></div><div id="sec4_1_18" class="NLM_sec NLM_sec_level_3"><div id="ac_i41" class="anchor-spacer"></div><h4 class="article-section__title" id="_i41"> 4-(Difluoromethyl)-5-[4-(morpholin-4-yl)-6-{3-oxa-8-azabicyclo[3.2.1]octan-8-yl}-1,3,5-triazin-2-yl]pyridin-2-amine (<b>12</b>)</h4><div class="NLM_p last"><b>12</b> was prepared according to general procedure 4 from intermediate <b>39</b> (150 mg, 482 μmol, 1.0 equiv) and boronic acid pinacol ester <b>64</b> (160 mg, 492 μmol, 1.0 equiv). Purification by column chromatography on silica gel (cyclohexane/EtOAc 2:3 → 3:7) gave compound <b>12</b> (115 mg, 274 μmol, 56%) as a colorless solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 9.02 (s, 1 H), 7.68 (t, <sup>2</sup><i>J</i><sub>H,F</sub> = 55 Hz, 1 H), 6.83 (s, 1 H), 4.94 (br s, 2 H), 4.74–4.60 (m, 2 H), 3.90–3.58 (m, 12 H), 2.12–1.93 (m, 4 H). <sup>13</sup>C{<sup>1</sup>H} NMR (101 MHz, CDCl<sub>3</sub>): δ 169.6 (s, 1 C), 164.9 (s, 1 C), 163.0 (s, 1 C), 160.2 (s, 1 C), 152.4 (s, 1 C), 143.7 (t, <sup>2</sup><i>J</i><sub>C,F</sub> = 23 Hz, 1 C), 121.5 (br s, 1 C), 111.5 (t, <sup>1</sup><i>J</i><sub>C,F</sub> = 238 Hz, 1 C), 104.1 (t, <sup>3</sup><i>J</i><sub>C,F</sub> = 7.9 Hz, 1 C), 72.0 (s, 1 C), 71.7 (s, 1 C), 66.9 (s, 2 C), 55.1 (s, 1 C), 54.6 (s, 1 C), 43.7 (s, 2 C), 27.1 (s, 1 C), 27.0 (s, 1 C). ESI-HRMS (<i>m</i>/<i>z</i>): [M + H]<sup>+</sup> calcd for C<sub>19</sub>H<sub>24</sub>F<sub>2</sub>N<sub>7</sub>O<sub>2</sub> 420.1954, found 420.1944. HPLC: <i>t</i><sub>R</sub> = 7.50 min (96.3% purity).</div></div><div id="sec4_1_19" class="NLM_sec NLM_sec_level_3"><div id="ac_i42" class="anchor-spacer"></div><h4 class="article-section__title" id="_i42"> 5-{4,6-Bis[(3<i>R</i>)-3-methylmorpholin-4-yl]-1,3,5-triazin-2-yl}-4-(difluoromethyl)pyridin-2-amine (<b>13</b>)</h4><div class="NLM_p last"><b>13</b> was prepared according to general procedure 5 from intermediate <b>41</b> (250 mg, 796 μmol, 1.0 equiv) and boronic acid pinacol ester <b>64</b> (285 mg, 876 μmol, 1.1 equiv). Purification by column chromatography on silica gel (cyclohexane/EtOAc 1:0 → 3:1) gave compound <b>13</b> (327 mg, 776 μmol, 97%) as a colorless solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 9.03 (s, 1 H), 7.69 (t, <sup>2</sup><i>J</i><sub>H,F</sub> = 55 Hz, 1 H), 6.82 (s, 1 H), 5.00 (br s, 2 H), 4.81–4.62 (m, 2 H), 4.48–4.29 (m, 2 H), 3.96 (dd, <i>J</i><sub>H,H</sub> = 11, 3.5 Hz, 2 H), 3.76 (d, <i>J</i><sub>H,H</sub> = 11 Hz, 2 H), 3.67 (dd, <i>J</i><sub>H,H</sub> = 11, 3.3 Hz, 2 H), 3.52 (td, <i>J</i><sub>H,H</sub> = 12, 3.0 Hz, 2 H), 3.34–3.23 (m, 2 H), 1.32 (t, <sup>3</sup><i>J</i><sub>H,H</sub> = 6.9 Hz, 6 H). <sup>13</sup>C{<sup>1</sup>H} NMR (101 MHz, CDCl<sub>3</sub>): δ 169.3 (s, 1C), 164.5 (br s, 2 C), 160.2 (s, 1 C), 152.4 (s, 1C), 143.6 (t, <sup>2</sup><i>J</i><sub>C,F</sub> = 22 Hz, 1 C), 121.6 (t, <sup>3</sup><i>J</i><sub>C,F</sub> = 4.8 Hz, 1 C), 111.5 (t, <sup>1</sup><i>J</i><sub>C,F</sub> = 239 Hz, 1 C), 104.1 (t, <sup>3</sup><i>J</i><sub>C,F</sub> = 7.9 Hz, 1 C), 71.2 (s, 2 C), 67.1 (s, 2 C), 46.5 (s, 2 C), 38.6 (s, 2 C), 14.4 (br s, 2 C). ESI-HRMS (<i>m</i>/<i>z</i>): [M + H]<sup>+</sup> calcd for C<sub>19</sub>H<sub>26</sub>F<sub>2</sub>N<sub>7</sub>O<sub>2</sub> 422.2111, found 422.2101. HPLC: <i>t</i><sub>R</sub> = 8.28 min (99.2% purity).</div></div><div id="sec4_1_20" class="NLM_sec NLM_sec_level_3"><div id="ac_i43" class="anchor-spacer"></div><h4 class="article-section__title" id="_i43"> 5-[4,6-Bis({8-oxa-3-azabicyclo[3.2.1]octan-3-yl})-1,3,5-triazin-2-yl]-4-(difluoromethyl)pyridin-2-amine (<b>14</b>)</h4><div class="NLM_p last"><b>14</b> was prepared according to general procedure 4 from intermediate <b>42</b> (100 mg, 296 μmol, 1.0 equiv) and boronic acid pinacol ester <b>64</b> (106 mg, 326 μmol, 1.1 equiv). Purification by column chromatography on silica gel (cyclohexane/EtOAc 3:7) gave compound <b>14</b> (118 mg, 265 μmol, 89%) as a colorless solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 9.03 (s, 1 H), 7.89 (t, <sup>2</sup><i>J</i><sub>H,F</sub> = 55 Hz, 1 H), 6.83 (s, 1 H), 4.83 (br s, 2 H), 4.50–4.23 (m, 8 H), 3.27–3.11 (m, 4 H), 2.00–1.88 (m, 4 H), 1.82–1.71 (m, 4 H). <sup>13</sup>C{<sup>1</sup>H} NMR (101 MHz, CDCl<sub>3</sub>): δ 168.8 (s, 1 C), 165.5 (s, 2 C), 160.0 (s, 1 C), 152.3 (s, 1 C), 143.5 (t, 1 C), 121.5 (br s, 1 C), 111.3 (t, <sup>1</sup><i>J</i><sub>C,F</sub> = 239 Hz, 1 C), 104.0 (t, <sup>3</sup><i>J</i><sub>C,F</sub> = 7.9 Hz, 1 C), 73.9 (s, 4 C), 49.3 (s, 2 C), 49.1 (s, 2 C), 27.7 (s, 4 C). ESI-HRMS (<i>m</i>/<i>z</i>): [M + H]<sup>+</sup> calcd for C<sub>21</sub>H<sub>26</sub>F<sub>2</sub>N<sub>7</sub>O<sub>2</sub> 446.2111, found 446.2100. HPLC: <i>t</i><sub>R</sub> = 7.71 min (98.4% purity).</div></div><div id="sec4_1_21" class="NLM_sec NLM_sec_level_3"><div id="ac_i44" class="anchor-spacer"></div><h4 class="article-section__title" id="_i44"> 5-{4,6-Bis[(1<i>S</i>,4<i>S</i>)-2-oxa-5-azabicyclo[2.2.1]heptan-5-yl]-1,3,5-triazin-2-yl}-4-(difluoromethyl)pyridin-2-amine (<b>15</b>)</h4><div class="NLM_p last"><b>15</b> was prepared according to general procedure 5 from intermediate <b>44</b> (200 mg, 645 μmol, 1.0 equiv) and boronic acid pinacol ester <b>64</b> (231 mg, 710 μmol, 1.1 equiv). Purification by column chromatography on silica gel (cyclohexane/EtOAc 1:0 → 2:3) gave compound <b>15</b> (191 mg, 458 μmol, 71%) as a colorless solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 9.12–9.01 (m, 1 H), 8.05–7.55 (m, 1 H), 6.83 (br s, 1 H), 5.12–4.99 (m, 2 H), 4.87 (br s, 2 H), 4.74–4.62 (m, 2 H), 3.95–3.83 (m, 4 H), 3.67–3.46 (m, 4 H), 2.00–1.85 (m, 4 H). <sup>13</sup>C{<sup>1</sup>H} NMR (101 MHz, CDCl<sub>3</sub>): δ 169.5–168.3 (m, 1 C), 163.6–162.8 (m, 2 C), 160.2 (s, 1 C), 152.5–152.2 (m, 1 C), 144.4–143.4 (m, 1 C), 121.7–120.8 (m, 1 C), 111.5 (t, <sup>1</sup><i>J</i><sub>C,F</sub> = 239 Hz, 1 C), 104.1 (t, <sup>3</sup><i>J</i><sub>C,F</sub> = 7.8 Hz, 1 C), 76.5 (s, 1 C), 76.4 (s, 1 C), 74.2 (s, 1 C), 73.9 (s, 1 C), 56.7 (s, 1 C), 56.3 (s, 1 C), 55.1 (s, 2 C), 36.8 (s, 1 C), 36.6 (s, 1 C). ESI-HRMS (<i>m</i>/<i>z</i>): [M + H]<sup>+</sup> calcd for C<sub>19</sub>H<sub>22</sub>F<sub>2</sub>N<sub>7</sub>O<sub>2</sub> 418.1798, found 418.1787. HPLC: <i>t</i><sub>R</sub> = 6.55 min (96.7% purity). Compound <b>15</b> exists as a mixture of rotamers.</div></div><div id="sec4_1_22" class="NLM_sec NLM_sec_level_3"><div id="ac_i45" class="anchor-spacer"></div><h4 class="article-section__title" id="_i45"> 5-{4,6-Bis[(1<i>R</i>,4<i>R</i>)-2-oxa-5-azabicyclo[2.2.1]heptan-5-yl]-1,3,5-triazin-2-yl}-4-(difluoromethyl)pyridin-2-amine (<b>16</b>)</h4><div class="NLM_p last"><b>16</b> was prepared according to general procedure 5 from intermediate <b>45</b> (200 mg, 645 μmol, 1.0 equiv) and boronic acid pinacol ester <b>64</b> (231 mg, 710 μmol, 1.1 equiv). Purification by column chromatography on silica gel (cyclohexane/EtOAc 1:0 → 2:3) gave compound <b>16</b> (123 mg, 295 μmol, 46%) as a colorless solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 9.13–9.02 (m, 1 H), 8.05–7.51 (m, 1 H), 6.84 (br s, 1 H), 5.10–5.03 (m, 2 H), 4.84 (br s, 2 H), 4.72–4.66 (m, 2 H), 3.95–3.82 (m, 4 H), 3.70–3.42 (m, 4 H), 2.00–1.87 (m, 4 H). <sup>13</sup>C{<sup>1</sup>H} NMR (101 MHz, CDCl<sub>3</sub>): δ 169.5–168.5 (m, 1 C), 163.5–163.0 (m, 2 C), 160.2 (br s, 1 C), 152.3 (t, <sup>3</sup><i>J</i><sub>C,F</sub> = 8.8 Hz, 1 C), 144.3–143.3 (m, 1 C), 121.6–120.9 (m, 1 C), 111.5 (t, <sup>1</sup><i>J</i><sub>C,F</sub> = 239 Hz, 1 C), 104.1 (t, <sup>3</sup><i>J</i><sub>C,F</sub> = 8.0 Hz, 1 C), 76.5–76.3 (m, 2 C), 74.3–73.9 (m, 2 C), 56.9–56.0 (m, 2 C), 55.1 (s, 2 C), 36.9–36.4 (m, 2 C). ESI-HRMS (<i>m</i>/<i>z</i>): [M + H]<sup>+</sup> calcd for C<sub>19</sub>H<sub>22</sub>F<sub>2</sub>N<sub>7</sub>O<sub>2</sub> 418.1798, found 418.1788. HPLC: <i>t</i><sub>R</sub> = 6.57 min (98.4% purity). Compound <b>16</b> exists as a mixture of rotamers.</div></div><div id="sec4_1_23" class="NLM_sec NLM_sec_level_3"><div id="ac_i46" class="anchor-spacer"></div><h4 class="article-section__title" id="_i46"> 5-[4,6-Bis({3-oxa-6-azabicyclo[3.1.1]heptan-6-yl})-1,3,5-triazin-2-yl]-4-(difluoromethyl)pyridin-2-amine (<b>17</b>)</h4><div class="NLM_p last"><b>17</b> was prepared according to general procedure 4 from intermediate <b>46</b> (40.0 mg, 129 μmol, 1.0 equiv) and boronic acid pinacol ester <b>64</b> (50.0 mg, 155 μmol, 1.2 equiv). Purification by column chromatography on silica gel (cyclohexane/EtOAc 1:4 → 0:1) gave compound <b>17</b> (35.2 mg, 84.3 μmol, 65%) as a colorless solid. <sup>1</sup>H NMR (400 MHz, (CD<sub>3</sub>)<sub>2</sub>SO): δ 8.91 (br s, 1 H), 7.84 (t, <sup>2</sup><i>J</i><sub>H,F</sub> = 55 Hz, 1 H), 6.90 (br s, 2 H), 6.75 (s, 1 H), 4.44 (br s, 2 H), 4.32 (br s, 2 H), 4.20–4.10 (m, 4 H), 3.80–3.70 (m, 4 H), 2.72–2.63 (m, 2 H), 1.79 (d, <i>J</i><sub>H,H</sub> = 8.2 Hz, 2 H). <sup>13</sup>C{<sup>1</sup>H} NMR (101 MHz, (CD<sub>3</sub>)<sub>2</sub>SO): δ 168.9 (s, 1 C), 165.6 (s, 1 C), 165.5 (s, 1 C), 161.8 (s, 1 C), 152.3 (s, 1 C), 142.4 (t, <sup>2</sup><i>J</i><sub>C,F</sub> = 20 Hz, 1 C), 117.2 (br s, 1 C), 111.7 (t, <sup>1</sup><i>J</i><sub>C,F</sub> = 237 Hz, 1 C), 103.2 (t, <sup>3</sup><i>J</i><sub>C,F</sub> = 9.0 Hz, 1 C), 64.9 (s, 2 C), 64.6 (s, 2 C), 61.3 (s, 2 C), 61.0 (s, 2 C), 27.7 (s, 2 C). ESI-HRMS (<i>m</i>/<i>z</i>): [M + H]<sup>+</sup> calcd for C<sub>19</sub>H<sub>22</sub>F<sub>2</sub>N<sub>7</sub>O<sub>2</sub> 418.1798, found 418.1784. HPLC: <i>t</i><sub>R</sub> = 6.44 min (99.7% purity).</div></div><div id="sec4_1_24" class="NLM_sec NLM_sec_level_3"><div id="ac_i47" class="anchor-spacer"></div><h4 class="article-section__title" id="_i47"> 5-{4,6-Bis[(3<i>R</i>)-3-ethylmorpholin-4-yl]-1,3,5-triazin-2-yl}-4-(difluoromethyl)pyridin-2-amine (<b>18</b>)</h4><div class="NLM_p last"><b>18</b> was prepared according to general procedure 4 from intermediate <b>47</b> (303 mg, 897 μmol, 1.0 equiv) and boronic acid pinacol ester <b>64</b> (288 mg, 886 μmol, 1.0 equiv). Purification by column chromatography on silica gel (cyclohexane/EtOAc 1:0 → 7:3) gave compound <b>18</b> (245 mg, 545 μmol, 61%) as a colorless solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 9.03 (s, 1 H), 7.69 (t, <sup>2</sup><i>J</i><sub>H,F</sub> = 55 Hz, 1 H), 6.84 (s, 1 H), 4.84 (br s, 2 H), 4.63–4.36 (m, 4 H), 3.98–3.83 (m, 4 H), 3.64–3.46 (m, 4 H), 3.30–3.13 (m, 2 H), 1.93–1.71 (m, 4 H), 0.94 (t, <sup>3</sup><i>J</i><sub>H,H</sub> = 7.4 Hz, 6 H). <sup>13</sup>C{<sup>1</sup>H} NMR (101 MHz, CDCl<sub>3</sub>): δ 169.2 (s, 1 C), 164.7 (s, 2 C), 160.2 (s, 1 C), 152.4 (s, 1 C), 143.6 (t, <sup>2</sup><i>J</i><sub>C,F</sub> = 22 Hz, 1 C), 121.7 (t, <sup>3</sup><i>J</i><sub>C,F</sub> = 4.7 Hz, 1 C), 111.4 (t, <sup>1</sup><i>J</i><sub>C,F</sub> = 239 Hz, 1 C), 104.1 (t, <sup>3</sup><i>J</i><sub>C,F</sub> = 7.6 Hz, 1 C), 68.5 (s, 2 C), 67.1 (s, 2 C), 52.2 (s, 2 C), 39.0 (br s, 2 C), 21.6 (s, 2 C), 11.0 (br s, 2 C). ESI-HRMS (<i>m</i>/<i>z</i>): [M + H]<sup>+</sup> calcd for C<sub>21</sub>H<sub>30</sub>F<sub>2</sub>N<sub>7</sub>O<sub>2</sub> 450.2424, found 450.2412. HPLC: <i>t</i><sub>R</sub> = 9.18 min (99.1% purity).</div></div><div id="sec4_1_25" class="NLM_sec NLM_sec_level_3"><div id="ac_i48" class="anchor-spacer"></div><h4 class="article-section__title" id="_i48"> 5-{4,6-Bis[(3<i>R</i>,5<i>S</i>)-3,5-dimethylmorpholin-4-yl]-1,3,5-triazin-2-yl}-4-(difluoromethyl)pyridin-2-amine (<b>19</b>)</h4><div class="NLM_p last"><b>19</b> was prepared according to general procedure 5 from intermediate <b>48</b> (200 mg, 585 μmol, 1.0 equiv) and boronic acid pinacol ester <b>64</b> (191 mg, 587 μmol, 1.0 equiv). Purification by column chromatography on silica gel (cyclohexane/EtOAc 1:0 → 1:1) gave compound <b>19</b> (110 mg, 245 μmol, 42%) as a colorless solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 9.10 (s, 1 H), 7.79 (t, <sup>2</sup><i>J</i><sub>H,F</sub> = 55 Hz, 1 H), 6.84 (s, 1 H), 4.82 (br s, 2 H), 4.64–4.53 (m, 4 H), 3.87–3.79 (m, 4 H), 3.69–3.61 (m, 4 H), 1.38 (d, <sup>3</sup><i>J</i><sub>H,H</sub> = 6.9 Hz, 12 H). <sup>13</sup>C{<sup>1</sup>H} NMR (101 MHz, CDCl<sub>3</sub>): δ 169.1 (s, 1 C), 164.1 (s, 2 C), 160.1 (s, 1 C), 152.6 (s, 1 C), 143.8 (t, <sup>2</sup><i>J</i><sub>C,F</sub> = 22 Hz, 1 C), 121.8 (t, <sup>3</sup><i>J</i><sub>C,F</sub> = 4.8 Hz, 1 C), 111.5 (t, <sup>1</sup><i>J</i><sub>C,F</sub> = 239 Hz, 1 C), 104.0 (t, <sup>3</sup><i>J</i><sub>C,F</sub> = 8.1 Hz, 1 C), 71.6 (s, 4 C), 45.9 (s, 4 C), 19.3 (s, 4 C). ESI-HRMS (<i>m</i>/<i>z</i>): [M + H]<sup>+</sup> calcd for C<sub>21</sub>H<sub>30</sub>F<sub>2</sub>N<sub>7</sub>O<sub>2</sub> 450.2424, found 450.2410. HPLC: <i>t</i><sub>R</sub> = 9.48 min (97.1% purity).</div></div><div id="sec4_1_26" class="NLM_sec NLM_sec_level_3"><div id="ac_i49" class="anchor-spacer"></div><h4 class="article-section__title" id="_i49"> 5-{4,6-Bis[(3<i>R</i>,5<i>R</i>)-3,5-dimethylmorpholin-4-yl]-1,3,5-triazin-2-yl}-4-(difluoromethyl)pyridin-2-amine (<b>20</b>)</h4><div class="NLM_p last"><b>20</b> was prepared according to general procedure 5 from intermediate <b>49</b> (247 mg, 723 μmol, 1.0 equiv) and boronic acid pinacol ester <b>64</b> (235 mg, 723 μmol, 1.0 equiv). Purification by column chromatography on silica gel (cyclohexane/EtOAc 1:0 → 3:2) gave compound <b>20</b> (156 mg, 347 μmol, 48%) as a colorless solid. <sup>1</sup>H NMR (400 MHz, (CD<sub>3</sub>)<sub>2</sub>SO): δ 8.91 (s, 1 H), 7.86 (t, <sup>2</sup><i>J</i><sub>H,F</sub> = 55 Hz, 1 H), 6.83 (br s, 2 H), 6.76 (s, 1 H), 4.36–4.24 (m, 4 H), 4.13 (dd, <sup>2</sup><i>J</i><sub>H,H</sub> = 11 Hz, <sup>3</sup><i>J</i><sub>H,H</sub> = 3.4 Hz, 4 H), 3.69 (dd, <sup>2</sup><i>J</i><sub>H,H</sub> = 11 Hz, <sup>3</sup><i>J</i><sub>H,H</sub> = 2.2 Hz, 4 H), 1.38 (d, <sup>3</sup><i>J</i><sub>H,H</sub> = 6.6 Hz, 12 H). <sup>13</sup>C{<sup>1</sup>H} NMR (101 MHz, CDCl<sub>3</sub>): δ 168.6 (s, 1 C), 163.6 (s, 2 C), 160.0 (s, 1 C), 152.5 (s, 1 C), 143.8 (t, <sup>2</sup><i>J</i><sub>C,F</sub> = 22 Hz, 1 C), 121.4 (t, <sup>3</sup><i>J</i><sub>C,F</sub> = 4.6 Hz, 1 C), 111.3 (t, <sup>1</sup><i>J</i><sub>C,F</sub> = 239 Hz, 1 C), 103.8 (t, <sup>3</sup><i>J</i><sub>C,F</sub> = 8.0 Hz, 1 C), 67.8 (s, 4 C), 48.1 (s, 4 C), 19.8 (s, 4 C). ESI-HRMS (<i>m</i>/<i>z</i>): [M + H]<sup>+</sup> calcd for C<sub>21</sub>H<sub>30</sub>F<sub>2</sub>N<sub>7</sub>O<sub>2</sub> 450.2424, found 450.2415. HPLC: <i>t</i><sub>R</sub> = 8.99 min (99.8% purity).</div></div><div id="sec4_1_27" class="NLM_sec NLM_sec_level_3"><div id="ac_i50" class="anchor-spacer"></div><h4 class="article-section__title" id="_i50"> 5-{4,6-Bis[(3<i>S</i>,5<i>S</i>)-3,5-dimethylmorpholin-4-yl]-1,3,5-triazin-2-yl}-4-(difluoromethyl)pyridin-2-amine (<b>21</b>)</h4><div class="NLM_p last"><b>21</b> was prepared according to general procedure 5 from intermediate <b>50</b> (232 mg, 679 μmol, 1.0 equiv) and boronic acid pinacol ester <b>64</b> (221 mg, 680 μmol, 1.0 equiv). Purification by column chromatography on silica gel (cyclohexane/EtOAc 1:0 → 3:2) gave compound <b>21</b> (171 mg, 380 μmol, 56%) as a colorless solid. <sup>1</sup>H NMR (400 MHz, (CD<sub>3</sub>)<sub>2</sub>SO): δ 8.91 (s, 1 H), 7.86 (t, <sup>2</sup><i>J</i><sub>H,F</sub> = 55 Hz, 1 H), 6.83 (br s, 2 H), 6.76 (s, 1 H), 4.36–4.24 (m, 4 H), 4.13 (dd, <sup>2</sup><i>J</i><sub>H,H</sub> = 11 Hz, <sup>3</sup><i>J</i><sub>H,H</sub> = 3.0 Hz, 4 H), 3.69 (dd, <sup>2</sup><i>J</i><sub>H,H</sub> = 11 Hz, <sup>3</sup><i>J</i><sub>H,H</sub> = 1.9 Hz, 4 H), 1.38 (d, <sup>3</sup><i>J</i><sub>H,H</sub> = 6.6 Hz, 12 H). <sup>13</sup>C{<sup>1</sup>H} NMR (101 MHz, CDCl<sub>3</sub>): δ 168.7 (s, 1 C), 163.8 (s, 2 C), 160.1 (s, 1 C), 152.6 (s, 1 C), 143.7 (t, <sup>2</sup><i>J</i><sub>C,F</sub> = 22 Hz, 1 C), 121.6 (t, <sup>3</sup><i>J</i><sub>C,F</sub> = 4.7 Hz, 1 C), 111.5 (t, <sup>1</sup><i>J</i><sub>C,F</sub> = 239 Hz, 1 C), 104.0 (t, <sup>3</sup><i>J</i><sub>C,F</sub> = 8.0 Hz, 1 C), 67.8 (s, 4 C), 48.1 (s, 4 C), 19.9 (s, 4 C). ESI-HRMS (<i>m</i>/<i>z</i>): [M + H]<sup>+</sup> calcd for C<sub>21</sub>H<sub>30</sub>F<sub>2</sub>N<sub>7</sub>O<sub>2</sub> 450.2424, found 450.2413. HPLC: <i>t</i><sub>R</sub> = 9.00 min (99.5% purity).</div></div><div id="sec4_1_28" class="NLM_sec NLM_sec_level_3"><div id="ac_i51" class="anchor-spacer"></div><h4 class="article-section__title" id="_i51"> 5-{4,6-Bis[(2<i>R</i>,6<i>S</i>)-2,6-dimethylmorpholin-4-yl]-1,3,5-triazin-2-yl}-4-(difluoromethyl)pyridin-2-amine (<b>22</b>)</h4><div class="NLM_p last"><b>22</b> was prepared according to general procedure 5 from intermediate <b>51</b> (209 mg, 612 μmol, 1.0 equiv) and boronic acid pinacol ester <b>64</b> (200 mg, 615 μmol, 1.0 equiv). Purification by column chromatography on silica gel (cyclohexane/EtOAc 1:0 → 3:2) gave compound <b>22</b> (206 mg, 458 μmol, 75%) as a colorless solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 9.02 (s, 1 H), 7.62 (t, <sup>2</sup><i>J</i><sub>H,F</sub> = 55 Hz, 1 H), 6.84 (s, 1 H), 4.83 (br s, 2 H), 4.71–4.45 (m, 4 H), 3.67–3.55 (m, 4 H), 2.67–2.52 (m, 4 H), 1.29–1.22 (m, 12 H). <sup>13</sup>C{<sup>1</sup>H} NMR (101 MHz, CDCl<sub>3</sub>): δ 169.2 (s, 1 C), 164.5 (s, 2 C), 160.2 (s, 1 C), 152.3 (s, 1 C), 143.6 (t, <sup>2</sup><i>J</i><sub>C,F</sub> = 22 Hz, 1 C), 121.7 (t, <sup>3</sup><i>J</i><sub>C,F</sub> = 4.7 Hz, 1 C), 111.4 (t, <sup>1</sup><i>J</i><sub>C,F</sub> = 239 Hz, 1 C), 104.2 (t, <sup>3</sup><i>J</i><sub>C,F</sub> = 7.7 Hz, 1 C), 71.9 (s, 4 C), 48.9 (br s, 4 C), 19.0 (s, 4 C). ESI-HRMS (<i>m</i>/<i>z</i>): [M + H]<sup>+</sup> calcd for C<sub>21</sub>H<sub>30</sub>F<sub>2</sub>N<sub>7</sub>O<sub>2</sub> 450.2424, found 450.2431. HPLC: <i>t</i><sub>R</sub> = 11.34 min (98.4% purity).</div></div><div id="sec4_1_29" class="NLM_sec NLM_sec_level_3"><div id="ac_i52" class="anchor-spacer"></div><h4 class="article-section__title" id="_i52"> 5-[4,6-Bis(2,2-dimethylmorpholin-4-yl)-1,3,5-triazin-2-yl]-4-(difluoromethyl)pyridin-2-amine (<b>23</b>)</h4><div class="NLM_p last"><b>23</b> was prepared according to general procedure 4 from intermediate <b>52</b> (93.0 mg, 272 μmol, 1.0 equiv) and boronic acid pinacol ester <b>64</b> (89.0 mg, 273 μmol, 1.0 equiv). Purification by column chromatography on silica gel (cyclohexane/EtOAc 1:0 → 3:2) gave compound <b>23</b> (77.0 mg, 171 μmol, 63%) as a colorless solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 9.03 (s, 1 H), 7.64 (t, <sup>2</sup><i>J</i><sub>H,F</sub> = 55 Hz, 1 H), 6.84 (s, 1 H), 4.83 (br s, 2 H), 3.91–3.56 (m, 12 H), 1.25 (s, 12 H). <sup>13</sup>C{<sup>1</sup>H} NMR (101 MHz, CDCl<sub>3</sub>): δ 169.3 (s, 1 C), 165.0 (s, 2 C), 160.2 (s, 1 C), 152.4 (s, 1 C), 143.7 (t, <sup>2</sup><i>J</i><sub>C,F</sub> = 22 Hz, 1 C), 121.7 (br s, 1 C), 111.4 (t, <sup>1</sup><i>J</i><sub>C,F</sub> = 238 Hz, 1 C), 104.1 (t, <sup>3</sup><i>J</i><sub>C,F</sub> = 7.7 Hz, 1 C), 71.7 (s, 2 C), 60.8 (br s, 2 C), 52.6 (s, 1 C), 52.4 (s, 1 C), 43.5 (s, 1 C), 43.1 (s, 1 C), 24.4 (br s, 4 C). ESI-HRMS (<i>m</i>/<i>z</i>): [M + H]<sup>+</sup> calcd for C<sub>21</sub>H<sub>30</sub>F<sub>2</sub>N<sub>7</sub>O<sub>2</sub> 450.2424, found 450.2426. HPLC: <i>t</i><sub>R</sub> = 8.77 min (96.6% purity).</div></div><div id="sec4_1_30" class="NLM_sec NLM_sec_level_3"><div id="ac_i53" class="anchor-spacer"></div><h4 class="article-section__title" id="_i53"> 5-[4,6-Bis({8-oxa-5-azaspiro[3.5]nonan-5-yl})-1,3,5-triazin-2-yl]-4-(difluoromethyl)pyridin-2-amine (<b>24</b>)</h4><div class="NLM_p last"><b>24</b> was prepared according to general procedure 4 from intermediate <b>53</b> (300 mg, 820 μmol, 1.0 equiv) and boronic acid pinacol ester <b>64</b> (267 mg, 821 μmol, 1.0 equiv). Purification by column chromatography on silica gel (cyclohexane/EtOAc 1:0 → 4:1) gave compound <b>24</b> (229 mg, 484 μmol, 59%) as a colorless solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.93 (s, 1 H), 7.64 (t, <sup>2</sup><i>J</i><sub>H,F</sub> = 55 Hz, 1 H), 6.82 (s, 1 H), 4.81 (br s, 2 H), 3.83–3.77 (m, 4 H), 3.76 (s, 4 H), 3.60–3.54 (m, 4 H), 2.61–2.47 (m, 4 H), 2.42–2.30 (m, 4 H), 1.87–1.64 (m, 4 H). <sup>13</sup>C{<sup>1</sup>H} NMR (101 MHz, CDCl<sub>3</sub>): δ 169.2 (s, 1 C), 165.7 (s, 2 C), 160.0 (s, 1 C), 152.5 (s, 1 C), 143.5 (t, <sup>2</sup><i>J</i><sub>C,F</sub> = 22 Hz, 1 C), 121.8 (t, <sup>3</sup><i>J</i><sub>C,F</sub> = 4.9 Hz, 1 C), 111.3 (t, <sup>1</sup><i>J</i><sub>C,F</sub> = 239 Hz, 1 C), 104.0 (t, <sup>3</sup><i>J</i><sub>C,F</sub> = 7.7 Hz, 1 C), 70.9 (s, 2 C), 66.2 (s, 2 C), 60.8 (s, 2 C), 43.5 (s, 2 C), 31.4 (s, 4 C), 15.0 (s, 2 C). ESI-HRMS (<i>m</i>/<i>z</i>): [M + H]<sup>+</sup> calcd for C<sub>23</sub>H<sub>30</sub>F<sub>2</sub>N<sub>7</sub>O<sub>2</sub> 474.2424, found 474.2428. HPLC: <i>t</i><sub>R</sub> = 9.86 min (98.7% purity).</div></div><div id="sec4_1_31" class="NLM_sec NLM_sec_level_3"><div id="ac_i54" class="anchor-spacer"></div><h4 class="article-section__title" id="_i54"> 5-[4,6-Bis({3,7-dioxa-9-azabicyclo[3.3.1]nonan-9-yl})-1,3,5-triazin-2-yl]-4-(difluoromethyl)pyridin-2-amine (<b>25</b>)</h4><div class="NLM_p last"><b>25</b> was prepared according to general procedure 5 from intermediate <b>54</b> (180 mg, 487 μmol, 1.0 equiv) and boronic acid pinacol ester <b>64</b> (159 mg, 489 μmol, 1.0 equiv). Purification by column chromatography on silica gel (cyclohexane/EtOAc/CH<sub>3</sub>OH 1:1:0 → 0:100:5) gave compound <b>25</b> (102 mg, 214 μmol, 44%) as a colorless solid. <sup>1</sup>H NMR (400 MHz, (CD<sub>3</sub>)<sub>2</sub>SO): δ 8.87 (s, 1 H), 7.70 (t, <sup>2</sup><i>J</i><sub>H,F</sub> = 55 Hz, 1 H), 6.89 (br s, 2 H), 6.76 (s, 1 H), 4.55–4.44 (m, 4 H), 4.07–3.96 (m, 8 H), 3.81–3.68 (m, 8 H). <sup>13</sup>C{<sup>1</sup>H} NMR (101 MHz, (CD<sub>3</sub>)<sub>2</sub>SO): δ 169.7 (s, 1 C), 163.4 (s, 2 C), 161.7 (s, 1 C), 152.3 (s, 1 C), 142.1 (t, <sup>2</sup><i>J</i><sub>C,F</sub> = 22 Hz, 1 C), 118.0 (t, <sup>3</sup><i>J</i><sub>C,F</sub> = 4.5 Hz, 1 C), 111.9 (t, <sup>1</sup><i>J</i><sub>C,F</sub> = 237 Hz, 1 C), 103.1 (t, <sup>3</sup><i>J</i><sub>C,F</sub> = 8.3 Hz, 1 C), 68.7 (s, 4 C), 68.5 (s, 4 C), 48.3(s, 2 C), 47.8 (s, 2 C). ESI-HRMS (<i>m</i>/<i>z</i>): [M + H]<sup>+</sup> calcd for C<sub>21</sub>H<sub>26</sub>F<sub>2</sub>N<sub>7</sub>O<sub>4</sub> 478.2009, found 478.2006. HPLC: <i>t</i><sub>R</sub> = 7.03 min (95.6% purity).</div></div><div id="sec4_1_32" class="NLM_sec NLM_sec_level_3"><div id="ac_i55" class="anchor-spacer"></div><h4 class="article-section__title" id="_i55"> 5-[4,6-Bis({3-oxa-9-azabicyclo[3.3.1]nonan-9-yl})-1,3,5-triazin-2-yl]-4-(difluoromethyl)pyridin-2-amine (<b>26</b>)</h4><div class="NLM_p last"><b>26</b> was prepared according to general procedure 5 from intermediate <b>55</b> (240 mg, 656 μmol, 1.0 equiv) and boronic acid pinacol ester <b>64</b> (213 mg, 655 μmol, 1.0 equiv). Purification by column chromatography on silica gel (cyclohexane/EtOAc 1:0 → 7:3) gave compound <b>26</b> (77.5 mg, 164 μmol, 25%) as a colorless solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 9.03–8.99 (m, 1 H), 7.82–7.51 (m, 1 H), 6.83 (br s, 1 H), 4.81 (br s, 2 H), 4.70 (br s, 2 H), 4.59 (br s, 2 H), 4.03–3.94 (m, 4 H), 3.88–3.80 (m, 4 H), 2.71–2.52 (m, 2 H), 1.98–1.78 (m, 8 H), 1.70–1.55 (m, 2 H). <sup>13</sup>C{<sup>1</sup>H} NMR (101 MHz, CDCl<sub>3</sub>): δ 169.8 (s, 1 C), 163.9 (s, 2 C), 160.1 (s, 1 C), 152.5–152.2 (m, 1 C), 143.6 (t, <sup>2</sup><i>J</i><sub>C,F</sub> = 22 Hz, 1 C), 122.0–121.7 (m, 1 C), 111.5 (t, <sup>1</sup><i>J</i><sub>C,F</sub> = 239 Hz, 1 C), 104.1 (t, <sup>3</sup><i>J</i><sub>C,F</sub> = 7.7 Hz, 1 C), 71.5–71.2 (m, 4 C), 48.0–47.8 (m, 2 C), 47.4–47.2 (m, 2 C), 29.3–28.7 (m, 4 C), 20.7 (s, 2 C). ESI-HRMS (<i>m</i>/<i>z</i>): [M + H]<sup>+</sup> calcd for C<sub>23</sub>H<sub>30</sub>F<sub>2</sub>N<sub>7</sub>O<sub>2</sub> 474.2424, found 474.2418. HPLC: <i>t</i><sub>R</sub> = 9.70 min (97.0% purity). Compound <b>26</b> exists as a mixture of rotamers.</div></div><div id="sec4_1_33" class="NLM_sec NLM_sec_level_3"><div id="ac_i56" class="anchor-spacer"></div><h4 class="article-section__title" id="_i56"> 5-[2,6-Bis(morpholin-4-yl)pyrimidin-4-yl]-4-(trifluoromethyl)pyridin-2-amine (BKM120 (<b>27</b>))</h4><div class="NLM_p last"><b>27</b> was prepared according to the literature.<a onclick="showRef(event, 'ref24 ref34'); return false;" href="javascript:void(0);" class="ref ref24 ref34">(24,34)</a></div></div><div id="sec4_1_34" class="NLM_sec NLM_sec_level_3"><div id="ac_i57" class="anchor-spacer"></div><h4 class="article-section__title" id="_i57"> 5-[2,6-Bis(morpholin-4-yl)pyrimidin-4-yl]-4-(difluoromethyl)pyridin-2-amine (<b>28</b>)</h4><div class="NLM_p last"><b>28</b> was prepared according to general procedure 5 from intermediate <b>57</b> (100 mg, 351 μmol, 1.0 equiv) and boronic acid pinacol ester <b>64</b> (125 mg, 384 μmol, 1.1 equiv). Purification by column chromatography on silica gel (cyclohexane/EtOAc 3:7) gave compound <b>28</b> (101 mg, 257 μmol, 73%) as a colorless solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.31 (s, 1 H), 7.30 (t, <sup>2</sup><i>J</i><sub>H,F</sub> = 55 Hz, 1 H), 6.85 (s, 1 H), 6.04 (s, 1 H), 4.73 (br s, 2 H), 3.81–3.72 (m, 12 H), 3.65–3.59 (m, 4 H). <sup>13</sup>C{<sup>1</sup>H} NMR (101 MHz, CDCl<sub>3</sub>): δ 163.7 (s, 1 C), 162.6 (s, 1 C), 161.5 (s, 1 C), 159.3 (s, 1 C), 149.5 (s, 1 C), 142.6 (t, <sup>2</sup><i>J</i><sub>C,F</sub> = 22 Hz, 1 C), 124.6 (t, <sup>3</sup><i>J</i><sub>C,F</sub> = 5.3 Hz, 1 C), 111.5 (t, <sup>1</sup><i>J</i><sub>C,F</sub> = 239 Hz, 1 C), 104.6 (t, <sup>3</sup><i>J</i><sub>C,F</sub> = 6.8 Hz, 1 C), 91.5 (s, 1 C), 67.0 (s, 2 C), 66.7 (s, 2 C), 44.5 (s, 2 C), 44.4 (s, 2 C). ESI-HRMS (<i>m</i>/<i>z</i>): [M + H]<sup>+</sup> calcd for C<sub>18</sub>H<sub>22</sub>F<sub>2</sub>N<sub>6</sub>O<sub>2</sub>, 393.1845; found: 393.1852. HPLC: <i>t</i><sub>R</sub> = 6.87 min (96.9% purity).</div></div><div id="sec4_1_35" class="NLM_sec NLM_sec_level_3"><div id="ac_i58" class="anchor-spacer"></div><h4 class="article-section__title" id="_i58"> 5-[4,6-Bis(morpholin-4-yl)pyrimidin-2-yl]-4-(trifluoromethyl)pyridin-2-amine (<b>29</b>)</h4><div class="NLM_p last"><b>29</b> was prepared according to the literature,<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> where the compound is referred to as BKM120-R1.</div></div><div id="sec4_1_36" class="NLM_sec NLM_sec_level_3"><div id="ac_i59" class="anchor-spacer"></div><h4 class="article-section__title" id="_i59"> 5-[4,6-Bis(morpholin-4-yl)pyrimidin-2-yl]-4-(difluoromethyl)pyridin-2-amine (<b>30</b>)</h4><div class="NLM_p last"><b>30</b> was prepared according to general procedure 5 from intermediate <b>58</b> (100 mg, 351 μmol, 1.0 equiv) and boronic acid pinacol ester <b>64</b> (125 mg, 384 μmol, 1.1 equiv). Purification by column chromatography on silica gel (cyclohexane/EtOAc 3:7) gave compound <b>30</b> (123 mg, 313 μmol, 89%) as a colorless solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.94 (br s, 1 H), 7.61 (t, <sup>2</sup><i>J</i><sub>H,F</sub> = 55 Hz, 1 H), 6.83 (s, 1 H), 5.50 (s, 1 H), 4.74 (br s, 2 H), 3.82–3.78 (m, 8 H), 3.61–3.57 (m, 8 H). <sup>13</sup>C{<sup>1</sup>H} NMR (101 MHz, (CD<sub>3</sub>)<sub>2</sub>SO): δ 163.4 (s, 2 C), 160.8 (s, 1 C), 160.7 (s, 1 C), 151.4 (s, 1 C), 141.4 (t, <sup>2</sup><i>J</i><sub>C,F</sub> = 22 Hz, 1 C), 120.5 (t, <sup>3</sup><i>J</i><sub>C,F</sub> = 4.8 Hz, 1 C), 112.0 (t, <sup>1</sup><i>J</i><sub>C,F</sub> = 237 Hz, 1 C), 102.8 (t, <sup>3</sup><i>J</i><sub>C,F</sub> = 7.7 Hz, 1 C), 79.6 (s, 1 C), 65.9 (s, 4 C), 44.3 (s, 4 C). ESI-HRMS (<i>m</i>/<i>z</i>): [M + H]<sup>+</sup> calcd for C<sub>18</sub>H<sub>23</sub>F<sub>2</sub>N<sub>6</sub>O<sub>2</sub> 393.1845, found 393.1848. HPLC: <i>t</i><sub>R</sub> = 6.58 min (96.4% purity).</div></div><div id="sec4_1_37" class="NLM_sec NLM_sec_level_3"><div id="ac_i60" class="anchor-spacer"></div><h4 class="article-section__title" id="_i60"> 5-[2,6-Bis({3-oxa-8-azabicyclo[3.2.1]octan-8-yl})pyrimidin-4-yl]-4-(trifluoromethyl)pyridin-2-amine (<b>31</b>)</h4><div class="NLM_p last"><b>31</b> was prepared according to general procedure 5 from intermediate <b>59</b> (108 mg, 321 μmol, 1.0 equiv) and boronic acid pinacol ester <b>72</b> (121 mg, 353 μmol, 1.1 equiv). Purification by column chromatography on silica gel (cyclohexane/EtOAc 1:0 → 1:4) gave compound <b>31</b> (110 mg, 238 μmol, 74%) as a yellowish solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.27 (s, 1 H), 6.78 (s, 1 H), 5.91 (s, 1 H), 4.77 (br s, 2 H), 4.63 (br s, 2 H), 4.52–4.31 (m, 2 H), 3.87–3.78 (m, 4 H), 3.63–3.55 (m, 4 H), 2.13–1.90 (m, 8 H). <sup>13</sup>C{<sup>1</sup>H} NMR (101 MHz, CDCl<sub>3</sub>): δ 163.0 (s, 1 C), 161.4 (s, 1 C), 161.1 (s, 1 C), 158.8 (s, 1 C), 150.9 (s, 1 C), 137.9 (q, <sup>2</sup><i>J</i><sub>C,F</sub> = 32 Hz, 1 C), 124.4 (br s, 1 C), 123.0 (q, <sup>1</sup><i>J</i><sub>C,F</sub> = 275 Hz, 1 C), 105.3 (q, <sup>3</sup><i>J</i><sub>C,F</sub> = 5.5 Hz, 1 C), 94.4 (br s, 1 C), 71.6 (s, 2 C), 71.0 (s, 2 C), 55.4 (s, 2 C), 55.2 (s, 2 C), 27.1 (s, 2 C), 27.0 (s, 2 C). ESI-HRMS (<i>m</i>/<i>z</i>): [M + H]<sup>+</sup> calcd for C<sub>22</sub>H<sub>26</sub>F<sub>3</sub>N<sub>6</sub>O<sub>2</sub> 463.2064, found 463.2046. HPLC: <i>t</i><sub>R</sub> = 8.16 min (96.5% purity).</div></div><div id="sec4_1_38" class="NLM_sec NLM_sec_level_3"><div id="ac_i61" class="anchor-spacer"></div><h4 class="article-section__title" id="_i61"> 5-[2,6-Bis({3-oxa-8-azabicyclo[3.2.1]octan-8-yl})pyrimidin-4-yl]-4-(difluoromethyl)pyridin-2-amine (<b>32</b>)</h4><div class="NLM_p last"><b>32</b> was prepared according to general procedure 5 from intermediate <b>59</b> (82.9 mg, 246 μmol, 1.0 equiv) and boronic acid pinacol ester <b>64</b> (80 mg, 246 μmol, 1.0 equiv). Purification by column chromatography on silica gel (EtOAc/CH3OH 50:1) gave compound <b>32</b> (66.7 mg, 150 μmol, 61%) as a colorless solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.31 (s, 1 H), 7.33 (t, <sup>2</sup><i>J</i><sub>H,F</sub> = 55 Hz, 1 H), 6.84 (s, 1 H), 5.98 (s, 1 H), 4.75 (br s, 2 H), 4.62 (br s, 2 H), 4.53–4.36 (m, 2 H), 3.86–3.76 (m, 4 H), 3.67–3.56 (m, 4 H), 2.15–1.91 (m, 8 H). <sup>13</sup>C{<sup>1</sup>H} NMR (101 MHz, (CD<sub>3</sub>)<sub>2</sub>SO): δ 162.4 (s, 1 C), 161.3 (s, 1 C), 160.6 (s, 1 C), 160.2 (s, 1 C), 149.7 (s, 1 C), 141.0 (t, <sup>2</sup><i>J</i><sub>C,F</sub> = 22 Hz, 1 C), 121.1 (br s, 1 C), 112.0 (t, <sup>1</sup><i>J</i><sub>C,F</sub> = 236 Hz, 1 C), 103.3 (t, <sup>3</sup><i>J</i><sub>C,F</sub> = 8.1 Hz, 1 C), 92.3 (s, 1 C), 70.5 (s, 2 C), 70.3 (s, 2 C), 54.7 (s, 2 C), 54.3 (s, 2 C), 26.6 (s, 2 C), 26.5 (s, 2 C). ESI-HRMS (<i>m</i>/<i>z</i>): [M + H]<sup>+</sup> calcd for C<sub>22</sub>H<sub>27</sub>F<sub>2</sub>N<sub>6</sub>O<sub>2</sub> 445.2158, found 445.2152. HPLC: <i>t</i><sub>R</sub> = 8.01 min (99.2% purity).</div></div><div id="sec4_1_39" class="NLM_sec NLM_sec_level_3"><div id="ac_i62" class="anchor-spacer"></div><h4 class="article-section__title" id="_i62"> 5-[4,6-Bis({3-oxa-8-azabicyclo[3.2.1]octan-8-yl})pyrimidin-2-yl]-4-(trifluoromethyl)pyridin-2-amine (<b>33</b>)</h4><div class="NLM_p last"><b>33</b> was prepared according to general procedure 5 from intermediate <b>60</b> (150 mg, 445 μmol, 1.0 equiv) and boronic acid pinacol ester <b>72</b> (169 mg, 492 μmol, 1.1 equiv). Purification by column chromatography on silica gel (EtOAc 100%) gave compound <b>33</b> (96.1 mg, 208 μmol, 47%) as a colorless solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.65 (s, 1 H), 6.77 (s, 1 H), 5.41 (s, 1 H), 4.76 (br s, 2 H), 4.45 (br s, 4 H), 3.83 (d, <i>J</i><sub>H,H</sub> = 11 Hz, 4 H), 3.59 (d, <i>J</i><sub>H,H</sub> = 11 Hz, 4 H), 2.14–1.96 (m, 8 H). <sup>13</sup>C{<sup>1</sup>H} NMR (101 MHz, CDCl<sub>3</sub>): δ 163.2 (s, 1 C), 161.6 (s, 2 C), 158.8 (s, 1 C), 152.6 (s, 1 C), 138.1 (q, <sup>2</sup><i>J</i><sub>C,F</sub> = 32 Hz, 1 C), 124.3 (br s, 1 C), 123.2 (q, <sup>1</sup><i>J</i><sub>C,F</sub> = 274 Hz, 1 C), 105.2 (q, <sup>3</sup><i>J</i><sub>C,F</sub> = 5.2 Hz, 1 C), 82.5 (s, 1 C), 70.9 (s, 4 C), 55.3 (s, 4 C), 27.0 (s, 4 C). ESI-HRMS (<i>m</i>/<i>z</i>): [M + H]<sup>+</sup> calcd for C<sub>22</sub>H<sub>26</sub>F<sub>3</sub>N<sub>6</sub>O<sub>2</sub> 463.2064, found 463.2064. HPLC: <i>t</i><sub>R</sub> = 7.64 min (95.7% purity).</div></div><div id="sec4_1_40" class="NLM_sec NLM_sec_level_3"><div id="ac_i63" class="anchor-spacer"></div><h4 class="article-section__title" id="_i63"> 5-[4,6-Bis({3-oxa-8-azabicyclo[3.2.1]octan-8-yl})pyrimidin-2-yl]-4-(difluoromethyl)pyridin-2-amine (<b>34</b>)</h4><div class="NLM_p last"><b>34</b> was prepared according to general procedure 5 from intermediate <b>60</b> (137 mg, 407 μmol, 1.0 equiv) and boronic acid pinacol ester <b>64</b> (133 mg, 409 μmol, 1.0 equiv). Purification by column chromatography on silica gel (EtOAc 100%) gave compound <b>34</b> (79.4 mg, 179 μmol, 44%) as a colorless solid. <sup>1</sup>H NMR (400 MHz, (CD<sub>3</sub>)<sub>2</sub>SO): δ 8.77 (s, 1 H), 7.73 (t, <sup>2</sup><i>J</i><sub>H,F</sub> = 55 Hz, 1 H), 6.72 (s, 1 H), 6.59 (br s, 2 H), 5.85 (s, 1 H), 4.52 (br s, 4 H), 3.64 (d, <i>J</i><sub>H,H</sub> = 11 Hz, 4 H), 3.52 (d, <i>J</i><sub>H,H</sub> = 11 Hz, 4 H), 1.99–1.82 (m, 8 H). <sup>13</sup>C{<sup>1</sup>H} NMR (101 MHz, (CD<sub>3</sub>)<sub>2</sub>SO): δ 161.8 (s, 1 C), 161.0 (s, 2 C), 160.7 (s, 1 C), 151.5 (s, 1 C), 114.4 (t, <sup>2</sup><i>J</i><sub>C,F</sub> = 21 Hz, 1 C), 120.4 (t, <sup>3</sup><i>J</i><sub>C,F</sub> = 4.5 Hz, 1 C), 112.1 (t, <sup>1</sup><i>J</i><sub>C,F</sub> = 237 Hz, 1 C), 102.8 (t, <sup>3</sup><i>J</i><sub>C,F</sub> = 7.9 Hz, 1 C), 82.4 (s, 1 C), 70.0 (s, 4 C), 54.5 (s, 4 C), 26.5 (s, 4 C). ESI-HRMS (<i>m</i>/<i>z</i>): [M + H]<sup>+</sup> calcd for C<sub>22</sub>H<sub>27</sub>F<sub>2</sub>N<sub>6</sub>O<sub>2</sub> 445.2158, found 445.2145. HPLC: <i>t</i><sub>R</sub> = 7.45 min (98.1% purity).</div></div><div id="sec4_1_41" class="NLM_sec NLM_sec_level_3"><div id="ac_i64" class="anchor-spacer"></div><h4 class="article-section__title" id="_i64"> 2,4-Dichloro-6-(morpholin-4-yl)-1,3,5-triazine (<b>35</b>) and 2-Chloro-4,6-bis(morpholin-4-yl)-1,3,5-triazine (<b>36</b>)</h4><div class="NLM_p last"><b>35</b> and <b>36</b> were prepared according to the literature.<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a></div></div><div id="sec4_1_42" class="NLM_sec NLM_sec_level_3"><div id="ac_i65" class="anchor-spacer"></div><h4 class="article-section__title" id="_i65"> 2-Chloro-4-[(3<i>R</i>)-3-methylmorpholin-4-yl]-6-(morpholin-4-yl)-1,3,5-triazine (<b>37</b>)</h4><div class="NLM_p last"><b>37</b> was prepared according to general procedure 3 from (<i>R</i>)-3-methylmorpholine (370 mg, 3.66 mmol, 1.1 equiv) and 4-(4,6-dichloro-1,3,5-triazin-2-yl)morpholine (<b>35</b>, 820 mg, 3.49 mmol, 1.0 equiv) in the presence of <i>N</i>,<i>N</i>-diisopropylethylamine (1.34 mL, 7.69 mmol, 2.1 equiv). Purification by column chromatography on silica gel (cyclohexane/EtOAc 1:0 → 4:1) gave compound <b>37</b> (953 mg, 3.18 mmol, 91%) as a colorless solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 4.76–4.56 (m, 1 H), 4.39–4.23 (m, 1 H), 3.93 (dd, <i>J</i><sub>H,H</sub> = 11, 3.6 Hz, 1 H), 3.86–3.65 (m, 9 H), 3.63 (dd, <i>J</i><sub>H,H</sub> = 12, 3.2 Hz, 1 H), 3.48 (td, <i>J</i><sub>H,H</sub> = 12, 3.0 Hz, 1 H), 3.30–3.19 (m, 1 H), 1.30 (d, <sup>3</sup><i>J</i><sub>H,H</sub> = 6.8 Hz, 3 H). <sup>13</sup>C{<sup>1</sup>H} NMR (101 MHz, CDCl<sub>3</sub>): δ 169.8 (s, 1 C), 164.6 (s, 1 C), 164.3 (s, 1 C), 71.0 (s, 1 C), 67.0 (s, 1 C), 66.8 (br s, 2 C), 46.8 (s, 1 C), 44.0 (s, 2 C), 39.0 (s, 1 C), 14.6 (br s, 1 C). MALDI-MS: <i>m</i>/<i>z</i> = 300.3 ([M + H]<sup>+</sup>).</div></div><div id="sec4_1_43" class="NLM_sec NLM_sec_level_3"><div id="ac_i66" class="anchor-spacer"></div><h4 class="article-section__title" id="_i66"> 3-[4-Chloro-6-(morpholin-4-yl)-1,3,5-triazin-2-yl]-8-oxa-3-azabicyclo[3.2.1]octane (<b>38</b>)</h4><div class="NLM_p last"><b>38</b> was prepared according to general procedure 3 from 8-oxa-3-azabicyclo[3.2.1]octane hydrochloride (67.0 mg, 448 μmol, 1.1 equiv) and 4-(4,6-dichloro-1,3,5-triazin-2-yl)morpholine (<b>35</b>, 100 mg, 425 μmol, 1.0 equiv) in the presence of <i>N</i>,<i>N</i>-diisopropylethylamine (148 μL, 850 μmol, 2.0 equiv). Purification by column chromatography on silica gel (cyclohexane/EtOAc 1:0 → 3:2) gave compound <b>38</b> (107 mg, 343 μmol, 81%) as a colorless solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 4.44–4.37 (m, 2 H), 4.29 (d, <i>J</i><sub>H,H</sub> = 13 Hz, 1 H), 4.22 (d, <i>J</i><sub>H,H</sub> = 13 Hz, 1 H), 3.89–3.66 (m, 8 H), 3.23–3.12 (m, 2 H), 1.99–1.87 (m, 2 H), 1.83–1.68 (m, 2 H). <sup>13</sup>C{<sup>1</sup>H} NMR (101 MHz, CDCl<sub>3</sub>): δ 169.6 (s, 1 C), 165.7 (s, 1 C), 164.4 (s, 1 C), 73.8 (s, 1 C), 73.7 (s, 1 C), 66.8 (s, 1 C), 66.6 (s, 1 C), 49.6 (s, 1 C), 49.5 (s, 1 C), 43.9 (br s, 2 C), 27.7 (s, 1 C), 27.6 (s, 1 C). MALDI-MS: <i>m</i>/<i>z</i> = 312.2 ([M + H]<sup>+</sup>).</div></div><div id="sec4_1_44" class="NLM_sec NLM_sec_level_3"><div id="ac_i67" class="anchor-spacer"></div><h4 class="article-section__title" id="_i67"> 8-[4-Chloro-6-(morpholin-4-yl)-1,3,5-triazin-2-yl]-3-oxa-8-azabicyclo[3.2.1]octane (<b>39</b>)</h4><div class="NLM_p last"><b>39</b> was prepared according to general procedure 3 from 3-oxa-8-azabicyclo[3.2.1]octane (159 mg, 1.40 mmol, 1.1 equiv) and 4-(4,6-dichloro-1,3,5-triazin-2-yl)morpholine (<b>35</b>, 300 mg, 1.28 mmol, 1.0 equiv) in the presence of <i>N</i>,<i>N</i>-diisopropylethylamine (470 μL, 2.69 mmol, 2.1 equiv). Purification by column chromatography on silica gel (cyclohexane/EtOAc 1:0 → 4:1) gave compound <b>39</b> (312 mg, 1.00 mmol, 78%) as a colorless solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 4.70–4.55 (m, 2 H), 3.88–3.57 (m, 12 H), 2.09–1.91 (m, 4 H). <sup>13</sup>C{<sup>1</sup>H} NMR (101 MHz, CDCl<sub>3</sub>): δ 169.9 (s, 1 C), 164.7 (s, 1 C), 162.4 (s, 1 C), 72.3 (s, 1 C), 71.7 (s, 1 C), 66.8 (br s, 2 C), 55.0 (s, 1 C), 54.9 (s, 1 C), 43.9 (br s, 2 C), 27.0 (s, 1 C), 26.8 (s, 1 C). MALDI-MS: <i>m</i>/<i>z</i> = 312.6 ([M + H]<sup>+</sup>).</div></div><div id="sec4_1_45" class="NLM_sec NLM_sec_level_3"><div id="ac_i68" class="anchor-spacer"></div><h4 class="article-section__title" id="_i68"> 2-Chloro-4,6-bis[(3<i>R</i>)-3-methylmorpholin-4-yl]-1,3,5-triazine (<b>41</b>)</h4><div class="NLM_p last"><b>41</b> was prepared according to general procedure 1 from cyanuric chloride (<b>40</b>, 508 mg, 2.75 mmol, 1.0 equiv) and (<i>R</i>)-3-methylmorpholine (558 mg, 5.52 mmol, 2.0 equiv) in the presence of <i>N</i>,<i>N</i>-diisopropylethylamine (1.06 mL, 6.07 mmol, 2.2 equiv). Purification by column chromatography on silica gel (cyclohexane/EtOAc 1:0 → 3:1) gave compound <b>41</b> (781 mg, 2.49 mmol, 91%) as a colorless solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 4.75–4.55 (m, 2 H), 4.41–4.21 (m, 2 H), 3.93 (dd, <i>J</i><sub>H,H</sub> = 11, 3.7 Hz, 2 H), 3.73 (d, <i>J</i><sub>H,H</sub> = 12 Hz, 2 H), 3.63 (dd, <i>J</i><sub>H,H</sub> = 12, 3.3 Hz, 2 H), 3.48 (td, <i>J</i><sub>H,H</sub> = 12, 3.0 Hz, 2 H), 3.29–3.18 (m, 2 H), 1.30 (d, <sup>3</sup><i>J</i><sub>H,H</sub> = 6.9 Hz, 6 H). <sup>13</sup>C{<sup>1</sup>H} NMR (101 MHz, CDCl<sub>3</sub>): δ 169.8 (s, 1 C), 164.3 (s, 2 C), 71.0 (s, 2 C), 67.0 (s, 2 C), 46.8 (s, 2 C), 38.9 (s, 2 C), 14.6 (br s, 2 C). MALDI-MS: <i>m</i>/<i>z</i> = 314.3 ([M + H]<sup>+</sup>).</div></div><div id="sec4_1_46" class="NLM_sec NLM_sec_level_3"><div id="ac_i69" class="anchor-spacer"></div><h4 class="article-section__title" id="_i69"> 3-(4-Chloro-6-{8-oxa-3-azabicyclo[3.2.1]octan-3-yl}-1,3,5-triazin-2-yl)-8-oxa-3-azabicyclo[3.2.1]octane (<b>42</b>)</h4><div class="NLM_p last"><b>42</b> was prepared according to general procedure 1 from cyanuric chloride (<b>40</b>, 1.63 g, 8.84 mmol, 1.0 equiv) and 8-oxa-3-azabicyclo[3.2.1]octane hydrochloride (2.65 g, 17.7 mmol, 2.0 equiv) in the presence of <i>N</i>,<i>N</i>-diisopropylethylamine (3.40 mL, 19.5 mmol, 2.2 equiv). Purification by column chromatography on silica gel (cyclohexane/EtOAc 4:1) gave compound <b>42</b> (2.80 g, 8.29 mmol, 94%) as a colorless solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 4.45–4.35 (m, 4 H), 4.33–4.16 (m, 4 H), 3.24–3.10 (m, 4 H), 2.10–1.85 (m, 4 H), 1.85–1.66 (m, 4 H). <sup>13</sup>C{<sup>1</sup>H} NMR (101 MHz, CDCl<sub>3</sub>): δ 169.4 (s, 1 C), 165.6 (s, 2 C), 73.8 (s, 2 C), 73.7 (br s, 2 C), 49.7–49.4 (m, 4 C), 27.8–27.4 (m, 4 C). MALDI-MS: <i>m</i>/<i>z</i> = 338.3 ([M + H]<sup>+</sup>).</div></div><div id="sec4_1_47" class="NLM_sec NLM_sec_level_3"><div id="ac_i70" class="anchor-spacer"></div><h4 class="article-section__title" id="_i70"> 8-(4-Chloro-6-{3-oxa-8-azabicyclo[3.2.1]octan-8-yl}-1,3,5-triazin-2-yl)-3-oxa-8-azabicyclo[3.2.1]octane (<b>43</b>)</h4><div class="NLM_p last"><b>43</b> was prepared according to general procedure 1 from cyanuric chloride (<b>40</b>, 1.23 g, 6.67 mmol, 1.0 equiv) and 3-oxa-8-azabicyclo[3.2.1]octane hydrochloride (2.00 g, 13.4 mmol, 2.0 equiv) in the presence of <i>N</i>,<i>N</i>-diisopropylethylamine (4.80 mL, 27.6 mmol, 4.1 equiv). Purification by column chromatography on silica gel (cyclohexane/EtOAc 4:1) gave compound <b>43</b> (1.79 g, 5.30 mmol, 79%) as a colorless solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 4.73–4.53 (m, 4 H), 3.78–3.57 (m, 8 H), 2.11–1.88 (m, 8 H). <sup>13</sup>C{<sup>1</sup>H} NMR (101 MHz, CDCl<sub>3</sub>): δ 169.9 (s, 1 C), 162.5 (s, 1 C), 162.4 (s, 1 C), 72.2 (s, 2 C), 71.6 (br s, 2 C), 54.9 (s, 2 C), 54.8 (s, 2 C), 26.9 (s, 2 C), 26.8 (s, 2 C). MALDI-MS: <i>m</i>/<i>z</i> = 338.2 ([M + H]<sup>+</sup>).</div></div><div id="sec4_1_48" class="NLM_sec NLM_sec_level_3"><div id="ac_i71" class="anchor-spacer"></div><h4 class="article-section__title" id="_i71"> (1<i>S</i>,4<i>S</i>)-5-{4-Chloro-6-[(1<i>S</i>,4<i>S</i>)-2-oxa-5-azabicyclo[2.2.1]heptan-5-yl]-1,3,5-triazin-2-yl}-2-oxa-5-azabicyclo[2.2.1]heptane (<b>44</b>)</h4><div class="NLM_p last"><b>44</b> was prepared according to general procedure 1 from cyanuric chloride (<b>40</b>, 200 mg, 1.09 mmol, 1.0 equiv) and (1<i>S</i>,4<i>S</i>)-2-oxa-5-azabicyclo[2.2.1]heptane hydrochloride (335 mg, 2.47 mmol, 2.3 equiv) in the presence of <i>N</i>,<i>N</i>-diisopropylethylamine (800 μL, 4.59 mmol, 4.2 equiv). Purification by column chromatography on silica gel (cyclohexane/EtOAc 1:1 →0:1) gave compound <b>44</b> (264 mg, 861 μmol, 79%) as a colorless solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 5.06 (br s, 1 H), 4.98 (br s, 1 H), 4.67 (br s, 2 H), 3.90–3.80 (m, 4 H), 3.64–3.41 (m, 4 H), 2.00–1.81 (m, 4 H). <sup>13</sup>C{<sup>1</sup>H} NMR (101 MHz, CDCl<sub>3</sub>): δ 169.5–168.5 (m, 1 C), 163.1–162.5 (m, 2 C), 76.5–76.1 (m, 2 C), 74.1 (br s, 1 C), 73.7 (s, 1 C), 56.8 (br s, 2 C), 55.2 (br s, 2 C), 36.7 (br s, 1 C), 36.5–36.4 (m, 1 C). MALDI-MS: <i>m</i>/<i>z</i> = 310.2 ([M + H]<sup>+</sup>). Compound <b>44</b> exists as a mixture of rotamers.</div></div><div id="sec4_1_49" class="NLM_sec NLM_sec_level_3"><div id="ac_i72" class="anchor-spacer"></div><h4 class="article-section__title" id="_i72"> (1<i>R</i>,4<i>R</i>)-5-{4-Chloro-6-[(1<i>R</i>,4<i>R</i>)-2-oxa-5-azabicyclo[2.2.1]heptan-5-yl]-1,3,5-triazin-2-yl}-2-oxa-5-azabicyclo[2.2.1]heptane (<b>45</b>)</h4><div class="NLM_p last"><b>45</b> was prepared according to general procedure 1 from cyanuric chloride (<b>40</b>, 200 mg, 1.09 mmol, 1.0 equiv) and (1<i>R</i>,4<i>R</i>)-2-oxa-5-azabicyclo[2.2.1]heptane hydrochloride (324 mg, 2.39 mmol, 2.2 equiv) in the presence of <i>N</i>,<i>N</i>-diisopropylethylamine (800 μL, 4.59 mmol, 4.2 equiv). Purification by column chromatography on silica gel (cyclohexane/EtOAc 1:1 →0:1) gave compound <b>45</b> (217 mg, 707 μmol, 65%) as a colorless solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 5.06 (br s, 1 H), 4.98 (br s, 1 H), 4.67 (br s, 2 H), 3.90–3.80 (m, 4 H), 3.64–3.41 (m, 4 H), 2.00–1.82 (m, 4 H). <sup>13</sup>C{<sup>1</sup>H} NMR (101 MHz, CDCl<sub>3</sub>): δ 169.5–168.5 (m, 1 C), 163.0–162.6 (m, 2 C), 76.4–76.1 (m, 2 C), 74.1 (br s, 1 C), 73.7 (s, 1 C), 56.8 (br s, 2 C), 55.2 (br s, 2 C), 36.7 (br s, 1 C), 36.6–36.3 (m, 1 C). MALDI-MS: <i>m</i>/<i>z</i> = 310.1 ([M + H]<sup>+</sup>). Compound <b>45</b> exists as a mixture of rotamers.</div></div><div id="sec4_1_50" class="NLM_sec NLM_sec_level_3"><div id="ac_i73" class="anchor-spacer"></div><h4 class="article-section__title" id="_i73"> 6-(4-Chloro-6-{3-oxa-6-azabicyclo[3.1.1]heptan-6-yl}-1,3,5-triazin-2-yl)-3-oxa-6-azabicyclo[3.1.1]heptane (<b>46</b>)</h4><div class="NLM_p last"><b>46</b> was prepared according to general procedure 1 from cyanuric chloride (<b>40</b>, 200 mg, 1.09 mmol, 1.0 equiv) and 3-oxa-6-azabicyclo[3.1.1]heptane trifluoroacetate (511 mg, 2.40 mmol, 2.2 equiv) in the presence of <i>N</i>,<i>N</i>-diisopropylethylamine (1.14 mL, 6.54 mmol, 6.0 equiv). Purification by column chromatography on silica gel (cyclohexane/EtOAc 2:3) gave compound <b>46</b> (258 mg, 833 μmol, 77%) as a colorless solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 4.54–4.46 (m, 2 H), 4.41–4.22 (m, 6 H), 3.87–3.74 (m, 4 H), 2.75–2.68 (m, 2 H), 1.96 (d, <sup>3</sup><i>J</i><sub>H,H</sub> = 8.2 Hz, 2 H). <sup>13</sup>C{<sup>1</sup>H} NMR (101 MHz, CDCl<sub>3</sub>): δ 169.6 (s, 1 C), 165.4 (s, 1 C), 165.2 (s, 1 C), 66.5 (s, 2 C), 65.8 (s, 2 C), 62.3 (s, 2 C), 62.2 (s, 2 C), 27.5 (s, 1 C), 27.4 (s, 1 C). MALDI-MS: <i>m</i>/<i>z</i> = 310.5 ([M + H]<sup>+</sup>).</div></div><div id="sec4_1_51" class="NLM_sec NLM_sec_level_3"><div id="ac_i74" class="anchor-spacer"></div><h4 class="article-section__title" id="_i74"> 2-Chloro-4,6-bis[(3<i>R</i>)-3-ethylmorpholin-4-yl]-1,3,5-triazine (<b>47</b>)</h4><div class="NLM_p last"><b>47</b> was prepared according to general procedure 1 from cyanuric chloride (<b>40</b>, 290 mg, 1.57 mmol, 1.0 equiv) and (<i>R</i>)-3-ethylmorpholine hydrochloride (500 mg, 3.30 mmol, 2.1 equiv) in the presence of <i>N</i>,<i>N</i>-diisopropylethylamine (1.15 mL, 6.60 mmol, 4.2 equiv). Purification by column chromatography on silica gel (cyclohexane/EtOAc 1:0 → 7:3) gave compound <b>47</b> (303 mg, 886 μmol, 56%) as a colorless solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 4.61–4.25 (m, 4 H), 3.95–3.78 (m, 4 H), 3.56 (dd, <i>J</i><sub>H,H</sub> = 12, 3.2 Hz, 2 H), 3.48 (dd, <i>J</i><sub>H,H</sub> = 12, 3.0 Hz, 2 H), 3.26–3.10 (m, 2 H), 1.86–1.71 (m, 4 H), 0.90 (t, <sup>3</sup><i>J</i><sub>H,H</sub> = 7.4 Hz, 6 H). <sup>13</sup>C{<sup>1</sup>H} NMR (101 MHz, CDCl<sub>3</sub>): δ 169.6 (s, 1 C), 164.7 (br s, 2 C), 68.7 (s, 1 C), 68.5 (s, 1 C), 67.0 (s, 1 C), 66.9 (s, 1 C), 52.5 (s, 1 C), 52.2 (s, 1 C), 39.3 (s, 1 C), 39.1 (s, 1 C), 21.7 (br s, 2 C), 11.0 (s, 1 C), 10.6 (s, 1 C). MALDI-MS: <i>m</i>/<i>z</i> = 342.2 ([M + H]<sup>+</sup>).</div></div><div id="sec4_1_52" class="NLM_sec NLM_sec_level_3"><div id="ac_i75" class="anchor-spacer"></div><h4 class="article-section__title" id="_i75"> 2-Chloro-4,6-bis[(3<i>R</i>,5<i>S</i>)-3,5-dimethylmorpholin-4-yl]-1,3,5-triazine (<b>48</b>)</h4><div class="NLM_p last"><b>48</b> was prepared according to general procedure 2 from cyanuric chloride (<b>40</b>, 382 mg, 2.07 mmol, 1.0 equiv) and (3<i>R</i>,5<i>S</i>)-3,5-dimethylmorpholine (500 mg, 4.34 mmol, 2.1 equiv) in the presence of <i>N</i>,<i>N</i>-diisopropylethylamine (1.50 mL, 8.69 mmol, 4.2 equiv). Purification by column chromatography on silica gel (cyclohexane/EtOAc 1:0 → 9:1) gave compound <b>48</b> (286 mg, 837 μmol, 41%) as a colorless solid. <sup>1</sup>H NMR (400 MHz, (CD<sub>3</sub>)<sub>2</sub>SO): δ 4.44–4.33 (m, 4 H), 3.77–3.69 (m, 4 H), 3.57–3.48 (m, 4 H), 1.25 (d, <sup>3</sup><i>J</i><sub>H,H</sub> = 6.9 Hz, 12 H). <sup>13</sup>C{<sup>1</sup>H} NMR (101 MHz, CDCl<sub>3</sub>): δ 169.6 (s, 1 C), 164.1 (s, 2 C), 71.4 (s, 4 C), 46.2 (s, 4 C), 19.2 (br s, 4 C). MALDI-MS: <i>m</i>/<i>z</i> = 342.7 ([M + H]<sup>+</sup>).</div></div><div id="sec4_1_53" class="NLM_sec NLM_sec_level_3"><div id="ac_i76" class="anchor-spacer"></div><h4 class="article-section__title" id="_i76"> 2-Chloro-4,6-bis[(3<i>R</i>,5<i>R</i>)-3,5-dimethylmorpholin-4-yl]-1,3,5-triazine (<b>49</b>)</h4><div class="NLM_p last"><b>49</b> was prepared according to general procedure 2 from (3<i>R</i>,5<i>R</i>)-3,5-dimethylmorpholine hydrochloride (345 mg, 2.28 mmol, 2.1 equiv) and cyanuric chloride (<b>40</b>, 200 mg, 1.08 mmol, 1.0 equiv) in the presence of <i>N</i>,<i>N</i>-diisopropylethylamine (790 μL, 4.54 mmol, 4.2 equiv). Purification by column chromatography on silica gel (cyclohexane/EtOAc 1:0 → 9:1) gave compound <b>49</b> (247 mg, 723 μmol, 67%) as a colorless solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 4.36–4.25 (m, 4 H), 4.21 (dd, <sup>2</sup><i>J</i><sub>H,H</sub> = 11 Hz, <sup>3</sup><i>J</i><sub>H,H</sub> = 3.4 Hz, 4 H), 3.73 (dd, <sup>2</sup><i>J</i><sub>H,H</sub> = 11 Hz, <sup>3</sup><i>J</i><sub>H,H</sub> = 2.3 Hz, 4 H), 1.43 (d, <sup>3</sup><i>J</i><sub>H,H</sub> = 6.7 Hz, 12 H). <sup>13</sup>C{<sup>1</sup>H} NMR (101 MHz, CDCl<sub>3</sub>): δ 169.0 (s, 1 C), 163.9 (br s, 2 C), 67.6 (s, 4 C), 48.4 (s, 4 C), 19.7 (s, 4 C). MALDI-MS: <i>m</i>/<i>z</i> = 342.3 ([M + H]<sup>+</sup>).</div></div><div id="sec4_1_54" class="NLM_sec NLM_sec_level_3"><div id="ac_i77" class="anchor-spacer"></div><h4 class="article-section__title" id="_i77"> 2-Chloro-4,6-bis[(3<i>S</i>,5<i>S</i>)-3,5-dimethylmorpholin-4-yl]-1,3,5-triazine (<b>50</b>)</h4><div class="NLM_p last"><b>50</b> was prepared according to general procedure 2 from (3<i>S</i>,5<i>S</i>)-3,5-dimethylmorpholine hydrochloride (345 mg, 2.28 mmol, 2.1 equiv) and cyanuric chloride (<b>40</b>, 200 mg, 1.08 mmol, 1.0 equiv) in the presence of <i>N</i>,<i>N</i>-diisopropylethylamine (790 μL, 4.54 mmol, 4.2 equiv). Purification by column chromatography on silica gel (cyclohexane/EtOAc 1:0 → 9:1) gave compound <b>50</b> (232 mg, 679 μmol, 63%) as a colorless solid. <sup>1</sup>H NMR (400 MHz, (CD<sub>3</sub>)<sub>2</sub>SO): δ 4.26–4.14 (m 4 H), 4.14–4.04 (m, 4 H), 3.65 (dd, <sup>2</sup><i>J</i><sub>H,H</sub> = 11 Hz, <sup>3</sup><i>J</i><sub>H,H</sub> = 2.2 Hz, 4 H), 1.34 (d, <sup>3</sup><i>J</i><sub>H,H</sub> = 2.2 Hz, 12 H). <sup>13</sup>C{<sup>1</sup>H} NMR (101 MHz, CDCl<sub>3</sub>): δ 169.0 (s, 1 C), 163.9 (br s, 2 C), 67.6 (s, 4 C), 48.4 (s, 4 C), 19.7 (s, 4 C). MALDI-MS: <i>m</i>/<i>z</i> = 342.7 ([M + H]<sup>+</sup>).</div></div><div id="sec4_1_55" class="NLM_sec NLM_sec_level_3"><div id="ac_i78" class="anchor-spacer"></div><h4 class="article-section__title" id="_i78"> 2-Chloro-4,6-bis[(2<i>R</i>,6<i>S</i>)-2,6-dimethylmorpholin-4-yl]-1,3,5-triazine (<b>51</b>)</h4><div class="NLM_p last"><b>51</b> was prepared according to general procedure 2 from (2<i>S</i>,6<i>R</i>)-2,6-dimethylmorpholine (656 mg, 5.70 mmol, 2.1 equiv) and cyanuric chloride (<b>40</b>, 500 mg, 2.72 mmol, 1.0 equiv) in the presence of <i>N</i>,<i>N</i>-diisopropylethylamine (2.00 mL, 11.4 mmol, 4.2 equiv). Purification by column chromatography on silica gel (cyclohexane/EtOAc 1:0 → 9:1) gave compound <b>51</b> (478 mg, 1.40 mmol, 51%) as a colorless solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 4.59–4.38 (m, 4 H), 3.64–3.51 (m, 4 H), 2.61–2.51 (m, 4 H), 1.24 (br s, 12 H). <sup>13</sup>C{<sup>1</sup>H} NMR (101 MHz, CDCl<sub>3</sub>): δ 169.6 (s, 1 C), 164.3 (s, 2 C), 71.9 (s, 2 C), 71.6 (s, 2 C), 48.9 (s, 4 C), 19.0 (s, 2 C), 18.8 (s, 2 C). MALDI-MS: <i>m</i>/<i>z</i> = 342.2 ([M + H]<sup>+</sup>).</div></div><div id="sec4_1_56" class="NLM_sec NLM_sec_level_3"><div id="ac_i79" class="anchor-spacer"></div><h4 class="article-section__title" id="_i79"> 2-Chloro-4,6-bis(2,2-dimethylmorpholin-4-yl)-1,3,5-triazine (<b>52</b>)</h4><div class="NLM_p last"><b>52</b> was prepared according to general procedure 1 from cyanuric chloride (<b>40</b>, 381 mg, 2.07 mmol, 1.0 equiv) and 2,2-dimethylmorpholine (500 mg, 4.34 mmol, 2.1 equiv) in the presence of <i>N</i>,<i>N</i>-diisopropylethylamine (1.50 mL, 8.69 mmol, 4.2 equiv). Purification by column chromatography on silica gel (cyclohexane/EtOAc 1:0 → 4:1) gave compound <b>52</b> (107 mg, 313 μmol, 15%) as a colorless solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 3.84–3.68 (m, 8 H), 3.65–3.52 (m, 4 H), 1.23 (s, 12 H). <sup>13</sup>C{<sup>1</sup>H} NMR (101 MHz, CDCl<sub>3</sub>): δ 169.8 (s, 1 C), 164.9 (s, 2 C), 71.6 (s, 1 C), 71.5 (s, 1 C), 60.7 (s, 1 C), 60.3 (s, 1 C), 52.6 (s, 2 C), 43.6 (s, 1 C), 43.4 (s, 1 C), 24.4 (s, 2 C), 24.2 (s, 2 C). MALDI-MS: <i>m</i>/<i>z</i> = 342.3 ([M + H]<sup>+</sup>).</div></div><div id="sec4_1_57" class="NLM_sec NLM_sec_level_3"><div id="ac_i80" class="anchor-spacer"></div><h4 class="article-section__title" id="_i80"> 5-(4-Chloro-6-{8-oxa-5-azaspiro[3.5]nonan-5-yl}-1,3,5-triazin-2-yl)-8-oxa-5-azaspiro[3.5]nonane (<b>53</b>)</h4><div class="NLM_p last"><b>53</b> was prepared according to general procedure 1 from cyanuric chloride (<b>40</b>, 345 mg, 1.87 mmol, 1.0 equiv) and 8-oxa-5-azaspiro[3.5]nonane (500 mg, 3.93 mmol, 2.1 equiv) in the presence of <i>N</i>,<i>N</i>-diisopropylethylamine (1.40 mL, 7.85 mmol, 4.2 equiv). Purification by column chromatography on silica gel (cyclohexane/EtOAc 1:0 → 9:1) gave compound <b>53</b> (451 mg, 1.23 mmol, 66%) as a colorless solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 3.80–3.65 (m, 8 H), 3.60–3.50 (m, 4 H), 2.55–2.42 (m, 4 H), 2.36–2.24 (m, 4 H), 1.84–1.71 (m, 2 H), 1.17–1.60 (m, 2 H). <sup>13</sup>C{<sup>1</sup>H} NMR (101 MHz, CDCl<sub>3</sub>): δ 168.8 (s, 1 C), 165.3 (s, 2 C), 71.1 (s, 2 C), 66.3 (s, 2 C), 61.0 (s, 2 C), 43.6 (s, 2 C), 31.2 (s, 4 C), 14.9 (s, 2 C). MALDI-MS: <i>m</i>/<i>z</i> = 366.2 ([M + H]<sup>+</sup>).</div></div><div id="sec4_1_58" class="NLM_sec NLM_sec_level_3"><div id="ac_i81" class="anchor-spacer"></div><h4 class="article-section__title" id="_i81"> 9-(4-Chloro-6-{3,7-dioxa-9-azabicyclo[3.3.1]nonan-9-yl}-1,3,5-triazin-2-yl)-3,7-dioxa-9-azabicyclo[3.3.1]nonane (<b>54</b>)</h4><div class="NLM_p last"><b>54</b> was prepared according to procedure 2 from 3,7-dioxa-9-azabicyclo[3.3.1]nonane (180 mg, 1.39 mmol, 2.0 equiv) and cyanuric chloride (<b>40</b>, 128 mg, 694 μmol, 1.0 equiv) in the presence of <i>N</i>,<i>N</i>-diisopropylethylamine (490 μL, 2.8 mmol, 4.0 equiv). Purification by column chromatography on silica gel (cyclohexane/EtOAc 1:1 → 0:1) gave compound <b>54</b> (191 mg, 516 μmol, 74%) as a colorless solid. <sup>1</sup>H NMR (400 MHz, (CD<sub>3</sub>)<sub>2</sub>SO): δ 4.42 (br s, 2 H), 4.32 (br s, 2 H), 4.05–3.91 (m, 8 H), 3.76–3.63 (m, 8 H). <sup>13</sup>C{<sup>1</sup>H} NMR (101 MHz, CDCl<sub>3</sub>): δ 170.6 (s, 1 C), 163.6 (s, 2 C), 69.8 (s, 4 C), 69.5 (s, 4 C), 48.9 (s, 2 C), 48.8 (s, 2 C). MALDI-MS: <i>m</i>/<i>z</i> = 370.2 ([M + H]<sup>+</sup>).</div></div><div id="sec4_1_59" class="NLM_sec NLM_sec_level_3"><div id="ac_i82" class="anchor-spacer"></div><h4 class="article-section__title" id="_i82"> 9-(4-Chloro-6-{3-oxa-9-azabicyclo[3.3.1]nonan-9-yl}-1,3,5-triazin-2-yl)-3-oxa-9-azabicyclo[3.3.1]nonane (<b>55</b>)</h4><div class="NLM_p last"><b>55</b> was prepared according to general procedure 1 from cyanuric chloride (<b>40</b>, 185 mg, 1.00 mmol, 1.0 equiv) and 3-oxa-9-azabicyclo[3.3.1]nonane hydrochloride (360 mg, 2.20 mmol, 2.2 equiv) in the presence of <i>N</i>,<i>N</i>-diisopropylethylamine (1.00 mL, 5.74 mmol, 5.7 equiv). Purification by column chromatography on silica gel (cyclohexane/EtOAc 1:0 → 9:1) gave compound <b>55</b> (297 mg, 812 μmol, 81%) as a colorless solid. <sup>1</sup>H NMR (400 MHz, (CD<sub>3</sub>)<sub>2</sub>SO): δ 4.48 (br s, 2 H), 4.42 (br s, 2 H), 3.95–3.86 (m, 4 H), 3.68–3.60 (m, 4 H), 2.51–2.38 (m, 2 H), 1.88–1.63 (m, 8 H), 1.59–1.49 (m, 2 H). <sup>13</sup>C{<sup>1</sup>H} NMR (101 MHz, CDCl<sub>3</sub>): δ 170.2 (s, 1 C), 163.5 (s, 2 C), 71.4–71.3 (m, 2 C), 71.2 (s, 1 C), 71.1 (s, 1 C), 47.9 (br s, 2 C), 47.8 (s, 1 C), 47.7 (s, 1 C), 29.4 (s, 1 C), 29.3 (s, 1 C), 28.9 (s, 1 C), 28.8 (s, 1 C), 20.5 (s, 2 C). MALDI-MS: <i>m</i>/<i>z</i> = 366.2 ([M + H]<sup>+</sup>).</div></div><div id="sec4_1_60" class="NLM_sec NLM_sec_level_3"><div id="ac_i83" class="anchor-spacer"></div><h4 class="article-section__title" id="_i83"> 4-[6-Chloro-2-(morpholin-4-yl)pyrimidin-4-yl]morpholine (<b>57</b>) and 4-[2-chloro-6-(morpholin-4-yl)pyrimidin-4-yl]morpholine (<b>58</b>)</h4><div class="NLM_p last"><b>57</b> and <b>58</b> were prepared according to the literature.<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a></div></div><div id="sec4_1_61" class="NLM_sec NLM_sec_level_3"><div id="ac_i84" class="anchor-spacer"></div><h4 class="article-section__title" id="_i84"> 8-(6-Chloro-2-{3-oxa-8-azabicyclo[3.2.1]octan-8-yl}pyrimidin-4-yl)-3-oxa-8-azabicyclo[3.2.1]octane (<b>59</b>) and 8-(2-Chloro-6-{3-oxa-8-azabicyclo[3.2.1]octan-8-yl}pyrimidin-4-yl)-3-oxa-8-azabicyclo[3.2.1]octane (<b>60</b>)</h4><div class="NLM_p last">To a solution of 2,4,6-trichloropyrimidine (<b>56</b>, 1.08 g, 5.88 mmol, 1.0 equiv) and 3-oxa-8-azabicyclo[3.2.1]octane hydrochloride (1.94 g, 13.0 mmol, 2.2 equiv) in ethanol (13 mL), <i>N</i>,<i>N</i>-diisopropylethylamine (4.51 mL, 25.9 mmol, 4.4 equiv) was added. The resulting mixture was stirred at reflux overnight. Then, the reaction mixture was allowed to cool down to room temperature, and the solvent was removed under reduced pressure. The residue was dissolved in CH<sub>2</sub>Cl<sub>2</sub> and washed with an aq satd NaHSO<sub>4</sub> solution, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and filtered, and the solvent was evaporated under reduced pressure. The products were separated by column chromatography on silica gel (cyclohexane/EtOAc 3:1 →1:1). Compound <b>59</b> (1.10 g, 3.27 mmol, 56%) and compound <b>60</b> (212 mg, 629 μmol, 11%) were obtained in two separate fractions. Compound <b>59</b>: <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 5.79 (s, 1 H), 4.59 (br s, 2 H), 4.52–4.15 (m, 2 H), 3.80–3.71 (m, 4 H), 3.62–3.55 (m, 4 H), 2.12–1.90 (m, 8 H). <sup>13</sup>C{<sup>1</sup>H} NMR (101 MHz, CDCl<sub>3</sub>): δ 161.5 (s, 1 C), 160.6 (s, 1 C), 160.2 (s, 1 C), 92.8 (s, 1 C), 71.7 (s, 2 C), 71.2 (s, 2 C), 55.4 (br s, 4 C), 27.1 (s, 2 C), 27.0 (s, 2 C). MALDI-MS: <i>m</i>/<i>z</i> = 337.1 ([M + H]<sup>+</sup>). Compound <b>60</b>: <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 5.25 (s, 1 H), 4.50–4.24 (m, 4 H), 3.76 (d, <i>J</i><sub>H,H</sub> = 11 Hz, 4 H), 3.62–3.54 (m, 4 H), 2.12–1.92 (m, 8 H). <sup>13</sup>C{<sup>1</sup>H} NMR (101 MHz, CDCl<sub>3</sub>): δ 161.8 (s, 2 C), 160.9 (s, 1 C), 81.4 (s, 1 C), 71.1 (br s, 4 C), 55.5 (s, 4 C), 26.9 (s, 4 C). MALDI-MS: <i>m</i>/<i>z</i> = 337.1 ([M + H]<sup>+</sup>).</div></div><div id="sec4_1_62" class="NLM_sec NLM_sec_level_3"><div id="ac_i85" class="anchor-spacer"></div><h4 class="article-section__title" id="_i85"> 4-(Difluoromethyl)pyridin-2-amine (<b>61</b>)</h4><div class="NLM_p last">Pd(OAc)<sub>2</sub> (275 mg, 1.22 mmol, 0.05 equiv) and 2-dicyclohexylphosphino-2′,4′,6′-triisopropylbiphenyl (XPhos, 1.17 g, 2.45 mmol, 0.10 equiv) were dissolved in dioxane (10 mL) under nitrogen atmosphere, and the resulting mixture was stirred at room temperature for 45 min. This solution was then added to a mixture of <i>tert</i>-butylcarbamate (4.30 g, 36.7 mmol, 1.5 equiv), Cs<sub>2</sub>CO<sub>3</sub> (15.9 g, 48.8 mmol, 2.0 equiv), and 2-chloro-4-(difluoromethyl)pyridine (4.00 g, 24.5 mmol, 1.0 equiv) in dioxane (80 mL) under nitrogen atmosphere. The reaction mixture was stirred at 90 °C for 3 h. After this time, the mixture was allowed to cool down to room temperature, diluted with EtOAc, washed with an aq satd NH<sub>4</sub>Cl solution (2×) and deionized H<sub>2</sub>O. The organic layer was dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and filtered, and the solvent was evaporated under reduced pressure. The brownish residue was mixed with 4 M HCl in dioxane (50 mL, excess) and CH<sub>3</sub>OH (20 mL) and heated at 80 °C for 45 min. Deionized H<sub>2</sub>O was added, and the aqueous layer was washed with EtOAc (3×). The aqueous layer was then basified to pH = 10, with solid NaOH. This aqueous layer was extracted with EtOAc (3×). The combined organic layers were dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated to dryness under reduced pressure. The desired product <b>61</b> (3.47 g, 24.1 mmol, 98%) was obtained as a colorless solid, which was used in the next step without further purification. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.16 (d, <sup>2</sup><i>J</i><sub>H,H</sub> = 5.2 Hz, 1 H), 6.74 (d, <sup>2</sup><i>J</i><sub>H,H</sub> = 4.8 Hz, 1 H), 6.59 (s, 1 H), 6.51 (t, <sup>2</sup><i>J</i><sub>H,F</sub> = 56 Hz, 1 H), 4.61 (br s, 2 H). <sup>13</sup>C{<sup>1</sup>H} NMR (101 MHz, CDCl<sub>3</sub>): δ 159.0 (s, 1 C), 149.1 (s, 1 C), 144.0 (t, <sup>2</sup><i>J</i><sub>C,F</sub> = 23 Hz, 1 C), 113.2 (t, <sup>1</sup><i>J</i><sub>C,F</sub> = 240 Hz, 1 C), 109.9 (t, <sup>3</sup><i>J</i><sub>C,F</sub> = 5.5 Hz, 1 C), 104.8 (t, <sup>3</sup><i>J</i><sub>C,F</sub> = 6.6 Hz, 1 C).</div></div><div id="sec4_1_63" class="NLM_sec NLM_sec_level_3"><div id="ac_i86" class="anchor-spacer"></div><h4 class="article-section__title" id="_i86"> 5-Bromo-4-(difluoromethyl)pyridin-2-amine (<b>62</b>)</h4><div class="NLM_p last">To a solution of 4-(difluoromethyl)pyridin-2-amine (<b>61</b>, 3.00 g, 20.8 mmol, 1.0 equiv) in tetrahydrofuran (60 mL), <i>N</i>-bromosuccinimide (3.89 g, 21.9 mmol, 1.05 equiv) was added at 0 °C. The resulting mixture was stirred overnight, while it was allowed to warm up to room temperature. EtOAc was added, and the organic layer was washed with an aq 8% Na<sub>2</sub>CO<sub>3</sub> solution. The organic layer was separated and acidified with an aq 3 M HCl solution. The aqueous layer was washed with EtOAc (3×) and then basified to pH = 10, with solid NaOH and extracted with EtOAc (3×). The combined organic layers were dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated to dryness under reduced pressure. The desired product <b>62</b> (3.65 g, 16.4 mmol, 79%) was obtained as a brownish solid, which was used in the next step without further purification. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.20 (s, 1 H), 6.75 (s, 1 H), 6.71 (t, <sup>2</sup><i>J</i><sub>H,F</sub> = 54 Hz, 1 H), 4.62 (br s, 2 H). <sup>13</sup>C{<sup>1</sup>H} NMR (101 MHz, CDCl<sub>3</sub>): δ 158.1 (s, 1 C), 150.7 (s, 1 C), 142.1 (t, <sup>2</sup><i>J</i><sub>C,F</sub> = 23 Hz, 1 C), 112.4 (t, <sup>1</sup><i>J</i><sub>C,F</sub> = 241 Hz, 1 C), 106.3 (t, <sup>3</sup><i>J</i><sub>C,F</sub> = 6.5 Hz, 1 C), 106.0 (t, <sup>3</sup><i>J</i><sub>C,F</sub> = 5.7 Hz, 1 C).</div></div><div id="sec4_1_64" class="NLM_sec NLM_sec_level_3"><div id="ac_i87" class="anchor-spacer"></div><h4 class="article-section__title" id="_i87"> <i>N</i>′-[5-Bromo-4-(difluoromethyl)pyridin-2-yl]-<i>N</i>,<i>N</i>-dimethylmethanimidamide (<b>63</b>)</h4><div class="NLM_p last">To a solution of 5-bromo-4-(difluoromethyl)pyridin-2-amine (<b>62</b>, 3.68 g, 16.5 mmol, 1.0 equiv) in tetrahydrofuran (50 mL), <i>N</i>,<i>N</i>-dimethylformamide dimethyl acetal (3.30 mL, 24.8 mmol, 1.5 equiv) was added, and the resulting mixture was stirred at 60 °C for 3 h. The mixture was allowed to cool down to room temperature, and the solvent was evaporated under reduced pressure. The crude product was purified by column chromatography on silica gel (cyclohexane/EtOAc 1:1) to afford the desired compound <b>63</b> as a yellowish solid (3.76 g, 13.5 mmol, 82%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.43 (s, 1 H), 8.34 (br s, 1 H), 7.17 (s, 1 H), 6.73 (t, <sup>2</sup><i>J</i><sub>H,F</sub> = 54 Hz, 1 H), 3.12 (s, 3 H), 3.10 (s, 3 H). <sup>13</sup>C{<sup>1</sup>H} NMR (101 MHz, CDCl<sub>3</sub>): δ 162.1 (s, 1 C), 155.8 (s, 1 C), 150.5 (s, 1 C), 141.9 (t, <sup>2</sup><i>J</i><sub>C,F</sub> = 23 Hz, 1 C), 115.8 (t, <sup>3</sup><i>J</i><sub>C,F</sub> = 6.2 Hz, 1 C), 112.6 (t, <sup>1</sup><i>J</i><sub>C,F</sub> = 240 Hz, 1 C), 110.4 (t, <sup>3</sup><i>J</i><sub>C,F</sub> = 5.7 Hz, 1 C), 41.0 (s, 1 C), 34.8 (s, 1 C).</div></div><div id="sec4_1_65" class="NLM_sec NLM_sec_level_3"><div id="ac_i88" class="anchor-spacer"></div><h4 class="article-section__title" id="_i88"> <i>N</i>′-[4-(Difluoromethyl)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-yl]-<i>N</i>,<i>N</i>-dimethylmethanimidamide (<b>64</b>)</h4><div class="NLM_p last">Step 1<i>:</i> To a 2 M solution of isopropylmagnesium chloride (3.10 mL, 6.20 mmol, 1.2 equiv) in tetrahydrofuran (6 mL) was slowly added a solution of <i>N</i>′-[5-bromo-4-(difluoromethyl)pyridin-2-yl]-<i>N</i>,<i>N</i>-dimethylmethanimidamide (<b>63</b>, 1.50 g, 5.39 mmol, 1.0 equiv) in tetrahydrofuran (5 mL) at 0 °C. The resulting brownish mixture was stirred at 0 °C for 45 min and then at room temperature for 15 min. After this time, TLC analysis showed complete consumption of the starting material. Step 2: 2-Isopropoxy-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (1.43 mL, 7.00 mmol, 1.3 equiv) was added, and the mixture was stirred at 60 °C for 3 h. The mixture was then placed in an Erlenmeyer flask, cooled to 0 °C, and quenched with a 15% aq NH<sub>4</sub>Cl solution. The layers were separated and the aqueous layer was extracted with EtOAc (3×). The combined organic layers were dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and filtered, and the solvent was evaporated under reduced pressure. The residue was dissolved in heptanes and washed with an aq satd NaHCO<sub>3</sub> solution. The organic layer was dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and filtered, and the solvents were evaporated under reduced pressure. The desired product <b>64</b> (1.64 g, 5.04 mmol, 94%) was obtained as a brownish oil, which was used in the next step without further purification. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.66 (s, 1 H), 8.51 (s, 1 H), 7.34–7.04 (m, 2 H), 3.12 (s, 3 H), 3.12 (s, 3 H), 1.34 (s, 12 H). <sup>13</sup>C{<sup>1</sup>H} NMR (101 MHz, CDCl<sub>3</sub>): δ 164.9 (s, 1 C), 156.3 (s, 1 C), 156.0 (s, 1 C), 149.2 (t, <sup>2</sup><i>J</i><sub>C,F</sub> = 22 Hz, 1 C), 115.5–112.3 (br s, 1 C), 113.3 (t, <sup>2</sup><i>J</i><sub>C,F</sub> = 6.4 Hz, 1 C), 112.6 (t, <sup>1</sup><i>J</i><sub>C,F</sub> = 238 Hz, 1 C), 84.0 (s, 2 C), 41.0 (s, 1 C), 34.8 (s, 1 C), 24.8 (s, 4 C). MALDI-MS: <i>m</i>/<i>z</i> = 326.0 ([M + H]<sup>+</sup>).</div></div><div id="sec4_1_66" class="NLM_sec NLM_sec_level_3"><div id="ac_i89" class="anchor-spacer"></div><h4 class="article-section__title" id="_i89"> (2-Amino-5-bromopyridin-4-yl)methanol (<b>65</b>)</h4><div class="NLM_p last">(2-Aminopyridin-4-yl)methanol (2.00 g, 16.1 mmol, 1.0 equiv) was dissolved in acetonitrile (80 mL) at −15 °C. <i>N</i>-Bromosuccinimide (3.01 g, 16.9 mmol, 1.1 equiv) was added portionwise, and the resulting reaction mixture was stirred at −15 °C for 1 h. Then the solvent was removed under reduced pressure, the crude residue was dissolved in EtOAc, and an aq satd Na<sub>2</sub>CO<sub>3</sub> solution was added. The organic layer was separated, and the aqueous layer was extracted with EtOAc (3×). The combined organic layers were dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and filtered, and the solvent was evaporated under reduced pressure. The desired product <b>65</b> (2.30 g, 11.3 mmol, 70%) was obtained as a colorless solid, which was used in the next step without further purification. <sup>1</sup>H NMR (400 MHz, (CD<sub>3</sub>)<sub>2</sub>SO): δ 7.86 (s, 1 H), 6.67 (br s, 1 H), 6.11 (br s, 2 H), 5.45 (t, <sup>3</sup><i>J</i><sub>H,H</sub> = 5.6 Hz, 1 H), 4.35 (dd, <sup>3</sup><i>J</i><sub>H,H</sub> = 5.6 Hz, <sup>4</sup><i>J</i><sub>H,H</sub> = 1.2 Hz, 2 H). <sup>13</sup>C{<sup>1</sup>H} NMR (101 MHz, (CD<sub>3</sub>)<sub>2</sub>SO): δ 159.3 (s, 1 C), 150.1 (s, 1 C), 148.0 (s, 1 C), 106.7 (s, 1 C), 104.4 (s, 1 C), 61.8 (s, 1 C).</div></div><div id="sec4_1_67" class="NLM_sec NLM_sec_level_3"><div id="ac_i90" class="anchor-spacer"></div><h4 class="article-section__title" id="_i90"> 5-Bromo-4-(fluoromethyl)pyridin-2-amine (<b>66</b>)</h4><div class="NLM_p last">To a solution of compound <b>65</b> (200 mg, 985 μmol, 1.0 equiv) in CH<sub>2</sub>Cl<sub>2</sub> (10 mL) at 0 °C under nitrogen atmosphere, <i>N,N</i>-diethyl-<i>S,S</i>-difluorosulfiliminium tetrafluoroborate (XtalFluor-E, 338 mg, 1.48 mmol, 1.5 equiv) and triethylamine trihydrofluoride (241 μL, 1.48 mmol, 1.5 equiv) were added. The resulting mixture was stirred overnight while it was allowed to warm up to room temperature. Then the mixture was poured onto aq satd NaHCO<sub>3</sub> solution at 0 °C and extracted with CH<sub>2</sub>Cl<sub>2</sub> (3×). The combined organic layers were dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and filtered, and the solvent was evaporated under reduced pressure. Purification by column chromatography on silica gel (CH<sub>2</sub>Cl<sub>2</sub>/EtOAc 1:0 → 7:3) gave compound <b>66</b> (70.9 mg, 346 μmol, 45%) as a colorless solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.09 (s, 1 H), 6.63 (s, 1 H), 5.35 (dd, <sup>2</sup><i>J</i><sub>H,F</sub> = 47 Hz, <sup>4</sup><i>J</i><sub>H,H</sub> = 1.1 Hz, 2 H), 4.52 (br s, 2 H). <sup>13</sup>C{<sup>1</sup>H} NMR (101 MHz, (CD<sub>3</sub>)<sub>2</sub>SO): δ 159.4 (s, 1 C), 148.9 (s, 1 C), 144.3 (d, <sup>2</sup><i>J</i><sub>C,F</sub> = 18 Hz, 1 C), 106.5 (d, <sup>3</sup><i>J</i><sub>C,F</sub> = 11 Hz, 1 C), 103.2 (d, <sup>3</sup><i>J</i><sub>C,F</sub> = 5.6 Hz, 1 C), 82.4 (d, <sup>1</sup><i>J</i><sub>C,F</sub> = 169 Hz, 1 C).</div></div><div id="sec4_1_68" class="NLM_sec NLM_sec_level_3"><div id="ac_i91" class="anchor-spacer"></div><h4 class="article-section__title" id="_i91"> <i>N</i>′-[5-Bromo-4-(fluoromethyl)pyridin-2-yl]-<i>N</i>,<i>N</i>-dimethylmethanimidamide (<b>67</b>)</h4><div class="NLM_p last">Compound <b>66</b> (57.0 mg, 278 μmol, 1.0 equiv) was dissolved in tetrahydrofuran (1.5 mL), and <i>N</i>,<i>N</i>-dimethylformamide dimethyl acetal (93.0 μL, 700 mmol, 2.5 equiv) was added. The reaction mixture was stirred at 70 °C overnight. Then the solvent was evaporated under reduced pressure. EtOAc and deionized H<sub>2</sub>O was added to the residue. The organic layer was separated, and the aqueous layer was extracted with EtOAc (3×). The combined organic layers were dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered, and reduced to dryness under reduced pressure. The desired product <b>67</b> (65.1 g, 250 μmol, 90%) was obtained as a colorless solid, which was used in the next step without further purification. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.40 (s, 1 H), 8.25 (s, 1 H), 7.06 (s, 1 H), 5.37 (d, <sup>2</sup><i>J</i><sub>H,F</sub> = 47 Hz, <sup>4</sup><i>J</i><sub>H,H</sub> = 1.1 Hz, 2 H), 3.10 (s, 3 H), 3.09 (s, 3 H). <sup>13</sup>C{<sup>1</sup>H} NMR (101 MHz, CDCl<sub>3</sub>): δ 161.9 (s, 1 C), 155.7 (s, 1 C), 149.5 (s, 1 C), 145.9 (d, <sup>2</sup><i>J</i><sub>C,F</sub> = 19 Hz, 1 C), 116.1 (d, <sup>3</sup><i>J</i><sub>C,F</sub> = 11 Hz, 1 C), 110.5 (d, <sup>3</sup><i>J</i><sub>C,F</sub> = 6.1 Hz, 1 C), 82.5 (d, <sup>1</sup><i>J</i><sub>C,F</sub> = 173 Hz, 1 C), 41.0 (s, 1 C), 34.9 (s, 1 C).</div></div><div id="sec4_1_69" class="NLM_sec NLM_sec_level_3"><div id="ac_i92" class="anchor-spacer"></div><h4 class="article-section__title" id="_i92"> <i>N</i>′-[5-Bromo-4-{[<i>tert</i>-butyl(dimethyl)silyl]oxymethyl]-2-pyridyl}-<i>N</i>,<i>N</i>-dimethyl-formamidine (<b>68</b>)</h4><div class="NLM_p last">Step 1: (2-Amino-5-bromopyridin-4-yl)methanol (<b>65</b>, 2.20 g, 10.8 mmol, 1.0 equiv) was dissolved in tetrahydrofuran (50 mL), and <i>N</i>,<i>N</i>-dimethylformamide dimethyl acetal (2.70 mL, 20.2 mmol, 1.9 equiv) was added. The reaction mixture was stirred at 70 °C overnight. Then the solvent was evaporated under reduced pressure. EtOAc and deionized H<sub>2</sub>O was added to the residue. The organic layer was separated, and the aqueous layer was extracted with EtOAc (3×). The combined organic layers were dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered, and reduced to dryness under reduced pressure. Step 2: The above residue and imidazole (2.21 g, 32.4 mmol, 3.0 equiv) were dissolved in <i>N</i>,<i>N</i>-dimethylformamide (90 mL), and <i>tert</i>-butyldimethylsilyl chloride (1.86 g, 12.3 mmol, 1.1 equiv) was added. The reaction mixture was stirred for 1 h at room temperature. An aq satd NaHCO<sub>3</sub> solution and EtOAc were added. The organic layer was separated, and the aqueous layer was extracted with EtOAc (3×). The combined organic layers were dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered, and reduced to dryness under reduced pressure. Purification by column chromatography on silica gel (cyclohexane/EtOAc 1:0 →1:1) gave compound <b>68</b> (1.82 g, 4.89 mmol, 45%) as a colorless semisolid. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD): δ 8.36 (s, 1 H), 8.17 (s, 1 H), 7.18 (s, 1 H), 4.70 (d, <sup>4</sup><i>J</i><sub>H,H</sub> = 1.2 Hz, 2 H), 3.15 (s, 3 H), 3.07 (s, 3 H), 0.99 (s, 9 H), 0.17 (s, 6 H). <sup>13</sup>C{<sup>1</sup>H} NMR (101 MHz, CD<sub>3</sub>OD): δ 162.8 (s, 1 C), 157.9 (s, 1 C), 152.3 (s, 1 C), 149.7 (s, 1 C), 116.9 (s, 1 C), 112.8 (s, 1 C), 65.1 (s, 1 C), 41.4 (s, 1 C), 35.2 (s, 1 C), 26.4 (s, 3 C), 19.3 (s, 1 C), – 5.35 (s, 2 C). MALDI-MS: <i>m</i>/<i>z</i> = 372.0 ([M + H]<sup>+</sup>).</div></div><div id="sec4_1_70" class="NLM_sec NLM_sec_level_3"><div id="ac_i93" class="anchor-spacer"></div><h4 class="article-section__title" id="_i93"> 5-Bromo-4-(dimethoxymethyl)pyridin-2-amine (<b>69</b>)</h4><div class="NLM_p last">4-(Dimethoxymethyl)pyridine-2-amine (2.00 g, 11.9 mmol, 1.0 equiv) was dissolved in 2-methyltetrahydrofuran (24 mL) at 0 °C. <i>N</i>-Bromosuccinimide (2.23 g, 12.5 mmol, 1.1 equiv) was added portionwise, and the resulting reaction mixture was stirred at 0 °C for 1 h. The cooling bath was removed, and the reaction mixture was further stirred at room temperature overnight. Then an aq satd Na<sub>2</sub>CO<sub>3</sub> solution was added. The organic layer was separated, and the aqueous layer was extracted with 2-methyltetrahydrofuran (2×). The combined organic layers were dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and filtered, and the solvent was evaporated under reduced pressure. Purification by column chromatography on silica gel (cyclohexane/EtOAc 1:0 → 4:1) gave compound <b>69</b> (2.59 g, 10.5 mmol, 88%) as a yellowish solid. <sup>1</sup>H NMR (400 MHz, (CD<sub>3</sub>)<sub>2</sub>SO): δ 7.98 (s, 1 H), 6.65 (s, 1 H), 6.23 (br s, 2 H), 5.28 (s, 1 H), 3.28 (s, 6 H). <sup>13</sup>C{<sup>1</sup>H} NMR (101 MHz, CDCl<sub>3</sub>): δ 157.9 (s, 1 C), 150.1 (s, 1 C), 146.0 (s, 1 C), 108.2 (s, 1 C), 108.0 (s, 1 C), 101.5 (s, 1 C), 53.9 (s, 2 C).</div></div><div id="sec4_1_71" class="NLM_sec NLM_sec_level_3"><div id="ac_i94" class="anchor-spacer"></div><h4 class="article-section__title" id="_i94"> <i>tert</i>-Butyl <i>N</i>-[5-Bromo-4-(dimethoxymethyl)pyridin-2-yl]-<i>N</i>-[(<i>tert</i>-butoxy)carbonyl]carba-mate (<b>70</b>)</h4><div class="NLM_p last"><b>70</b> was prepared according to general procedure 7 from intermediate <b>69</b> (2.58 g, 10.4 mmol, 1.0 equiv). Purification by column chromatography on silica gel (cyclohexane/EtOAc 1:0 → 9:1) gave the desired product <b>70</b> (1.29 g, 2.88 mmol, 28%) as a yellowish oil. <sup>1</sup>H NMR (400 MHz, (CD<sub>3</sub>)<sub>2</sub>SO): δ 8.65 (s, 1 H), 7.44 (s, 1 H), 5.50 (s, 1 H), 3.32 (s, 6 H), 1.39 (s, 18 H). <sup>13</sup>C{<sup>1</sup>H} NMR (101 MHz, CDCl<sub>3</sub>): δ 151.6 (s, 1 C), 151.0 (s, 2 C), 150.9 (s, 1 C), 147.0 (s, 1 C), 121.7 (s, 1 C), 118.6 (s, 1 C), 100.7 (s, 1 C), 83.4 (s, 2 C), 53.4 (s, 2 C), 28.0 (s, 6 C).</div></div><div id="sec4_1_72" class="NLM_sec NLM_sec_level_3"><div id="ac_i95" class="anchor-spacer"></div><h4 class="article-section__title" id="_i95"> <i>tert</i>-Butyl <i>N</i>-(5-Bromo-4-methoxypyridin-2-yl)-<i>N</i>-[(<i>tert</i>-butoxy)carbonyl]carbamate (<b>71</b>)</h4><div class="NLM_p last"><b>71</b> was prepared according to general procedure 7 from 5-bromo-4-methoxypyridin-2-amine (2.00 g, 9.85 mmol, 1.0 equiv). Purification by column chromatography on silica gel (cyclohexane/EtOAc 1:0 → 4:1) gave the desired product <b>71</b> (914 mg, 2.27 mmol, 23%) as a colorless solid. <sup>1</sup>H NMR (400 MHz, (CD<sub>3</sub>)<sub>2</sub>SO): δ 8.44 (s, 1 H), 7.26 (s, 1 H), 3.93 (s, 3 H), 1.40 (s, 18 H). <sup>13</sup>C{<sup>1</sup>H} NMR (101 MHz, (CD<sub>3</sub>)<sub>2</sub>SO): δ 162.7 (s, 1 C), 152.8 (s, 1 C), 150.5 (s, 1 C), 149.7 (s, 2 C), 107.5 (s, 1 C), 106.2 (s, 1 C), 82.8 (s, 2 C), 57.0 (s, 1 C), 27.5 (s, 6 C).</div></div><div id="sec4_1_73" class="NLM_sec NLM_sec_level_3"><div id="ac_i96" class="anchor-spacer"></div><h4 class="article-section__title" id="_i96"> <i>N</i>,<i>N</i>-Dimethyl-<i>N</i>′-[5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-4-(trifluoromethyl)pyridin-2-yl]methanimidamide (<b>72</b>)</h4><div class="NLM_p last"><b>72</b> was prepared according to the literature.<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a></div></div></div><div id="sec4_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i97" class="anchor-spacer"></div><h3 class="article-section__title" id="_i97"> Determination of Inhibitor Dissociation Constants</h3><div class="NLM_p last">Dissociation constants of compounds (<i>K</i><sub>i</sub>) for p110α and mTOR were determined by commercial LanthaScreen (Life Technologies) and evaluated as described in detail in ref <a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a>. In brief, AlexaFluor647-labeled Kinase Tracer314 (no PV6087) with a <i>K</i><sub>d</sub> of 2.2 nM was used at 20 nM for p110α, and at a final concentration of 10 nM for mTOR (<i>K</i><sub>d</sub> of 19 nM). Recombinant N-terminally (His)<sub>6</sub>-tagged p110α was detected with biotinylated anti-(His)<sub>6</sub>-tag antibody (2 nM, no. PV6089) and LanthaScreen Eu-Steptavidin (2 nM, no. PV5899); N-terminal GST fused to truncated mTOR (amino acids 1360–2549; no. PR8683B) was detected with a LanthaScreen Eu-labeled anti-GST antibody (2 nM, no. PV5594). The p110α assay buffer was composed of 50 mM HEPES pH 7.5, 10 mM MgCl<sub>2</sub>, 1 mM EGTA, and 0.01% (v/v) Brij-35, and the mTOR assay buffer contained 50 mM HEPES, 5 mM MgCl<sub>2</sub>, 1 mM EGTA, and 0.01% Pluronic F-127.</div></div><div id="sec4_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i98" class="anchor-spacer"></div><h3 class="article-section__title" id="_i98"> Structure Modeling of PI3K and mTOR Kinase Complexes</h3><div class="NLM_p last">The coordinates of the PQR309 (<b>1</b>)–PI3Kγ complex (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5OQ4">5OQ4</a>; resolution of 2.7 Å) and mTOR kinase bound to PI103 (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4JT6">4JT6</a>; 3.6 Å) were used as starting points to dock molecules into the ATP-binding sites. Docking of inhibitors was performed using SwissDock (<a href="http://swissdock.ch" class="extLink">swissdock.ch</a>), and energy minimization was performed using YASARA’s default settings. Alternatively, ligands in crystal structures were manually replaced or substituted. Further measurements and figures were generated in PyMOL 1.7 and Maestro 11.1.</div></div><div id="sec4_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i99" class="anchor-spacer"></div><h3 class="article-section__title" id="_i99"> Kinome Profiling</h3><div class="NLM_p last">Selectivity and kinase cross-reactivities of indicated compounds were assessed with the ScanMax platform from DiscoverX.<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> Binding of immobilized ligand to DNA-tagged kinases was completed with 10 μM compound, and kinase bound to the immobilized ligand was determined by quantitative PCR of the respective DNA tags. Binding constants were determined by competing immobilized ligand kinase interactions with an 11-point 3-fold serial dilution of compound starting from 30 μM. Binding constants were calculated by a dose–response curve using the Hill equation with Hill Slope set to −1.<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a></div></div><div id="sec4_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i100" class="anchor-spacer"></div><h3 class="article-section__title" id="_i100"> Cell Cycle Analysis</h3><div class="NLM_p last">A2058 cells (1–2 × 10<sup>5</sup> cells/mL) or SKOV3 cells (0.25–0.5 × 10<sup>5</sup> cells/mL) were seeded in DMEM supplemented with 10% heat-inactivated FCS, 1% <span class="smallcaps smallerCapital">l</span>-glutamine, and 1% penicillin–streptomycin (2 mL/well of 6-well plates). The day after, inhibitors (5 μM for A2058, 2 μM for SKOV3) were added for 24 h. Subsequently, nonadherent cells were collected by centrifugation, adherent cells were detached, fixed, and permeabilized, combined with the previously nonadherent cells, in PBS supplemented with 4% paraformaldehyde/1% bovine serum albumin/0.1% TritonX-100 for 30 min at 4 °C then washed with 1% bovine serum albumin/0.1% TritonX-100 in PBS followed by DNA-staining with 1 μg/mL Hoechst33342 in 1% bovine serum albumin/0.1% TritonX-100 in PBS (>1 h, RT, in the dark). Cell cycle profiles were acquired by fluorescence activated cell sorting (FACSCanto II, Becton Dickinson) and analyzed with FlowJo (Treestar) software.</div></div><div id="sec4_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i101" class="anchor-spacer"></div><h3 class="article-section__title" id="_i101"> Viability Studies on <b>66</b> Cell Lines</h3><div class="NLM_p last">The NTRC Oncolines 66 cell lines were exposed for 72 h to 9-point 3-fold serial dilutions of PQR620 (<b>3</b>) as described in ref <a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a>. The IC<sub>50</sub>s were calculated by nonlinear regression using IDBS XLfit 5. The percentage growth after 72 h (%-growth) was normalized as follows: 100% × (luminescence<sub><i>t</i>=72h</sub>/luminescence<sub>untreated,<i>t</i>=72h</sub>). This was fitted to a four-parameter logistics curve: % growth = bottom + (top – bottom)/(1+ 10<sup>[(logIC<sub>50</sub>–log<i>x</i>)×HillSlope]</sup>), where bottom and top are the asymptotic minimum and maximum cell growth that the compound allows in that assay.</div></div><div id="sec4_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i102" class="anchor-spacer"></div><h3 class="article-section__title" id="_i102"> Microscopy-Based Proliferation Assay for A2058 and SKOV3 Cells</h3><div class="NLM_p last">IC<sub>50</sub>s of A2058 or SKOV3 cell proliferation were determined and calculated as in ref <a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a>.</div></div><div id="sec4_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i103" class="anchor-spacer"></div><h3 class="article-section__title" id="_i103"> Cellular PI3K and mTOR Signaling</h3><div class="NLM_p last">Downstream signals emerging from TORC2 (phosphorylation of Ser473 of PKB/Akt; rabbit polyclonal antibody from Cell Signaling Technology (CST), no. 4058) and TORC1 (phosphorylation of Ser235/236 on the ribosomal protein S6; rabbit monoclonal antibody from CST, no. 4856) were measured by In-Cell Western plating 2 × 10<sup>4</sup> A2058 or 1.6 × 10<sup>4</sup> SKOV3 cells/well in 96-well plates (Cell Carrier, PerkinElmer) for 24 h (37 °C, 5% CO<sub>2</sub>) before exposing cells for 1 h to inhibitors or DMSO. Then, cells were fixed (4% PFA in PBS for 30 min at RT), blocked (1% BSA/0.1% Triton X-100/5% goat serum in PBS for 30 min, RT), and stained with CST primary antibodies (1:500). Tubulin staining (mouse anti-α-tubulin, 1:2000, Sigma no. T9026) was assessed as an internal standard. Secondary antibody [IRDye680-conjugated goat antimouse, and IRDye800-conjugated goat antirabbit antibodies (LICOR no. 926-68070 and no. 926-32211), both 1:500] fluorescence was detected on an Odyssey CLx infrared imaging scanner (LICOR). Percentage of remaining phospho-substrate signals were calculated in relation to cellular tubulin.<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a></div></div><div id="sec4_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i104" class="anchor-spacer"></div><h3 class="article-section__title" id="_i104"> Western Blotting</h3><div class="NLM_p last">Cells were lysed in lysis buffer (20 mM Tris-HCl pH 8, 138 mM NaCl, 2.7 mM KCl, 5% glycerol, 1% NP-40), and cleared supernatants were denatured by boiling (96 °C, 6 min) after adding 5× sample buffer. Cellular protein amounts were adjusted and subjected to SDS-PAGE and transferred to Immobilon FL membranes (Millipore). Primary antibodies to pSer473-PKB/Akt (no. 4058L), pThr308-PKB/Akt (no. 4056L), PKB/AKT (no. 2929S), pT389-S6K1 (no. 9206S), and pS235/236 ribosomal protein S6 (no. 4856S); S6K1 (no. 9202S), ribosomal protein S6 (no. 2317S), pSer65 4EBP1 (no. 9456), and 4EBP1 (no. 9452S) were all from CST; α-tubulin (no. T9026) was from Sigma. HRP-conjugated secondary antibodies were detected by chemiluminescence on a Fusion FX (Vilber Lourmat) imaging system.</div></div><div id="sec4_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i105" class="anchor-spacer"></div><h3 class="article-section__title" id="_i105"> Formulation of Compounds and in Vivo Pharmacology</h3><div class="NLM_p last">PQR620 (<b>3</b>) and PQR309 (<b>1</b>) (12.5 mg) were dissolved in DMSO (0.25 mL) by vortexing and sonication. After the addition of 2.25 mL of 20% HP-β-CD (hydroxypropyl-β-cyclodextrin/water), the mixture was vortexed and sonicated to get 2.5 mL dosing solution (dose volume: 10 μL/g). Formulations were homogeneous at the time of application. Experimental procedures in male C57BL/6J mice were in accordance with regulations of the Landesamt für Gesundheit and Verbraucherschutz, Saarbrücken); female Sprague–Dawley (SD) rat studies were carried out according to the NRC Guide for the Care and Use of Laboratory Animals, authorized by the French authorities (Agreement no. A21231011EA) and overviewed by the Animal Care and Use Committee of Oncodesign (CNREEA agreement no. 91).</div></div><div id="sec4_11" class="NLM_sec NLM_sec_level_2"><div id="ac_i106" class="anchor-spacer"></div><h3 class="article-section__title" id="_i106"> OVCAR-3 Xenograft Mouse Tumor Model</h3><div id="sec4_11_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i107" class="anchor-spacer"></div><h4 class="article-section__title" id="_i107"> OVCAR-3 Cell cCulture</h4><div class="NLM_p last">Cells were cultured as monolayer in DMEM medium supplemented with 10% fetal bovine serum at 37 °C and 5% CO<sub>2</sub>. Cells were passaged by trypsin-EDTA treatment and harvested in the exponential growth phase tumor inoculation.</div></div><div id="sec4_11_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i108" class="anchor-spacer"></div><h4 class="article-section__title" id="_i108"> Tumor Inoculation and Group Assignments</h4><div class="NLM_p last">Each mouse (female BALB/c nude; age: 8–9 weeks) was inoculated subcutaneously with 5 × 10<sup>6</sup> cells (in 0.1 mL PBS) into the right flank. At treatment start mean tumor size was ca. 157 mm<sup>3</sup>, body weight and tumor volume were assessed, and randomized groups using a randomized block design based on tumor volumes were established. Tumor cell inoculation is depicted as day 0.</div></div><div id="sec4_11_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i109" class="anchor-spacer"></div><h4 class="article-section__title" id="_i109"> Data Collection and Termination</h4><div class="NLM_p last">Animals were monitored daily for mobility, visual estimation of food and water consumption, eye/hair matting, morbidity, mortality, tumor growth and potential macroscopic adverse effects of drug treatment. Body weight and tumor volumes were determined three times weekly. The latter was determined in two dimensions using a caliper, and the volume was expressed in mm<sup>3</sup> using the formula:<span class="NLM_disp-formula" id="ueq1"><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b01262/20181119/images/medium/jm-2018-012622_m001.gif" alt="" id="_i110" /></img></span>where <i>a</i> and <i>b</i> are the long and short diameters of the tumor. All mice were terminated on day 45 after the tumor inoculation, when the excised tumor was weighted. BALB/c nude mice were from Shanghai Lingchang Bio-Technology Co. Ltd. All animal procedures were approved by the Institutional Animal Care and Use Committee (IACUC) of CrownBio. Care and use of animals was in accordance with the regulations of the Association for Assessment and Accreditation of Laboratory Animal Care (AAALAC).</div></div></div><div id="sec4_12" class="NLM_sec NLM_sec_level_2"><div id="ac_i111" class="anchor-spacer"></div><h3 class="article-section__title" id="_i111"> Determination of Seizures in <i>Tsc1</i><sup>GFAP</sup> Conditional Knockout Mice</h3><div class="NLM_p">A previously established mouse model of TSC with conditional inactivation of the Tsc1 gene in glial fibrillary acidic protein (GFAP)-positive cells (<i>Tsc1</i><sup>GFAP</sup> conditional knockout mice), which develops progressive epilepsy, encephalopathy, and premature death, was used.<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a></div><div id="sec4_12_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i112" class="anchor-spacer"></div><h4 class="article-section__title" id="_i112"> Animals</h4><div class="NLM_p last">Tsc1<sup>flox/flox</sup>/GFAP-Cre mice of either sex were bred at PsychoGenics using breeding pairs obtained from M. Wong’s Laboratory (Washington University, St. Louis, MO) to generate a tissue-specific knockout of Tsc1 in GFAP-positive cells. All mice were handled according to the PsychoGenics ethical guidelines. Light/dark cycles were maintained at 12 h/12 h, temperature was 20–23 °C, and humidity ∼50%. Food and water ad libitum. Mice were randomly assigned to designated treatment groups, and dosing was performed during the light cycle phase. Assessment and approval of the study by the Association for Assessment and Accreditation of Laboratory Animal Care (approval IACUC 282_0616).</div></div><div id="sec4_12_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i113" class="anchor-spacer"></div><h4 class="article-section__title" id="_i113"> Surgery</h4><div class="NLM_p last">Aseptic techniques were used throughout all surgery. Mice were anesthetized with isoflurane with homeostatic heating to maintain core temperature at 37 ± 1 °C. An 8201-EEG head mount (Pinnacle Technology, Inc., Lawrence, KS) with bihemispheric leads in the frontal and parietal cortices and an indwelling local field potential electrode targeting the region above the CA1 were used. Before, during, and after surgery, animals were administered fluids, nutrition, antibiotics, and analgesics as required/recommended by the Program of Veterinary Care (PVC) team and IACUC, in concert with the Attending Veterinarian and/or according to IACUC Guidelines. Mice were implanted with electrodes at the age of postnatal day (PND) 22 to PND27 and allowed to recover for up to 4 weeks of age (PND35).</div></div><div id="sec4_12_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i114" class="anchor-spacer"></div><h4 class="article-section__title" id="_i114"> EEG Recording</h4><div class="NLM_p last">EEG was recorded continuously using the Pinnacle Technology 8206 data conditioning and acquisition system (DCAS), and real-time visualization of all EEG channels from all mice was observed using Sirenia or PAL-8400 software. Synchronized video recordings were collected for the duration of the EEG recordings.</div></div><div id="sec4_12_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i115" class="anchor-spacer"></div><h4 class="article-section__title" id="_i115"> Test Compound and Treatments</h4><div class="NLM_p last">Vehicle (sulfobutyl-ether-β-cyclodextrin, Captisol, Dexolve; SBECD) was obtained from DavosPharma (Liberty, MO). Compounds were initially dissolved in acidified 23.5% SBECD (5.0 mL of 40% SBECD + 3.5 mL of H<sub>2</sub>O + 0.2 M HCl as needed). Solution pH was adjusted to be within 2.2 and 2.7 using 0.2 M NaOH and diluted to a final volume of 10.0 mL to yield a Vehicle of 20% SBECD (pH 3.0 ± 0.1). Mice in the study were randomly assigned to one of the following treatment groups: Vehicle 10 mL/kg (20% SBECD; PND21-53; po qd), PQR620 (<b>3</b>) (100 mg/kg; group B; PND21-53; po qd), and PQR309 (<b>1</b>) (50 mg/kg; group C; PND21-53; po qd). Stock 40% SBECD was stored at 4 °C. Vehicle and compound solutions were prepared fresh weekly.</div></div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes-2"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i116"><a href="/doi/suppl/10.1021/acs.jmedchem.8b01262" class="ext-link">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_65252" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_65252" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a href="/" class="ext-link">ACS Publications website</a> at DOI: <a href="/doi/abs/10.1021/acs.jmedchem.8b01262" class="ext-link">10.1021/acs.jmedchem.8b01262</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">Information on amino acid conservation of PI3K/mTOR structural elements influencing the −CHF<sub>2</sub> dipole and structural elements of PI3K/mTOR close to morpholine bridge; a docking model of mTOR kinase with bound PQR620 (<b>3</b>); SD errors of mTOR and lipid kinase binding; a TREEspot data visualization of KINOMEScan interactions (of PQR620 (<b>3</b>), INK128 (<b>73</b>), SB2602 (<b>74</b>), and PP242 (<b>75</b>), selectivity profile analyses, and the raw date of kinase interactions (KINOMEscan of PQR620 (<b>3</b>)); in vitro pharmacology, enzyme and uptake assays, cancer cell line panel for compound PQR620 (<b>3</b>); quantification of cell cycle distribution of A2058 and SKOV3 cells after exposure to PQR620 (<b>3</b>), INK128 (<b>73</b>), PP242 (<b>75</b>), SB2602 (<b>74</b>), rapamycin, and GDC0941 (<b>76</b>) and phosphoprotein levels in A2058 and SKOV3 cells after drug exposure; correlation of cancer mutations and sensitivity to PQR620 (<b>3</b>) in cancer cell line panel; mouse PK data; unspecific rat brain tissue binding values for PQR620 (<b>3</b>); MDCK permeability data and P-gp dependence; collection of compound activity data, clogP and PSA; compound structures overview; <sup>1</sup>H NMR spectra; <sup>13</sup>C{<sup>1</sup>} NMR spectra; MALDI-MS spectra. ESI-HRMS spectra; and HPLC chromatograms (<a href="/doi/suppl/10.1021/acs.jmedchem.8b01262/suppl_file/jm8b01262_si_001.pdf" class="ext-link">PDF</a>)</p></li><li><p class="inline">Molecular formula strings and selected data (<a href="/doi/suppl/10.1021/acs.jmedchem.8b01262/suppl_file/jm8b01262_si_002.csv" class="ext-link">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.8b01262/suppl_file/jm8b01262_si_001.pdf">jm8b01262_si_001.pdf (21.44 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.8b01262/suppl_file/jm8b01262_si_002.csv">jm8b01262_si_002.csv (4.57 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.8b01262/suppl_file/jm8b01262_si_003.xlsx">jm8b01262_si_003.xlsx (41.91 kb)</a></li></ul></div></div></div><span class="author-information-subsection-header">Accession Codes</span><p class="last">PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5OQ4">5OQ4</a> was used for docking of compound PQR620 (<b>3</b>) into PI3Kγ. PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4JT6">4JT6</a> was used for docking of compound PQR620 (<b>3</b>) into mTOR kinase.</p><div class="testing" data-doi="10.1021/acs.jmedchem.8b01262" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_06070" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_06070" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Matthias P. Wymann</span> - <span class="hlFld-Affiliation affiliation">Department
of Biomedicine, University of Basel, Mattenstrasse 28, 4058 Basel, Switzerland</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-3349-4281" title="Orcid link">http://orcid.org/0000-0003-3349-4281</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#fc919d888894959d8fd28b85919d9292bc8992959e9d8fd29f94"><span class="__cf_email__" data-cfemail="2c414d585844454d5f025b55414d42426c5942454e4d5f024f44">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Denise Rageot</span> - <span class="hlFld-Affiliation affiliation">Department
of Biomedicine, University of Basel, Mattenstrasse 28, 4058 Basel, Switzerland</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-2833-5481" title="Orcid link">http://orcid.org/0000-0002-2833-5481</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Thomas Bohnacker</span> - <span class="hlFld-Affiliation affiliation">Department
of Biomedicine, University of Basel, Mattenstrasse 28, 4058 Basel, Switzerland</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Anna Melone</span> - <span class="hlFld-Affiliation affiliation">Department
of Biomedicine, University of Basel, Mattenstrasse 28, 4058 Basel, Switzerland</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jean-Baptiste Langlois</span> - <span class="hlFld-Affiliation affiliation">Department
of Biomedicine, University of Basel, Mattenstrasse 28, 4058 Basel, Switzerland</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Chiara Borsari</span> - <span class="hlFld-Affiliation affiliation">Department
of Biomedicine, University of Basel, Mattenstrasse 28, 4058 Basel, Switzerland</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-4688-8362" title="Orcid link">http://orcid.org/0000-0002-4688-8362</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Petra Hillmann</span> - <span class="hlFld-Affiliation affiliation">PIQUR
Therapeutics AG, Hochbergerstrasse
60, 4057 Basel, Switzerland</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Alexander M. Sele</span> - <span class="hlFld-Affiliation affiliation">Department
of Biomedicine, University of Basel, Mattenstrasse 28, 4058 Basel, Switzerland</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-4903-7934" title="Orcid link">http://orcid.org/0000-0002-4903-7934</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Florent Beaufils</span> - <span class="hlFld-Affiliation affiliation">Department
of Biomedicine, University of Basel, Mattenstrasse 28, 4058 Basel, Switzerland</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Marketa Zvelebil</span> - <span class="hlFld-Affiliation affiliation">Department
of Biomedicine, University of Basel, Mattenstrasse 28, 4058 Basel, Switzerland</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Paul Hebeisen</span> - <span class="hlFld-Affiliation affiliation">PIQUR
Therapeutics AG, Hochbergerstrasse
60, 4057 Basel, Switzerland</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Wolfgang Löscher</span> - <span class="hlFld-Affiliation affiliation">Department
of Pharmacology, Toxicology, and Pharmacy, University of Veterinary Medicine Hannover, and Center for Systems
Neuroscience, 30559 Hannover, Germany</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">John Burke</span> - <span class="hlFld-Affiliation affiliation">Department
of Biochemistry and Microbiology, University
of Victoria, Victoria, British Columbia V8W 2Y2, Canada</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-7904-9859" title="Orcid link">http://orcid.org/0000-0001-7904-9859</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Doriano Fabbro</span> - <span class="hlFld-Affiliation affiliation">PIQUR
Therapeutics AG, Hochbergerstrasse
60, 4057 Basel, Switzerland</span></div></li></ul></li><li><span class="author-information-subsection-header">Author Contributions</span><p>D.R., T.B., and A.M. contributed equally. The manuscript was written through contributions of all authors. All authors have given approval to the final version of the manuscript.</p></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare the following competing financial interest(s): PHe, FB, and DF are current or past employees of PIQUR Therapeutics AG, Basel; and PHi, PHe, DF, and MPW are shareholders of PIQUR Therapeutics AG.<br /></br></div></li></ul></div><div class="ack" id="ACK-d7e9748-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i119">Acknowledgments</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_84551" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_84551" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">We thank A. Pfaltz, R.A. Ettlin, W. Dieterle, S. Mukherjee, J. Mestan and M. Lang for advice and discussions; S. Bünger and A. Dall Asen for technical assistance; E. Teillet, A. Fournier, F. Imeri for early synthetic efforts. This work was supported by the Swiss Commission for Technology and Innovation (CTI) by PFLS-LS grants 14032.1, 15811.2, and 17241.1; the Stiftung für Krebsbekämpfung grant 341, Swiss National Science Foundation grants 310030_153211 and 316030_133860 (to MPW), and 310030B_138659; and in part by European Union’s Horizon 2020 research and innovation program under the Marie Skłodowska-Curie grant agreement 675392; by the Cancer Research Society grant CRS-22641 (to J.B.), and a grant from the Epilepsy Foundation of America.</p></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">Abbreviations Used</td></tr><tr><td class="NLM_term">ESI</td><td class="NLM_def"><p class="first last">electrospray ionization</p></td></tr><tr><td class="NLM_term">GPCR</td><td class="NLM_def"><p class="first last">G-protein coupled receptor</p></td></tr><tr><td class="NLM_term">mTOR</td><td class="NLM_def"><p class="first last">mechanistical (or mammalian) target of rapamycin</p></td></tr><tr><td class="NLM_term">TORC1</td><td class="NLM_def"><p class="first last">mTOR complex 1</p></td></tr><tr><td class="NLM_term">TSC</td><td class="NLM_def"><p class="first last">tuberous sclerosis complex</p></td></tr><tr><td class="NLM_term">PI3K</td><td class="NLM_def"><p class="first last">phosphoinositide 3-kinase</p></td></tr><tr><td class="NLM_term">PKB/Akt</td><td class="NLM_def"><p class="first last">protein kinase B/Akt</p></td></tr><tr><td class="NLM_term">PTEN</td><td class="NLM_def"><p class="first last">phosphatase and tensin homologue</p></td></tr><tr><td class="NLM_term">PtdIns(3,4,5)<i>P</i><sub>3</sub></td><td class="NLM_def"><p class="first last">phosphatidylinositol(3,4,5)-trisphosphate</p></td></tr><tr><td class="NLM_term">PyBpin</td><td class="NLM_def"><p class="first last">pyridine boronic acid pinacol ester</p></td></tr><tr><td class="NLM_term">S6RP</td><td class="NLM_def"><p class="first last">ribosomal protein S6</p></td></tr><tr><td class="NLM_term">S6K</td><td class="NLM_def"><p class="first last">p70 S6 kinase</p></td></tr><tr><td class="NLM_term">VPS34</td><td class="NLM_def"><p class="first last">vacuolar protein sorting 34, the class III PI3K</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i121">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_86432" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_86432" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 35 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wymann, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schneiter, R.</span></span> <span> </span><span class="NLM_article-title">Lipid signalling in disease</span>. <i>Nat. Rev. Mol. Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">162</span>– <span class="NLM_lpage">176</span>, <span class="refDoi"> DOI: 10.1038/nrm2335</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01262&amp;key=10.1038%2Fnrm2335" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01262&amp;key=18216772" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01262&amp;key=1%3ACAS%3A528%3ADC%252BD1cXovFOgug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2008&pages=162-176&author=M.+P.+Wymannauthor=R.+Schneiter&title=Lipid+signalling+in+disease&doi=10.1038%2Fnrm2335"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Lipid signalling in disease</span></div><div class="casAuthors">Wymann, Matthias P.; Schneiter, Roger</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Molecular Cell Biology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">162-176</span>CODEN:
                <span class="NLM_cas:coden">NRMCBP</span>;
        ISSN:<span class="NLM_cas:issn">1471-0072</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Signaling lipids such as eicosanoids, phosphoinositides, sphingolipids and fatty acids control important cellular processes, including cell proliferation, apoptosis, metab. and migration.  Extracellular signals from cytokines, growth factors and nutrients control the activity of a key set of lipid-modifying enzymes: phospholipases, prostaglandin synthase, 5-lipoxygenase, phosphoinositide 3-kinase, sphingosine kinase and sphingomyelinase.  These enzymes and their downstream targets constitute a complex lipid signaling network with multiple nodes of interaction and cross-regulation.  Imbalances in this network contribute to the pathogenesis of human disease.  Although the function of a particular signaling lipid is traditionally studied in isolation, this review attempts a more integrated overview of the key role of these signaling lipids in inflammation, cancer and metabolic disease, and discusses emerging strategies for therapeutic intervention.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrZYZ1NX2T9QbVg90H21EOLACvtfcHk0ljWL9tS_zb0Yw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXovFOgug%253D%253D&md5=c96aabfdfa8e93c9e98386f1a407de85</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1038%2Fnrm2335&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrm2335%26sid%3Dliteratum%253Aachs%26aulast%3DWymann%26aufirst%3DM.%2BP.%26aulast%3DSchneiter%26aufirst%3DR.%26atitle%3DLipid%2520signalling%2520in%2520disease%26jtitle%3DNat.%2520Rev.%2520Mol.%2520Cell%2520Biol.%26date%3D2008%26volume%3D9%26spage%3D162%26epage%3D176%26doi%3D10.1038%2Fnrm2335" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit1b"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rudge, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koos, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vaidialingam, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pavletich, N. P.</span></span> <span> </span><span class="NLM_article-title">mTOR kinase structure, mechanism and regulation</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>497</i></span>,  <span class="NLM_fpage">217</span>– <span class="NLM_lpage">223</span>, <span class="refDoi"> DOI: 10.1038/nature12122</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01262&amp;key=10.1038%2Fnature12122" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01262&amp;key=23636326" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01262&amp;key=1%3ACAS%3A528%3ADC%252BC3sXmvFyns7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=497&publication_year=2013&pages=217-223&author=H.+Yangauthor=D.+G.+Rudgeauthor=J.+D.+Koosauthor=B.+Vaidialingamauthor=H.+J.+Yangauthor=N.+P.+Pavletich&title=mTOR+kinase+structure%2C+mechanism+and+regulation&doi=10.1038%2Fnature12122"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1bR"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">mTOR kinase structure, mechanism and regulation</span></div><div class="casAuthors">Yang, Haijuan; Rudge, Derek G.; Koos, Joseph D.; Vaidialingam, Bhamini; Yang, Hyo J.; Pavletich, Nikola P.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">497</span>
        (<span class="NLM_cas:issue">7448</span>),
    <span class="NLM_cas:pages">217-223</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The mammalian target of rapamycin (mTOR), a phosphoinositide 3-kinase-related protein kinase, controls cell growth in response to nutrients and growth factors and is frequently deregulated in cancer.  Here we report co-crystal structures of a complex of truncated mTOR and mammalian lethal with SEC13 protein 8 (mLST8) with an ATP transition state mimic (MgF3-) and with ATP-site inhibitors (Torin2, PP242, and PI-103).  The structures reveal an intrinsically active kinase conformation, with catalytic residues and a catalytic mechanism remarkably similar to canonical protein kinases.  The active site is highly recessed owing to the FKBP12-rapamycin-binding (FRB) domain and an inhibitory helix protruding from the catalytic cleft.  MTOR-activating mutations map to the structural framework that holds these elements in place, indicating that the kinase is controlled by restricted access.  In vitro biochem. shows that the FRB domain acts as a gatekeeper, with its rapamycin-binding site interacting with substrates to grant them access to the restricted active site.  Rapamycin-FKBP12 inhibits the kinase by directly blocking substrate recruitment and by further restricting active-site access.  The structures also reveal active-site residues and conformational changes that underlie inhibitor potency and specificity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrjvPQtdm6yCbVg90H21EOLACvtfcHk0ljWL9tS_zb0Yw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXmvFyns7k%253D&md5=07809555fbdf2004819a7f2da5727baf</span></div><a href="/servlet/linkout?suffix=cit1b&amp;dbid=16384&amp;doi=10.1038%2Fnature12122&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature12122%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DH.%26aulast%3DRudge%26aufirst%3DD.%2BG.%26aulast%3DKoos%26aufirst%3DJ.%2BD.%26aulast%3DVaidialingam%26aufirst%3DB.%26aulast%3DYang%26aufirst%3DH.%2BJ.%26aulast%3DPavletich%26aufirst%3DN.%2BP.%26atitle%3DmTOR%2520kinase%2520structure%252C%2520mechanism%2520and%2520regulation%26jtitle%3DNature%26date%3D2013%26volume%3D497%26spage%3D217%26epage%3D223%26doi%3D10.1038%2Fnature12122" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit1c"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shimobayashi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hall, M. N.</span></span> <span> </span><span class="NLM_article-title">Making new contacts: the mTOR network in metabolism and signalling crosstalk</span>. <i>Nat. Rev. Mol. Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">155</span>– <span class="NLM_lpage">162</span>, <span class="refDoi"> DOI: 10.1038/nrm3757</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01262&amp;key=10.1038%2Fnrm3757" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01262&amp;key=24556838" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01262&amp;key=1%3ACAS%3A528%3ADC%252BC2cXivFagtrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2014&pages=155-162&author=M.+Shimobayashiauthor=M.+N.+Hall&title=Making+new+contacts%3A+the+mTOR+network+in+metabolism+and+signalling+crosstalk&doi=10.1038%2Fnrm3757"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1cR"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Making new contacts: the mTOR network in metabolism and signaling crosstalk</span></div><div class="casAuthors">Shimobayashi, Mitsugu; Hall, Michael N.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Molecular Cell Biology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">155-162</span>CODEN:
                <span class="NLM_cas:coden">NRMCBP</span>;
        ISSN:<span class="NLM_cas:issn">1471-0072</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  More than 20 yr after its discovery, the understanding of target of rapamycin (TOR) signaling continues to grow.  Recent global 'omics' studies have revealed physiol. roles of mammalian TOR (mTOR) in protein, nucleotide, and lipid synthesis.  Furthermore, emerging evidence provides new insight into the control of mTOR by other pathways such as Hippo, Wnt, and Notch signaling.  Together, this progress has expanded the list of downstream effectors and upstream regulators of mTOR signaling.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr5vMA8Y0_Pe7Vg90H21EOLACvtfcHk0ljhbff2uveHXA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXivFagtrk%253D&md5=4dd29cf176c3de7a5cb0fd6b03600a6b</span></div><a href="/servlet/linkout?suffix=cit1c&amp;dbid=16384&amp;doi=10.1038%2Fnrm3757&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrm3757%26sid%3Dliteratum%253Aachs%26aulast%3DShimobayashi%26aufirst%3DM.%26aulast%3DHall%26aufirst%3DM.%2BN.%26atitle%3DMaking%2520new%2520contacts%253A%2520the%2520mTOR%2520network%2520in%2520metabolism%2520and%2520signalling%2520crosstalk%26jtitle%3DNat.%2520Rev.%2520Mol.%2520Cell%2520Biol.%26date%3D2014%26volume%3D15%26spage%3D155%26epage%3D162%26doi%3D10.1038%2Fnrm3757" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit1d"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Saxton, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sabatini, D. M.</span></span> <span> </span><span class="NLM_article-title">mTOR signaling in growth, metabolism, and disease</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>168</i></span>,  <span class="NLM_fpage">960</span>– <span class="NLM_lpage">976</span>, <span class="refDoi"> DOI: 10.1016/j.cell.2017.02.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1d&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01262&amp;key=10.1016%2Fj.cell.2017.02.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1d&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01262&amp;key=28283069" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1d&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01262&amp;key=1%3ACAS%3A528%3ADC%252BC2sXkt1Ogtb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=168&publication_year=2017&pages=960-976&author=R.+A.+Saxtonauthor=D.+M.+Sabatini&title=mTOR+signaling+in+growth%2C+metabolism%2C+and+disease&doi=10.1016%2Fj.cell.2017.02.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1dR"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">mTOR signaling in growth, metabolism, and disease</span></div><div class="casAuthors">Saxton, Robert A.; Sabatini, David M.</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">168</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">960-976</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">A review.  The mechanistic target of rapamycin (mTOR) coordinates eukaryotic cell growth and metab. with environmental inputs, including nutrients and growth factors.  Extensive research over the past two decades has established a central role for mTOR in regulating many fundamental cell processes, from protein synthesis to autophagy, and deregulated mTOR signaling is implicated in the progression of cancer and diabetes, as well as the aging process.  Here, we review recent advances in our understanding of mTOR function, regulation, and importance in mammalian physiol.  We also highlight how the mTOR signaling network contributes to human disease and discuss the current and future prospects for therapeutically targeting mTOR in the clinic.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpvvk5jg6e_MrVg90H21EOLACvtfcHk0ljhbff2uveHXA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXkt1Ogtb4%253D&md5=3fdee3d04bf88d3aafc532d4e2f1e2dc</span></div><a href="/servlet/linkout?suffix=cit1d&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2017.02.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2017.02.004%26sid%3Dliteratum%253Aachs%26aulast%3DSaxton%26aufirst%3DR.%2BA.%26aulast%3DSabatini%26aufirst%3DD.%2BM.%26atitle%3DmTOR%2520signaling%2520in%2520growth%252C%2520metabolism%252C%2520and%2520disease%26jtitle%3DCell%26date%3D2017%26volume%3D168%26spage%3D960%26epage%3D976%26doi%3D10.1016%2Fj.cell.2017.02.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Laplante, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sabatini, D. M.</span></span> <span> </span><span class="NLM_article-title">mTOR signaling in growth control and disease</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>149</i></span>,  <span class="NLM_fpage">274</span>– <span class="NLM_lpage">293</span>, <span class="refDoi"> DOI: 10.1016/j.cell.2012.03.017</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01262&amp;key=10.1016%2Fj.cell.2012.03.017" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01262&amp;key=22500797" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01262&amp;key=1%3ACAS%3A528%3ADC%252BC38Xls1eguro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=149&publication_year=2012&pages=274-293&author=M.+Laplanteauthor=D.+M.+Sabatini&title=mTOR+signaling+in+growth+control+and+disease&doi=10.1016%2Fj.cell.2012.03.017"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">mTOR signaling in growth control and disease</span></div><div class="casAuthors">Laplante, Mathieu; Sabatini, David M.</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">149</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">274-293</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">A review.  The mechanistic target of rapamycin (mTOR) signaling pathway senses and integrates a variety of environmental cues to regulate organismal growth and homeostasis.  The pathway regulates many major cellular processes and is implicated in an increasing no. of pathol. conditions, including cancer, obesity, type 2 diabetes, and neurodegeneration.  Here, we review recent advances in our understanding of the mTOR pathway and its role in health, disease, and aging.  We further discuss pharmacol. approaches to treat human pathologies linked to mTOR deregulation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqjbKBX-sScfrVg90H21EOLACvtfcHk0ljOKB_EJf9ZIw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xls1eguro%253D&md5=d1adac8ec64da63358e0af26a17ceb4e</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2012.03.017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2012.03.017%26sid%3Dliteratum%253Aachs%26aulast%3DLaplante%26aufirst%3DM.%26aulast%3DSabatini%26aufirst%3DD.%2BM.%26atitle%3DmTOR%2520signaling%2520in%2520growth%2520control%2520and%2520disease%26jtitle%3DCell%26date%3D2012%26volume%3D149%26spage%3D274%26epage%3D293%26doi%3D10.1016%2Fj.cell.2012.03.017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sarbassov, D. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guertin, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ali, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sabatini, D. M.</span></span> <span> </span><span class="NLM_article-title">Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>307</i></span>,  <span class="NLM_fpage">1098</span>– <span class="NLM_lpage">1101</span>, <span class="refDoi"> DOI: 10.1126/science.1106148</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01262&amp;key=10.1126%2Fscience.1106148" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01262&amp;key=15718470" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01262&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtlSrtbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=307&publication_year=2005&pages=1098-1101&author=D.+D.+Sarbassovauthor=D.+A.+Guertinauthor=S.+M.+Aliauthor=D.+M.+Sabatini&title=Phosphorylation+and+regulation+of+Akt%2FPKB+by+the+rictor-mTOR+complex&doi=10.1126%2Fscience.1106148"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Phosphorylation and Regulation of Akt/PKB by the Rictor-mTOR Complex</span></div><div class="casAuthors">Sarbassov, Dos D.; Guertin, David A.; Ali, Siraj M.; Sabatini, David M.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">307</span>
        (<span class="NLM_cas:issue">5712</span>),
    <span class="NLM_cas:pages">1098-1101</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Deregulation of Akt/protein kinase B (PKB) is implicated in the pathogenesis of cancer and diabetes.  Akt/PKB activation requires the phosphorylation of Thr308 in the activation loop by the phosphoinositide-dependent kinase 1 (PDK1) and Ser473 within the carboxyl-terminal hydrophobic motif by an unknown kinase.  We show that in Drosophila and human cells the target of rapamycin (TOR) kinase and its assocd. protein rictor are necessary for Ser473 phosphorylation and that a redn. in rictor or mammalian TOR (mTOR) expression inhibited an Akt/PKB effector.  The rictor-mTOR complex directly phosphorylated Akt/PKB on Ser473 in vitro and facilitated Thr308 phosphorylation by PDK1.  Rictor-mTOR may serve as a drug target in tumors that have lost the expression of PTEN, a tumor suppressor that opposes Akt/PKB activation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqfO1KyVE3glrVg90H21EOLACvtfcHk0ljOKB_EJf9ZIw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtlSrtbY%253D&md5=de758fd8128561e34301e67a42ae13a6</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1126%2Fscience.1106148&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1106148%26sid%3Dliteratum%253Aachs%26aulast%3DSarbassov%26aufirst%3DD.%2BD.%26aulast%3DGuertin%26aufirst%3DD.%2BA.%26aulast%3DAli%26aufirst%3DS.%2BM.%26aulast%3DSabatini%26aufirst%3DD.%2BM.%26atitle%3DPhosphorylation%2520and%2520regulation%2520of%2520Akt%252FPKB%2520by%2520the%2520rictor-mTOR%2520complex%26jtitle%3DScience%26date%3D2005%26volume%3D307%26spage%3D1098%26epage%3D1101%26doi%3D10.1126%2Fscience.1106148" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gan, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chin, Y. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ogura, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blenis, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cantley, L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toker, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, W.</span></span> <span> </span><span class="NLM_article-title">PtdIns(3,4,5)P3-dependent activation of the mTORC2 kinase complex</span>. <i>Cancer Discovery</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">1194</span>– <span class="NLM_lpage">1209</span>, <span class="refDoi"> DOI: 10.1158/2159-8290.CD-15-0460</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01262&amp;key=10.1158%2F2159-8290.CD-15-0460" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2015&pages=1194-1209&author=P.+Liuauthor=W.+Ganauthor=Y.+R.+Chinauthor=K.+Oguraauthor=J.+Guoauthor=J.+Zhangauthor=B.+Wangauthor=J.+Blenisauthor=L.+C.+Cantleyauthor=A.+Tokerauthor=B.+Suauthor=W.+Wei&title=PtdIns%283%2C4%2C5%29P3-dependent+activation+of+the+mTORC2+kinase+complex&doi=10.1158%2F2159-8290.CD-15-0460"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1158%2F2159-8290.CD-15-0460&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2159-8290.CD-15-0460%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DP.%26aulast%3DGan%26aufirst%3DW.%26aulast%3DChin%26aufirst%3DY.%2BR.%26aulast%3DOgura%26aufirst%3DK.%26aulast%3DGuo%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DB.%26aulast%3DBlenis%26aufirst%3DJ.%26aulast%3DCantley%26aufirst%3DL.%2BC.%26aulast%3DToker%26aufirst%3DA.%26aulast%3DSu%26aufirst%3DB.%26aulast%3DWei%26aufirst%3DW.%26atitle%3DPtdIns%25283%252C4%252C5%2529P3-dependent%2520activation%2520of%2520the%2520mTORC2%2520kinase%2520complex%26jtitle%3DCancer%2520Discovery%26date%3D2015%26volume%3D5%26spage%3D1194%26epage%3D1209%26doi%3D10.1158%2F2159-8290.CD-15-0460" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Benjamin, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colombi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moroni, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hall, M. N.</span></span> <span> </span><span class="NLM_article-title">Rapamycin passes the torch: a new generation of mTOR inhibitors</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">868</span>– <span class="NLM_lpage">880</span>, <span class="refDoi"> DOI: 10.1038/nrd3531</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01262&amp;key=10.1038%2Fnrd3531" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01262&amp;key=22037041" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01262&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtlyis7vI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2011&pages=868-880&author=D.+Benjaminauthor=M.+Colombiauthor=C.+Moroniauthor=M.+N.+Hall&title=Rapamycin+passes+the+torch%3A+a+new+generation+of+mTOR+inhibitors&doi=10.1038%2Fnrd3531"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Rapamycin passes the torch: a new generation of mTOR inhibitors</span></div><div class="casAuthors">Benjamin, Don; Colombi, Marco; Moroni, Christoph; Hall, Michael N.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">868-880</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Mammalian target of rapamycin (mTOR) is an atypical protein kinase that controls growth and metab. in response to nutrients, growth factors and cellular energy levels, and it is frequently dysregulated in cancer and metabolic disorders.  Rapamycin is an allosteric inhibitor of mTOR, and was approved as an immuno-suppressant in 1999.  In recent years, interest has focused on its potential as an anticancer drug.  However, the performance of rapamycin and its analogs (rapalogues) has been undistinguished despite isolated successes in subsets of cancer, suggesting that the full therapeutic potential of targeting mTOR has yet to be exploited.  A new generation of ATP-competitive inhibitors that directly target the mTOR catalytic site display potent and comprehensive mTOR inhibition and are in early clin. trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqTizwX9wDprrVg90H21EOLACvtfcHk0ljOKB_EJf9ZIw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtlyis7vI&md5=a909649a82f3a2ce11c6b8fee78fa69e</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1038%2Fnrd3531&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd3531%26sid%3Dliteratum%253Aachs%26aulast%3DBenjamin%26aufirst%3DD.%26aulast%3DColombi%26aufirst%3DM.%26aulast%3DMoroni%26aufirst%3DC.%26aulast%3DHall%26aufirst%3DM.%2BN.%26atitle%3DRapamycin%2520passes%2520the%2520torch%253A%2520a%2520new%2520generation%2520of%2520mTOR%2520inhibitors%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2011%26volume%3D10%26spage%3D868%26epage%3D880%26doi%3D10.1038%2Fnrd3531" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Choi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schreiber, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clardy, J.</span></span> <span> </span><span class="NLM_article-title">Structure of the FKBP12-rapamycin complex interacting with the binding domain of human FRAP</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>273</i></span>,  <span class="NLM_fpage">239</span>– <span class="NLM_lpage">242</span>, <span class="refDoi"> DOI: 10.1126/science.273.5272.239</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01262&amp;key=10.1126%2Fscience.273.5272.239" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01262&amp;key=8662507" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01262&amp;key=1%3ACAS%3A528%3ADyaK28Xkt1Crs7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=273&publication_year=1996&pages=239-242&author=J.+Choiauthor=J.+Chenauthor=S.+L.+Schreiberauthor=J.+Clardy&title=Structure+of+the+FKBP12-rapamycin+complex+interacting+with+the+binding+domain+of+human+FRAP&doi=10.1126%2Fscience.273.5272.239"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Structure of the FKBP12-rapamycin complex interacting with the binding domain of human FRAP</span></div><div class="casAuthors">Choi, Jungwon; Chen, Jie; Schreiber, Stuart L.; Clardy, Jon</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, D. C.)</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">273</span>
        (<span class="NLM_cas:issue">5272</span>),
    <span class="NLM_cas:pages">239-242</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Rapamycin, a potent immunosuppressive agent, binds two proteins: the FK506-binding protein (FKBP12) and the FKBP-rapamycin-assocd. protein (FRAP).  A crystal structure of the ternary complex of human FKBP12, rapamycin, and the FKBP12-rapamycin-binding (FRB) domain of human FRAP at a resoln. of 2.7 angstroms revealed the two proteins bound together as a result of the ability of rapamycin to occupy two different hydrophobic binding pockets simultaneously.  The structure shows extensive interactions between rapamycin and both proteins, but fewer interactions between the proteins.  The structure of the FRB domain of FRAP clarifies both rapamycin-independent and -dependent effects obsd. for mutants of FRAP and its homologs in the family of proteins related to the ataxia-telangiectasis mutant gene product, and it illustrates how a small cell-permeable mol. can mediate protein dimerization.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqwBLM2PsItYLVg90H21EOLACvtfcHk0lghv6WF1PFy-A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28Xkt1Crs7k%253D&md5=c72a82e14c09d9a705215b4ac0525336</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1126%2Fscience.273.5272.239&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.273.5272.239%26sid%3Dliteratum%253Aachs%26aulast%3DChoi%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DSchreiber%26aufirst%3DS.%2BL.%26aulast%3DClardy%26aufirst%3DJ.%26atitle%3DStructure%2520of%2520the%2520FKBP12-rapamycin%2520complex%2520interacting%2520with%2520the%2520binding%2520domain%2520of%2520human%2520FRAP%26jtitle%3DScience%26date%3D1996%26volume%3D273%26spage%3D239%26epage%3D242%26doi%3D10.1126%2Fscience.273.5272.239" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7a"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Eisen, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tuzcu, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dorent, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kobashigawa, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mancini, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valantine-von Kaeppler, H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Starling, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sorensen, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hummel, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lind, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abeywickrama, K. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bernhardt, P.</span></span> <span> </span><span class="NLM_article-title">Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>349</i></span>,  <span class="NLM_fpage">847</span>– <span class="NLM_lpage">858</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa022171</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01262&amp;key=10.1056%2FNEJMoa022171" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01262&amp;key=12944570" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01262&amp;key=1%3ACAS%3A528%3ADC%252BD3sXmvVSntrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=349&publication_year=2003&pages=847-858&author=H.+J.+Eisenauthor=E.+M.+Tuzcuauthor=R.+Dorentauthor=J.+Kobashigawaauthor=D.+Manciniauthor=H.+A.+Valantine-von+Kaepplerauthor=R.+C.+Starlingauthor=K.+Sorensenauthor=M.+Hummelauthor=J.+M.+Lindauthor=K.+H.+Abeywickramaauthor=P.+Bernhardt&title=Everolimus+for+the+prevention+of+allograft+rejection+and+vasculopathy+in+cardiac-transplant+recipients&doi=10.1056%2FNEJMoa022171"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7aR"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients</span></div><div class="casAuthors">Eisen, Howard J.; Tuzcu, E. Murat; Dorent, Richard; Kobashigawa, Jon; Mancini, Donna; Valantine-von Kaeppler, Hannah A.; Starling, Randall C.; Sorensen, Keld; Hummel, Manfred; Lind, Joan M.; Abeywickrama, Kamal H.; Bernhardt, Peter; Bernhardt, P.; Abeywickrama, K. H.; Lind, J.; Cretin, N.; Le Breton, S.; Kabir, J.; Murphy, J.; Laupacis, A.; Wells, G. A.; Mills, R.; Parry, G.; Tuzcu, E. M.; Nissen, S. E.; Schoenhagen, P.; Crowe, T.; Magyar, W.; Caughlin, J.; Shalling, P.; Werle, C.; Carrier, M.; Normandin, D.; Vezina, J.; Masters, R.; Davies, R.; Ross, H.; Cardella, C.; Delgado, D.; O'Grady, C.; Haddad, H.; Howlett, J.; Hirsch, G.; Kells, C.; O'Neill, B. J.; Giddens, K.; Perrone, S. V.; Favaloro, L.; Favaloro, R.; Kapplinsky, E.; Natello, A.; Grimm, M.; Laufer, G.; Wieselthaler, G.; Zuckermann, A.; Deviatko, E.; Vanhaecke, J.; Van Cleemput, J.; Droogne, W.; Strijckmans, A.; Goenen, M.; Timmermans, T.; Wellens, F.; Goethals, M.; Tack, W.; Kiowski, W.; Oechslin, E.; Brunner, H.; Schindler, R.; Haverich, A.; Pethig, K.; Bara, C.; Scheibner, I.; Hetzer, R.; Hummel, M.; Kapell, S.; Wenzel, E.; Soerensen, K.; Moelgaard, H.; Egeblad, H.; Nielsen-Kudsk, J. E.; Eiskjaer, H.; Tram, E.-M.; Arizon, J. M.; Concha, M.; Valles, F.; Granados, A. L.; Crespo, M. G.; Paniangua-Martin, M. J.; Tabuyo, T.; Juffe, A.; Rodriguez, J. A.; Pulpon, L. A.; Segovia, J.; Gandjbakhch, I.; Dorent, R.; Leger, P.; Levasseur, J.-P.; Vaissier, E.; De Lentdecker, P.; Dreyfus, G.; Dureau, G.; Boissonat, P.; Sebbag, L.; Roussouliere, A.; Parameshwar, J.; Schofield, P.; Steel, L.; Beresford, V.; Yonan, N.; Martyszczuk, R.; Reader, J.; Frigerio, M.; Masciocco, G.; Grassi, M.; Garbellini, M.; Oliva, F.; Vigano, M.; Pellegrini, C.; Rinaldi, M.; D'Armini, A. M.; Casarotto, D.; Cambino, A.; Luca, T.; Feltrin, G.; Gerosa, G.; Fiocchi, R.; Gamba, A.; Mammana, C.; Iamele, L.; Guagliomi, G.; Faggian, G.; Mazzucco, A.; Forni, A.; Simonsen, S.; Geiran, O.; Relbo, A.; Grov, I.; Garlicki, M.; Kao, W.; Downer, C.; Eisen, H. J.; Furukawa, S.; Rubin, S.; Berman, G. O.; Margulies, K. B.; Mather, P.; Wald, J.; Garcia, J.; Levelle, L.; Wong, J.; Hill, J.; Aranda, J.; Leach, D.; Ebling, A.; Kobashigawa, J.; Chait, J.; Wang, E.; Cole, B.; Patel, J.; Moriguchi, J.; Laks, H.; Tobis, J.; Espejo, M.; Mancini, D.; Cordisco, M. E.; Donchez, L.; Frazier, O. H.; Connelly, J. H.; Thomas, C. D.; Renlund, D.; Moore, S. A.; Taylor, D.; Kfoury, A. G.; Campbell, B.; Eidson, M.; Smith, A.; Book, W.; Snell, G.; Valantine-von Kaeppler, H. A.; Woodman, K.; Kari, K.; Majem, R.; Parekh, H.; Weishaar, D.; Trammell, J.; Smart, F.; Bowers, S.; Starling, R. C.; Gus, B.; Young, J. B.; McCarthy, P.; James, K.; McCurry, K.; Zaldonis, D.; Benza, R.; Rayburn, B.; Bourge, R.; Aaronson, K.; Pagani, F. D.; Koelling, T. M.; Dyke, D. B.; Baliga, R.; McLean, D.; Hauptman, P. J.; Rawlings, M.; Jarcho, J.; Symko, B.; Miller, L. W.; Schaefer, K. K.; Hare, J.; Kasper, E.; Lindenfeld, J.; Clegg, L.; Love, R. B.; Jacobs, L.; Davis, S. F.; Thole, P. A.; Goldberg, L. R.; Chambers, S.; Twomey, C.; Dec, G. W.; Cocca-Spoffard, D.; Camuso, J.; Hosenpud, J.; Tector, A. J.; Courch, J.; Hudson, D.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">349</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">847-858</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Background: Everolimus, a novel proliferation inhibitor and immunosuppressive agent, may suppress cardiac-allograft vasculopathy.  We conducted a randomized, double-blind, clin. trial comparing everolimus with azathioprine in recipients of a first heart transplant.  Methods: A total of 634 patients were randomly assigned to receive 1.5 mg of everolimus per day (209 patients), 3.0 mg of everolimus per day (211 patients), or 1.0 to 3.0 mg of azathioprine per kg of body wt. per day (214 patients), in combination with cyclosporine, corticosteroids, and statins.  The primary efficacy end point was a composite of death, graft loss or retransplantation, loss to follow-up, biopsy-proved acute rejection of grade 3A, or rejection with hemodynamic compromise.  Results: At six months, the percentage of patients who had reached the primary efficacy end point was significantly smaller in the group given 3.0 mg of everolimus (27.0 %, P<0.001) and the group given 1.5 mg of everolimus (36.4 %, P=0.03) than in the azathioprine group (46.7 %).  Intravascular ultrasonog. showed that the av. increase in maximal intimal thickness 12 mo after transplantation was significantly smaller in the two everolimus groups than in the azathioprine group.  The incidence of vasculopathy was also significantly lower in the 1.5-mg group (35.7 %, P=0.045) and the 3.0-mg group (30.4 %, P=0.01) than in the azathioprine group (52.8 %).  The rates of cytomegalovirus infection were significantly lower in the 1.5-mg group (7.7 %, P<0.001) and the 3.0-mg group (7.6 %, P<0.001) than in the azathioprine group (21.5 %).  Rates of bacterial infection were significantly higher in the 3.0-mg group than in the azathioprine group.  Serum creatinine levels were also significantly higher in the two everolimus groups than in the azathioprine group.  Conclusions: Everolimus was more efficacious than azathioprine in reducing the severity and incidence of cardiac-allograft vasculopathy, suggesting that everolimus therapy may alleviate this serious problem.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrvK3FiFj8DlrVg90H21EOLACvtfcHk0lghv6WF1PFy-A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXmvVSntrc%253D&md5=f8f5cec33d3070c8806cdd2cfd3b7ede</span></div><a href="/servlet/linkout?suffix=cit7a&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa022171&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa022171%26sid%3Dliteratum%253Aachs%26aulast%3DEisen%26aufirst%3DH.%2BJ.%26aulast%3DTuzcu%26aufirst%3DE.%2BM.%26aulast%3DDorent%26aufirst%3DR.%26aulast%3DKobashigawa%26aufirst%3DJ.%26aulast%3DMancini%26aufirst%3DD.%26aulast%3DValantine-von%2BKaeppler%26aufirst%3DH.%2BA.%26aulast%3DStarling%26aufirst%3DR.%2BC.%26aulast%3DSorensen%26aufirst%3DK.%26aulast%3DHummel%26aufirst%3DM.%26aulast%3DLind%26aufirst%3DJ.%2BM.%26aulast%3DAbeywickrama%26aufirst%3DK.%2BH.%26aulast%3DBernhardt%26aufirst%3DP.%26atitle%3DEverolimus%2520for%2520the%2520prevention%2520of%2520allograft%2520rejection%2520and%2520vasculopathy%2520in%2520cardiac-transplant%2520recipients%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2003%26volume%3D349%26spage%3D847%26epage%3D858%26doi%3D10.1056%2FNEJMoa022171" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit7b"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jacob, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nair, A. B.</span></span> <span> </span><span class="NLM_article-title">A review on therapeutic drug monitoring of the mTOR class of immunosuppressants: everolimus and sirolimus</span>. <i>Drugs Ther Perspect</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>33</i></span>,  <span class="NLM_fpage">290</span>– <span class="NLM_lpage">301</span>, <span class="refDoi"> DOI: 10.1007/s40267-017-0403-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01262&amp;key=10.1007%2Fs40267-017-0403-0" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2017&pages=290-301&author=S.+Jacobauthor=A.+B.+Nair&title=A+review+on+therapeutic+drug+monitoring+of+the+mTOR+class+of+immunosuppressants%3A+everolimus+and+sirolimus&doi=10.1007%2Fs40267-017-0403-0"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit7b&amp;dbid=16384&amp;doi=10.1007%2Fs40267-017-0403-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40267-017-0403-0%26sid%3Dliteratum%253Aachs%26aulast%3DJacob%26aufirst%3DS.%26aulast%3DNair%26aufirst%3DA.%2BB.%26atitle%3DA%2520review%2520on%2520therapeutic%2520drug%2520monitoring%2520of%2520the%2520mTOR%2520class%2520of%2520immunosuppressants%253A%2520everolimus%2520and%2520sirolimus%26jtitle%3DDrugs%2520Ther%2520Perspect%26date%3D2017%26volume%3D33%26spage%3D290%26epage%3D301%26doi%3D10.1007%2Fs40267-017-0403-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit7c"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Alalawi, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Halawa, A.</span></span> <span> </span><span class="NLM_article-title">mTOR Inhibitors in the current practice</span>. <i>J. Clin. Exp. Nephrol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>1</i></span>,  <span class="NLM_fpage">26</span>, <span class="refDoi"> DOI: 10.21767/2472-5056.100026</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01262&amp;key=10.21767%2F2472-5056.100026" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2017&pages=26&author=F.+Alalawiauthor=A.+Sharmaauthor=A.+Halawa&title=mTOR+Inhibitors+in+the+current+practice&doi=10.21767%2F2472-5056.100026"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit7c&amp;dbid=16384&amp;doi=10.21767%2F2472-5056.100026&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.21767%252F2472-5056.100026%26sid%3Dliteratum%253Aachs%26aulast%3DAlalawi%26aufirst%3DF.%26aulast%3DSharma%26aufirst%3DA.%26aulast%3DHalawa%26aufirst%3DA.%26atitle%3DmTOR%2520Inhibitors%2520in%2520the%2520current%2520practice%26jtitle%3DJ.%2520Clin.%2520Exp.%2520Nephrol.%26date%3D2017%26volume%3D1%26spage%3D26%26doi%3D10.21767%2F2472-5056.100026" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Costa, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simon, D. I.</span></span> <span> </span><span class="NLM_article-title">Molecular basis of restenosis and drug-eluting stents</span>. <i>Circulation</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>111</i></span>,  <span class="NLM_fpage">2257</span>– <span class="NLM_lpage">2273</span>, <span class="refDoi"> DOI: 10.1161/01.CIR.0000163587.36485.A7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01262&amp;key=10.1161%2F01.CIR.0000163587.36485.A7" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=111&publication_year=2005&pages=2257-2273&author=M.+A.+Costaauthor=D.+I.+Simon&title=Molecular+basis+of+restenosis+and+drug-eluting+stents&doi=10.1161%2F01.CIR.0000163587.36485.A7"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1161%2F01.CIR.0000163587.36485.A7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1161%252F01.CIR.0000163587.36485.A7%26sid%3Dliteratum%253Aachs%26aulast%3DCosta%26aufirst%3DM.%2BA.%26aulast%3DSimon%26aufirst%3DD.%2BI.%26atitle%3DMolecular%2520basis%2520of%2520restenosis%2520and%2520drug-eluting%2520stents%26jtitle%3DCirculation%26date%3D2005%26volume%3D111%26spage%3D2257%26epage%3D2273%26doi%3D10.1161%2F01.CIR.0000163587.36485.A7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Motzer, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Escudier, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oudard, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hutson, T. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Porta, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bracarda, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grunwald, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thompson, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Figlin, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hollaender, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Urbanowitz, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berg, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kay, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lebwohl, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ravaud, A.</span></span> <span> </span><span class="NLM_article-title">Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial</span>. <i>Lancet</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>372</i></span>,  <span class="NLM_fpage">449</span>– <span class="NLM_lpage">456</span>, <span class="refDoi"> DOI: 10.1016/S0140-6736(08)61039-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01262&amp;key=10.1016%2FS0140-6736%2808%2961039-9" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=372&publication_year=2008&pages=449-456&author=R.+J.+Motzerauthor=B.+Escudierauthor=S.+Oudardauthor=T.+E.+Hutsonauthor=C.+Portaauthor=S.+Bracardaauthor=V.+Grunwaldauthor=J.+A.+Thompsonauthor=R.+A.+Figlinauthor=N.+Hollaenderauthor=G.+Urbanowitzauthor=W.+J.+Bergauthor=A.+Kayauthor=D.+Lebwohlauthor=A.+Ravaud&title=Efficacy+of+everolimus+in+advanced+renal+cell+carcinoma%3A+a+double-blind%2C+randomised%2C+placebo-controlled+phase+III+trial&doi=10.1016%2FS0140-6736%2808%2961039-9"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2808%2961039-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252808%252961039-9%26sid%3Dliteratum%253Aachs%26aulast%3DMotzer%26aufirst%3DR.%2BJ.%26aulast%3DEscudier%26aufirst%3DB.%26aulast%3DOudard%26aufirst%3DS.%26aulast%3DHutson%26aufirst%3DT.%2BE.%26aulast%3DPorta%26aufirst%3DC.%26aulast%3DBracarda%26aufirst%3DS.%26aulast%3DGrunwald%26aufirst%3DV.%26aulast%3DThompson%26aufirst%3DJ.%2BA.%26aulast%3DFiglin%26aufirst%3DR.%2BA.%26aulast%3DHollaender%26aufirst%3DN.%26aulast%3DUrbanowitz%26aufirst%3DG.%26aulast%3DBerg%26aufirst%3DW.%2BJ.%26aulast%3DKay%26aufirst%3DA.%26aulast%3DLebwohl%26aufirst%3DD.%26aulast%3DRavaud%26aufirst%3DA.%26atitle%3DEfficacy%2520of%2520everolimus%2520in%2520advanced%2520renal%2520cell%2520carcinoma%253A%2520a%2520double-blind%252C%2520randomised%252C%2520placebo-controlled%2520phase%2520III%2520trial%26jtitle%3DLancet%26date%3D2008%26volume%3D372%26spage%3D449%26epage%3D456%26doi%3D10.1016%2FS0140-6736%2808%2961039-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jerusalem, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rorive, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collignon, J.</span></span> <span> </span><span class="NLM_article-title">Use of mTOR inhibitors in the treatment of breast cancer: an evaluation of factors that influence patient outcomes</span>. <i>Breast Cancer: Targets Ther.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">43</span>– <span class="NLM_lpage">57</span>, <span class="refDoi"> DOI: 10.2147/BCTT.S38679</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01262&amp;key=10.2147%2FBCTT.S38679" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01262&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhs12gsrjE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2014&pages=43-57&author=G.+Jerusalemauthor=A.+Roriveauthor=J.+Collignon&title=Use+of+mTOR+inhibitors+in+the+treatment+of+breast+cancer%3A+an+evaluation+of+factors+that+influence+patient+outcomes&doi=10.2147%2FBCTT.S38679"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Use of mTOR inhibitors in the treatment of breast cancer: an evaluation of factors that influence patient outcomes</span></div><div class="casAuthors">Jerusalem, Guy; Rorive, Andree; Collignon, Joelle</div><div class="citationInfo"><span class="NLM_cas:title">Breast Cancer: Targets and Therapy</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">43-57, 15</span>CODEN:
                <span class="NLM_cas:coden">BCTTA9</span>;
        ISSN:<span class="NLM_cas:issn">1179-1314</span>.
    
            (<span class="NLM_cas:orgname">Dove Medical Press Ltd.</span>)
        </div><div class="casAbstract">A review.  Many systemic treatment options are available for advanced breast cancer, including endocrine therapy, chemotherapy, anti-human epidermal growth factor receptor 2 (HER2) therapy, and other targeted agents.  Recently, everolimus, a mammalian target of rapamycin (mTOR) inhibitor, combined with exemestane, an aromatase inhibitor, has been approved in Europe and the USA for patients suffering from estrogen receptor-pos., HER2-neg. advanced breast cancer previously treated by a nonsteroidal aromatase inhibitor, based on the results of BOLERO-2 (Breast cancer trials of OraL EveROlimus).  This study showed a statistically significant and clin. meaningful improvement in median progression-free survival.  Results concerning the impact on overall survival are expected in the near future.  This clin. oriented review focuses on the use of mTOR inhibitors in breast cancer.  Results reported with first-generation mTOR inhibitors (ridaforolimus, temsirolimus, everolimus) are discussed.  The current and potential role of mTOR inhibitors is reported according to breast cancer subtype (estrogen receptor-pos. HER2-neg., triple-neg., and HER2-pos. ER-pos./neg. disease).  Everolimus is currently being evaluated in the adjuvant setting in high-risk estrogen receptor-pos., HER2-neg. early breast cancer.  Continuing mTOR inhibition or alternatively administering other drugs targeting the phosphatidylinositol-3-kinase/protein kinase B-mTOR pathway after progression on treatments including an mTOR inhibitor is under evaluation.  Potential biomarkers to select patients showing a more pronounced benefit are reviewed, but we are not currently using these biomarkers in routine practice.  Subgroup anal. of BOLERO 2 has shown that the benefit is consistent in all subgroups and that it is impossible to select patients not benefiting from addn. of everolimus to exemestane.  Side effects and impact on quality of life are other important issues discussed in this review.  Second-generation mTOR inhibitors and dual mTOR-phosphatidylinositol-3-kinase inhibitors are currently being evaluated in clin. trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqXjFYIcn4ct7Vg90H21EOLACvtfcHk0lg32S9MjHJbxA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhs12gsrjE&md5=9a12c70c7c917baa41d282bc135b12af</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.2147%2FBCTT.S38679&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2147%252FBCTT.S38679%26sid%3Dliteratum%253Aachs%26aulast%3DJerusalem%26aufirst%3DG.%26aulast%3DRorive%26aufirst%3DA.%26aulast%3DCollignon%26aufirst%3DJ.%26atitle%3DUse%2520of%2520mTOR%2520inhibitors%2520in%2520the%2520treatment%2520of%2520breast%2520cancer%253A%2520an%2520evaluation%2520of%2520factors%2520that%2520influence%2520patient%2520outcomes%26jtitle%3DBreast%2520Cancer%253A%2520Targets%2520Ther.%26date%3D2014%26volume%3D6%26spage%3D43%26epage%3D57%26doi%3D10.2147%2FBCTT.S38679" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Arachchige
Don, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, X. F. S.</span></span> <span> </span><span class="NLM_article-title">Recent clinical trials of mTOR-targeted cancer therapies</span>. <i>Rev. Recent Clin. Trials</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">24</span>– <span class="NLM_lpage">35</span>, <span class="refDoi"> DOI: 10.2174/157488711793980147</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01262&amp;key=10.2174%2F157488711793980147" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01262&amp;key=20868343" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01262&amp;key=1%3ACAS%3A528%3ADC%252BC3MXlvFWntL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2011&pages=24-35&author=A.+S.+Arachchige%0ADonauthor=X.+F.+S.+Zheng&title=Recent+clinical+trials+of+mTOR-targeted+cancer+therapies&doi=10.2174%2F157488711793980147"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Recent clinical trials of mTOR-targeted cancer therapies</span></div><div class="casAuthors">Arachchige Don, Aruni S.; Zheng, X. F. Steven</div><div class="citationInfo"><span class="NLM_cas:title">Reviews on Recent Clinical Trials</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">24-35</span>CODEN:
                <span class="NLM_cas:coden">RRCTB2</span>;
        ISSN:<span class="NLM_cas:issn">1574-8871</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  The mammalian target of rapamycin (mTOR) is a central component within a complex intracellular signaling network that regulates various processes including cell growth, proliferation, metab., and angiogenesis.  A hyperactive PI3k/Akt/mTOR signaling pathway is found in many human cancers and alterations in this pathway are assocd. with the development and progression of cancer.  Drugs that target and inhibit mTOR activity are therefore expected to provide therapeutic value in a no. of cancer types.  Several classes of mTOR-targeted therapeutics are currently being evaluated in cancer clin. trials, including the rapamycins, dual PI3K-mTOR inhibitors, and ATP-competitive mTORC1/2 inhibitors.  This review summarizes important findings from recently completed trials of mTOR inhibitors and also discusses preliminary data from ongoing trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoX3gLMv9DD_bVg90H21EOLACvtfcHk0lg32S9MjHJbxA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXlvFWntL0%253D&md5=fe90e00863d466ccdacc9caba00b249e</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.2174%2F157488711793980147&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F157488711793980147%26sid%3Dliteratum%253Aachs%26aulast%3DArachchige%2BDon%26aufirst%3DA.%2BS.%26aulast%3DZheng%26aufirst%3DX.%2BF.%2BS.%26atitle%3DRecent%2520clinical%2520trials%2520of%2520mTOR-targeted%2520cancer%2520therapies%26jtitle%3DRev.%2520Recent%2520Clin.%2520Trials%26date%3D2011%26volume%3D6%26spage%3D24%26epage%3D35%26doi%3D10.2174%2F157488711793980147" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shor, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gibbons, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abraham, R. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, K.</span></span> <span> </span><span class="NLM_article-title">Targeting mTOR globally in cancer: thinking beyond rapamycin</span>. <i>Cell Cycle</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">3831</span>– <span class="NLM_lpage">3837</span>, <span class="refDoi"> DOI: 10.4161/cc.8.23.10070</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01262&amp;key=10.4161%2Fcc.8.23.10070" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01262&amp;key=19901542" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01262&amp;key=1%3ACAS%3A528%3ADC%252BC3cXotlWrtL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2009&pages=3831-3837&author=B.+Shorauthor=J.+J.+Gibbonsauthor=R.+T.+Abrahamauthor=K.+Yu&title=Targeting+mTOR+globally+in+cancer%3A+thinking+beyond+rapamycin&doi=10.4161%2Fcc.8.23.10070"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting mTOR globally in cancer: thinking beyond rapamycin</span></div><div class="casAuthors">Shor, Boris; Gibbons, James J.; Abraham, Robert T.; Yu, Ker</div><div class="citationInfo"><span class="NLM_cas:title">Cell Cycle</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">3831-3837</span>CODEN:
                <span class="NLM_cas:coden">CCEYAS</span>;
        ISSN:<span class="NLM_cas:issn">1538-4101</span>.
    
            (<span class="NLM_cas:orgname">Landes Bioscience</span>)
        </div><div class="casAbstract">A review.  The mammalian target of rapamycin (mTOR) is centrally involved in growth, survival and metab.  In cancer, mTOR is frequently hyperactivated and is a clin. validated target for drug development.  Until recently, we have relied largely on the use of rapamycin to study mTOR function and its anticancer potential.  Recent insights now indicate that rapamycin is a partial inhibitor of mTOR through allosteric inhibition of mTOR complex-1 (mTORC1) but not mTOR complex-2 (mTORC2).  Both the mechanism of action and the cellular response to mTORC1 inhibition by rapamycin and related drugs may limit the effectiveness of these compds. as antitumor agents.  We and others have recently reported the discovery of second-generation ATP-competitive mTOR kinase inhibitors (TKIs) that bind to the active sites of mTORC1 and mTORC2, thereby targeting mTOR signaling function globally (reviewed in refs. 1-4).  The discovery of specific, active-site mTOR inhibitors has opened a new chapter in the 40-plus year old odyssey that began with the discovery of rapamycin from a soil sample collected on Easter Island.  Here, we discuss recent studies that highlight the emergence of rapamycin-resistant mTOR function in protein synthesis, cell growth, survival and metab.  It is shown that these rapamycin-resistant mTOR functions are profoundly inhibited by TKIs.  A more complete suppression of mTOR global signaling network by the new inhibitors is expected to yield a deeper and broader antitumor response in the clinic.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoy9EP_1DwoGrVg90H21EOLACvtfcHk0lg32S9MjHJbxA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXotlWrtL4%253D&md5=4dab0a66742fadd9087aa2c439704f27</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.4161%2Fcc.8.23.10070&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4161%252Fcc.8.23.10070%26sid%3Dliteratum%253Aachs%26aulast%3DShor%26aufirst%3DB.%26aulast%3DGibbons%26aufirst%3DJ.%2BJ.%26aulast%3DAbraham%26aufirst%3DR.%2BT.%26aulast%3DYu%26aufirst%3DK.%26atitle%3DTargeting%2520mTOR%2520globally%2520in%2520cancer%253A%2520thinking%2520beyond%2520rapamycin%26jtitle%3DCell%2520Cycle%26date%3D2009%26volume%3D8%26spage%3D3831%26epage%3D3837%26doi%3D10.4161%2Fcc.8.23.10070" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13a"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Slotkin, E. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patwardhan, P. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vasudeva, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Stanchina, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tap, W. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwartz, G. K.</span></span> <span> </span><span class="NLM_article-title">MLN0128, an ATP-competitive mTOR kinase inhibitor with potent in vitro and in vivo antitumor activity, as potential therapy for bone and soft-tissue sarcoma</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">395</span>– <span class="NLM_lpage">406</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-14-0711</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01262&amp;key=10.1158%2F1535-7163.MCT-14-0711" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01262&amp;key=25519700" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01262&amp;key=1%3ACAS%3A528%3ADC%252BC2MXitlOjsbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2015&pages=395-406&author=E.+K.+Slotkinauthor=P.+P.+Patwardhanauthor=S.+D.+Vasudevaauthor=E.+de+Stanchinaauthor=W.+D.+Tapauthor=G.+K.+Schwartz&title=MLN0128%2C+an+ATP-competitive+mTOR+kinase+inhibitor+with+potent+in+vitro+and+in+vivo+antitumor+activity%2C+as+potential+therapy+for+bone+and+soft-tissue+sarcoma&doi=10.1158%2F1535-7163.MCT-14-0711"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13aR"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">MLN0128, an ATP-Competitive mTOR Kinase Inhibitor with Potent In Vitro and In Vivo Antitumor Activity, as Potential Therapy for Bone and Soft-Tissue Sarcoma</span></div><div class="casAuthors">Slotkin, Emily K.; Patwardhan, Parag P.; Vasudeva, Shyamprasad D.; de Stanchina, Elisa; Tap, William D.; Schwartz, Gary K.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">395-406</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The mammalian target of rapamycin (mTOR) is a serine/threonine protein kinase that exists in two complexes (mTORC1 and mTORC2) and integrates extracellular and intracellular signals to act as a master regulator of cell growth, survival, and metab.  The PI3K/AKT/mTOR prosurvival pathway is often dysregulated in multiple sarcoma subtypes.  First-generation allosteric inhibitors of mTORC1 (rapalogues) have been extensively tested with great preclin. promise, but have had limited clin. utility.  Here, we report that MLN0128, a second-generation, ATP-competitive, pan-mTOR kinase inhibitor, acts on both mTORC1 and mTORC2 and has potent in vitro and in vivo antitumor activity in multiple sarcoma subtypes.  In vitro, MLN0128 inhibits mTORC1/2 targets in a concn.-dependent fashion and shows striking antiproliferative effect in rhabdomyosarcoma (RMS), Ewing sarcoma, malignant peripheral nerve sheath tumor, synovial sarcoma, osteosarcoma, and liposarcoma.  Unlike rapamycin, MLN0128 inhibits phosphorylation of 4EBP1 and NDRG1 as well as prevents the reactivation of pAKT that occurs via neg. feedback release with mTORC1 inhibition alone.  In xenograft models, MLN0128 treatment results in suppression of tumor growth with two dosing schedules (1 mg/kg daily and 3 mg/kg b.i.d. t.i.w.).  At the 3 mg/kg dosing schedule, MLN0128 treatment results in significantly better tumor growth suppression than rapamycin in RMS and Ewing sarcoma models.  In addn., MLN0128 induces apoptosis in models of RMS both in vitro and in vivo.  Results from our study strongly suggest that MLN0128 treatment should be explored further as potential therapy for sarcoma.  Mol Cancer Ther; 14(2); 395-406. ©2014 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq2RbwSW4yjmLVg90H21EOLACvtfcHk0lgQAikPfmKbuA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXitlOjsbo%253D&md5=7c1d867aae6e5ca99c63b554295a539a</span></div><a href="/servlet/linkout?suffix=cit13a&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-14-0711&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-14-0711%26sid%3Dliteratum%253Aachs%26aulast%3DSlotkin%26aufirst%3DE.%2BK.%26aulast%3DPatwardhan%26aufirst%3DP.%2BP.%26aulast%3DVasudeva%26aufirst%3DS.%2BD.%26aulast%3Dde%2BStanchina%26aufirst%3DE.%26aulast%3DTap%26aufirst%3DW.%2BD.%26aulast%3DSchwartz%26aufirst%3DG.%2BK.%26atitle%3DMLN0128%252C%2520an%2520ATP-competitive%2520mTOR%2520kinase%2520inhibitor%2520with%2520potent%2520in%2520vitro%2520and%2520in%2520vivo%2520antitumor%2520activity%252C%2520as%2520potential%2520therapy%2520for%2520bone%2520and%2520soft-tissue%2520sarcoma%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2015%26volume%3D14%26spage%3D395%26epage%3D406%26doi%3D10.1158%2F1535-7163.MCT-14-0711" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit13b"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hsieh, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edlind, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ingolia, N. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janes, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sher, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, E. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stumpf, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christensen, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonham, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ren, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jessen, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feldman, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weissman, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shokat, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rommel, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruggero, D.</span></span> <span> </span><span class="NLM_article-title">The translational landscape of mTOR signalling steers cancer initiation and metastasis</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>485</i></span>,  <span class="NLM_fpage">55</span>– <span class="NLM_lpage">61</span>, <span class="refDoi"> DOI: 10.1038/nature10912</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01262&amp;key=10.1038%2Fnature10912" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01262&amp;key=22367541" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01262&amp;key=1%3ACAS%3A528%3ADC%252BC38Xislynsbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=485&publication_year=2012&pages=55-61&author=A.+C.+Hsiehauthor=Y.+Liuauthor=M.+P.+Edlindauthor=N.+T.+Ingoliaauthor=M.+R.+Janesauthor=A.+Sherauthor=E.+Y.+Shiauthor=C.+R.+Stumpfauthor=C.+Christensenauthor=M.+J.+Bonhamauthor=S.+Wangauthor=P.+Renauthor=M.+Martinauthor=K.+Jessenauthor=M.+E.+Feldmanauthor=J.+S.+Weissmanauthor=K.+M.+Shokatauthor=C.+Rommelauthor=D.+Ruggero&title=The+translational+landscape+of+mTOR+signalling+steers+cancer+initiation+and+metastasis&doi=10.1038%2Fnature10912"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13bR"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">The translational landscape of mTOR signaling steers cancer initiation and metastasis</span></div><div class="casAuthors">Hsieh, Andrew C.; Liu, Yi; Edlind, Merritt P.; Ingolia, Nicholas T.; Janes, Matthew R.; Sher, Annie; Shi, Evan Y.; Stumpf, Craig R.; Christensen, Carly; Bonham, Michael J.; Wang, Shunyou; Ren, Pingda; Martin, Michael; Jessen, Katti; Feldman, Morris E.; Weissman, Jonathan S.; Shokat, Kevan M.; Rommel, Christian; Ruggero, Davide</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">485</span>
        (<span class="NLM_cas:issue">7396</span>),
    <span class="NLM_cas:pages">55-61</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The mammalian target of rapamycin (mTOR) kinase is a master regulator of protein synthesis that couples nutrient sensing to cell growth and cancer.  However, the downstream translationally regulated nodes of gene expression that may direct cancer development are poorly characterized.  Using ribosome profiling, we uncover specialized translation of the prostate cancer genome by oncogenic mTOR signaling, revealing a remarkably specific repertoire of genes involved in cell proliferation, metab. and invasion.  We extend these findings by functionally characterizing a class of translationally controlled pro-invasion mRNAs that we show direct prostate cancer invasion and metastasis downstream of oncogenic mTOR signaling.  Furthermore, we develop a clin. relevant ATP site inhibitor of mTOR, INK128, which reprograms this gene expression signature with therapeutic benefit for prostate cancer metastasis, for which there is presently no cure.  Together, these findings extend our understanding of how the cancerous' translation machinery steers specific cancer cell behaviors, including metastasis, and may be therapeutically targeted.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGps08bxDEwvObVg90H21EOLACvtfcHk0lgQAikPfmKbuA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xislynsbw%253D&md5=37bf86fb8f86317ec13acf8f355e7ba8</span></div><a href="/servlet/linkout?suffix=cit13b&amp;dbid=16384&amp;doi=10.1038%2Fnature10912&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature10912%26sid%3Dliteratum%253Aachs%26aulast%3DHsieh%26aufirst%3DA.%2BC.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DEdlind%26aufirst%3DM.%2BP.%26aulast%3DIngolia%26aufirst%3DN.%2BT.%26aulast%3DJanes%26aufirst%3DM.%2BR.%26aulast%3DSher%26aufirst%3DA.%26aulast%3DShi%26aufirst%3DE.%2BY.%26aulast%3DStumpf%26aufirst%3DC.%2BR.%26aulast%3DChristensen%26aufirst%3DC.%26aulast%3DBonham%26aufirst%3DM.%2BJ.%26aulast%3DWang%26aufirst%3DS.%26aulast%3DRen%26aufirst%3DP.%26aulast%3DMartin%26aufirst%3DM.%26aulast%3DJessen%26aufirst%3DK.%26aulast%3DFeldman%26aufirst%3DM.%2BE.%26aulast%3DWeissman%26aufirst%3DJ.%2BS.%26aulast%3DShokat%26aufirst%3DK.%2BM.%26aulast%3DRommel%26aufirst%3DC.%26aulast%3DRuggero%26aufirst%3DD.%26atitle%3DThe%2520translational%2520landscape%2520of%2520mTOR%2520signalling%2520steers%2520cancer%2520initiation%2520and%2520metastasis%26jtitle%3DNature%26date%3D2012%26volume%3D485%26spage%3D55%26epage%3D61%26doi%3D10.1038%2Fnature10912" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14a"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mortensen, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fultz, K. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Packard, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khambatta, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gamez, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leisten, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Apuy, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghoreishi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hickman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Narla, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bissonette, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richardson, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peng, S. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perrin-Ninkovic, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tran, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, W. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tong, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cathers, B. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moghaddam, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Canan, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Worland, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sankar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raymon, H. K.</span></span> <span> </span><span class="NLM_article-title">CC-223, a potent and selective inhibitor of mTOR kinase: in vitro and in vivo characterization</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">1295</span>– <span class="NLM_lpage">1305</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-14-1052</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01262&amp;key=10.1158%2F1535-7163.MCT-14-1052" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01262&amp;key=25855786" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01262&amp;key=1%3ACAS%3A528%3ADC%252BC2MXpsFOgurk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2015&pages=1295-1305&author=D.+S.+Mortensenauthor=K.+E.+Fultzauthor=S.+Xuauthor=W.+Xuauthor=G.+Packardauthor=G.+Khambattaauthor=J.+C.+Gamezauthor=J.+Leistenauthor=J.+Zhaoauthor=J.+Apuyauthor=K.+Ghoreishiauthor=M.+Hickmanauthor=R.+K.+Narlaauthor=R.+Bissonetteauthor=S.+Richardsonauthor=S.+X.+Pengauthor=S.+Perrin-Ninkovicauthor=T.+Tranauthor=T.+Shiauthor=W.+Q.+Yangauthor=Z.+Tongauthor=B.+E.+Cathersauthor=M.+F.+Moghaddamauthor=S.+S.+Cananauthor=P.+Worlandauthor=S.+Sankarauthor=H.+K.+Raymon&title=CC-223%2C+a+potent+and+selective+inhibitor+of+mTOR+kinase%3A+in+vitro+and+in+vivo+characterization&doi=10.1158%2F1535-7163.MCT-14-1052"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14aR"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">CC-223, a Potent and Selective Inhibitor of mTOR Kinase: In Vitro and In Vivo Characterization</span></div><div class="casAuthors">Mortensen, Deborah S.; Fultz, Kimberly E.; Xu, Shuichan; Xu, Weiming; Packard, Garrick; Khambatta, Godrej; Gamez, James C.; Leisten, Jim; Zhao, Jingjing; Apuy, Julius; Ghoreishi, Kamran; Hickman, Matt; Narla, Rama Krishna; Bissonette, Rene; Richardson, Samantha; Peng, Sophie X.; Perrin-Ninkovic, Sophie; Tran, Tam; Shi, Tao; Yang, Wen Qing; Tong, Zeen; Cathers, Brian E.; Moghaddam, Mehran F.; Canan, Stacie S.; Worland, Peter; Sankar, Sabita; Raymon, Heather K.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1295-1305</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">MTOR is a serine/threonine kinase that regulates cell growth, metab., proliferation, and survival. mTOR complex-1 (mTORC1) and mTOR complex-2 (mTORC2) are crit. mediators of the PI3K-AKT pathway, which is frequently mutated in many cancers, leading to hyperactivation of mTOR signaling.  Although rapamycin analogs, allosteric inhibitors that target only the mTORC1 complex, have shown some clin. activity, it is hypothesized that mTOR kinase inhibitors, blocking both mTORC1 and mTORC2 signaling, will have expanded therapeutic potential.  Here, we describe the preclin. characterization of CC-223.  CC-223 is a potent, selective, and orally bioavailable inhibitor of mTOR kinase, demonstrating inhibition of mTORC1 (pS6RP and p4EBP1) and mTORC2 [pAKT(S473)] in cellular systems.  Growth inhibitory activity was demonstrated in hematol. and solid tumor cell lines. mTOR kinase inhibition in cells, by CC-223, resulted in more complete inhibition of the mTOR pathway biomarkers and improved antiproliferative activity as compared with rapamycin.  Growth inhibitory activity and apoptosis was demonstrated in a panel of hematol. cancer cell lines.  Correlative anal. revealed that IRF4 expression level assocs. with resistance, whereas mTOR pathway activation seems to assoc. with sensitivity.  Treatment with CC-223 afforded in vivo tumor biomarker inhibition in tumor-bearing mice, after a single oral dose.  CC-223 exhibited dose-dependent tumor growth inhibition in multiple solid tumor xenografts.  Significant inhibition of mTOR pathway markers pS6RP and pAKT in CC-223-treated tumors suggests that the obsd. antitumor activity of CC-223 was mediated through inhibition of both mTORC1 and mTORC2.  CC-223 is currently in phase I clin. trials.  Mol Cancer Ther; 14(6); 1295-305. ©2015 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrDt9130-L0z7Vg90H21EOLACvtfcHk0lgf1nWgFKno-g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXpsFOgurk%253D&md5=f33b21dc89dedaf14fab54a819afb917</span></div><a href="/servlet/linkout?suffix=cit14a&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-14-1052&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-14-1052%26sid%3Dliteratum%253Aachs%26aulast%3DMortensen%26aufirst%3DD.%2BS.%26aulast%3DFultz%26aufirst%3DK.%2BE.%26aulast%3DXu%26aufirst%3DS.%26aulast%3DXu%26aufirst%3DW.%26aulast%3DPackard%26aufirst%3DG.%26aulast%3DKhambatta%26aufirst%3DG.%26aulast%3DGamez%26aufirst%3DJ.%2BC.%26aulast%3DLeisten%26aufirst%3DJ.%26aulast%3DZhao%26aufirst%3DJ.%26aulast%3DApuy%26aufirst%3DJ.%26aulast%3DGhoreishi%26aufirst%3DK.%26aulast%3DHickman%26aufirst%3DM.%26aulast%3DNarla%26aufirst%3DR.%2BK.%26aulast%3DBissonette%26aufirst%3DR.%26aulast%3DRichardson%26aufirst%3DS.%26aulast%3DPeng%26aufirst%3DS.%2BX.%26aulast%3DPerrin-Ninkovic%26aufirst%3DS.%26aulast%3DTran%26aufirst%3DT.%26aulast%3DShi%26aufirst%3DT.%26aulast%3DYang%26aufirst%3DW.%2BQ.%26aulast%3DTong%26aufirst%3DZ.%26aulast%3DCathers%26aufirst%3DB.%2BE.%26aulast%3DMoghaddam%26aufirst%3DM.%2BF.%26aulast%3DCanan%26aufirst%3DS.%2BS.%26aulast%3DWorland%26aufirst%3DP.%26aulast%3DSankar%26aufirst%3DS.%26aulast%3DRaymon%26aufirst%3DH.%2BK.%26atitle%3DCC-223%252C%2520a%2520potent%2520and%2520selective%2520inhibitor%2520of%2520mTOR%2520kinase%253A%2520in%2520vitro%2520and%2520in%2520vivo%2520characterization%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2015%26volume%3D14%26spage%3D1295%26epage%3D1305%26doi%3D10.1158%2F1535-7163.MCT-14-1052" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit14b"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jin, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, A.</span></span> <span> </span><span class="NLM_article-title">Preclinical study of CC223 as a potential anti-ovarian cancer agent</span>. <i>Oncotarget</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">58469</span>– <span class="NLM_lpage">58479</span>, <span class="refDoi"> DOI: 10.18632/oncotarget.17753</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01262&amp;key=10.18632%2Foncotarget.17753" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01262&amp;key=28938571" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01262&amp;key=1%3ACAS%3A280%3ADC%252BC1M%252FhtlOjuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=58469-58479&author=Z.+Jinauthor=H.+Niuauthor=X.+Wangauthor=L.+Zhangauthor=Q.+Wangauthor=A.+Yang&title=Preclinical+study+of+CC223+as+a+potential+anti-ovarian+cancer+agent&doi=10.18632%2Foncotarget.17753"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14bR"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Preclinical study of CC223 as a potential anti-ovarian cancer agent</span></div><div class="casAuthors">Jin Zhenzhen; Niu Huanfu; Wang Xuenan; Wang Qin; Yang Aijun; Zhang Lei</div><div class="citationInfo"><span class="NLM_cas:title">Oncotarget</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">35</span>),
    <span class="NLM_cas:pages">58469-58479</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Aberrant activation of mTOR contributes to ovarian cancer progression.  CC223 is a novel and potent mTOR kinase inhibitor.  The current study tested its activity against human ovarian cancer cells.  We showed that CC223, at nM concentrations, inhibited survival and proliferation of established/primary human ovarian cancer cells.  Further, significant apoptosis activation was observed in CC223-treated ovarian cancer cells.  CC223 disrupted assembly of mTOR complex 1 (mTORC1) and mTORC2 in SKOV3 cells.  Meanwhile, activation of mTORC1 and mTORC2 was almost completely blocked by CC223.  Intriguingly, restoring mTOR activation by introduction of a constitutively-active Akt1 only partially inhibited CC223-induced cytotoxicity in SKOV3 cells.  Further studies showed that CC223 inhibited sphingosine kinase 1 (SphK1) activity and induced reactive oxygen species (ROS) production in SKOV3 cells.  At last, oral administration of CC223 potently inhibited SKOV3 xenografted tumor growth in nude mice.  The results of this study imply that CC223 could be further studied as a potential anti-ovarian cancer agent.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRcU4AE24nN2t1QT_1O5WBYfW6udTcc2eYkD3LkNyWUe7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1M%252FhtlOjuw%253D%253D&md5=091fdb75cec2ddb9018ba74c124041e8</span></div><a href="/servlet/linkout?suffix=cit14b&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.17753&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.17753%26sid%3Dliteratum%253Aachs%26aulast%3DJin%26aufirst%3DZ.%26aulast%3DNiu%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DQ.%26aulast%3DYang%26aufirst%3DA.%26atitle%3DPreclinical%2520study%2520of%2520CC223%2520as%2520a%2520potential%2520anti-ovarian%2520cancer%2520agent%26jtitle%3DOncotarget%26date%3D2017%26volume%3D8%26spage%3D58469%26epage%3D58479%26doi%3D10.18632%2Foncotarget.17753" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pike, K. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malagu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hummersone, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Menear, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duggan, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gomez, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, N. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruston, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pass, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pass, M.</span></span> <span> </span><span class="NLM_article-title">Optimization of potent and selective dual mTORC1 and mTORC2 inhibitors: the discovery of AZD8055 and AZD2014</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">1212</span>– <span class="NLM_lpage">1216</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2013.01.019</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01262&amp;key=10.1016%2Fj.bmcl.2013.01.019" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01262&amp;key=23375793" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01262&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvFajs7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2013&pages=1212-1216&author=K.+G.+Pikeauthor=K.+Malaguauthor=M.+G.+Hummersoneauthor=K.+A.+Menearauthor=H.+M.+Dugganauthor=S.+Gomezauthor=N.+M.+Martinauthor=L.+Rustonauthor=S.+L.+Passauthor=M.+Pass&title=Optimization+of+potent+and+selective+dual+mTORC1+and+mTORC2+inhibitors%3A+the+discovery+of+AZD8055+and+AZD2014&doi=10.1016%2Fj.bmcl.2013.01.019"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Optimization of potent and selective dual mTORC1 and mTORC2 inhibitors: The discovery of AZD8055 and AZD2014</span></div><div class="casAuthors">Pike, Kurt G.; Malagu, Karine; Hummersone, Marc G.; Menear, Keith A.; Duggan, Heather M. E.; Gomez, Sylvie; Martin, Niall M. B.; Ruston, Linette; Pass, Sarah L.; Pass, Martin</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1212-1216</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The optimization of a potent and highly selective series of dual mTORC1 and mTORC2 inhibitors is described.  An initial focus on improving cellular potency while maintaining or improving other key parameters, such as aq. soly. and margins over hERG IC50, led to the discovery of the clin. candidate AZD8055.  Further optimization, particularly aimed at reducing the rate of metab. in human hepatocyte incubations, resulted in the discovery of the clin. candidate AZD2014.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo07emMEKp9mrVg90H21EOLACvtfcHk0lgf1nWgFKno-g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvFajs7c%253D&md5=325cb45f84bb4357005315ab3b27c0aa</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2013.01.019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2013.01.019%26sid%3Dliteratum%253Aachs%26aulast%3DPike%26aufirst%3DK.%2BG.%26aulast%3DMalagu%26aufirst%3DK.%26aulast%3DHummersone%26aufirst%3DM.%2BG.%26aulast%3DMenear%26aufirst%3DK.%2BA.%26aulast%3DDuggan%26aufirst%3DH.%2BM.%26aulast%3DGomez%26aufirst%3DS.%26aulast%3DMartin%26aufirst%3DN.%2BM.%26aulast%3DRuston%26aufirst%3DL.%26aulast%3DPass%26aufirst%3DS.%2BL.%26aulast%3DPass%26aufirst%3DM.%26atitle%3DOptimization%2520of%2520potent%2520and%2520selective%2520dual%2520mTORC1%2520and%2520mTORC2%2520inhibitors%253A%2520the%2520discovery%2520of%2520AZD8055%2520and%2520AZD2014%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2013%26volume%3D23%26spage%3D1212%26epage%3D1216%26doi%3D10.1016%2Fj.bmcl.2013.01.019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Crino, P. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nathanson, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Henske, E. P.</span></span> <span> </span><span class="NLM_article-title">The tuberous sclerosis complex</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>355</i></span>,  <span class="NLM_fpage">1345</span>– <span class="NLM_lpage">1356</span>, <span class="refDoi"> DOI: 10.1056/NEJMra055323</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01262&amp;key=10.1056%2FNEJMra055323" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01262&amp;key=17005952" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01262&amp;key=1%3ACAS%3A528%3ADC%252BD2sXisVGit7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=355&publication_year=2006&pages=1345-1356&author=P.+B.+Crinoauthor=K.+L.+Nathansonauthor=E.+P.+Henske&title=The+tuberous+sclerosis+complex&doi=10.1056%2FNEJMra055323"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">The tuberous sclerosis complex</span></div><div class="casAuthors">Crino, Peter B.; Nathanson, Katherine L.; Henske, Elizabeth Petri</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">355</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">1345-1356</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGreefc8lvD2Q7Vg90H21EOLACvtfcHk0ljZ15b0z5uXiQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXisVGit7c%253D&md5=1cbf19b05ac03452756cf07e2d518e95</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1056%2FNEJMra055323&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMra055323%26sid%3Dliteratum%253Aachs%26aulast%3DCrino%26aufirst%3DP.%2BB.%26aulast%3DNathanson%26aufirst%3DK.%2BL.%26aulast%3DHenske%26aufirst%3DE.%2BP.%26atitle%3DThe%2520tuberous%2520sclerosis%2520complex%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2006%26volume%3D355%26spage%3D1345%26epage%3D1356%26doi%3D10.1056%2FNEJMra055323" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Meikle, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pollizzi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Egnor, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kramvis, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lane, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sahin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwiatkowski, D. J.</span></span> <span> </span><span class="NLM_article-title">Response of a neuronal model of tuberous sclerosis to mammalian target of rapamycin (mTOR) inhibitors: effects on mTORC1 and Akt signaling lead to improved survival and function</span>. <i>J. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>28</i></span>,  <span class="NLM_fpage">5422</span>– <span class="NLM_lpage">5432</span>, <span class="refDoi"> DOI: 10.1523/JNEUROSCI.0955-08.2008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01262&amp;key=10.1523%2FJNEUROSCI.0955-08.2008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01262&amp;key=18495876" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01262&amp;key=1%3ACAS%3A528%3ADC%252BD1cXmslWisbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2008&pages=5422-5432&author=L.+Meikleauthor=K.+Pollizziauthor=A.+Egnorauthor=I.+Kramvisauthor=H.+Laneauthor=M.+Sahinauthor=D.+J.+Kwiatkowski&title=Response+of+a+neuronal+model+of+tuberous+sclerosis+to+mammalian+target+of+rapamycin+%28mTOR%29+inhibitors%3A+effects+on+mTORC1+and+Akt+signaling+lead+to+improved+survival+and+function&doi=10.1523%2FJNEUROSCI.0955-08.2008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Response of a neuronal model of tuberous sclerosis to mammalian target of rapamycin (mTOR) inhibitors: effects on mTORC1 and Akt signaling lead to improved survival and function</span></div><div class="casAuthors">Meikle, Lynsey; Pollizzi, Kristen; Egnor, Anna; Kramvis, Ioannis; Lane, Heidi; Sahin, Mustafa; Kwiatkowski, David J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neuroscience</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">5422-5432</span>CODEN:
                <span class="NLM_cas:coden">JNRSDS</span>;
        ISSN:<span class="NLM_cas:issn">0270-6474</span>.
    
            (<span class="NLM_cas:orgname">Society for Neuroscience</span>)
        </div><div class="casAbstract">Tuberous sclerosis (TSC) is a hamartoma syndrome attributable to mutations in either TSC1 or TSC2 in which brain involvement causes epilepsy, mental retardation, and autism.  We have reported recently a mouse neuronal model of TSC in which Tsc1 is ablated in most neurons during cortical development.  We have tested rapamycin and RAD001 [40-O-(2-hydroxyethyl)-rapamycin], both mammalian target of rapamycin mTORC1 inhibitors, as potential therapeutic agents in this model.  Median survival is improved from 33 d to more than 100 d; behavior, phenotype, and wt. gain are all also markedly improved.  There is brain penetration of both drugs, with accumulation over time with repetitive treatment, and effective redn. of levels of phospho-S6, a downstream target of mTORC1.  In addn., there is restoration of phospho-Akt and phospho-glycogen synthase kinase 3 levels in the treated mice, consistent with restoration of Akt function.  Neurofilament abnormalities, myelination, and cell enlargement are all improved by the treatment.  However, dysplastic neuronal features persist, and there are only modest changes in dendritic spine d. and length.  Strikingly, mice treated with rapamycin or RAD001 for 23 d only (postnatal days 7-30) displayed a persistent improvement in phenotype, with median survival of 78 d.  In summary, rapamycin/RAD001 are highly effective therapies for this neuronal model of TSC, with benefit apparently attributable to effects on mTORC1 and Akt signaling and, consequently, cell size and myelination.  Although caution is appropriate, the results suggest the possibility that rapamycin/RAD001 may have benefit in the treatment of TSC brain disease, including infantile spasms.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp7NYIU5vQOo7Vg90H21EOLACvtfcHk0ljZ15b0z5uXiQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXmslWisbY%253D&md5=213ca3d5a365d9fc0bddf139fd97a278</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1523%2FJNEUROSCI.0955-08.2008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1523%252FJNEUROSCI.0955-08.2008%26sid%3Dliteratum%253Aachs%26aulast%3DMeikle%26aufirst%3DL.%26aulast%3DPollizzi%26aufirst%3DK.%26aulast%3DEgnor%26aufirst%3DA.%26aulast%3DKramvis%26aufirst%3DI.%26aulast%3DLane%26aufirst%3DH.%26aulast%3DSahin%26aufirst%3DM.%26aulast%3DKwiatkowski%26aufirst%3DD.%2BJ.%26atitle%3DResponse%2520of%2520a%2520neuronal%2520model%2520of%2520tuberous%2520sclerosis%2520to%2520mammalian%2520target%2520of%2520rapamycin%2520%2528mTOR%2529%2520inhibitors%253A%2520effects%2520on%2520mTORC1%2520and%2520Akt%2520signaling%2520lead%2520to%2520improved%2520survival%2520and%2520function%26jtitle%3DJ.%2520Neurosci.%26date%3D2008%26volume%3D28%26spage%3D5422%26epage%3D5432%26doi%3D10.1523%2FJNEUROSCI.0955-08.2008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Krueger, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilfong, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mays, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Talley, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Agricola, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tudor, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Capal, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holland-Bouley, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Franz, D. N.</span></span> <span> </span><span class="NLM_article-title">Long-term treatment of epilepsy with everolimus in tuberous sclerosis</span>. <i>Neurology</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>87</i></span>,  <span class="NLM_fpage">2408</span>– <span class="NLM_lpage">2415</span>, <span class="refDoi"> DOI: 10.1212/WNL.0000000000003400</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01262&amp;key=10.1212%2FWNL.0000000000003400" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=87&publication_year=2016&pages=2408-2415&author=D.+A.+Kruegerauthor=A.+A.+Wilfongauthor=M.+Maysauthor=C.+M.+Talleyauthor=K.+Agricolaauthor=C.+Tudorauthor=J.+Capalauthor=K.+Holland-Bouleyauthor=D.+N.+Franz&title=Long-term+treatment+of+epilepsy+with+everolimus+in+tuberous+sclerosis&doi=10.1212%2FWNL.0000000000003400"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1212%2FWNL.0000000000003400&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1212%252FWNL.0000000000003400%26sid%3Dliteratum%253Aachs%26aulast%3DKrueger%26aufirst%3DD.%2BA.%26aulast%3DWilfong%26aufirst%3DA.%2BA.%26aulast%3DMays%26aufirst%3DM.%26aulast%3DTalley%26aufirst%3DC.%2BM.%26aulast%3DAgricola%26aufirst%3DK.%26aulast%3DTudor%26aufirst%3DC.%26aulast%3DCapal%26aufirst%3DJ.%26aulast%3DHolland-Bouley%26aufirst%3DK.%26aulast%3DFranz%26aufirst%3DD.%2BN.%26atitle%3DLong-term%2520treatment%2520of%2520epilepsy%2520with%2520everolimus%2520in%2520tuberous%2520sclerosis%26jtitle%3DNeurology%26date%3D2016%26volume%3D87%26spage%3D2408%26epage%3D2415%26doi%3D10.1212%2FWNL.0000000000003400" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">MacKeigan, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krueger, D. A.</span></span> <span> </span><span class="NLM_article-title">Differentiating the mTOR inhibitors everolimus and sirolimus in the treatment of tuberous sclerosis complex</span>. <i>Neuro Oncol</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">1550</span>– <span class="NLM_lpage">1559</span>, <span class="refDoi"> DOI: 10.1093/neuonc/nov152</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01262&amp;key=10.1093%2Fneuonc%2Fnov152" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01262&amp;key=26289591" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01262&amp;key=1%3ACAS%3A528%3ADC%252BC28XitVCntbfO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2015&pages=1550-1559&author=J.+P.+MacKeiganauthor=D.+A.+Krueger&title=Differentiating+the+mTOR+inhibitors+everolimus+and+sirolimus+in+the+treatment+of+tuberous+sclerosis+complex&doi=10.1093%2Fneuonc%2Fnov152"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Differentiating the mTOR inhibitors everolimus and sirolimus in the treatment of tuberous sclerosis complex</span></div><div class="casAuthors">MacKeigan, Jeffrey P.; Krueger, Darcy A.</div><div class="citationInfo"><span class="NLM_cas:title">Neuro-Oncology (Cary, NC, United States)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1550-1559</span>CODEN:
                <span class="NLM_cas:coden">NEURJR</span>;
        ISSN:<span class="NLM_cas:issn">1522-8517</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Tuberous sclerosis complex (TSC) is a genetic autosomal dominant disorder characterized by benign tumor-like lesions, called hamartomas, in multiple organ systems, including the brain, skin, heart, kidneys, and lung.  These hamartomas cause a diverse set of clin. problems based on their location and often result in epilepsy, learning difficulties, and behavioral problems.  TSC is caused by mutations within the TSC1 or TSC2 genes that inactivate the genes' tumor-suppressive function and drive hamartomatous cell growth.  In normal cells, TSC1 and TSC2 integrate growth signals and nutrient inputs to down regulate signaling to mammalian target of rapamycin (mTOR), an evolutionarily conserved serine-threonine kinase that controls cell growth and cell survival.  The mol. connection between TSC and mTOR led to the clin. use of allosteric mTOR inhibitors (sirolimus and everolimus) for the treatment of TSC.  Everolimus is approved for subependymal giant cell astrocytomas and renal angiomyolipomas in patients with TSC.  Sirolimus, though not approved for TSC, has undergone considerable investigation to treat various aspects of the disease.  Everolimus and sirolimus selectively inhibit mTOR signaling with similar mol. mechanisms, but with distinct clin. profiles.  This review differentiates mTOR inhibitors in TSC while describing the mol. mechanisms, pathogenic mutations, and clin. trial outcomes for managing TSC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoCumDeMj3tErVg90H21EOLACvtfcHk0ljIsRxbupGp3Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XitVCntbfO&md5=0d400bd50e7edfd9abcf1492573a7378</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1093%2Fneuonc%2Fnov152&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fneuonc%252Fnov152%26sid%3Dliteratum%253Aachs%26aulast%3DMacKeigan%26aufirst%3DJ.%2BP.%26aulast%3DKrueger%26aufirst%3DD.%2BA.%26atitle%3DDifferentiating%2520the%2520mTOR%2520inhibitors%2520everolimus%2520and%2520sirolimus%2520in%2520the%2520treatment%2520of%2520tuberous%2520sclerosis%2520complex%26jtitle%3DNeuro%2520Oncol%26date%3D2015%26volume%3D17%26spage%3D1550%26epage%3D1559%26doi%3D10.1093%2Fneuonc%2Fnov152" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">McCormack, F. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Inoue, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moss, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singer, L. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strange, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakata, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barker, A. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chapman, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brantly, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stocks, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, K. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lynch, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldberg, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, L. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kinder, B. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Downey, G. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sullivan, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colby, T. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McKay, R. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cohen, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Korbee, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taveira-DaSilva, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krischer, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trapnell, B. C.</span></span>; <span class="NLM_contrib-group">National Institutes of Health Rare Lung Diseases Consortium</span>; <span class="NLM_contrib-group">MILES Trial Group</span> <span> </span><span class="NLM_article-title">Efficacy and safety of sirolimus in lymphangioleiomyomatosis</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>364</i></span>,  <span class="NLM_fpage">1595</span>– <span class="NLM_lpage">1606</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1100391</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01262&amp;key=10.1056%2FNEJMoa1100391" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01262&amp;key=21410393" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01262&amp;key=1%3ACAS%3A528%3ADC%252BC3MXlsFegtr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=364&publication_year=2011&pages=1595-1606&author=F.+X.+McCormackauthor=Y.+Inoueauthor=J.+Mossauthor=L.+G.+Singerauthor=C.+Strangeauthor=K.+Nakataauthor=A.+F.+Barkerauthor=J.+T.+Chapmanauthor=M.+L.+Brantlyauthor=J.+M.+Stocksauthor=K.+K.+Brownauthor=J.+P.+Lynchauthor=H.+J.+Goldbergauthor=L.+R.+Youngauthor=B.+W.+Kinderauthor=G.+P.+Downeyauthor=E.+J.+Sullivanauthor=T.+V.+Colbyauthor=R.+T.+McKayauthor=M.+M.+Cohenauthor=L.+Korbeeauthor=A.+M.+Taveira-DaSilvaauthor=H.+S.+Leeauthor=J.+P.+Krischerauthor=B.+C.+Trapnellauthor=National+Institutes+of+Health+Rare+Lung+Diseases+Consortiumauthor=MILES+Trial+Group&title=Efficacy+and+safety+of+sirolimus+in+lymphangioleiomyomatosis&doi=10.1056%2FNEJMoa1100391"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Efficacy and safety of sirolimus in lymphangioleiomyomatosis</span></div><div class="casAuthors">McCormack, Francis X.; Inoue, Yoshikazu; Moss, Joel; Singer, Lianne G.; Strange, Charlie; Nakata, Koh; Barker, Alan F.; Chapman, Jeffrey T.; Brantly, Mark L.; Stocks, James M.; Brown, Kevin K.; Lynch, Joseph P., III; Goldberg, Hilary J.; Young, Lisa R.; Kinder, Brent W.; Downey, Gregory P.; Sullivan, Eugene J.; Colby, Thomas V.; McKay, Roy T.; Cohen, Marsha M.; Korbee, Leslie; Taveira-Dasilva, Angelo M.; Lee, Hye-Seung; Krischer, Jeffrey P.; Trapnell, Bruce C.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">364</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">1595-1606</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Lymphangioleiomyomatosis (LAM) is a progressive, cystic lung disease in women; it is assocd. with inappropriate activation of mammalian target of rapamycin (mTOR) signaling, which regulates cellular growth and lymphangiogenesis.  Sirolimus (also called rapamycin) inhibits mTOR and has shown promise in phase 1-2 trials involving patients with LAM.  METHODS: We conducted a two-stage trial of sirolimus involving 89 patients with LAM who had moderate lung impairment - a 12-mo randomized, double-blind comparison of sirolimus with placebo, followed by a 12-mo observation period.  The primary end point was the difference between the groups in the rate of change (slope) in forced expiratory vol. in 1 s (FEV1).  RESULTS: During the treatment period, the FEV, slope was -12 ± 2 mL per mo in the placebo group (43 patients) and 12 mL per mo in the sirolimus group (46 patients) (P < 0.001).  The abs. between-group difference in the mean change in FEV, during the treatment period was 153 mL, or approx. 11% of the mean FEV1 at enrollment.  As compared with the placebo group, the sirolimus group had improvement from baseline to 12 mo in measures of forced vital capacity, functional residual capacity, serum vascular endothelial growth factor D (VEGF-D), and quality of life and functional performance.  There was no significant between-group difference in this interval in the change in 6-min walk distance or diffusing capacity of the lung for carbon monoxide.  After discontinuation of sirolimus, the decline in lung function resumed in the sirolimus group and paralleled that in the placebo group.  Adverse events were more common with sirolimus, but the frequency of serious adverse events did not differ significantly between the groups.  CONCLUSIONS: In patients with LAM, sirolimus stabilized lung function, reduced serum VEGF-D levels, and was assocd. with a redn. in symptoms and improvement in quality of life.  Therapy with sirolimus may be useful in selected patients with LAM.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGreoHXYwZz-c7Vg90H21EOLACvtfcHk0lipVECLSyGyqg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXlsFegtr0%253D&md5=46799ffecf19fb0e039f4e6ae35e9c32</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1100391&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1100391%26sid%3Dliteratum%253Aachs%26aulast%3DMcCormack%26aufirst%3DF.%2BX.%26aulast%3DInoue%26aufirst%3DY.%26aulast%3DMoss%26aufirst%3DJ.%26aulast%3DSinger%26aufirst%3DL.%2BG.%26aulast%3DStrange%26aufirst%3DC.%26aulast%3DNakata%26aufirst%3DK.%26aulast%3DBarker%26aufirst%3DA.%2BF.%26aulast%3DChapman%26aufirst%3DJ.%2BT.%26aulast%3DBrantly%26aufirst%3DM.%2BL.%26aulast%3DStocks%26aufirst%3DJ.%2BM.%26aulast%3DBrown%26aufirst%3DK.%2BK.%26aulast%3DLynch%26aufirst%3DJ.%2BP.%26aulast%3DGoldberg%26aufirst%3DH.%2BJ.%26aulast%3DYoung%26aufirst%3DL.%2BR.%26aulast%3DKinder%26aufirst%3DB.%2BW.%26aulast%3DDowney%26aufirst%3DG.%2BP.%26aulast%3DSullivan%26aufirst%3DE.%2BJ.%26aulast%3DColby%26aufirst%3DT.%2BV.%26aulast%3DMcKay%26aufirst%3DR.%2BT.%26aulast%3DCohen%26aufirst%3DM.%2BM.%26aulast%3DKorbee%26aufirst%3DL.%26aulast%3DTaveira-DaSilva%26aufirst%3DA.%2BM.%26aulast%3DLee%26aufirst%3DH.%2BS.%26aulast%3DKrischer%26aufirst%3DJ.%2BP.%26aulast%3DTrapnell%26aufirst%3DB.%2BC.%26aulast%3D%26aulast%3D%26atitle%3DEfficacy%2520and%2520safety%2520of%2520sirolimus%2520in%2520lymphangioleiomyomatosis%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2011%26volume%3D364%26spage%3D1595%26epage%3D1606%26doi%3D10.1056%2FNEJMoa1100391" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Talboom, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Velazquez, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oddo, S.</span></span> <span> </span><span class="NLM_article-title">The mammalian target of rapamycin at the crossroad between cognitive aging and Alzheimer’s disease</span>. <i>NPJ. Aging Mech. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>1</i></span>,  <span class="NLM_fpage">15008</span>, <span class="refDoi"> DOI: 10.1038/npjamd.2015.8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01262&amp;key=10.1038%2Fnpjamd.2015.8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01262&amp;key=28721257" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01262&amp;key=1%3ACAS%3A280%3ADC%252BC1cjovFaisg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2015&pages=15008&author=J.+S.+Talboomauthor=R.+Velazquezauthor=S.+Oddo&title=The+mammalian+target+of+rapamycin+at+the+crossroad+between+cognitive+aging+and+Alzheimer%E2%80%99s+disease&doi=10.1038%2Fnpjamd.2015.8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">The mammalian target of rapamycin at the crossroad between cognitive aging and Alzheimer's disease</span></div><div class="casAuthors">Talboom Joshua S; Velazquez Ramon; Oddo Salvatore; Oddo Salvatore</div><div class="citationInfo"><span class="NLM_cas:title">NPJ aging and mechanisms of disease</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">15008</span>
        ISSN:<span class="NLM_cas:issn">2056-3973</span>.
    </div><div class="casAbstract">Age-dependent cognitive decline is a major debilitating event affecting even individuals who are otherwise healthy.  Understanding the molecular basis underlying these changes may increase the healthspan of the elderly population.  It may also reveal insights into the pathogenesis of numerous neurodegenerative disorders characterized by cognitive deficits, as aging is the major risk factor for most of these disorders.  Alzheimer's disease (AD), the most common neurodegenerative disorder, first manifests itself as deficits in encoding new memories.  As AD progresses, these deficits spread to other cognitive domains that further debilitate the person before contributing to their demise.  Suppression of the mammalian target of rapamycin (mTOR) increases healthspan and lifespan in several organisms.  Numerous reports have linked alterations in mTOR signaling to age-dependent cognitive decline and the pathogenesis of AD.  This review will discuss recent work highlighting the complex role of mTOR in cognitive aging and in the pathogenesis of AD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSA0TQF8zU3rf69nzq6467DfW6udTcc2eYYJuAjbZeyObntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1cjovFaisg%253D%253D&md5=3a98d9e1b3facf63a929fa6d5d35667c</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1038%2Fnpjamd.2015.8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnpjamd.2015.8%26sid%3Dliteratum%253Aachs%26aulast%3DTalboom%26aufirst%3DJ.%2BS.%26aulast%3DVelazquez%26aufirst%3DR.%26aulast%3DOddo%26aufirst%3DS.%26atitle%3DThe%2520mammalian%2520target%2520of%2520rapamycin%2520at%2520the%2520crossroad%2520between%2520cognitive%2520aging%2520and%2520Alzheimer%25E2%2580%2599s%2520disease%26jtitle%3DNPJ.%2520Aging%2520Mech.%2520Dis.%26date%3D2015%26volume%3D1%26spage%3D15008%26doi%3D10.1038%2Fnpjamd.2015.8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22a"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ravikumar, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vacher, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berger, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davies, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oroz, L. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scaravilli, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Easton, D. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duden, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Kane, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rubinsztein, D. C.</span></span> <span> </span><span class="NLM_article-title">Inhibition of mTOR induces autophagy and reduces toxicity of polyglutamine expansions in fly and mouse models of Huntington disease</span>. <i>Nat. Genet.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>36</i></span>,  <span class="NLM_fpage">585</span>– <span class="NLM_lpage">595</span>, <span class="refDoi"> DOI: 10.1038/ng1362</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01262&amp;key=10.1038%2Fng1362" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01262&amp;key=15146184" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01262&amp;key=1%3ACAS%3A528%3ADC%252BD2cXksVajt7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2004&pages=585-595&author=B.+Ravikumarauthor=C.+Vacherauthor=Z.+Bergerauthor=J.+E.+Daviesauthor=S.+Luoauthor=L.+G.+Orozauthor=F.+Scaravilliauthor=D.+F.+Eastonauthor=R.+Dudenauthor=C.+J.+O%E2%80%99Kaneauthor=D.+C.+Rubinsztein&title=Inhibition+of+mTOR+induces+autophagy+and+reduces+toxicity+of+polyglutamine+expansions+in+fly+and+mouse+models+of+Huntington+disease&doi=10.1038%2Fng1362"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22aR"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of mTOR induces autophagy and reduces toxicity of polyglutamine expansions in fly and mouse models of Huntington disease</span></div><div class="casAuthors">Ravikumar, Brinda; Vacher, Coralie; Berger, Zdenek; Davies, Janet E.; Luo, Shouqing; Oroz, Lourdes G.; Scaravilli, Francesco; Easton, Douglas F.; Duden, Rainer; O'Kane, Cahir J.; Rubinsztein, David C.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Genetics</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">585-595</span>CODEN:
                <span class="NLM_cas:coden">NGENEC</span>;
        ISSN:<span class="NLM_cas:issn">1061-4036</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Huntington disease is one of nine inherited neurodegenerative disorders caused by a polyglutamine tract expansion.  Expanded polyglutamine proteins accumulate abnormally in intracellular aggregates.  Here we show that mammalian target of rapamycin (mTOR) is sequestered in polyglutamine aggregates in cell models, transgenic mice and human brains.  Sequestration of mTOR impairs its kinase activity and induces autophagy, a key clearance pathway for mutant huntingtin fragments.  This protects against polyglutamine toxicity, as the specific mTOR inhibitor rapamycin attenuates huntingtin accumulation and cell death in cell models of Huntington disease, and inhibition of autophagy has the converse effects.  Furthermore, rapamycin protects against neurodegeneration in a fly model of Huntington disease, and the rapamycin analog CCI-779 improved performance on four different behavioral tasks and decreased aggregate formation in a mouse model of Huntington disease.  Our data provide proof-of-principle for the potential of inducing autophagy to treat Huntington disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpe6pwZ9IPbhLVg90H21EOLACvtfcHk0liWm2PzftqL9Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXksVajt7s%253D&md5=39f48bebe54daa65eb21715819b703c4</span></div><a href="/servlet/linkout?suffix=cit22a&amp;dbid=16384&amp;doi=10.1038%2Fng1362&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fng1362%26sid%3Dliteratum%253Aachs%26aulast%3DRavikumar%26aufirst%3DB.%26aulast%3DVacher%26aufirst%3DC.%26aulast%3DBerger%26aufirst%3DZ.%26aulast%3DDavies%26aufirst%3DJ.%2BE.%26aulast%3DLuo%26aufirst%3DS.%26aulast%3DOroz%26aufirst%3DL.%2BG.%26aulast%3DScaravilli%26aufirst%3DF.%26aulast%3DEaston%26aufirst%3DD.%2BF.%26aulast%3DDuden%26aufirst%3DR.%26aulast%3DO%25E2%2580%2599Kane%26aufirst%3DC.%2BJ.%26aulast%3DRubinsztein%26aufirst%3DD.%2BC.%26atitle%3DInhibition%2520of%2520mTOR%2520induces%2520autophagy%2520and%2520reduces%2520toxicity%2520of%2520polyglutamine%2520expansions%2520in%2520fly%2520and%2520mouse%2520models%2520of%2520Huntington%2520disease%26jtitle%3DNat.%2520Genet.%26date%3D2004%26volume%3D36%26spage%3D585%26epage%3D595%26doi%3D10.1038%2Fng1362" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit22b"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Floto, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sarkar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perlstein, E. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kampmann, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schreiber, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rubinsztein, D. C.</span></span> <span> </span><span class="NLM_article-title">Small molecule enhancers of rapamycin-induced TOR inhibition promote autophagy, reduce toxicity in Huntington’s disease models and enhance killing of mycobacteria by macrophages</span>. <i>Autophagy</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">620</span>– <span class="NLM_lpage">622</span>, <span class="refDoi"> DOI: 10.4161/auto.4898</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01262&amp;key=10.4161%2Fauto.4898" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2007&pages=620-622&author=R.+A.+Flotoauthor=S.+Sarkarauthor=E.+O.+Perlsteinauthor=B.+Kampmannauthor=S.+L.+Schreiberauthor=D.+C.+Rubinsztein&title=Small+molecule+enhancers+of+rapamycin-induced+TOR+inhibition+promote+autophagy%2C+reduce+toxicity+in+Huntington%E2%80%99s+disease+models+and+enhance+killing+of+mycobacteria+by+macrophages&doi=10.4161%2Fauto.4898"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit22b&amp;dbid=16384&amp;doi=10.4161%2Fauto.4898&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4161%252Fauto.4898%26sid%3Dliteratum%253Aachs%26aulast%3DFloto%26aufirst%3DR.%2BA.%26aulast%3DSarkar%26aufirst%3DS.%26aulast%3DPerlstein%26aufirst%3DE.%2BO.%26aulast%3DKampmann%26aufirst%3DB.%26aulast%3DSchreiber%26aufirst%3DS.%2BL.%26aulast%3DRubinsztein%26aufirst%3DD.%2BC.%26atitle%3DSmall%2520molecule%2520enhancers%2520of%2520rapamycin-induced%2520TOR%2520inhibition%2520promote%2520autophagy%252C%2520reduce%2520toxicity%2520in%2520Huntington%25E2%2580%2599s%2520disease%2520models%2520and%2520enhance%2520killing%2520of%2520mycobacteria%2520by%2520macrophages%26jtitle%3DAutophagy%26date%3D2007%26volume%3D3%26spage%3D620%26epage%3D622%26doi%3D10.4161%2Fauto.4898" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Beaufils, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cmiljanovic, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cmiljanovic, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bohnacker, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Melone, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marone, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jackson, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sele, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borsari, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mestan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hebeisen, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hillmann, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giese, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zvelebil, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fabbro, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rageot, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wymann, M. P.</span></span> <span> </span><span class="NLM_article-title">5-(4,6-dimorpholino-1,3,5-triazin-2-yl)-4-(trifluoromethyl)pyridin-2-amine (PQR309), a potent, brain-penetrant, orally bioavailable, pan-class I PI3K/mTOR inhibitor as clinical candidate in oncology</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">7524</span>– <span class="NLM_lpage">7538</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b00930</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b00930" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01262&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtlKhurrP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=7524-7538&author=F.+Beaufilsauthor=N.+Cmiljanovicauthor=V.+Cmiljanovicauthor=T.+Bohnackerauthor=A.+Meloneauthor=R.+Maroneauthor=E.+Jacksonauthor=X.+Zhangauthor=A.+Seleauthor=C.+Borsariauthor=J.+Mestanauthor=P.+Hebeisenauthor=P.+Hillmannauthor=B.+Gieseauthor=M.+Zvelebilauthor=D.+Fabbroauthor=R.+L.+Williamsauthor=D.+Rageotauthor=M.+P.+Wymann&title=5-%284%2C6-dimorpholino-1%2C3%2C5-triazin-2-yl%29-4-%28trifluoromethyl%29pyridin-2-amine+%28PQR309%29%2C+a+potent%2C+brain-penetrant%2C+orally+bioavailable%2C+pan-class+I+PI3K%2FmTOR+inhibitor+as+clinical+candidate+in+oncology&doi=10.1021%2Facs.jmedchem.7b00930"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">5-(4,6-Dimorpholino-1,3,5-triazin-2-yl)-4-(trifluoromethyl)pyridin-2-amine (PQR309), a Potent, Brain-Penetrant, Orally Bioavailable, Pan-Class I PI3K/mTOR Inhibitor as Clinical Candidate in Oncology</span></div><div class="casAuthors">Beaufils, Florent; Cmiljanovic, Natasa; Cmiljanovic, Vladimir; Bohnacker, Thomas; Melone, Anna; Marone, Romina; Jackson, Eileen; Zhang, Xuxiao; Sele, Alexander; Borsari, Chiara; Mestan, Jurgen; Hebeisen, Paul; Hillmann, Petra; Giese, Bernd; Zvelebil, Marketa; Fabbro, Doriano; Williams, Roger L.; Rageot, Denise; Wymann, Matthias P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">7524-7538</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Phosphoinositide 3-kinase (PI3K) is deregulated in a wide variety of human tumors and triggers activation of protein kinase B (PKB/Akt) and mammalian target of rapamycin (mTOR).  Here we describe the preclin. characterization of compd. 1 (PQR309, bimiralisib), a potent 4,6-dimorpholino-1,3,5-triazine-based pan-class I PI3K inhibitor, which targets mTOR kinase in a balanced fashion at higher concns.  No off-target interactions were detected for 1 in a wide panel of protein kinase, enzyme, and receptor ligand assays.  Moreover, 1 did not bind tubulin, which was obsd. for the structurally related 4 (BKM120, buparlisib).  Compd. 1 is orally available, crosses the blood-brain barrier, and displayed favorable pharmacokinetic parameters in mice, rats, and dogs.  Compd. 1 demonstrated efficiency in inhibiting proliferation in tumor cell lines and a rat xenograft model.  This, together with the compd.'s safety profile, identifies 1 as a clin. candidate with a broad application range in oncol., including treatment of brain tumors or CNS metastasis.  Compd. 1 is currently in phase II clin. trials for advanced solid tumors and refractory lymphoma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqtvYAarVqsarVg90H21EOLACvtfcHk0ljpRvtIzzWuwA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtlKhurrP&md5=54d4db75f6a8bda3f12eaf1d196352fd</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b00930&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b00930%26sid%3Dliteratum%253Aachs%26aulast%3DBeaufils%26aufirst%3DF.%26aulast%3DCmiljanovic%26aufirst%3DN.%26aulast%3DCmiljanovic%26aufirst%3DV.%26aulast%3DBohnacker%26aufirst%3DT.%26aulast%3DMelone%26aufirst%3DA.%26aulast%3DMarone%26aufirst%3DR.%26aulast%3DJackson%26aufirst%3DE.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DSele%26aufirst%3DA.%26aulast%3DBorsari%26aufirst%3DC.%26aulast%3DMestan%26aufirst%3DJ.%26aulast%3DHebeisen%26aufirst%3DP.%26aulast%3DHillmann%26aufirst%3DP.%26aulast%3DGiese%26aufirst%3DB.%26aulast%3DZvelebil%26aufirst%3DM.%26aulast%3DFabbro%26aufirst%3DD.%26aulast%3DWilliams%26aufirst%3DR.%2BL.%26aulast%3DRageot%26aufirst%3DD.%26aulast%3DWymann%26aufirst%3DM.%2BP.%26atitle%3D5-%25284%252C6-dimorpholino-1%252C3%252C5-triazin-2-yl%2529-4-%2528trifluoromethyl%2529pyridin-2-amine%2520%2528PQR309%2529%252C%2520a%2520potent%252C%2520brain-penetrant%252C%2520orally%2520bioavailable%252C%2520pan-class%2520I%2520PI3K%252FmTOR%2520inhibitor%2520as%2520clinical%2520candidate%2520in%2520oncology%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D7524%26epage%3D7538%26doi%3D10.1021%2Facs.jmedchem.7b00930" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bohnacker, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prota, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beaufils, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burke, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Melone, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Inglis, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rageot, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sele, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cmiljanovic, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cmiljanovic, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bargsten, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aher, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Akhmanova, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Díaz, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fabbro, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zvelebil, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steinmetz, M. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wymann, M. P.</span></span> <span> </span><span class="NLM_article-title">Deconvolution of Buparlisib’s mechanism of action defines specific PI3K and tubulin inhibitors for therapeutic intervention</span>. <i>Nat. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">14683</span>, <span class="refDoi"> DOI: 10.1038/ncomms14683</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01262&amp;key=10.1038%2Fncomms14683" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01262&amp;key=28276440" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01262&amp;key=1%3ACAS%3A280%3ADC%252BC1czksV2ruw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=14683&author=T.+Bohnackerauthor=A.+E.+Protaauthor=F.+Beaufilsauthor=J.+E.+Burkeauthor=A.+Meloneauthor=A.+J.+Inglisauthor=D.+Rageotauthor=A.+M.+Seleauthor=V.+Cmiljanovicauthor=N.+Cmiljanovicauthor=K.+Bargstenauthor=A.+Aherauthor=A.+Akhmanovaauthor=J.+F.+D%C3%ADazauthor=D.+Fabbroauthor=M.+Zvelebilauthor=R.+L.+Williamsauthor=M.+O.+Steinmetzauthor=M.+P.+Wymann&title=Deconvolution+of+Buparlisib%E2%80%99s+mechanism+of+action+defines+specific+PI3K+and+tubulin+inhibitors+for+therapeutic+intervention&doi=10.1038%2Fncomms14683"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Deconvolution of Buparlisib's mechanism of action defines specific PI3K and tubulin inhibitors for therapeutic intervention</span></div><div class="casAuthors">Bohnacker Thomas; Beaufils Florent; Melone Anna; Rageot Denise; Sele Alexander M; Cmiljanovic Vladimir; Cmiljanovic Natasa; Wymann Matthias P; Prota Andrea E; Bargsten Katja; Steinmetz Michel O; Burke John E; Inglis Alison J; Williams Roger L; Aher Amol; Akhmanova Anna; Diaz J Fernando; Fabbro Doriano; Zvelebil Marketa</div><div class="citationInfo"><span class="NLM_cas:title">Nature communications</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">14683</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BKM120 (Buparlisib) is one of the most advanced phosphoinositide 3-kinase (PI3K) inhibitors for the treatment of cancer, but it interferes as an off-target effect with microtubule polymerization.  Here, we developed two chemical derivatives that differ from BKM120 by only one atom.  We show that these minute changes separate the dual activity of BKM120 into discrete PI3K and tubulin inhibitors.  Analysis of the compounds cellular growth arrest phenotypes and microtubule dynamics suggest that the antiproliferative activity of BKM120 is mainly due to microtubule-dependent cytotoxicity rather than through inhibition of PI3K.  Crystal structures of BKM120 and derivatives in complex with tubulin and PI3K provide insights into the selective mode of action of this class of drugs.  Our results raise concerns over BKM120's generally accepted mode of action, and provide a unique mechanistic basis for next-generation PI3K inhibitors with improved safety profiles and flexibility for use in combination therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRzPPj8gFbG6HWEEzDrymxmfW6udTcc2eYRnapetFIxsbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1czksV2ruw%253D%253D&md5=97d27a7d83bf6ab6094a587565f82bf6</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1038%2Fncomms14683&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fncomms14683%26sid%3Dliteratum%253Aachs%26aulast%3DBohnacker%26aufirst%3DT.%26aulast%3DProta%26aufirst%3DA.%2BE.%26aulast%3DBeaufils%26aufirst%3DF.%26aulast%3DBurke%26aufirst%3DJ.%2BE.%26aulast%3DMelone%26aufirst%3DA.%26aulast%3DInglis%26aufirst%3DA.%2BJ.%26aulast%3DRageot%26aufirst%3DD.%26aulast%3DSele%26aufirst%3DA.%2BM.%26aulast%3DCmiljanovic%26aufirst%3DV.%26aulast%3DCmiljanovic%26aufirst%3DN.%26aulast%3DBargsten%26aufirst%3DK.%26aulast%3DAher%26aufirst%3DA.%26aulast%3DAkhmanova%26aufirst%3DA.%26aulast%3DD%25C3%25ADaz%26aufirst%3DJ.%2BF.%26aulast%3DFabbro%26aufirst%3DD.%26aulast%3DZvelebil%26aufirst%3DM.%26aulast%3DWilliams%26aufirst%3DR.%2BL.%26aulast%3DSteinmetz%26aufirst%3DM.%2BO.%26aulast%3DWymann%26aufirst%3DM.%2BP.%26atitle%3DDeconvolution%2520of%2520Buparlisib%25E2%2580%2599s%2520mechanism%2520of%2520action%2520defines%2520specific%2520PI3K%2520and%2520tubulin%2520inhibitors%2520for%2520therapeutic%2520intervention%26jtitle%3DNat.%2520Commun.%26date%3D2017%26volume%3D8%26spage%3D14683%26doi%3D10.1038%2Fncomms14683" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25a"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sessler, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rahm, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Becker, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldberg, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lippard, S. J.</span></span> <span> </span><span class="NLM_article-title">CF<sub>2</sub>H, a Hydrogen Bond Donor</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>139</i></span>,  <span class="NLM_fpage">9325</span>– <span class="NLM_lpage">9332</span>, <span class="refDoi"> DOI: 10.1021/jacs.7b04457</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jacs.7b04457" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref25/cit25a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01262&amp;key=1%3ACAS%3A528%3ADC%252BC2sXpt1Kgtbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=139&publication_year=2017&pages=9325-9332&author=C.+D.+Sesslerauthor=M.+Rahmauthor=S.+Beckerauthor=J.+M.+Goldbergauthor=F.+Wangauthor=S.+J.+Lippard&title=CF2H%2C+a+Hydrogen+Bond+Donor&doi=10.1021%2Fjacs.7b04457"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25aR"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">CF2H, a Hydrogen Bond Donor</span></div><div class="casAuthors">Sessler, Chanan D.; Rahm, Martin; Becker, Sabine; Goldberg, Jacob M.; Wang, Fang; Lippard, Stephen J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">139</span>
        (<span class="NLM_cas:issue">27</span>),
    <span class="NLM_cas:pages">9325-9332</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The CF2H group, a potential surrogate for the OH group, can act as an unusual hydrogen bond donor, as confirmed ty crystallog., spectroscopic, and computational methods.  Here, we demonstrate the bioisosterism of the OH and CF2H groups and the important roles of CF2-H···O hydrogen bonds in influencing intermol. interactions and conformational preferences.  Exptl. evidence, corroborated by theory, reveals the distinctive nature of CF2H hydrogen bonding interactions relative to their normal OH hydrogen bonding counterparts.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrOs-3evXpSKbVg90H21EOLACvtfcHk0ljVN9qaWxGBkg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXpt1Kgtbo%253D&md5=f2345db11c3f695f3056c3c8cdad746c</span></div><a href="/servlet/linkout?suffix=cit25a&amp;dbid=16384&amp;doi=10.1021%2Fjacs.7b04457&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjacs.7b04457%26sid%3Dliteratum%253Aachs%26aulast%3DSessler%26aufirst%3DC.%2BD.%26aulast%3DRahm%26aufirst%3DM.%26aulast%3DBecker%26aufirst%3DS.%26aulast%3DGoldberg%26aufirst%3DJ.%2BM.%26aulast%3DWang%26aufirst%3DF.%26aulast%3DLippard%26aufirst%3DS.%2BJ.%26atitle%3DCF2H%252C%2520a%2520Hydrogen%2520Bond%2520Donor%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2017%26volume%3D139%26spage%3D9325%26epage%3D9332%26doi%3D10.1021%2Fjacs.7b04457" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit25b"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zafrani, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yeffet, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sod-Moriah, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berliner, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amir, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marciano, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gershonov, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saphier, S.</span></span> <span> </span><span class="NLM_article-title">Difluoromethyl Bioisostere: examining the “lipophilic hydrogen bond donor” concept</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">797</span>– <span class="NLM_lpage">804</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b01691</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b01691" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref25/cit25b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01262&amp;key=1%3ACAS%3A528%3ADC%252BC2sXis12jtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=797-804&author=Y.+Zafraniauthor=D.+Yeffetauthor=G.+Sod-Moriahauthor=A.+Berlinerauthor=D.+Amirauthor=D.+Marcianoauthor=E.+Gershonovauthor=S.+Saphier&title=Difluoromethyl+Bioisostere%3A+examining+the+%E2%80%9Clipophilic+hydrogen+bond+donor%E2%80%9D+concept&doi=10.1021%2Facs.jmedchem.6b01691"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25bR"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Difluoromethyl Bioisostere: Examining the "Lipophilic Hydrogen Bond Donor" Concept</span></div><div class="casAuthors">Zafrani, Yossi; Yeffet, Dina; Sod-Moriah, Gali; Berliner, Anat; Amir, Dafna; Marciano, Daniele; Gershonov, Eytan; Saphier, Sigal</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">797-804</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">There is a growing interest in org. compds. contg. the difluoromethyl group, as it is considered a lipophilic hydrogen bond donor that may act as a bioisostere of hydroxyl, thiol, or amine groups.  A series of difluoromethyl anisoles and thioanisoles was prepd. and their drug-like properties, hydrogen bonding, and lipophilicity were studied.  The hydrogen bond acidity parameters A (0.085-0.126) were detd. using Abraham's solute 1H NMR anal.  The difluoromethyl group acts as a hydrogen bond donor on a scale similar to that of thiophenol, aniline, and amine groups but not as that of hydroxyl.  Although difluoromethyl is considered a lipophilicity enhancing group, the range of the exptl. Δlog P(water-octanol) values (log P(XCF2H) - log P(XCH3)) spanned from -0.1 to +0.4.  For both parameters, a linear correlation was found between the measured values and Hammett σ consts.  These results may aid in the rational design of drugs contg. the difluoromethyl moiety.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrJEzcH0xPatbVg90H21EOLACvtfcHk0ljVN9qaWxGBkg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXis12jtw%253D%253D&md5=36159f57b99aa812693f32ff38e88406</span></div><a href="/servlet/linkout?suffix=cit25b&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b01691&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b01691%26sid%3Dliteratum%253Aachs%26aulast%3DZafrani%26aufirst%3DY.%26aulast%3DYeffet%26aufirst%3DD.%26aulast%3DSod-Moriah%26aufirst%3DG.%26aulast%3DBerliner%26aufirst%3DA.%26aulast%3DAmir%26aufirst%3DD.%26aulast%3DMarciano%26aufirst%3DD.%26aulast%3DGershonov%26aufirst%3DE.%26aulast%3DSaphier%26aufirst%3DS.%26atitle%3DDifluoromethyl%2520Bioisostere%253A%2520examining%2520the%2520%25E2%2580%259Clipophilic%2520hydrogen%2520bond%2520donor%25E2%2580%259D%2520concept%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D797%26epage%3D804%26doi%3D10.1021%2Facs.jmedchem.6b01691" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zask, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaplan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verheijen, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richard, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Curran, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brooijmans, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bennett, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toral-Barza, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hollander, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ayral-Kaloustian, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, K.</span></span> <span> </span><span class="NLM_article-title">Morpholine derivatives greatly enhance the selectivity of mammalian target of rapamycin (mTOR) inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>52</i></span>,  <span class="NLM_fpage">7942</span>– <span class="NLM_lpage">7945</span>, <span class="refDoi"> DOI: 10.1021/jm901415x</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm901415x" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01262&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsVWrtb3J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=7942-7945&author=A.+Zaskauthor=J.+Kaplanauthor=J.+C.+Verheijenauthor=D.+J.+Richardauthor=K.+Curranauthor=N.+Brooijmansauthor=E.+M.+Bennettauthor=L.+Toral-Barzaauthor=I.+Hollanderauthor=S.+Ayral-Kaloustianauthor=K.+Yu&title=Morpholine+derivatives+greatly+enhance+the+selectivity+of+mammalian+target+of+rapamycin+%28mTOR%29+inhibitors&doi=10.1021%2Fjm901415x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Morpholine Derivatives Greatly Enhance the Selectivity of Mammalian Target of Rapamycin (mTOR) Inhibitors</span></div><div class="casAuthors">Zask, Arie; Kaplan, Joshua; Verheijen, Jeroen C.; Richard, David J.; Curran, Kevin; Brooijmans, Natasja; Bennett, Eric M.; Toral-Barza, Lourdes; Hollander, Irwin; Ayral-Kaloustian, Semiramis; Yu, Ker</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">7942-7945</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Dramatic improvements in mTOR-targeting selectivity were achieved by replacing morpholine in pyrazolopyrimidine inhibitors with bridged morpholines.  Analogs I [R1 = (R)- or (S)-3-methyl-4-morpholinyl, 2-methyl-4-morpholinyl, 8-oxa-3-azabicyclo[3.2.1]octan-3-yl, etc.; R2 = Me, Et, cyclopropyl, FCH2CH2, 3-pyridyl, 4-pyridyl; R3 = F3CCH2, 1-methoxycarbonyl-4-piperidinyl, 1-ethoxycarbonyl-4-piperidinyl, 3-pyridylmethyl] with subnanomolar mTOR IC50 values and up to 26000-fold selectivity vs. PI3Kα were prepd.  Chiral morpholines gave inhibitors whose enantiomers had different selectivity and potency profiles.  Mol. modeling suggests that a single amino acid difference between PI3K and mTOR (Phe961Leu) accounts for the profound selectivity seen by creating a deeper pocket in mTOR that can accommodate bridged morpholines.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpK2HnMHqTHqbVg90H21EOLACvtfcHk0ljVN9qaWxGBkg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsVWrtb3J&md5=5ef1eee5aa79531970049d3d26b46eb2</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1021%2Fjm901415x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm901415x%26sid%3Dliteratum%253Aachs%26aulast%3DZask%26aufirst%3DA.%26aulast%3DKaplan%26aufirst%3DJ.%26aulast%3DVerheijen%26aufirst%3DJ.%2BC.%26aulast%3DRichard%26aufirst%3DD.%2BJ.%26aulast%3DCurran%26aufirst%3DK.%26aulast%3DBrooijmans%26aufirst%3DN.%26aulast%3DBennett%26aufirst%3DE.%2BM.%26aulast%3DToral-Barza%26aufirst%3DL.%26aulast%3DHollander%26aufirst%3DI.%26aulast%3DAyral-Kaloustian%26aufirst%3DS.%26aulast%3DYu%26aufirst%3DK.%26atitle%3DMorpholine%2520derivatives%2520greatly%2520enhance%2520the%2520selectivity%2520of%2520mammalian%2520target%2520of%2520rapamycin%2520%2528mTOR%2529%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D7942%26epage%3D7945%26doi%3D10.1021%2Fjm901415x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Walker, E. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pacold, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perisic, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stephens, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hawkins, P. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wymann, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, R. L.</span></span> <span> </span><span class="NLM_article-title">Structural determinants of phosphoinositide 3-kinase inhibition by wortmannin, LY294002, quercetin, myricetin, and staurosporine</span>. <i>Mol. Cell</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">909</span>– <span class="NLM_lpage">919</span>, <span class="refDoi"> DOI: 10.1016/S1097-2765(05)00089-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01262&amp;key=10.1016%2FS1097-2765%2805%2900089-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01262&amp;key=11090628" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01262&amp;key=1%3ACAS%3A528%3ADC%252BD3cXnvVegurY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2000&pages=909-919&author=E.+H.+Walkerauthor=M.+E.+Pacoldauthor=O.+Perisicauthor=L.+Stephensauthor=P.+T.+Hawkinsauthor=M.+P.+Wymannauthor=R.+L.+Williams&title=Structural+determinants+of+phosphoinositide+3-kinase+inhibition+by+wortmannin%2C+LY294002%2C+quercetin%2C+myricetin%2C+and+staurosporine&doi=10.1016%2FS1097-2765%2805%2900089-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Structural determinants of phosphoinositide 3-kinase inhibition by wortmannin, LY294002, quercetin, myricetin, and staurosporine</span></div><div class="casAuthors">Walker, Edward H.; Pacold, Michael E.; Perisic, Olga; Stephens, Len; Hawkins, Philip T.; Wymann, Matthias P.; Williams, Roger L.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cell</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">909-919</span>CODEN:
                <span class="NLM_cas:coden">MOCEFL</span>;
        ISSN:<span class="NLM_cas:issn">1097-2765</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">The specific phosphoinositide 3-kinase (P13K) inhibitors wortmannin and LY294002 have been invaluable tools for elucidating the roles of these enzymes in signal transduction pathways.  The X-ray crystallog. structures of P13K bound to these lipid kinase inhibitors and to the broad-spectrum protein kinase inhibitors quercetin, myricetin, and staurosporine reveal how these compds. fit into the ATP binding pocket.  With a nanomolar IC50, wortmannin most closely fits and fills the active site and induces a conformational change in the catalytic domain.  Surprisingly, LY294002 and the lead compd. on which it was designed, quercetin, as well as the closely related flavonoid myricetin bind P13K in remarkably different orientations that are related to each other by 1800 rotations.  Staurosporine/P13K interactions are reminiscent of low-affinity protein kinase/staurosporine complexes.  These results provide a rich basis for development of isoform-specific P13K inhibitors with therapeutic potential.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpgIbTky2xQmbVg90H21EOLACvtfcHk0ljI-BO2lC9QsA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXnvVegurY%253D&md5=5dd92f9b48c437e43c0023fdff10c1ac</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1016%2FS1097-2765%2805%2900089-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1097-2765%252805%252900089-4%26sid%3Dliteratum%253Aachs%26aulast%3DWalker%26aufirst%3DE.%2BH.%26aulast%3DPacold%26aufirst%3DM.%2BE.%26aulast%3DPerisic%26aufirst%3DO.%26aulast%3DStephens%26aufirst%3DL.%26aulast%3DHawkins%26aufirst%3DP.%2BT.%26aulast%3DWymann%26aufirst%3DM.%2BP.%26aulast%3DWilliams%26aufirst%3DR.%2BL.%26atitle%3DStructural%2520determinants%2520of%2520phosphoinositide%25203-kinase%2520inhibition%2520by%2520wortmannin%252C%2520LY294002%252C%2520quercetin%252C%2520myricetin%252C%2520and%2520staurosporine%26jtitle%3DMol.%2520Cell%26date%3D2000%26volume%3D6%26spage%3D909%26epage%3D919%26doi%3D10.1016%2FS1097-2765%2805%2900089-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Davis, M. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hunt, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herrgard, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ciceri, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wodicka, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pallares, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hocker, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Treiber, D. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zarrinkar, P. P.</span></span> <span> </span><span class="NLM_article-title">Comprehensive analysis of kinase inhibitor selectivity</span>. <i>Nat. Biotechnol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>29</i></span>,  <span class="NLM_fpage">1046</span>– <span class="NLM_lpage">1051</span>, <span class="refDoi"> DOI: 10.1038/nbt.1990</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01262&amp;key=10.1038%2Fnbt.1990" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01262&amp;key=22037378" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01262&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtlyisrrK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2011&pages=1046-1051&author=M.+I.+Davisauthor=J.+P.+Huntauthor=S.+Herrgardauthor=P.+Ciceriauthor=L.+M.+Wodickaauthor=G.+Pallaresauthor=M.+Hockerauthor=D.+K.+Treiberauthor=P.+P.+Zarrinkar&title=Comprehensive+analysis+of+kinase+inhibitor+selectivity&doi=10.1038%2Fnbt.1990"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Comprehensive analysis of kinase inhibitor selectivity</span></div><div class="casAuthors">Davis, Mindy I.; Hunt, Jeremy P.; Herrgard, Sanna; Ciceri, Pietro; Wodicka, Lisa M.; Pallares, Gabriel; Hocker, Michael; Treiber, Daniel K.; Zarrinkar, Patrick P.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Biotechnology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1046-1051</span>CODEN:
                <span class="NLM_cas:coden">NABIF9</span>;
        ISSN:<span class="NLM_cas:issn">1087-0156</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">We tested the interaction of 72 kinase inhibitors with 442 kinases covering >80% of the human catalytic protein kinome.  Our data show that, as a class, type II inhibitors are more selective than type I inhibitors, but that there are important exceptions to this trend.  The data further illustrate that selective inhibitors have been developed against the majority of kinases targeted by the compds. tested.  Anal. of the interaction patterns reveals a class of 'group-selective' inhibitors broadly active against a single subfamily of kinases, but selective outside that subfamily.  The data set suggests compds. to use as tools to study kinases for which no dedicated inhibitors exist.  It also provides a foundation for further exploring kinase inhibitor biol. and toxicity, as well as for studying the structural basis of the obsd. interaction patterns.  Our findings will help to realize the direct enabling potential of genomics for drug development and basic research about cellular signaling.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoEZnKVs6Xt5rVg90H21EOLACvtfcHk0ljI-BO2lC9QsA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtlyisrrK&md5=67639f702cb48ffb2c60e9a250f0df5e</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1038%2Fnbt.1990&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnbt.1990%26sid%3Dliteratum%253Aachs%26aulast%3DDavis%26aufirst%3DM.%2BI.%26aulast%3DHunt%26aufirst%3DJ.%2BP.%26aulast%3DHerrgard%26aufirst%3DS.%26aulast%3DCiceri%26aufirst%3DP.%26aulast%3DWodicka%26aufirst%3DL.%2BM.%26aulast%3DPallares%26aufirst%3DG.%26aulast%3DHocker%26aufirst%3DM.%26aulast%3DTreiber%26aufirst%3DD.%2BK.%26aulast%3DZarrinkar%26aufirst%3DP.%2BP.%26atitle%3DComprehensive%2520analysis%2520of%2520kinase%2520inhibitor%2520selectivity%26jtitle%3DNat.%2520Biotechnol.%26date%3D2011%26volume%3D29%26spage%3D1046%26epage%3D1051%26doi%3D10.1038%2Fnbt.1990" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Brandt, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hillmann, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Noack, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Römermann, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Öhler, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rageot, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beaufils, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Melone, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sele, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wymann, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fabbro, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Löscher, W.</span></span> <span> </span><span class="NLM_article-title">The novel, catalytic mTORC1/2 inhibitor PQR620 and the PI3K/mTORC1/2 inhibitor PQR530 effectively cross the blood-brain barrier and increase seizure threshold in a mouse model of chronic epilepsy</span>. <i>Neuropharmacology</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>140</i></span>,  <span class="NLM_fpage">107</span>– <span class="NLM_lpage">120</span>, <span class="refDoi"> DOI: 10.1016/j.neuropharm.2018.08.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01262&amp;key=10.1016%2Fj.neuropharm.2018.08.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01262&amp;key=30081001" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01262&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsVGhtbjJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=140&publication_year=2018&pages=107-120&author=C.+Brandtauthor=P.+Hillmannauthor=A.+Noackauthor=K.+R%C3%B6mermannauthor=L.+A.+%C3%96hlerauthor=D.+Rageotauthor=F.+Beaufilsauthor=A.+Meloneauthor=A.+M.+Seleauthor=M.+P.+Wymannauthor=D.+Fabbroauthor=W.+L%C3%B6scher&title=The+novel%2C+catalytic+mTORC1%2F2+inhibitor+PQR620+and+the+PI3K%2FmTORC1%2F2+inhibitor+PQR530+effectively+cross+the+blood-brain+barrier+and+increase+seizure+threshold+in+a+mouse+model+of+chronic+epilepsy&doi=10.1016%2Fj.neuropharm.2018.08.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">The novel, catalytic mTORC1/2 inhibitor PQR620 and the PI3K/mTORC1/2 inhibitor PQR530 effectively cross the blood-brain barrier and increase seizure threshold in a mouse model of chronic epilepsy</span></div><div class="casAuthors">Brandt, Claudia; Hillmann, Petra; Noack, Andreas; Roemermann, Kerstin; Oehler, Leon A.; Rageot, Denise; Beaufils, Florent; Melone, Anna; Sele, Alexander M.; Wymann, Matthias P.; Fabbro, Doriano; Loescher, Wolfgang</div><div class="citationInfo"><span class="NLM_cas:title">Neuropharmacology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">140</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">107-120</span>CODEN:
                <span class="NLM_cas:coden">NEPHBW</span>;
        ISSN:<span class="NLM_cas:issn">0028-3908</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The mTOR signaling pathway has emerged as a possible therapeutic target for epilepsy.  Clin. trials have shown that mTOR inhibitors such as everolimus reduce seizures in tuberous sclerosis complex patients with intractable epilepsy.  Furthermore, accumulating preclin. data suggest that mTOR inhibitors may have anti-seizure or anti-epileptogenic actions in other types of epilepsy.  However, the chronic use of rapalogs such as everolimus is limited by poor tolerability, particularly by immunosuppression, poor brain penetration and induction of feedback loops which might contribute to their limited therapeutic efficacy.  Here we describe two novel, brain-permeable and well tolerated small mol. 1,3,5-triazine derivs., the catalytic mTORC1/C2 inhibitor PQR620 and the dual pan-PI3K/mTOR inhibitor PQR530.  These derivs. were compared with the mTORC1 inhibitors rapamycin and everolimus as well as the anti-seizure drugs phenobarbital and levetiracetam.  The anti-seizure potential of these compds. was detd. by evaluating the electroconvulsive seizure threshold in normal and epileptic mice.  Rapamycin and everolimus only poorly penetrated into the brain (brain:plasma ratio 0.0057 for rapamycin and 0.016 for everolimus).  In contrast, the novel compds. rapidly entered the brain, reaching brain:plasma ratios of ∼1.6.  Furthermore, they significantly decreased phosphorylation of S6 ribosomal protein in the hippocampus of normal and epileptic mice, demonstrating effective mTOR inhibition.  PQR620 and PQR530 significantly increased seizure threshold at tolerable doses.  The effect of PQR620 was more marked in epileptic vs. nonepileptic mice, matching the efficacy of levetiracetam.  Overall, the novel compds. described here have the potential to overcome the disadvantages of rapalogs for treatment of epilepsy and mTORopathies directly connected to mutations in the mTOR signaling cascade.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqvQmF8jJglOLVg90H21EOLACvtfcHk0ljI-BO2lC9QsA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsVGhtbjJ&md5=38f76201f9fb8c4643e59979b2bb4121</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1016%2Fj.neuropharm.2018.08.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.neuropharm.2018.08.002%26sid%3Dliteratum%253Aachs%26aulast%3DBrandt%26aufirst%3DC.%26aulast%3DHillmann%26aufirst%3DP.%26aulast%3DNoack%26aufirst%3DA.%26aulast%3DR%25C3%25B6mermann%26aufirst%3DK.%26aulast%3D%25C3%2596hler%26aufirst%3DL.%2BA.%26aulast%3DRageot%26aufirst%3DD.%26aulast%3DBeaufils%26aufirst%3DF.%26aulast%3DMelone%26aufirst%3DA.%26aulast%3DSele%26aufirst%3DA.%2BM.%26aulast%3DWymann%26aufirst%3DM.%2BP.%26aulast%3DFabbro%26aufirst%3DD.%26aulast%3DL%25C3%25B6scher%26aufirst%3DW.%26atitle%3DThe%2520novel%252C%2520catalytic%2520mTORC1%252F2%2520inhibitor%2520PQR620%2520and%2520the%2520PI3K%252FmTORC1%252F2%2520inhibitor%2520PQR530%2520effectively%2520cross%2520the%2520blood-brain%2520barrier%2520and%2520increase%2520seizure%2520threshold%2520in%2520a%2520mouse%2520model%2520of%2520chronic%2520epilepsy%26jtitle%3DNeuropharmacology%26date%3D2018%26volume%3D140%26spage%3D107%26epage%3D120%26doi%3D10.1016%2Fj.neuropharm.2018.08.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Marone, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Erhart, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mertz, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bohnacker, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schnell, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cmiljanovic, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stauffer, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia-Echeverria, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giese, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maira, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wymann, M. P.</span></span> <span> </span><span class="NLM_article-title">Targeting melanoma with dual phosphoinositide 3-kinase/mammalian target of rapamycin inhibitors</span>. <i>Mol. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">601</span>– <span class="NLM_lpage">613</span>, <span class="refDoi"> DOI: 10.1158/1541-7786.MCR-08-0366</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01262&amp;key=10.1158%2F1541-7786.MCR-08-0366" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01262&amp;key=19372588" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01262&amp;key=1%3ACAS%3A528%3ADC%252BD1MXks1anur8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2009&pages=601-613&author=R.+Maroneauthor=D.+Erhartauthor=A.+C.+Mertzauthor=T.+Bohnackerauthor=C.+Schnellauthor=V.+Cmiljanovicauthor=F.+Staufferauthor=C.+Garcia-Echeverriaauthor=B.+Gieseauthor=S.+M.+Mairaauthor=M.+P.+Wymann&title=Targeting+melanoma+with+dual+phosphoinositide+3-kinase%2Fmammalian+target+of+rapamycin+inhibitors&doi=10.1158%2F1541-7786.MCR-08-0366"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting Melanoma with Dual Phosphoinositide 3-Kinase/Mammalian Target of Rapamycin Inhibitors</span></div><div class="casAuthors">Marone, Romina; Erhart, Dominik; Mertz, Ann C.; Bohnacker, Thomas; Schnell, Christian; Cmiljanovic, Vladimir; Stauffer, Frederic; Garcia-Echeverria, Carlos; Giese, Bernd; Maira, Sauveur-Michel; Wymann, Matthias P.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Research</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">601-613</span>CODEN:
                <span class="NLM_cas:coden">MCROC5</span>;
        ISSN:<span class="NLM_cas:issn">1541-7786</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Phosphoinositide 3-kinase (PI3K)/protein kinase B/Akt and Ras/mitogen-activated protein kinase pathways are often constitutively activated in melanoma and have thus been considered as promising drug targets.  Exposure of melanoma cells to NVP-BAG956, NVP-BBD130, and NVP-BEZ235, a series of novel, potent, and stable dual PI3K/mammalian target of rapamycin (mTOR) inhibitors, resulted in complete G1 growth arrest, redn. of cyclin D1, and increased levels of p27KIP1, but negligible apoptosis.  In contrast, treatment of melanoma with the pan-class I PI3K inhibitor ZSTK474 or the mTORC1 inhibitor rapamycin resulted only in minor redn. of cell proliferation.  In a syngeneic B16 mouse melanoma tumor model, orally administered NVP-BBD130 and NVP-BEZ235 efficiently attenuated tumor growth at primary and lymph node metastatic sites with no obvious toxicity.  Metastatic melanoma in inhibitor-treated mice displayed reduced nos. of proliferating and significantly smaller tumor cells.  In addn., neovascularization was blocked and tumoral necrosis increased when compared with vehicle-treated mice.  In conclusion, compds. targeting PI3K and mTOR simultaneously were advantageous to attenuate melanoma growth and they develop their potential by targeting tumor growth directly, and indirectly via their interference with angiogenesis.  Based on the above results, NVP-BEZ235, which has entered phase I/II clin. trials in patients with advanced solid tumors, has a potential in metastatic melanoma therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo75H1e5k7uxrVg90H21EOLACvtfcHk0lhLwkrMFVZFzg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXks1anur8%253D&md5=1098c3d2f8e0c169550adb0409fff1e2</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1158%2F1541-7786.MCR-08-0366&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1541-7786.MCR-08-0366%26sid%3Dliteratum%253Aachs%26aulast%3DMarone%26aufirst%3DR.%26aulast%3DErhart%26aufirst%3DD.%26aulast%3DMertz%26aufirst%3DA.%2BC.%26aulast%3DBohnacker%26aufirst%3DT.%26aulast%3DSchnell%26aufirst%3DC.%26aulast%3DCmiljanovic%26aufirst%3DV.%26aulast%3DStauffer%26aufirst%3DF.%26aulast%3DGarcia-Echeverria%26aufirst%3DC.%26aulast%3DGiese%26aufirst%3DB.%26aulast%3DMaira%26aufirst%3DS.%2BM.%26aulast%3DWymann%26aufirst%3DM.%2BP.%26atitle%3DTargeting%2520melanoma%2520with%2520dual%2520phosphoinositide%25203-kinase%252Fmammalian%2520target%2520of%2520rapamycin%2520inhibitors%26jtitle%3DMol.%2520Cancer%2520Res.%26date%3D2009%26volume%3D7%26spage%3D601%26epage%3D613%26doi%3D10.1158%2F1541-7786.MCR-08-0366" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">O’Reilly, K. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rojo, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">She, Q. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Solit, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mills, G. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lane, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hofmann, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hicklin, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ludwig, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baselga, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosen, N.</span></span> <span> </span><span class="NLM_article-title">mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>66</i></span>,  <span class="NLM_fpage">1500</span>– <span class="NLM_lpage">1508</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-05-2925</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01262&amp;key=10.1158%2F0008-5472.CAN-05-2925" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01262&amp;key=16452206" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01262&amp;key=1%3ACAS%3A528%3ADC%252BD28XpsVegtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2006&pages=1500-1508&author=K.+E.+O%E2%80%99Reillyauthor=F.+Rojoauthor=Q.+B.+Sheauthor=D.+Solitauthor=G.+B.+Millsauthor=D.+Smithauthor=H.+Laneauthor=F.+Hofmannauthor=D.+J.+Hicklinauthor=D.+L.+Ludwigauthor=J.+Baselgaauthor=N.+Rosen&title=mTOR+inhibition+induces+upstream+receptor+tyrosine+kinase+signaling+and+activates+Akt&doi=10.1158%2F0008-5472.CAN-05-2925"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">mTOR Inhibition Induces Upstream Receptor Tyrosine Kinase Signaling and Activates Akt</span></div><div class="casAuthors">O'Reilly, Kathryn E.; Rojo, Fredi; She, Qing-Bai; Solit, David; Mills, Gordon B.; Smith, Debra; Lane, Heidi; Hofmann, Francesco; Hicklin, Daniel J.; Ludwig, Dale L.; Baselga, Jose; Rosen, Neal</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">66</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1500-1508</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Stimulation of the insulin and insulin-like growth factor I (IGF-I) receptor activates the phosphoinositide-3-kinase/Akt/mTOR pathway causing pleiotropic cellular effects including an mTOR-dependent loss in insulin receptor substrate-1 expression leading to feedback down-regulation of signaling through the pathway.  In model systems, tumors exhibiting mutational activation of phosphoinositide-3-kinase/Akt kinase, a common event in cancers, are hypersensitive to mTOR inhibitors, including rapamycin.  Despite the activity in model systems, in patients, mTOR inhibitors exhibit more modest antitumor activity.  We now show that mTOR inhibition induces insulin receptor substrate-1 expression and abrogates feedback inhibition of the pathway, resulting in Akt activation both in cancer cell lines and in patient tumors treated with the rapamycin deriv., RAD001.  IGF-I receptor inhibition prevents rapamycin-induced Akt activation and sensitizes tumor cells to inhibition of mTOR.  In contrast, IGF-I reverses the antiproliferative effects of rapamycin in serum-free medium.  The data suggest that feedback down-regulation of receptor tyrosine kinase signaling is a frequent event in tumor cells with constitutive mTOR activation.  Reversal of this feedback loop by rapamycin may attenuate its therapeutic effects, whereas combination therapy that ablates mTOR function and prevents Akt activation may have improved antitumor activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpIDQUdQ-jbi7Vg90H21EOLACvtfcHk0lhLwkrMFVZFzg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XpsVegtg%253D%253D&md5=758cd9999dc156bf498edf32174fc2e7</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-05-2925&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-05-2925%26sid%3Dliteratum%253Aachs%26aulast%3DO%25E2%2580%2599Reilly%26aufirst%3DK.%2BE.%26aulast%3DRojo%26aufirst%3DF.%26aulast%3DShe%26aufirst%3DQ.%2BB.%26aulast%3DSolit%26aufirst%3DD.%26aulast%3DMills%26aufirst%3DG.%2BB.%26aulast%3DSmith%26aufirst%3DD.%26aulast%3DLane%26aufirst%3DH.%26aulast%3DHofmann%26aufirst%3DF.%26aulast%3DHicklin%26aufirst%3DD.%2BJ.%26aulast%3DLudwig%26aufirst%3DD.%2BL.%26aulast%3DBaselga%26aufirst%3DJ.%26aulast%3DRosen%26aufirst%3DN.%26atitle%3DmTOR%2520inhibition%2520induces%2520upstream%2520receptor%2520tyrosine%2520kinase%2520signaling%2520and%2520activates%2520Akt%26jtitle%3DCancer%2520Res.%26date%3D2006%26volume%3D66%26spage%3D1500%26epage%3D1508%26doi%3D10.1158%2F0008-5472.CAN-05-2925" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kleinert, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sylow, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fazakerley, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krycer, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oxbøll, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jordy, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jensen, T. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schjerling, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kiens, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">James, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruegg, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richter, E. A.</span></span> <span> </span><span class="NLM_article-title">Acute mTOR inhibition induces insulin resistance and alters substrate utilization in vivo</span>. <i>Mol. Metab.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">630</span>– <span class="NLM_lpage">641</span>, <span class="refDoi"> DOI: 10.1016/j.molmet.2014.06.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01262&amp;key=10.1016%2Fj.molmet.2014.06.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01262&amp;key=25161886" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01262&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtFyjtLzK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2014&pages=630-641&author=M.+Kleinertauthor=L.+Sylowauthor=D.+J.+Fazakerleyauthor=J.+R.+Krycerauthor=K.+C.+Thomasauthor=A.+J.+Oxb%C3%B8llauthor=A.+B.+Jordyauthor=T.+E.+Jensenauthor=G.+Yangauthor=P.+Schjerlingauthor=B.+Kiensauthor=D.+E.+Jamesauthor=M.+A.+Rueggauthor=E.+A.+Richter&title=Acute+mTOR+inhibition+induces+insulin+resistance+and+alters+substrate+utilization+in+vivo&doi=10.1016%2Fj.molmet.2014.06.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Acute mTOR inhibition induces insulin resistance and alters substrate utilization in vivo</span></div><div class="casAuthors">Kleinert, Maximilian; Sylow, Lykke; Fazakerley, Daniel J.; Krycer, James R.; Thomas, Kristen C.; Oxboell, Anne-Julie; Jordy, Andreas B.; Jensen, Thomas E.; Yang, Guang; Schjerling, Peter; Kiens, Bente; James, David E.; Ruegg, Markus A.; Richter, Erik A.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Metabolism</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">630-641</span>CODEN:
                <span class="NLM_cas:coden">MMOEAS</span>;
        ISSN:<span class="NLM_cas:issn">2212-8778</span>.
    
            (<span class="NLM_cas:orgname">Elsevier GmbH</span>)
        </div><div class="casAbstract">The effect of acute inhibition of both mTORC1 and mTORC2 on metab. is unknown.  A single injection of the mTOR kinase inhibitor, AZD8055, induced a transient, yet marked increase in fat oxidn. and insulin resistance in mice, whereas the mTORC1 inhibitor rapamycin had no effect.  AZD8055, but not rapamycin reduced insulin-stimulated glucose uptake into incubated muscles, despite normal GLUT4 translocation in muscle cells.  AZD8055 inhibited glycolysis in MEF cells.  Abrogation of mTORC2 activity by SIN1 deletion impaired glycolysis and AZD8055 had no effect in SIN1 KO MEFs.  Re-expression of wildtype SIN1 rescued glycolysis.  Glucose intolerance following AZD8055 administration was absent in mice lacking the mTORC2 subunit Rictor in muscle, and in vivo glucose uptake into Rictor-deficient muscle was reduced despite normal Akt activity.  Taken together, acute mTOR inhibition is detrimental to glucose homeostasis in part by blocking muscle mTORC2, indicating its importance in muscle metab. in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGouv-4unEc1lbVg90H21EOLACvtfcHk0lg46Qaxes93Jw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtFyjtLzK&md5=963cffe34095e3c60fe38d2393e733b6</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1016%2Fj.molmet.2014.06.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.molmet.2014.06.004%26sid%3Dliteratum%253Aachs%26aulast%3DKleinert%26aufirst%3DM.%26aulast%3DSylow%26aufirst%3DL.%26aulast%3DFazakerley%26aufirst%3DD.%2BJ.%26aulast%3DKrycer%26aufirst%3DJ.%2BR.%26aulast%3DThomas%26aufirst%3DK.%2BC.%26aulast%3DOxb%25C3%25B8ll%26aufirst%3DA.%2BJ.%26aulast%3DJordy%26aufirst%3DA.%2BB.%26aulast%3DJensen%26aufirst%3DT.%2BE.%26aulast%3DYang%26aufirst%3DG.%26aulast%3DSchjerling%26aufirst%3DP.%26aulast%3DKiens%26aufirst%3DB.%26aulast%3DJames%26aufirst%3DD.%2BE.%26aulast%3DRuegg%26aufirst%3DM.%2BA.%26aulast%3DRichter%26aufirst%3DE.%2BA.%26atitle%3DAcute%2520mTOR%2520inhibition%2520induces%2520insulin%2520resistance%2520and%2520alters%2520substrate%2520utilization%2520in%2520vivo%26jtitle%3DMol.%2520Metab.%26date%3D2014%26volume%3D3%26spage%3D630%26epage%3D641%26doi%3D10.1016%2Fj.molmet.2014.06.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zeng, L. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gutmann, D. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, M.</span></span> <span> </span><span class="NLM_article-title">Rapamycin prevents epilepsy in a mouse model of tuberous sclerosis complex</span>. <i>Ann. Neurol.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">444</span>– <span class="NLM_lpage">453</span>, <span class="refDoi"> DOI: 10.1002/ana.21331</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01262&amp;key=10.1002%2Fana.21331" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01262&amp;key=18389497" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01262&amp;key=1%3ACAS%3A528%3ADC%252BD1cXmsFGqt7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2008&pages=444-453&author=L.+H.+Zengauthor=L.+Xuauthor=D.+H.+Gutmannauthor=M.+Wong&title=Rapamycin+prevents+epilepsy+in+a+mouse+model+of+tuberous+sclerosis+complex&doi=10.1002%2Fana.21331"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Rapamycin prevents epilepsy in a mouse model of tuberous sclerosis complex</span></div><div class="casAuthors">Zeng, Ling-Hui; Xu, Lin; Gutmann, David H.; Wong, Michael</div><div class="citationInfo"><span class="NLM_cas:title">Annals of Neurology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">444-453</span>CODEN:
                <span class="NLM_cas:coden">ANNED3</span>;
        ISSN:<span class="NLM_cas:issn">0364-5134</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">Objective: Tuberous sclerosis complex (TSC) represents one of the most common genetic causes of epilepsy.  TSC gene inactivation leads to hyperactivation of the mammalian target of rapamycin signaling pathway, raising the intriguing possibility that mammalian target of rapamycin inhibitors might be effective in preventing or treating epilepsy in patients with TSC.  Mice with conditional inactivation of the Tsc1 gene primarily in glia (Tsc1GFAPCKO mice) develop glial proliferation, progressive epilepsy, and premature death.  Here, we tested whether rapamycin could prevent or reverse epilepsy, as well as other cellular and mol. brain abnormalities in Tsc1GFAPCKO mice.  Methods: Tsc1GFAPCKO mice and littermate control animals were treated with rapamycin or vehicle starting at postnatal day 14 (early treatment) or 6 wk of age (late treatment), corresponding to times before and after onset of neurol. abnormalities in Tsc1GFAPCKO mice.  Mice were monitored for seizures by serial video-EEG and for long-term survival.  Brains were examd. histol. for astrogliosis and neuronal organization.  Expression of phospho-S6 and other mol. markers correlating with epileptogenesis was measured by Western blotting.  Results: Early treatment with rapamycin prevented the development of epilepsy and premature death obsd. in vehicle-treated Tsc1GFAPCKO mice.  Late treatment with rapamycin suppressed seizures and prolonged survival in Tsc1GFAPCKO mice that had already developed epilepsy.  Correspondingly, rapamycin inhibited the abnormal activation of the mammalian target of rapamycin pathway, astrogliosis, and neuronal disorganization, and increased brain size in Tsc1GFAPCKO mice.  Interpretation: Rapamycin has strong efficacy for preventing seizures and prolonging survival in Tsc1GFAPCKO mice.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoDrvRnEyf-tLVg90H21EOLACvtfcHk0lg46Qaxes93Jw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXmsFGqt7c%253D&md5=e4dbf8b71250ec0594029fed56c0d8c2</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1002%2Fana.21331&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fana.21331%26sid%3Dliteratum%253Aachs%26aulast%3DZeng%26aufirst%3DL.%2BH.%26aulast%3DXu%26aufirst%3DL.%26aulast%3DGutmann%26aufirst%3DD.%2BH.%26aulast%3DWong%26aufirst%3DM.%26atitle%3DRapamycin%2520prevents%2520epilepsy%2520in%2520a%2520mouse%2520model%2520of%2520tuberous%2520sclerosis%2520complex%26jtitle%3DAnn.%2520Neurol.%26date%3D2008%26volume%3D63%26spage%3D444%26epage%3D453%26doi%3D10.1002%2Fana.21331" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Burger, M.
T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pecchi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wagman, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ni, Z. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knapp, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hendrickson, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Atallah, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pfister, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bartulis, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frazier, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ng, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verhagen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haznedar, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huh, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iwanowicz, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xin, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Menezes, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Merritt, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiesmann, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaufman, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crawford, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bussiere, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shoemaker, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zaror, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maira, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Voliva, C. F.</span></span> <span> </span><span class="NLM_article-title">Identification of NVP-BKM120 as a potent, selective, orally bioavailable class I PI3 kinase inhibitor for treating cancer</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">774</span>– <span class="NLM_lpage">779</span>, <span class="refDoi"> DOI: 10.1021/ml200156t</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml200156t" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01262&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtVOktrrI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2011&pages=774-779&author=M.%0AT.+Burgerauthor=S.+Pecchiauthor=A.+Wagmanauthor=Z.+J.+Niauthor=M.+Knappauthor=T.+Hendricksonauthor=G.+Atallahauthor=K.+Pfisterauthor=Y.+Zhangauthor=S.+Bartulisauthor=K.+Frazierauthor=S.+Ngauthor=A.+Smithauthor=J.+Verhagenauthor=J.+Haznedarauthor=K.+Huhauthor=E.+Iwanowiczauthor=X.+Xinauthor=D.+Menezesauthor=H.+Merrittauthor=I.+Leeauthor=M.+Wiesmannauthor=S.+Kaufmanauthor=K.+Crawfordauthor=M.+Chinauthor=D.+Bussiereauthor=K.+Shoemakerauthor=I.+Zarorauthor=S.+M.+Mairaauthor=C.+F.+Voliva&title=Identification+of+NVP-BKM120+as+a+potent%2C+selective%2C+orally+bioavailable+class+I+PI3+kinase+inhibitor+for+treating+cancer&doi=10.1021%2Fml200156t"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of NVP-BKM120 as a Potent, Selective, Orally Bioavailable Class I PI3 Kinase Inhibitor for Treating Cancer</span></div><div class="casAuthors">Burger, Matthew T.; Pecchi, Sabina; Wagman, Allan; Ni, Zhi-Jie; Knapp, Mark; Hendrickson, Thomas; Atallah, Gordana; Pfister, Keith; Zhang, Yanchen; Bartulis, Sarah; Frazier, Kelly; Ng, Simon; Smith, Aaron; Verhagen, Joelle; Haznedar, Joshua; Huh, Kay; Iwanowicz, Ed; Xin, Xiaohua; Menezes, Daniel; Merritt, Hanne; Lee, Isabelle; Wiesmann, Marion; Kaufman, Susan; Crawford, Kenneth; Chin, Michael; Bussiere, Dirksen; Shoemaker, Kevin; Zaror, Isabel; Maira, Sauveur-Michel; Voliva, Charles F.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">774-779</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Phosphoinositide-3-kinases (PI3Ks) are important oncol. targets due to the deregulation of this signaling pathway in a wide variety of human cancers.  Herein we describe the structure guided optimization of a series of 2-morpholino, 4-substituted, 6-heterocyclic pyrimidines where the pharmacokinetic properties were improved by modulating the electronics of the 6-position heterocycle, and the overall druglike properties were fine-tuned further by modification of the 4-position substituent.  The resulting 2,4-bismorpholino 6-heterocyclic pyrimidines are potent class I PI3K inhibitors showing mechanism modulation in PI3K dependent cell lines and in vivo efficacy in tumor xenograft models with PI3K pathway deregulation (A2780 ovarian and U87MG glioma).  These efforts culminated in the discovery of 15 (NVP-BKM120), currently in Phase II clin. trials for the treatment of cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpzJ68B9pPbMbVg90H21EOLACvtfcHk0lg46Qaxes93Jw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtVOktrrI&md5=5d00d73dda1fc0d8f0f07d12900282ed</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1021%2Fml200156t&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml200156t%26sid%3Dliteratum%253Aachs%26aulast%3DBurger%26aufirst%3DM.%2BT.%26aulast%3DPecchi%26aufirst%3DS.%26aulast%3DWagman%26aufirst%3DA.%26aulast%3DNi%26aufirst%3DZ.%2BJ.%26aulast%3DKnapp%26aufirst%3DM.%26aulast%3DHendrickson%26aufirst%3DT.%26aulast%3DAtallah%26aufirst%3DG.%26aulast%3DPfister%26aufirst%3DK.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DBartulis%26aufirst%3DS.%26aulast%3DFrazier%26aufirst%3DK.%26aulast%3DNg%26aufirst%3DS.%26aulast%3DSmith%26aufirst%3DA.%26aulast%3DVerhagen%26aufirst%3DJ.%26aulast%3DHaznedar%26aufirst%3DJ.%26aulast%3DHuh%26aufirst%3DK.%26aulast%3DIwanowicz%26aufirst%3DE.%26aulast%3DXin%26aufirst%3DX.%26aulast%3DMenezes%26aufirst%3DD.%26aulast%3DMerritt%26aufirst%3DH.%26aulast%3DLee%26aufirst%3DI.%26aulast%3DWiesmann%26aufirst%3DM.%26aulast%3DKaufman%26aufirst%3DS.%26aulast%3DCrawford%26aufirst%3DK.%26aulast%3DChin%26aufirst%3DM.%26aulast%3DBussiere%26aufirst%3DD.%26aulast%3DShoemaker%26aufirst%3DK.%26aulast%3DZaror%26aufirst%3DI.%26aulast%3DMaira%26aufirst%3DS.%2BM.%26aulast%3DVoliva%26aufirst%3DC.%2BF.%26atitle%3DIdentification%2520of%2520NVP-BKM120%2520as%2520a%2520potent%252C%2520selective%252C%2520orally%2520bioavailable%2520class%2520I%2520PI3%2520kinase%2520inhibitor%2520for%2520treating%2520cancer%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2011%26volume%3D2%26spage%3D774%26epage%3D779%26doi%3D10.1021%2Fml200156t" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fabian, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Biggs, W. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Treiber, D. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Atteridge, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Azimioara, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benedetti, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carter, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ciceri, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edeen, P. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Floyd, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ford, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galvin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gerlach, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grotzfeld, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herrgard, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Insko, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Insko, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lélias, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mehta, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Milanov, Z. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Velasco, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wodicka, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, H. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zarrinkar, P. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lockhart, D. J.</span></span> <span> </span><span class="NLM_article-title">A small molecule-kinase interaction map for clinical kinase inhibitors</span>. <i>Nat. Biotechnol.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">329</span>– <span class="NLM_lpage">336</span>, <span class="refDoi"> DOI: 10.1038/nbt1068</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01262&amp;key=10.1038%2Fnbt1068" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01262&amp;key=15711537" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01262&amp;key=1%3ACAS%3A528%3ADC%252BD2MXitF2nt7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2005&pages=329-336&author=M.+A.+Fabianauthor=W.+H.+Biggsauthor=D.+K.+Treiberauthor=C.+E.+Atteridgeauthor=M.+D.+Azimioaraauthor=M.+G.+Benedettiauthor=T.+A.+Carterauthor=P.+Ciceriauthor=P.+T.+Edeenauthor=M.+Floydauthor=J.+M.+Fordauthor=M.+Galvinauthor=J.+L.+Gerlachauthor=R.+M.+Grotzfeldauthor=S.+Herrgardauthor=D.+E.+Inskoauthor=M.+A.+Inskoauthor=A.+G.+Laiauthor=J.+M.+L%C3%A9liasauthor=S.+A.+Mehtaauthor=Z.+V.+Milanovauthor=A.+M.+Velascoauthor=L.+M.+Wodickaauthor=H.+K.+Patelauthor=P.+P.+Zarrinkarauthor=D.+J.+Lockhart&title=A+small+molecule-kinase+interaction+map+for+clinical+kinase+inhibitors&doi=10.1038%2Fnbt1068"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">A small molecule-kinase interaction map for clinical kinase inhibitors</span></div><div class="casAuthors">Fabian, Miles A.; Biggs, William H.; Treiber, Daniel K.; Atteridge, Corey E.; Azimioara, Mihai D.; Benedetti, Michael G.; Carter, Todd A.; Ciceri, Pietro; Edeen, Philip T.; Floyd, Mark; Ford, Julia M.; Galvin, Margaret; Gerlach, Jay L.; Grotzfeld, Robert M.; Herrgard, Sanna; Insko, Darren E.; Insko, Michael A.; Lai, Andiliy G.; Lelias, Jean-Michel; Mehta, Shamal A.; Milanov, Zdravko V.; Velasco, Anne Marie; Wodicka, Lisa M.; Patel, Hitesh K.; Zarrinkar, Patrick P.; Lockhart, David J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Biotechnology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">329-336</span>CODEN:
                <span class="NLM_cas:coden">NABIF9</span>;
        ISSN:<span class="NLM_cas:issn">1087-0156</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Kinase inhibitors show great promise as a new class of therapeutics.  Here the authors describe an efficient way to det. kinase inhibitor specificity by measuring binding of small mols. to the ATP site of kinases.  The authors have profiled 20 kinase inhibitors, including 16 that are approved drugs or in clin. development, against a panel of 119 protein kinases.  The authors find that specificity varies widely and is not strongly correlated with chem. structure or the identity of the intended target.  Many novel interactions were identified, including tight binding of the p38 inhibitor BIRB-796 to an imatinib-resistant variant of the ABL kinase, and binding of imatinib to the SRC-family kinase LCK.  The authors also show that mutations in the epidermal growth factor receptor (EGFR) found in gefitinib-responsive patients do not affect the binding affinity of gefitinib or erlotinib.  Our results represent a systematic small mol.-protein interaction map for clin. compds. across a large no. of related proteins.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqA0vNmMOXrnrVg90H21EOLACvtfcHk0lgYNJl_xFNByQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXitF2nt7w%253D&md5=6aedd5ceb8f77cd26ee50425dcec7bdf</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1038%2Fnbt1068&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnbt1068%26sid%3Dliteratum%253Aachs%26aulast%3DFabian%26aufirst%3DM.%2BA.%26aulast%3DBiggs%26aufirst%3DW.%2BH.%26aulast%3DTreiber%26aufirst%3DD.%2BK.%26aulast%3DAtteridge%26aufirst%3DC.%2BE.%26aulast%3DAzimioara%26aufirst%3DM.%2BD.%26aulast%3DBenedetti%26aufirst%3DM.%2BG.%26aulast%3DCarter%26aufirst%3DT.%2BA.%26aulast%3DCiceri%26aufirst%3DP.%26aulast%3DEdeen%26aufirst%3DP.%2BT.%26aulast%3DFloyd%26aufirst%3DM.%26aulast%3DFord%26aufirst%3DJ.%2BM.%26aulast%3DGalvin%26aufirst%3DM.%26aulast%3DGerlach%26aufirst%3DJ.%2BL.%26aulast%3DGrotzfeld%26aufirst%3DR.%2BM.%26aulast%3DHerrgard%26aufirst%3DS.%26aulast%3DInsko%26aufirst%3DD.%2BE.%26aulast%3DInsko%26aufirst%3DM.%2BA.%26aulast%3DLai%26aufirst%3DA.%2BG.%26aulast%3DL%25C3%25A9lias%26aufirst%3DJ.%2BM.%26aulast%3DMehta%26aufirst%3DS.%2BA.%26aulast%3DMilanov%26aufirst%3DZ.%2BV.%26aulast%3DVelasco%26aufirst%3DA.%2BM.%26aulast%3DWodicka%26aufirst%3DL.%2BM.%26aulast%3DPatel%26aufirst%3DH.%2BK.%26aulast%3DZarrinkar%26aufirst%3DP.%2BP.%26aulast%3DLockhart%26aufirst%3DD.%2BJ.%26atitle%3DA%2520small%2520molecule-kinase%2520interaction%2520map%2520for%2520clinical%2520kinase%2520inhibitors%26jtitle%3DNat.%2520Biotechnol.%26date%3D2005%26volume%3D23%26spage%3D329%26epage%3D336%26doi%3D10.1038%2Fnbt1068" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1','cit1b','cit1c','cit1d'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7a','cit7b','cit7c'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13a','cit13b'],'ref14':['cit14a','cit14b'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22a','cit22b'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25a','cit25b'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 33 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Yossi Zafrani, Galit Parvari, Dafna Amir, Lee Ghindes-Azaria, Shlomi Elias, Alexander Pevzner, Gil Fridkin, Anat Berliner, Eytan Gershonov, Yoav Eichen, Sigal Saphier, <span class="NLM_string-name hlFld-ContribAuthor">Shahaf Katalan</span>. </span><span class="cited-content_cbyCitation_article-title">Modulation of the H-Bond Basicity of Functional Groups by α-Fluorine-Containing Functions and its Implications for Lipophilicity and Bioisosterism. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>64 </em>
                                    (8)
                                     , 4516-4531. <a href="https://doi.org/10.1021/acs.jmedchem.0c01868" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c01868</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c01868&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c01868%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DModulation%252Bof%252Bthe%252BH-Bond%252BBasicity%252Bof%252BFunctional%252BGroups%252Bby%252B%2525CE%2525B1-Fluorine-Containing%252BFunctions%252Band%252Bits%252BImplications%252Bfor%252BLipophilicity%252Band%252BBioisosterism%26aulast%3DZafrani%26aufirst%3DYossi%26date%3D2021%26date%3D2021%26date%3D2020%26date%3D28102020%26date%3D12042021%26volume%3D64%26issue%3D8%26spage%3D4516%26epage%3D4531" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Elena Lenci, Lorenzo Calugi, <span class="NLM_string-name hlFld-ContribAuthor">Andrea Trabocchi</span>. </span><span class="cited-content_cbyCitation_article-title">Occurrence of Morpholine in Central Nervous System Drug Discovery. </span><span class="cited-content_cbyCitation_journal-name">ACS Chemical Neuroscience</span><span> <strong>2021,</strong> <em>12 </em>
                                    (3)
                                     , 378-390. <a href="https://doi.org/10.1021/acschemneuro.0c00729" title="DOI URL">https://doi.org/10.1021/acschemneuro.0c00729</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acschemneuro.0c00729&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facschemneuro.0c00729%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Chemical%2520Neuroscience%26atitle%3DOccurrence%252Bof%252BMorpholine%252Bin%252BCentral%252BNervous%252BSystem%252BDrug%252BDiscovery%26aulast%3DLenci%26aufirst%3DElena%26date%3D2021%26date%3D2021%26date%3D2021%26date%3D2020%26date%3D13112020%26date%3D11012021%26date%3D18012021%26volume%3D12%26issue%3D3%26spage%3D378%26epage%3D390" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Chiara Borsari, Erhan Keles, Denise Rageot, Andrea Treyer, Thomas Bohnacker, Lukas Bissegger, Martina De Pascale, Anna Melone, Rohitha Sriramaratnam, Florent Beaufils, Matthias Hamburger, Paul Hebeisen, Wolfgang Löscher, Doriano Fabbro, Petra Hillmann, <span class="NLM_string-name hlFld-ContribAuthor">Matthias P. Wymann</span>. </span><span class="cited-content_cbyCitation_article-title">4-(Difluoromethyl)-5-(4-((3R,5S)-3,5-dimethylmorpholino)-6-((R)-3-methylmorpholino)-1,3,5-triazin-2-yl)pyridin-2-amine (PQR626), a Potent, Orally Available, and Brain-Penetrant mTOR Inhibitor for the Treatment of Neurological Disorders. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (22)
                                     , 13595-13617. <a href="https://doi.org/10.1021/acs.jmedchem.0c00620" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c00620</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c00620&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c00620%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3D4-%252528Difluoromethyl%252529-5-%2525284-%252528%2525283R%25252C5S%252529-3%25252C5-dimethylmorpholino%252529-6-%252528%252528R%252529-3-methylmorpholino%252529-1%25252C3%25252C5-triazin-2-yl%252529pyridin-2-amine%252B%252528PQR626%252529%25252C%252Ba%252BPotent%25252C%252BOrally%252BAvailable%25252C%252Band%252BBrain-Penetrant%252BmTOR%252BInhibitor%252Bfor%252Bthe%252BTreatment%252Bof%252BNeurological%252BDisorders%26aulast%3DBorsari%26aufirst%3DChiara%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D15042020%26date%3D09112020%26volume%3D63%26issue%3D22%26spage%3D13595%26epage%3D13617" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Sofiane Hocine, Gilles Berger, <span class="NLM_string-name hlFld-ContribAuthor">Stephen Hanessian</span>. </span><span class="cited-content_cbyCitation_article-title">Design and Synthesis of Backbone-Fused, Conformationally Constrained Morpholine-Proline Chimeras. </span><span class="cited-content_cbyCitation_journal-name">The Journal of Organic Chemistry</span><span> <strong>2020,</strong> <em>85 </em>
                                    (6)
                                     , 4237-4247. <a href="https://doi.org/10.1021/acs.joc.9b03413" title="DOI URL">https://doi.org/10.1021/acs.joc.9b03413</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.joc.9b03413&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.joc.9b03413%26sid%3Dliteratum%253Aachs%26jtitle%3DThe%2520Journal%2520of%2520Organic%2520Chemistry%26atitle%3DDesign%252Band%252BSynthesis%252Bof%252BBackbone-Fused%25252C%252BConformationally%252BConstrained%252BMorpholine-Proline%252BChimeras%26aulast%3DHocine%26aufirst%3DSofiane%26date%3D2020%26date%3D2020%26date%3D2019%26date%3D18122019%26date%3D05032020%26volume%3D85%26issue%3D6%26spage%3D4237%26epage%3D4247" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Simone Bonazzi, Carleton P. Goold, Audrey Gray, Noel M. Thomsen, Jill Nunez, Rajeshri G. Karki, Aakruti Gorde, Jonathan D. Biag, Hasnain A. Malik, Yingchuan Sun, Guiqing Liang, Danuta Lubicka, Sarah Salas, Nancy Labbe-Giguere, Erin P. Keaney, Stephanie McTighe, Shanming Liu, Lin Deng, Grazia Piizzi, Franco Lombardo, Doug Burdette, Jean-Cosme Dodart, Christopher J. Wilson, Stefan Peukert, Daniel Curtis, Lawrence G. Hamann, <span class="NLM_string-name hlFld-ContribAuthor">Leon O. Murphy</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of a Brain-Penetrant ATP-Competitive Inhibitor of the Mechanistic Target of Rapamycin (mTOR) for CNS Disorders. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (3)
                                     , 1068-1083. <a href="https://doi.org/10.1021/acs.jmedchem.9b01398" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b01398</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b01398&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.9b01398%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252Ba%252BBrain-Penetrant%252BATP-Competitive%252BInhibitor%252Bof%252Bthe%252BMechanistic%252BTarget%252Bof%252BRapamycin%252B%252528mTOR%252529%252Bfor%252BCNS%252BDisorders%26aulast%3DBonazzi%26aufirst%3DSimone%26date%3D2020%26date%3D2020%26date%3D2019%26date%3D23082019%26date%3D31012020%26date%3D20012020%26volume%3D63%26issue%3D3%26spage%3D1068%26epage%3D1083" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Denise Rageot, Florent Beaufils, Chiara Borsari, Alix Dall’Asen, Markus Neuburger, Paul Hebeisen, <span class="NLM_string-name hlFld-ContribAuthor">Matthias P. Wymann</span>. </span><span class="cited-content_cbyCitation_article-title">Scalable, Economical, and Practical Synthesis of 4-(Difluoromethyl)pyridin-2-amine, a Key Intermediate for Lipid Kinase Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Organic Process Research & Development</span><span> <strong>2019,</strong> <em>23 </em>
                                    (11)
                                     , 2416-2424. <a href="https://doi.org/10.1021/acs.oprd.9b00312" title="DOI URL">https://doi.org/10.1021/acs.oprd.9b00312</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.oprd.9b00312&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.oprd.9b00312%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520Process%2520Research%2520%2526%2520Development%26atitle%3DScalable%25252C%252BEconomical%25252C%252Band%252BPractical%252BSynthesis%252Bof%252B4-%252528Difluoromethyl%252529pyridin-2-amine%25252C%252Ba%252BKey%252BIntermediate%252Bfor%252BLipid%252BKinase%252BInhibitors%26aulast%3DRageot%26aufirst%3DDenise%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D09072019%26date%3D10102019%26date%3D25092019%26volume%3D23%26issue%3D11%26spage%3D2416%26epage%3D2424" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Jian-Shu Wang, Kai-Shun Huang, Wen-Yong Han, Bao-Dong Cui, Nan-Wei Wan, <span class="NLM_string-name hlFld-ContribAuthor">Yong-Zheng Chen</span>. </span><span class="cited-content_cbyCitation_article-title">Ex Situ Generation of Difluorodiazoethane (CF2HCHN2): Application in the Regioselective Synthesis of CF2H-Containing Pyrazoles. </span><span class="cited-content_cbyCitation_journal-name">Organic Letters</span><span> <strong>2019,</strong> <em>21 </em>
                                    (21)
                                     , 8751-8755. <a href="https://doi.org/10.1021/acs.orglett.9b03371" title="DOI URL">https://doi.org/10.1021/acs.orglett.9b03371</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.orglett.9b03371&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.orglett.9b03371%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520Letters%26atitle%3DEx%252BSitu%252BGeneration%252Bof%252BDifluorodiazoethane%252B%252528CF2HCHN2%252529%25253A%252BApplication%252Bin%252Bthe%252BRegioselective%252BSynthesis%252Bof%252BCF2H-Containing%252BPyrazoles%26aulast%3DWang%26aufirst%3DJian-Shu%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D24092019%26date%3D23102019%26volume%3D21%26issue%3D21%26spage%3D8751%26epage%3D8755" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Chiara Borsari, Denise Rageot, Florent Beaufils, Thomas Bohnacker, Erhan Keles, Ivan Buslov, Anna Melone, Alexander M. Sele, Paul Hebeisen, Doriano Fabbro, Petra Hillmann, <span class="NLM_string-name hlFld-ContribAuthor">Matthias P. Wymann</span>. </span><span class="cited-content_cbyCitation_article-title">Preclinical Development of PQR514, a Highly Potent PI3K Inhibitor Bearing a Difluoromethyl–Pyrimidine Moiety. </span><span class="cited-content_cbyCitation_journal-name">ACS Medicinal Chemistry Letters</span><span> <strong>2019,</strong> <em>10 </em>
                                    (10)
                                     , 1473-1479. <a href="https://doi.org/10.1021/acsmedchemlett.9b00333" title="DOI URL">https://doi.org/10.1021/acsmedchemlett.9b00333</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsmedchemlett.9b00333&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsmedchemlett.9b00333%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DPreclinical%252BDevelopment%252Bof%252BPQR514%25252C%252Ba%252BHighly%252BPotent%252BPI3K%252BInhibitor%252BBearing%252Ba%252BDifluoromethyl%2525E2%252580%252593Pyrimidine%252BMoiety%26aulast%3DBorsari%26aufirst%3DChiara%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D22072019%26date%3D03092019%26date%3D11092019%26date%3D03092019%26volume%3D10%26issue%3D10%26spage%3D1473%26epage%3D1479" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Chiara Borsari, Denise Rageot, Alix Dall’Asen, Thomas Bohnacker, Anna Melone, Alexander M. Sele, Eileen Jackson, Jean-Baptiste Langlois, Florent Beaufils, Paul Hebeisen, Doriano Fabbro, Petra Hillmann, <span class="NLM_string-name hlFld-ContribAuthor">Matthias P. Wymann</span>. </span><span class="cited-content_cbyCitation_article-title">A Conformational Restriction Strategy for the Identification of a Highly Selective Pyrimido-pyrrolo-oxazine mTOR Inhibitor. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>62 </em>
                                    (18)
                                     , 8609-8630. <a href="https://doi.org/10.1021/acs.jmedchem.9b00972" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b00972</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b00972&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.9b00972%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DA%252BConformational%252BRestriction%252BStrategy%252Bfor%252Bthe%252BIdentification%252Bof%252Ba%252BHighly%252BSelective%252BPyrimido-pyrrolo-oxazine%252BmTOR%252BInhibitor%26aulast%3DBorsari%26aufirst%3DChiara%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D19062019%26date%3D11092019%26date%3D29082019%26volume%3D62%26issue%3D18%26spage%3D8609%26epage%3D8630" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Denise Rageot, Thomas Bohnacker, Erhan Keles, Jacob A. McPhail, Reece M. Hoffmann, Anna Melone, Chiara Borsari, Rohitha Sriramaratnam, Alexander M. Sele, Florent Beaufils, Paul Hebeisen, Doriano Fabbro, Petra Hillmann, John E. Burke, <span class="NLM_string-name hlFld-ContribAuthor">Matthias P. Wymann</span>. </span><span class="cited-content_cbyCitation_article-title">(S)-4-(Difluoromethyl)-5-(4-(3-methylmorpholino)-6-morpholino-1,3,5-triazin-2-yl)pyridin-2-amine (PQR530), a Potent, Orally Bioavailable, and Brain-Penetrable Dual Inhibitor of Class I PI3K and mTOR Kinase. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>62 </em>
                                    (13)
                                     , 6241-6261. <a href="https://doi.org/10.1021/acs.jmedchem.9b00525" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b00525</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b00525&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.9b00525%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3D%252528S%252529-4-%252528Difluoromethyl%252529-5-%2525284-%2525283-methylmorpholino%252529-6-morpholino-1%25252C3%25252C5-triazin-2-yl%252529pyridin-2-amine%252B%252528PQR530%252529%25252C%252Ba%252BPotent%25252C%252BOrally%252BBioavailable%25252C%252Band%252BBrain-Penetrable%252BDual%252BInhibitor%252Bof%252BClass%252BI%252BPI3K%252Band%252BmTOR%252BKinase%26aulast%3DRageot%26aufirst%3DDenise%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D26032019%26date%3D20062019%26date%3D07062019%26volume%3D62%26issue%3D13%26spage%3D6241%26epage%3D6261" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jeroen B. I.  Sap</span>, <span class="hlFld-ContribAuthor ">Claudio F.  Meyer</span>, <span class="hlFld-ContribAuthor ">Natan J. W.  Straathof</span>, <span class="hlFld-ContribAuthor ">Ndidi  Iwumene</span>, <span class="hlFld-ContribAuthor ">Christopher W.  am Ende</span>, <span class="hlFld-ContribAuthor ">Andrés A.  Trabanco</span>, <span class="hlFld-ContribAuthor ">Véronique  Gouverneur</span>. </span><span class="cited-content_cbyCitation_article-title">Late-stage difluoromethylation: concepts, developments and perspective. </span><span class="cited-content_cbyCitation_journal-name">Chemical Society Reviews</span><span> <strong>2021,</strong> <em>50 </em>
                                    (14)
                                     , 8214-8247. <a href="https://doi.org/10.1039/D1CS00360G" title="DOI URL">https://doi.org/10.1039/D1CS00360G</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/D1CS00360G&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FD1CS00360G%26sid%3Dliteratum%253Aachs%26jtitle%3DChemical%2520Society%2520Reviews%26atitle%3DLate-stage%252Bdifluoromethylation%25253A%252Bconcepts%25252C%252Bdevelopments%252Band%252Bperspective%26aulast%3DSap%26aufirst%3DJeroen%2BB.%2BI.%26date%3D2021%26date%3D2021%26volume%3D50%26issue%3D14%26spage%3D8214%26epage%3D8247" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Chiara  Borsari</span>, <span class="hlFld-ContribAuthor ">Martina  De Pascale</span>, <span class="hlFld-ContribAuthor ">Matthias P.  Wymann</span>. </span><span class="cited-content_cbyCitation_article-title">Chemical and Structural Strategies to Selectively Target mTOR Kinase. </span><span class="cited-content_cbyCitation_journal-name">ChemMedChem</span><span> <strong>2021,</strong> <em>9 </em><a href="https://doi.org/10.1002/cmdc.202100332" title="DOI URL">https://doi.org/10.1002/cmdc.202100332</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/cmdc.202100332&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fcmdc.202100332%26sid%3Dliteratum%253Aachs%26jtitle%3DChemMedChem%26atitle%3DChemical%252Band%252BStructural%252BStrategies%252Bto%252BSelectively%252BTarget%252BmTOR%252BKinase%26aulast%3DBorsari%26aufirst%3DChiara%26date%3D2021%26date%3D2021%26volume%3D9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jian-hua  Zha</span>, <span class="hlFld-ContribAuthor ">Ying-chen  Xia</span>, <span class="hlFld-ContribAuthor ">Chun-lin  Ye</span>, <span class="hlFld-ContribAuthor ">Zhi  Hu</span>, <span class="hlFld-ContribAuthor ">Qin  Zhang</span>, <span class="hlFld-ContribAuthor ">Han  Xiao</span>, <span class="hlFld-ContribAuthor ">Ben-tong  Yu</span>, <span class="hlFld-ContribAuthor ">Wei-hua  Xu</span>, <span class="hlFld-ContribAuthor ">Guo-qiu  Xu</span>. </span><span class="cited-content_cbyCitation_article-title">The Anti-Non-Small Cell Lung Cancer Cell Activity by a mTOR Kinase Inhibitor PQR620. </span><span class="cited-content_cbyCitation_journal-name">Frontiers in Oncology</span><span> <strong>2021,</strong> <em>11 </em><a href="https://doi.org/10.3389/fonc.2021.669518" title="DOI URL">https://doi.org/10.3389/fonc.2021.669518</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3389/fonc.2021.669518&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3389%2Ffonc.2021.669518%26sid%3Dliteratum%253Aachs%26jtitle%3DFrontiers%2520in%2520Oncology%26atitle%3DThe%252BAnti-Non-Small%252BCell%252BLung%252BCancer%252BCell%252BActivity%252Bby%252Ba%252BmTOR%252BKinase%252BInhibitor%252BPQR620%26aulast%3DZha%26aufirst%3DJian-hua%26date%3D2021%26date%3D2021%26volume%3D11" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Paul  Richardson</span>. </span><span class="cited-content_cbyCitation_article-title">Applications of fluorine to the construction of bioisosteric elements for the purposes of novel drug discovery. </span><span class="cited-content_cbyCitation_journal-name">Expert Opinion on Drug Discovery</span><span> <strong>2021,</strong> <em>3 </em>, 1-26. <a href="https://doi.org/10.1080/17460441.2021.1933427" title="DOI URL">https://doi.org/10.1080/17460441.2021.1933427</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/17460441.2021.1933427&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F17460441.2021.1933427%26sid%3Dliteratum%253Aachs%26jtitle%3DExpert%2520Opinion%2520on%2520Drug%2520Discovery%26atitle%3DApplications%252Bof%252Bfluorine%252Bto%252Bthe%252Bconstruction%252Bof%252Bbioisosteric%252Belements%252Bfor%252Bthe%252Bpurposes%252Bof%252Bnovel%252Bdrug%252Bdiscovery%26aulast%3DRichardson%26aufirst%3DPaul%26date%3D2021%26date%3D2021%26volume%3D3%26spage%3D1%26epage%3D26" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Chiara  Borsari</span>, <span class="hlFld-ContribAuthor ">Erhan  Keles</span>, <span class="hlFld-ContribAuthor ">Andrea  Treyer</span>, <span class="hlFld-ContribAuthor ">Martina  De Pascale</span>, <span class="hlFld-ContribAuthor ">Paul  Hebeisen</span>, <span class="hlFld-ContribAuthor ">Matthias  Hamburger</span>, <span class="hlFld-ContribAuthor ">Matthias P.  Wymann</span>. </span><span class="cited-content_cbyCitation_article-title">Second-generation tricyclic pyrimido-pyrrolo-oxazine mTOR inhibitor with predicted blood–brain barrier permeability. </span><span class="cited-content_cbyCitation_journal-name">RSC Medicinal Chemistry</span><span> <strong>2021,</strong> <em>12 </em>
                                    (4)
                                     , 579-583. <a href="https://doi.org/10.1039/D0MD00408A" title="DOI URL">https://doi.org/10.1039/D0MD00408A</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/D0MD00408A&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FD0MD00408A%26sid%3Dliteratum%253Aachs%26jtitle%3DRSC%2520Medicinal%2520Chemistry%26atitle%3DSecond-generation%252Btricyclic%252Bpyrimido-pyrrolo-oxazine%252BmTOR%252Binhibitor%252Bwith%252Bpredicted%252Bblood%2525E2%252580%252593brain%252Bbarrier%252Bpermeability%26aulast%3DBorsari%26aufirst%3DChiara%26date%3D2021%26date%3D2021%26volume%3D12%26issue%3D4%26spage%3D579%26epage%3D583" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ruoyu  He</span>, <span class="hlFld-ContribAuthor ">Bingyong  Xu</span>, <span class="hlFld-ContribAuthor ">Li  Ping</span>, <span class="hlFld-ContribAuthor ">Xiaoqing  Lv</span>. </span><span class="cited-content_cbyCitation_article-title">Structural optimization towards promising β-methyl-4-acrylamido quinoline derivatives as PI3K/mTOR dual inhibitors for anti-cancer therapy: The in vitro and in vivo biological evaluation. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>214 </em>, 113249. <a href="https://doi.org/10.1016/j.ejmech.2021.113249" title="DOI URL">https://doi.org/10.1016/j.ejmech.2021.113249</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2021.113249&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2021.113249%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DStructural%252Boptimization%252Btowards%252Bpromising%252B%2525CE%2525B2-methyl-4-acrylamido%252Bquinoline%252Bderivatives%252Bas%252BPI3K%25252FmTOR%252Bdual%252Binhibitors%252Bfor%252Banti-cancer%252Btherapy%25253A%252BThe%252Bin%2525C2%2525A0vitro%252Band%252Bin%2525C2%2525A0vivo%252Bbiological%252Bevaluation%26aulast%3DHe%26aufirst%3DRuoyu%26date%3D2021%26volume%3D214%26spage%3D113249" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ab  Majeed Ganai</span>, <span class="hlFld-ContribAuthor ">Tabasum  Khan Pathan</span>, <span class="hlFld-ContribAuthor ">Girish A.  Hampannavar</span>, <span class="hlFld-ContribAuthor ">Chandrakant  Pawar</span>, <span class="hlFld-ContribAuthor ">Vincent A.  Obakachi</span>, <span class="hlFld-ContribAuthor ">Babita  Kushwaha</span>, <span class="hlFld-ContribAuthor ">Narva  Deshwar Kushwaha</span>, <span class="hlFld-ContribAuthor ">Rajshekhar  Karpoormath</span>. </span><span class="cited-content_cbyCitation_article-title">Recent Advances on the s‐Triazine Scaffold with Emphasis on Synthesis, Structure‐Activity and Pharmacological Aspects: A Concise Review. </span><span class="cited-content_cbyCitation_journal-name">ChemistrySelect</span><span> <strong>2021,</strong> <em>6 </em>
                                    (7)
                                     , 1616-1660. <a href="https://doi.org/10.1002/slct.202004591" title="DOI URL">https://doi.org/10.1002/slct.202004591</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/slct.202004591&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fslct.202004591%26sid%3Dliteratum%253Aachs%26jtitle%3DChemistrySelect%26atitle%3DRecent%252BAdvances%252Bon%252Bthe%252Bs%2525E2%252580%252590Triazine%252BScaffold%252Bwith%252BEmphasis%252Bon%252BSynthesis%25252C%252BStructure%2525E2%252580%252590Activity%252Band%252BPharmacological%252BAspects%25253A%252BA%252BConcise%252BReview%26aulast%3DMajeed%2BGanai%26aufirst%3DAb%26date%3D2021%26date%3D2021%26volume%3D6%26issue%3D7%26spage%3D1616%26epage%3D1660" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Junbo  Hu</span>, <span class="hlFld-ContribAuthor ">Yanli  Zhang</span>, <span class="hlFld-ContribAuthor ">Na  Tang</span>, <span class="hlFld-ContribAuthor ">Yanju  Lu</span>, <span class="hlFld-ContribAuthor ">Peng  Guo</span>, <span class="hlFld-ContribAuthor ">Ziming  Huang</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of novel 1,3,5-triazine derivatives as potent inhibitor of cervical cancer via dual inhibition of PI3K/mTOR. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry</span><span> <strong>2021,</strong> <em>32 </em>, 115997. <a href="https://doi.org/10.1016/j.bmc.2021.115997" title="DOI URL">https://doi.org/10.1016/j.bmc.2021.115997</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmc.2021.115997&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmc.2021.115997%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252Bnovel%252B1%25252C3%25252C5-triazine%252Bderivatives%252Bas%252Bpotent%252Binhibitor%252Bof%252Bcervical%252Bcancer%252Bvia%252Bdual%252Binhibition%252Bof%252BPI3K%25252FmTOR%26aulast%3DHu%26aufirst%3DJunbo%26date%3D2021%26volume%3D32%26spage%3D115997" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">David P.  Rotella</span>. </span><span class="cited-content_cbyCitation_article-title">Heterocycles in drug discovery: Properties and preparation. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2021,</strong>,, 149-183. <a href="https://doi.org/10.1016/bs.aihch.2020.10.002" title="DOI URL">https://doi.org/10.1016/bs.aihch.2020.10.002</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/bs.aihch.2020.10.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fbs.aihch.2020.10.002%26sid%3Dliteratum%253Aachs%26atitle%3DHeterocycles%252Bin%252Bdrug%252Bdiscovery%25253A%252BProperties%252Band%252Bpreparation%26aulast%3DRotella%26aufirst%3DDavid%2BP.%26date%3D2021%26spage%3D149%26epage%3D183%26pub%3DElsevier%26atitle%3DApplications%252Bof%252BHeterocycles%252Bin%252Bthe%252BDesign%252Bof%252BDrugs%252Band%252BAgricultural%252BProducts%26date%3D2021%26volume%3D134" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Wiebke  Theilmann</span>, <span class="hlFld-ContribAuthor ">Birthe  Gericke</span>, <span class="hlFld-ContribAuthor ">Alina  Schidlitzki</span>, <span class="hlFld-ContribAuthor ">Syed Muhammad  Muneeb Anjum</span>, <span class="hlFld-ContribAuthor ">Saskia  Borsdorf</span>, <span class="hlFld-ContribAuthor ">Timon  Harries</span>, <span class="hlFld-ContribAuthor ">Steven L.  Roberds</span>, <span class="hlFld-ContribAuthor ">Dean J.  Aguiar</span>, <span class="hlFld-ContribAuthor ">Daniela  Brunner</span>, <span class="hlFld-ContribAuthor ">Steven C.  Leiser</span>, <span class="hlFld-ContribAuthor ">Dekun  Song</span>, <span class="hlFld-ContribAuthor ">Doriano  Fabbro</span>, <span class="hlFld-ContribAuthor ">Petra  Hillmann</span>, <span class="hlFld-ContribAuthor ">Matthias P.  Wymann</span>, <span class="hlFld-ContribAuthor ">Wolfgang  Löscher</span>. </span><span class="cited-content_cbyCitation_article-title">Novel brain permeant mTORC1/2 inhibitors are as efficacious as rapamycin or everolimus in mouse models of acquired partial epilepsy and tuberous sclerosis complex. </span><span class="cited-content_cbyCitation_journal-name">Neuropharmacology</span><span> <strong>2020,</strong> <em>180 </em>, 108297. <a href="https://doi.org/10.1016/j.neuropharm.2020.108297" title="DOI URL">https://doi.org/10.1016/j.neuropharm.2020.108297</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.neuropharm.2020.108297&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.neuropharm.2020.108297%26sid%3Dliteratum%253Aachs%26jtitle%3DNeuropharmacology%26atitle%3DNovel%252Bbrain%252Bpermeant%252BmTORC1%25252F2%252Binhibitors%252Bare%252Bas%252Befficacious%252Bas%252Brapamycin%252Bor%252Beverolimus%252Bin%252Bmouse%252Bmodels%252Bof%252Bacquired%252Bpartial%252Bepilepsy%252Band%252Btuberous%252Bsclerosis%252Bcomplex%26aulast%3DTheilmann%26aufirst%3DWiebke%26date%3D2020%26volume%3D180%26spage%3D108297" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Cecilia  Zavala-Tecuapetla</span>, <span class="hlFld-ContribAuthor ">Manola  Cuellar-Herrera</span>, <span class="hlFld-ContribAuthor ">Hiram  Luna-Munguia</span>. </span><span class="cited-content_cbyCitation_article-title">Insights into Potential Targets for Therapeutic Intervention in Epilepsy. </span><span class="cited-content_cbyCitation_journal-name">International Journal of Molecular Sciences</span><span> <strong>2020,</strong> <em>21 </em>
                                    (22)
                                     , 8573. <a href="https://doi.org/10.3390/ijms21228573" title="DOI URL">https://doi.org/10.3390/ijms21228573</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/ijms21228573&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fijms21228573%26sid%3Dliteratum%253Aachs%26jtitle%3DInternational%2520Journal%2520of%2520Molecular%2520Sciences%26atitle%3DInsights%252Binto%252BPotential%252BTargets%252Bfor%252BTherapeutic%252BIntervention%252Bin%252BEpilepsy%26aulast%3DZavala-Tecuapetla%26aufirst%3DCecilia%26date%3D2020%26date%3D2020%26volume%3D21%26issue%3D22%26spage%3D8573" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ting-Ting  Wu</span>, <span class="hlFld-ContribAuthor ">Qing-Qing  Guo</span>, <span class="hlFld-ContribAuthor ">Zi-Li  Chen</span>, <span class="hlFld-ContribAuthor ">Li-Li  Wang</span>, <span class="hlFld-ContribAuthor ">Yao  Du</span>, <span class="hlFld-ContribAuthor ">Rui  Chen</span>, <span class="hlFld-ContribAuthor ">Yuan-Hu  Mao</span>, <span class="hlFld-ContribAuthor ">Sheng-Gang  Yang</span>, <span class="hlFld-ContribAuthor ">Jing  Huang</span>, <span class="hlFld-ContribAuthor ">Jian-Ta  Wang</span>, <span class="hlFld-ContribAuthor ">Ling  Wang</span>, <span class="hlFld-ContribAuthor ">Lei  Tang</span>, <span class="hlFld-ContribAuthor ">Ji-Quan  Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">Design, synthesis and bioevaluation of novel substituted triazines as potential dual PI3K/mTOR inhibitors. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>204 </em>, 112637. <a href="https://doi.org/10.1016/j.ejmech.2020.112637" title="DOI URL">https://doi.org/10.1016/j.ejmech.2020.112637</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2020.112637&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2020.112637%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDesign%25252C%252Bsynthesis%252Band%252Bbioevaluation%252Bof%252Bnovel%252Bsubstituted%252Btriazines%252Bas%252Bpotential%252Bdual%252BPI3K%25252FmTOR%252Binhibitors%26aulast%3DWu%26aufirst%3DTing-Ting%26date%3D2020%26volume%3D204%26spage%3D112637" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Nadia G.  Zaki</span>, <span class="hlFld-ContribAuthor ">Walaa H.  Mahmoud</span>, <span class="hlFld-ContribAuthor ">Ahmed M.  El Kerdawy</span>, <span class="hlFld-ContribAuthor ">Abanoub Mosaad  Abdallah</span>, <span class="hlFld-ContribAuthor ">Gehad G.  Mohamed</span>. </span><span class="cited-content_cbyCitation_article-title">Structural characterization, thermal, DFT, cytotoxicity, and antimetastatic properties of cocaine complexes with La(III), Er(III), and Yb(III). </span><span class="cited-content_cbyCitation_journal-name">Research on Chemical Intermediates</span><span> <strong>2020,</strong> <em>46 </em>
                                    (6)
                                     , 3193-3216. <a href="https://doi.org/10.1007/s11164-020-04146-3" title="DOI URL">https://doi.org/10.1007/s11164-020-04146-3</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s11164-020-04146-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs11164-020-04146-3%26sid%3Dliteratum%253Aachs%26jtitle%3DResearch%2520on%2520Chemical%2520Intermediates%26atitle%3DStructural%252Bcharacterization%25252C%252Bthermal%25252C%252BDFT%25252C%252Bcytotoxicity%25252C%252Band%252Bantimetastatic%252Bproperties%252Bof%252Bcocaine%252Bcomplexes%252Bwith%252BLa%252528III%252529%25252C%252BEr%252528III%252529%25252C%252Band%252BYb%252528III%252529%26aulast%3DZaki%26aufirst%3DNadia%2BG.%26date%3D2020%26date%3D2020%26volume%3D46%26issue%3D6%26spage%3D3193%26epage%3D3216" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xueyan  Li</span>, <span class="hlFld-ContribAuthor ">Yanjiang  Yu</span>, <span class="hlFld-ContribAuthor ">Ruobing  Qi</span>, <span class="hlFld-ContribAuthor ">Dachang  Bai</span>. </span><span class="cited-content_cbyCitation_article-title">Facile access to fluoroalkylated 2-aminopyridines by Cu-catalyzed [3 + 3] couplings of oxime esters with β-CF3 acrylonitrile. </span><span class="cited-content_cbyCitation_journal-name">Tetrahedron Letters</span><span> <strong>2020,</strong> <em>61 </em>
                                    (20)
                                     , 151858. <a href="https://doi.org/10.1016/j.tetlet.2020.151858" title="DOI URL">https://doi.org/10.1016/j.tetlet.2020.151858</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.tetlet.2020.151858&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.tetlet.2020.151858%26sid%3Dliteratum%253Aachs%26jtitle%3DTetrahedron%2520Letters%26atitle%3DFacile%252Baccess%252Bto%252Bfluoroalkylated%252B2-aminopyridines%252Bby%252BCu-catalyzed%252B%25255B3%2525C2%2525A0%25252B%2525C2%2525A03%25255D%252Bcouplings%252Bof%252Boxime%252Besters%252Bwith%252B%2525CE%2525B2-CF3%252Bacrylonitrile%26aulast%3DLi%26aufirst%3DXueyan%26date%3D2020%26volume%3D61%26issue%3D20%26spage%3D151858" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Archana  Kumari</span>, <span class="hlFld-ContribAuthor ">Rajesh K.  Singh</span>. </span><span class="cited-content_cbyCitation_article-title">Morpholine as ubiquitous pharmacophore in medicinal chemistry: Deep insight into the structure-activity relationship (SAR). </span><span class="cited-content_cbyCitation_journal-name">Bioorganic Chemistry</span><span> <strong>2020,</strong> <em>96 </em>, 103578. <a href="https://doi.org/10.1016/j.bioorg.2020.103578" title="DOI URL">https://doi.org/10.1016/j.bioorg.2020.103578</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bioorg.2020.103578&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bioorg.2020.103578%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520Chemistry%26atitle%3DMorpholine%252Bas%252Bubiquitous%252Bpharmacophore%252Bin%252Bmedicinal%252Bchemistry%25253A%252BDeep%252Binsight%252Binto%252Bthe%252Bstructure-activity%252Brelationship%252B%252528SAR%252529%26aulast%3DKumari%26aufirst%3DArchana%26date%3D2020%26volume%3D96%26spage%3D103578" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Nadia G.  Zaki</span>, <span class="hlFld-ContribAuthor ">Walaa H.  Mahmoud</span>, <span class="hlFld-ContribAuthor ">Ahmed M.  El Kerdawy</span>, <span class="hlFld-ContribAuthor ">Abanoub Mosaad  Abdallah</span>, <span class="hlFld-ContribAuthor ">Gehad G.  Mohamed</span>. </span><span class="cited-content_cbyCitation_article-title">Heteroleptic complexes of cocaine/TMEDA with some f block metals: Synthesis, DFT studies, spectral, thermal, cytotoxicity and antimetastatic properties. </span><span class="cited-content_cbyCitation_journal-name">Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy</span><span> <strong>2020,</strong> <em>229 </em>, 117938. <a href="https://doi.org/10.1016/j.saa.2019.117938" title="DOI URL">https://doi.org/10.1016/j.saa.2019.117938</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.saa.2019.117938&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.saa.2019.117938%26sid%3Dliteratum%253Aachs%26jtitle%3DSpectrochimica%2520Acta%2520Part%2520A%253A%2520Molecular%2520and%2520Biomolecular%2520Spectroscopy%26atitle%3DHeteroleptic%252Bcomplexes%252Bof%252Bcocaine%25252FTMEDA%252Bwith%252Bsome%252Bf%252Bblock%252Bmetals%25253A%252BSynthesis%25252C%252BDFT%252Bstudies%25252C%252Bspectral%25252C%252Bthermal%25252C%252Bcytotoxicity%252Band%252Bantimetastatic%252Bproperties%26aulast%3DZaki%26aufirst%3DNadia%2BG.%26date%3D2020%26volume%3D229%26spage%3D117938" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yossi  Zafrani</span>, <span class="hlFld-ContribAuthor ">Sigal  Saphier</span>, <span class="hlFld-ContribAuthor ">Eytan  Gershonov</span>. </span><span class="cited-content_cbyCitation_article-title">Utilizing the CF
              2
              H moiety as a H-bond-donating group in drug discovery. </span><span class="cited-content_cbyCitation_journal-name">Future Medicinal Chemistry</span><span> <strong>2020,</strong> <em>12 </em>
                                    (5)
                                     , 361-365. <a href="https://doi.org/10.4155/fmc-2019-0309" title="DOI URL">https://doi.org/10.4155/fmc-2019-0309</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.4155/fmc-2019-0309&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.4155%2Ffmc-2019-0309%26sid%3Dliteratum%253Aachs%26jtitle%3DFuture%2520Medicinal%2520Chemistry%26atitle%3DUtilizing%252Bthe%252BCF%252B2%252BH%252Bmoiety%252Bas%252Ba%252BH-bond-donating%252Bgroup%252Bin%252Bdrug%252Bdiscovery%26aulast%3DZafrani%26aufirst%3DYossi%26date%3D2020%26volume%3D12%26issue%3D5%26spage%3D361%26epage%3D365" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Elisabeth  Singer</span>, <span class="hlFld-ContribAuthor ">Carolin  Walter</span>, <span class="hlFld-ContribAuthor ">Doriano  Fabbro</span>, <span class="hlFld-ContribAuthor ">Denise  Rageot</span>, <span class="hlFld-ContribAuthor ">Florent  Beaufils</span>, <span class="hlFld-ContribAuthor ">Matthias P.  Wymann</span>, <span class="hlFld-ContribAuthor ">Nadine  Rischert</span>, <span class="hlFld-ContribAuthor ">Olaf  Riess</span>, <span class="hlFld-ContribAuthor ">Petra  Hillmann</span>, <span class="hlFld-ContribAuthor ">Huu Phuc  Nguyen</span>. </span><span class="cited-content_cbyCitation_article-title">Brain-penetrant PQR620 mTOR and PQR530 PI3K/mTOR inhibitor reduce huntingtin levels in cell models of HD. </span><span class="cited-content_cbyCitation_journal-name">Neuropharmacology</span><span> <strong>2020,</strong> <em>162 </em>, 107812. <a href="https://doi.org/10.1016/j.neuropharm.2019.107812" title="DOI URL">https://doi.org/10.1016/j.neuropharm.2019.107812</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.neuropharm.2019.107812&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.neuropharm.2019.107812%26sid%3Dliteratum%253Aachs%26jtitle%3DNeuropharmacology%26atitle%3DBrain-penetrant%252BPQR620%252BmTOR%252Band%252BPQR530%252BPI3K%25252FmTOR%252Binhibitor%252Breduce%252Bhuntingtin%252Blevels%252Bin%252Bcell%252Bmodels%252Bof%252BHD%26aulast%3DSinger%26aufirst%3DElisabeth%26date%3D2020%26volume%3D162%26spage%3D107812" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Birthe  Gericke</span>, <span class="hlFld-ContribAuthor ">Claudia  Brandt</span>, <span class="hlFld-ContribAuthor ">Wiebke  Theilmann</span>, <span class="hlFld-ContribAuthor ">Lisa  Welzel</span>, <span class="hlFld-ContribAuthor ">Alina  Schidlitzki</span>, <span class="hlFld-ContribAuthor ">Friederike  Twele</span>, <span class="hlFld-ContribAuthor ">Edith  Kaczmarek</span>, <span class="hlFld-ContribAuthor ">Muneeb  Anjum</span>, <span class="hlFld-ContribAuthor ">Petra  Hillmann</span>, <span class="hlFld-ContribAuthor ">Wolfgang  Löscher</span>. </span><span class="cited-content_cbyCitation_article-title">Selective inhibition of mTORC1/2 or PI3K/mTORC1/2 signaling does not prevent or modify epilepsy in the intrahippocampal kainate mouse model. </span><span class="cited-content_cbyCitation_journal-name">Neuropharmacology</span><span> <strong>2020,</strong> <em>162 </em>, 107817. <a href="https://doi.org/10.1016/j.neuropharm.2019.107817" title="DOI URL">https://doi.org/10.1016/j.neuropharm.2019.107817</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.neuropharm.2019.107817&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.neuropharm.2019.107817%26sid%3Dliteratum%253Aachs%26jtitle%3DNeuropharmacology%26atitle%3DSelective%252Binhibition%252Bof%252BmTORC1%25252F2%252Bor%252BPI3K%25252FmTORC1%25252F2%252Bsignaling%252Bdoes%252Bnot%252Bprevent%252Bor%252Bmodify%252Bepilepsy%252Bin%252Bthe%252Bintrahippocampal%252Bkainate%252Bmouse%252Bmodel%26aulast%3DGericke%26aufirst%3DBirthe%26date%3D2020%26volume%3D162%26spage%3D107817" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Petra  Hillmann</span>, <span class="hlFld-ContribAuthor ">Doriano  Fabbro</span>. </span><span class="cited-content_cbyCitation_article-title">PI3K/mTOR Pathway Inhibition: Opportunities in Oncology and Rare Genetic Diseases. </span><span class="cited-content_cbyCitation_journal-name">International Journal of Molecular Sciences</span><span> <strong>2019,</strong> <em>20 </em>
                                    (22)
                                     , 5792. <a href="https://doi.org/10.3390/ijms20225792" title="DOI URL">https://doi.org/10.3390/ijms20225792</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/ijms20225792&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fijms20225792%26sid%3Dliteratum%253Aachs%26jtitle%3DInternational%2520Journal%2520of%2520Molecular%2520Sciences%26atitle%3DPI3K%25252FmTOR%252BPathway%252BInhibition%25253A%252BOpportunities%252Bin%252BOncology%252Band%252BRare%252BGenetic%252BDiseases%26aulast%3DHillmann%26aufirst%3DPetra%26date%3D2019%26date%3D2019%26volume%3D20%26issue%3D22%26spage%3D5792" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Chiara  Tarantelli</span>, <span class="hlFld-ContribAuthor ">Eugenio  Gaudio</span>, <span class="hlFld-ContribAuthor ">Petra  Hillmann</span>, <span class="hlFld-ContribAuthor ">Filippo  Spriano</span>, <span class="hlFld-ContribAuthor ">Giulio  Sartori</span>, <span class="hlFld-ContribAuthor ">Luca  Aresu</span>, <span class="hlFld-ContribAuthor ">Luciano  Cascione</span>, <span class="hlFld-ContribAuthor ">Denise  Rageot</span>, <span class="hlFld-ContribAuthor ">Ivo  Kwee</span>, <span class="hlFld-ContribAuthor ">Florent  Beaufils</span>, <span class="hlFld-ContribAuthor ">Emanuele  Zucca</span>, <span class="hlFld-ContribAuthor ">Anastasios  Stathis</span>, <span class="hlFld-ContribAuthor ">Matthias P.  Wymann</span>, <span class="hlFld-ContribAuthor ">Vladimir  Cmiljanovic</span>, <span class="hlFld-ContribAuthor ">Doriano  Fabbro</span>, <span class="hlFld-ContribAuthor ">Francesco  Bertoni</span>. </span><span class="cited-content_cbyCitation_article-title">The Novel TORC1/2 Kinase Inhibitor PQR620 Has Anti-Tumor Activity in Lymphomas as a Single Agent and in Combination with Venetoclax. </span><span class="cited-content_cbyCitation_journal-name">Cancers</span><span> <strong>2019,</strong> <em>11 </em>
                                    (6)
                                     , 775. <a href="https://doi.org/10.3390/cancers11060775" title="DOI URL">https://doi.org/10.3390/cancers11060775</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/cancers11060775&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fcancers11060775%26sid%3Dliteratum%253Aachs%26jtitle%3DCancers%26atitle%3DThe%252BNovel%252BTORC1%25252F2%252BKinase%252BInhibitor%252BPQR620%252BHas%252BAnti-Tumor%252BActivity%252Bin%252BLymphomas%252Bas%252Ba%252BSingle%252BAgent%252Band%252Bin%252BCombination%252Bwith%252BVenetoclax%26aulast%3DTarantelli%26aufirst%3DChiara%26date%3D2019%26date%3D2019%26volume%3D11%26issue%3D6%26spage%3D775" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Michele  Montaruli</span>, <span class="hlFld-ContribAuthor ">Domenico  Alberga</span>, <span class="hlFld-ContribAuthor ">Fulvio  Ciriaco</span>, <span class="hlFld-ContribAuthor ">Daniela  Trisciuzzi</span>, <span class="hlFld-ContribAuthor ">Anna Rita  Tondo</span>, <span class="hlFld-ContribAuthor ">Giuseppe Felice  Mangiatordi</span>, <span class="hlFld-ContribAuthor ">Orazio  Nicolotti</span>. </span><span class="cited-content_cbyCitation_article-title">Accelerating Drug Discovery by Early Protein Drug Target Prediction Based on a Multi-Fingerprint Similarity Search †. </span><span class="cited-content_cbyCitation_journal-name">Molecules</span><span> <strong>2019,</strong> <em>24 </em>
                                    (12)
                                     , 2233. <a href="https://doi.org/10.3390/molecules24122233" title="DOI URL">https://doi.org/10.3390/molecules24122233</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/molecules24122233&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fmolecules24122233%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecules%26atitle%3DAccelerating%252BDrug%252BDiscovery%252Bby%252BEarly%252BProtein%252BDrug%252BTarget%252BPrediction%252BBased%252Bon%252Ba%252BMulti-Fingerprint%252BSimilarity%252BSearch%252B%2525E2%252580%2525A0%26aulast%3DMontaruli%26aufirst%3DMichele%26date%3D2019%26date%3D2019%26volume%3D24%26issue%3D12%26spage%3D2233" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jeroen B. I.  Sap</span>, <span class="hlFld-ContribAuthor ">Thomas C.  Wilson</span>, <span class="hlFld-ContribAuthor ">Choon Wee  Kee</span>, <span class="hlFld-ContribAuthor ">Natan J. W.  Straathof</span>, <span class="hlFld-ContribAuthor ">Christopher W. am  Ende</span>, <span class="hlFld-ContribAuthor ">Paramita  Mukherjee</span>, <span class="hlFld-ContribAuthor ">Lei  Zhang</span>, <span class="hlFld-ContribAuthor ">Christophe  Genicot</span>, <span class="hlFld-ContribAuthor ">Véronique  Gouverneur</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis of
              18
              F-difluoromethylarenes using aryl boronic acids, ethyl bromofluoroacetate and [
              18
              F]fluoride. </span><span class="cited-content_cbyCitation_journal-name">Chemical Science</span><span> <strong>2019,</strong> <em>10 </em>
                                    (11)
                                     , 3237-3241. <a href="https://doi.org/10.1039/C8SC05096A" title="DOI URL">https://doi.org/10.1039/C8SC05096A</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C8SC05096A&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC8SC05096A%26sid%3Dliteratum%253Aachs%26jtitle%3DChemical%2520Science%26atitle%3DSynthesis%252Bof%252B18%252BF-difluoromethylarenes%252Busing%252Baryl%252Bboronic%252Bacids%25252C%252Bethyl%252Bbromofluoroacetate%252Band%252B%25255B%252B18%252BF%25255Dfluoride%26aulast%3DSap%26aufirst%3DJeroen%2BB.%2BI.%26date%3D2019%26date%3D2019%26volume%3D10%26issue%3D11%26spage%3D3237%26epage%3D3241" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b01262/20181119/images/medium/jm-2018-012622_0013.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b01262/20181119/images/large/jm-2018-012622_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01262&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b01262/20181119/images/medium/jm-2018-012622_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b01262/20181119/images/large/jm-2018-012622_0001.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Schematic design and optimization cascade leading to the mTOR kinase-selective ATP-binding site inhibitor PQR620 (<b>3</b>). Binding affinity for mTOR kinase was increased by the substitution of the trifluoromethyl group in PQR309 (<b>1</b>) with a difluoromethyl group in compound <b>2</b>. The introduction of substituted morpholino groups was then explored to reduce PI3K binding, resulting in PQR620 (<b>3</b>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b01262/20181119/images/large/jm-2018-012622_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01262&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b01262/20181119/images/medium/jm-2018-012622_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b01262/20181119/images/large/jm-2018-012622_0002.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Predicted interactions of compound <b>2</b> with the catalytic core of PI3Kγ (gray) and mTOR kinase (teal). Displayed are amino acids in close contact with the inhibitor; three-digit numbers refer to PI3Kγ, four-digit codes to mTOR kinase. Labeled spheres: N, nitrogen atom of the hinge region Val (882/2240); S, sulfur atom of Met804; F and H, difluoromethyl group. (A) One morpholine group (left) of <b>2</b> interacts with the nitrogen atom of the hinge region Val. Here the hydrogen atom of the difluoromethyl group is oriented to form an intramolecular interaction with the triazine core. (B) The hinge region valine interaction is oriented toward the back, and the hydrogen atom of the difluoromethyl group is well positioned to form an interaction with Glu2190 of mTOR. (A,B) Compound <b>2</b> in PI3Kγ was modeled based on a PQR309 (<b>1</b>)–PI3Kγ complex<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5OQ4">5OQ4</a>; resolution of 2.7 Å), and the mTOR–compound <b>2</b> complex was derived from a 3.6 Å resolution structure of PI103 bound to mTOR (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4JT6">4JT6</a>) by docking as described in ref <a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a>. A comparative listing of amino acid residues depicted here across PI3K isoforms can be found in Supporting Information, <a href="/doi/suppl/10.1021/acs.jmedchem.8b01262/suppl_file/jm8b01262_si_001.pdf" class="ext-link">Table S1</a>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b01262/20181119/images/large/jm-2018-012622_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01262&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b01262/20181119/images/medium/jm-2018-012622_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b01262/20181119/images/large/jm-2018-012622_0003.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Steric clashes of PQR620 (<b>3</b>) docked into PI3Kγ (light gray). Two opposite conformations of the ethylene bridges of the morpholines of PQR620 (<b>3</b>) that allow the morpholine oxygen to form a hydrogen bond with the hinge Val882 nitrogen (N) are shown. (A) In the “bridge-up” conformation, the ethylene bridge of PQR620 (<b>3</b>) (yellow) points toward Met953 and is flanked by a rigid part of PI3Kγ,<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> represented by Tyr867, Phe961, and Ile963 (colored in brown). (B) When the surface of PI3Kγ is depicted as a mesh and PQR620 (<b>3</b>) as space filling model (atom size set to 0.9 times of van der Waals radii), steric clashes become visible as penetrations of the PI3Kγ surface mesh. (C) In the “bridge-down” conformation (pink), steric clashes imposed by the ethylene bridges in PQR620 (<b>3</b>) occur with the backbone of Ile881 and Glu880 and side chains of Ile831 and Ile881. As for <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>, the models were derived from coordinates of a PQR309 (<b>1</b>)–PI3Kγ complex<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5OQ4">5OQ4</a>; resolution of 2.7 Å). A comparative listing of amino acid residues depicted here across PI3K isoforms can be found in Supporting Information, <a href="/doi/suppl/10.1021/acs.jmedchem.8b01262/suppl_file/jm8b01262_si_001.pdf" class="ext-link">Table S2</a>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b01262/20181119/images/large/jm-2018-012622_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01262&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b01262/20181119/images/medium/jm-2018-012622_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b01262/20181119/images/large/jm-2018-012622_0009.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of Trisubstituted Compounds with Triazine and Pyrimidine Core<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b01262/20181119/images/large/jm-2018-012622_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01262&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (i) morpholine derivative (<i>M</i><sub>n</sub>-H), DIPEA, EtOH, 0 °C → rt, o/n (for <b>37</b>–<b>39</b>); (ii) 2-aminopyridine-5-boronic acid pinacol ester or 2-amino-4-methyl-pyridine-5-boronic acid pinacol ester, Pd(dppf)Cl<sub>2</sub> (cat.), Na<sub>2</sub>CO<sub>3</sub>, 1,2-dimethoxyethane/H<sub>2</sub>O, 90 °C, 16 h (for <b>4</b>, <b>5</b>); (iii) (1) boronic ester <b>72</b>, Pd(OAc)<sub>2</sub>/PPh<sub>3</sub> (cat.), K<sub>2</sub>CO<sub>3</sub>, THF/H<sub>2</sub>O, 55 °C, 2 h, (2) HCl, H<sub>2</sub>O, 55 °C, 16 h (for PQR309); (iv) boronic ester <b>64</b>, XPhosPdG2 (cat.), K<sub>3</sub>PO<sub>4</sub>, dioxane/H<sub>2</sub>O, 95 °C, o/n (for <b>10</b>, <b>11</b>, <b>12</b>, <b>14</b>, <b>17</b>, <b>18</b>, <b>23</b>, <b>24</b>, PQR620); (v) boronic ester generated in situ, XPhosPdG2 (cat.), K<sub>3</sub>PO<sub>4</sub>, dioxane/H<sub>2</sub>O, 95 °C, 3.5 h, (2) TFA, CH<sub>2</sub>Cl<sub>2</sub>, add. at 0 °C, rt, 6 h (for <b>8</b>); (vi) (1) boronic ester <b>64</b> or <b>72</b> or boronic ester generated in situ, XPhosPdG2 (cat.), K<sub>3</sub>PO<sub>4</sub>, dioxane/H<sub>2</sub>O, 95 °C, 3–16 h, (2) HCl, dioxane/H<sub>2</sub>O, 60 °C, 3–16 h (for <b>2</b>, <b>6</b>, <b>7</b>, <b>13</b>, <b>15</b>, <b>16</b>, <b>19</b>–<b>22</b>, <b>25</b>, <b>26</b>, <b>28</b>, <b>30</b>–<b>34</b>; for <b>9</b> the reaction was carried out in ethanol at 80 °C); (vii) <i>M</i><sub>n</sub>-H, DIPEA, CH<sub>2</sub>Cl<sub>2</sub>, 0 °C → rt, o/n (for <b>41</b>–<b>47</b>, <b>52</b>, <b>53</b>, <b>55</b>); (viii) <i>M</i><sub>n</sub>-H, DIPEA, THF, add at 0 °C, 70 °C, o/n (for <b>48</b>–<b>51</b>, <b>54</b>); (ix) morpholine derivative (<i>M</i><sub>n</sub>-H), DIPEA, EtOH, Δ, o/n (for <b>57</b>–<b>60</b>); (x) (1) boronic ester <b>72</b>, Pd(OAc)<sub>2</sub>/PPh<sub>3</sub> (cat.), K<sub>2</sub>CO<sub>3</sub>, dioxane/H<sub>2</sub>O, 80 °C, 16 h, (2) HCl, H<sub>2</sub>O, 60 °C, 18 h (for BKM120, <b>29</b><a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a>).</p></p></figure><figure data-id="fig4" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b01262/20181119/images/medium/jm-2018-012622_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b01262/20181119/images/large/jm-2018-012622_0004.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Waterfall plot representing the potency of PQR620 (<b>3</b>) in a full NTRC (Netherlands Translational Research Center BV) Oncolines cell panel of 66 cancer cell lines. Concentrations of half-maximal growth inhibition (IC<sub>50</sub>) for PQR620 (<b>3</b>) were obtained from dose–response growth curves, and individual IC<sub>50</sub> values of a cell line was related to the mean IC<sub>50</sub> of all cells lines; cell lines were sorted by lowest to highest sensitivity for PQR620 (<b>3</b>) from left (SK-N-FI) to right (A-498). Individual cell lines and values (IC<sub>50</sub> and GI<sub>50</sub>) are given in Supporting Information, <a href="/doi/suppl/10.1021/acs.jmedchem.8b01262/suppl_file/jm8b01262_si_001.pdf" class="ext-link">Table S6</a>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b01262/20181119/images/large/jm-2018-012622_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01262&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b01262/20181119/images/medium/jm-2018-012622_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b01262/20181119/images/large/jm-2018-012622_0005.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Proliferation, cell cycle, and cellular signaling. A2058 (A) and SKOV3 (B) cells were exposed to indicated inhibitors for 72 h; cell numbers are shown as % of DMSO controls. The dashed line indicates cell numbers at <i>t</i> = 0 h, as % of cells of DMSO control at 72 h (<i>n</i> = 9, three independent experiments (ie); rapamycin and GDC0941 (<b>76</b>) <i>n</i> = 6; 2 ie; each data point measured at least in triplicate, mean ± SEM. Cell cycle distribution of (C) A2058 and (D) SKOV3 cells after 24 h exposure to (C) 5 μM or (D) 2 μM of drugs or DMSO. After Hoechst33342 staining, cell cycle profiles were determined by FACS. Quantification and statistics are provided in Supporting Information, <a href="/doi/suppl/10.1021/acs.jmedchem.8b01262/suppl_file/jm8b01262_si_001.pdf" class="ext-link">Figure S5</a>. (E) A2058 and (F) SKOV3 cells were incubated for 1 h with compounds and then subjected to in cell western detection of phosphorylation of PKB/Akt and S6. Phospho-protein signals are presented as % of DMSO controls (<i>n</i> = 3, mean ± SEM); immunoblots of phospho-PKB/Akt, S6, S6K, and 4E-BP1 are in Supporting Information, <a href="/doi/suppl/10.1021/acs.jmedchem.8b01262/suppl_file/jm8b01262_si_001.pdf" class="ext-link">Figure S5</a>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b01262/20181119/images/large/jm-2018-012622_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01262&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b01262/20181119/images/medium/jm-2018-012622_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b01262/20181119/images/large/jm-2018-012622_0006.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. PK and PD in female Sprague–Dawley rats (left panels) and male C57BL/6JRj mice (right panels). (A,B) Plasma and brain levels (broken lines) of indicated drugs determined after a single dose po of 10 mg/kg in rats, and 50 mg/kg in mice.* (C,D) Brain/plasma ratio over time calculated from values above. Plasma (E,F) insulin and (G,H) glucose levels measured in animals above. All experiments depicted as mean ± SEM (<i>n</i> = 3); error bars are omitted where smaller than symbols. *PQR620 data in (B) was compared to rapamycin and everolimus in ref <a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b01262/20181119/images/large/jm-2018-012622_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01262&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b01262/20181119/images/medium/jm-2018-012622_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b01262/20181119/images/large/jm-2018-012622_0007.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. OVCAR-3 human ovarian cancer xenograft model in BALB/c nude mice: tumor cells were subcutaneously inoculated at day 0, and daily oral application of the indicated agents was started at day 17 (28 × QD). (A) Body weight was determined at the depicted time points. Body weight loss of >10% was observed in one mouse (of 8) in the PQR620 (<b>3</b>) treatment group. (B) The tumor size was measured and calculated as described in the <a class="ref internalNav" href="#sec4" aria-label="Experimental Section">Experimental Section</a>. (C) The tumor weight was determined at day 45 after inoculation. Statistics: (*<i>p</i> < 0.05; <sup>$</sup><i>p</i> < 0.001; <sup>$$</sup><i>p</i> < 0.0001; <i>n</i> = 8; (A,B) Two-Way ANOVA with Bonferroni or Dunnett’s correction for multicomparisons, mean ± SEM; (C) mean ± SD, One-Way ANOVA with Tukey’s correction for multicomparisons.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b01262/20181119/images/large/jm-2018-012622_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01262&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig8" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b01262/20181119/images/medium/jm-2018-012622_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b01262/20181119/images/large/jm-2018-012622_0008.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Effects of mTOR and PI3K inhibition on frequency of electrographic seizures caused by neuron-specific elimination of TSC1.<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a> (A) Tsc1<sup>GFAP</sup> conditional knockout mice were treated from postnatal days 21–53 with vehicle, PQR620 (<b>3</b>) (100 mg/kg), or PQR309 (<b>1</b>) (50 mg/kg). In three observation intervals, EEG traces were recorded, and the number of seizures were determined (depicted as seizure count/48 h; mean ± SEM, <i>n</i> = 30–48. Two-Way ANOVA test with Dunnet’s multiple comparison related to vehicle control; *<i>p</i> = 0.032; **<i>p</i> = 0.0021; ***<i>p</i> = 0.0002). (B) Body weights averaged over the whole observation time in the three treatment groups (mean ± SEM, <i>n</i> ≥ 13).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-22/acs.jmedchem.8b01262/20181119/images/large/jm-2018-012622_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01262&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i121">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_27705" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_27705" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 35 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wymann, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schneiter, R.</span></span> <span> </span><span class="NLM_article-title">Lipid signalling in disease</span>. <i>Nat. Rev. Mol. Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">162</span>– <span class="NLM_lpage">176</span>, <span class="refDoi"> DOI: 10.1038/nrm2335</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01262&amp;key=10.1038%2Fnrm2335" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01262&amp;key=18216772" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01262&amp;key=1%3ACAS%3A528%3ADC%252BD1cXovFOgug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2008&pages=162-176&author=M.+P.+Wymannauthor=R.+Schneiter&title=Lipid+signalling+in+disease&doi=10.1038%2Fnrm2335"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Lipid signalling in disease</span></div><div class="casAuthors">Wymann, Matthias P.; Schneiter, Roger</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Molecular Cell Biology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">162-176</span>CODEN:
                <span class="NLM_cas:coden">NRMCBP</span>;
        ISSN:<span class="NLM_cas:issn">1471-0072</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Signaling lipids such as eicosanoids, phosphoinositides, sphingolipids and fatty acids control important cellular processes, including cell proliferation, apoptosis, metab. and migration.  Extracellular signals from cytokines, growth factors and nutrients control the activity of a key set of lipid-modifying enzymes: phospholipases, prostaglandin synthase, 5-lipoxygenase, phosphoinositide 3-kinase, sphingosine kinase and sphingomyelinase.  These enzymes and their downstream targets constitute a complex lipid signaling network with multiple nodes of interaction and cross-regulation.  Imbalances in this network contribute to the pathogenesis of human disease.  Although the function of a particular signaling lipid is traditionally studied in isolation, this review attempts a more integrated overview of the key role of these signaling lipids in inflammation, cancer and metabolic disease, and discusses emerging strategies for therapeutic intervention.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrZYZ1NX2T9QbVg90H21EOLACvtfcHk0ljQjnMswhvoVw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXovFOgug%253D%253D&md5=c96aabfdfa8e93c9e98386f1a407de85</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1038%2Fnrm2335&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrm2335%26sid%3Dliteratum%253Aachs%26aulast%3DWymann%26aufirst%3DM.%2BP.%26aulast%3DSchneiter%26aufirst%3DR.%26atitle%3DLipid%2520signalling%2520in%2520disease%26jtitle%3DNat.%2520Rev.%2520Mol.%2520Cell%2520Biol.%26date%3D2008%26volume%3D9%26spage%3D162%26epage%3D176%26doi%3D10.1038%2Fnrm2335" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit1b"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rudge, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koos, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vaidialingam, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pavletich, N. P.</span></span> <span> </span><span class="NLM_article-title">mTOR kinase structure, mechanism and regulation</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>497</i></span>,  <span class="NLM_fpage">217</span>– <span class="NLM_lpage">223</span>, <span class="refDoi"> DOI: 10.1038/nature12122</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01262&amp;key=10.1038%2Fnature12122" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01262&amp;key=23636326" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01262&amp;key=1%3ACAS%3A528%3ADC%252BC3sXmvFyns7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=497&publication_year=2013&pages=217-223&author=H.+Yangauthor=D.+G.+Rudgeauthor=J.+D.+Koosauthor=B.+Vaidialingamauthor=H.+J.+Yangauthor=N.+P.+Pavletich&title=mTOR+kinase+structure%2C+mechanism+and+regulation&doi=10.1038%2Fnature12122"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1bR"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">mTOR kinase structure, mechanism and regulation</span></div><div class="casAuthors">Yang, Haijuan; Rudge, Derek G.; Koos, Joseph D.; Vaidialingam, Bhamini; Yang, Hyo J.; Pavletich, Nikola P.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">497</span>
        (<span class="NLM_cas:issue">7448</span>),
    <span class="NLM_cas:pages">217-223</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The mammalian target of rapamycin (mTOR), a phosphoinositide 3-kinase-related protein kinase, controls cell growth in response to nutrients and growth factors and is frequently deregulated in cancer.  Here we report co-crystal structures of a complex of truncated mTOR and mammalian lethal with SEC13 protein 8 (mLST8) with an ATP transition state mimic (MgF3-) and with ATP-site inhibitors (Torin2, PP242, and PI-103).  The structures reveal an intrinsically active kinase conformation, with catalytic residues and a catalytic mechanism remarkably similar to canonical protein kinases.  The active site is highly recessed owing to the FKBP12-rapamycin-binding (FRB) domain and an inhibitory helix protruding from the catalytic cleft.  MTOR-activating mutations map to the structural framework that holds these elements in place, indicating that the kinase is controlled by restricted access.  In vitro biochem. shows that the FRB domain acts as a gatekeeper, with its rapamycin-binding site interacting with substrates to grant them access to the restricted active site.  Rapamycin-FKBP12 inhibits the kinase by directly blocking substrate recruitment and by further restricting active-site access.  The structures also reveal active-site residues and conformational changes that underlie inhibitor potency and specificity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrjvPQtdm6yCbVg90H21EOLACvtfcHk0lgpZoayUidhFg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXmvFyns7k%253D&md5=07809555fbdf2004819a7f2da5727baf</span></div><a href="/servlet/linkout?suffix=cit1b&amp;dbid=16384&amp;doi=10.1038%2Fnature12122&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature12122%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DH.%26aulast%3DRudge%26aufirst%3DD.%2BG.%26aulast%3DKoos%26aufirst%3DJ.%2BD.%26aulast%3DVaidialingam%26aufirst%3DB.%26aulast%3DYang%26aufirst%3DH.%2BJ.%26aulast%3DPavletich%26aufirst%3DN.%2BP.%26atitle%3DmTOR%2520kinase%2520structure%252C%2520mechanism%2520and%2520regulation%26jtitle%3DNature%26date%3D2013%26volume%3D497%26spage%3D217%26epage%3D223%26doi%3D10.1038%2Fnature12122" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit1c"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shimobayashi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hall, M. N.</span></span> <span> </span><span class="NLM_article-title">Making new contacts: the mTOR network in metabolism and signalling crosstalk</span>. <i>Nat. Rev. Mol. Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">155</span>– <span class="NLM_lpage">162</span>, <span class="refDoi"> DOI: 10.1038/nrm3757</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01262&amp;key=10.1038%2Fnrm3757" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01262&amp;key=24556838" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01262&amp;key=1%3ACAS%3A528%3ADC%252BC2cXivFagtrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2014&pages=155-162&author=M.+Shimobayashiauthor=M.+N.+Hall&title=Making+new+contacts%3A+the+mTOR+network+in+metabolism+and+signalling+crosstalk&doi=10.1038%2Fnrm3757"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1cR"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Making new contacts: the mTOR network in metabolism and signaling crosstalk</span></div><div class="casAuthors">Shimobayashi, Mitsugu; Hall, Michael N.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Molecular Cell Biology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">155-162</span>CODEN:
                <span class="NLM_cas:coden">NRMCBP</span>;
        ISSN:<span class="NLM_cas:issn">1471-0072</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  More than 20 yr after its discovery, the understanding of target of rapamycin (TOR) signaling continues to grow.  Recent global 'omics' studies have revealed physiol. roles of mammalian TOR (mTOR) in protein, nucleotide, and lipid synthesis.  Furthermore, emerging evidence provides new insight into the control of mTOR by other pathways such as Hippo, Wnt, and Notch signaling.  Together, this progress has expanded the list of downstream effectors and upstream regulators of mTOR signaling.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr5vMA8Y0_Pe7Vg90H21EOLACvtfcHk0lgpZoayUidhFg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXivFagtrk%253D&md5=4dd29cf176c3de7a5cb0fd6b03600a6b</span></div><a href="/servlet/linkout?suffix=cit1c&amp;dbid=16384&amp;doi=10.1038%2Fnrm3757&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrm3757%26sid%3Dliteratum%253Aachs%26aulast%3DShimobayashi%26aufirst%3DM.%26aulast%3DHall%26aufirst%3DM.%2BN.%26atitle%3DMaking%2520new%2520contacts%253A%2520the%2520mTOR%2520network%2520in%2520metabolism%2520and%2520signalling%2520crosstalk%26jtitle%3DNat.%2520Rev.%2520Mol.%2520Cell%2520Biol.%26date%3D2014%26volume%3D15%26spage%3D155%26epage%3D162%26doi%3D10.1038%2Fnrm3757" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit1d"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Saxton, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sabatini, D. M.</span></span> <span> </span><span class="NLM_article-title">mTOR signaling in growth, metabolism, and disease</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>168</i></span>,  <span class="NLM_fpage">960</span>– <span class="NLM_lpage">976</span>, <span class="refDoi"> DOI: 10.1016/j.cell.2017.02.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1d&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01262&amp;key=10.1016%2Fj.cell.2017.02.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1d&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01262&amp;key=28283069" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1d&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01262&amp;key=1%3ACAS%3A528%3ADC%252BC2sXkt1Ogtb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=168&publication_year=2017&pages=960-976&author=R.+A.+Saxtonauthor=D.+M.+Sabatini&title=mTOR+signaling+in+growth%2C+metabolism%2C+and+disease&doi=10.1016%2Fj.cell.2017.02.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1dR"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">mTOR signaling in growth, metabolism, and disease</span></div><div class="casAuthors">Saxton, Robert A.; Sabatini, David M.</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">168</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">960-976</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">A review.  The mechanistic target of rapamycin (mTOR) coordinates eukaryotic cell growth and metab. with environmental inputs, including nutrients and growth factors.  Extensive research over the past two decades has established a central role for mTOR in regulating many fundamental cell processes, from protein synthesis to autophagy, and deregulated mTOR signaling is implicated in the progression of cancer and diabetes, as well as the aging process.  Here, we review recent advances in our understanding of mTOR function, regulation, and importance in mammalian physiol.  We also highlight how the mTOR signaling network contributes to human disease and discuss the current and future prospects for therapeutically targeting mTOR in the clinic.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpvvk5jg6e_MrVg90H21EOLACvtfcHk0lgT5Cy4w9-KGA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXkt1Ogtb4%253D&md5=3fdee3d04bf88d3aafc532d4e2f1e2dc</span></div><a href="/servlet/linkout?suffix=cit1d&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2017.02.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2017.02.004%26sid%3Dliteratum%253Aachs%26aulast%3DSaxton%26aufirst%3DR.%2BA.%26aulast%3DSabatini%26aufirst%3DD.%2BM.%26atitle%3DmTOR%2520signaling%2520in%2520growth%252C%2520metabolism%252C%2520and%2520disease%26jtitle%3DCell%26date%3D2017%26volume%3D168%26spage%3D960%26epage%3D976%26doi%3D10.1016%2Fj.cell.2017.02.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Laplante, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sabatini, D. M.</span></span> <span> </span><span class="NLM_article-title">mTOR signaling in growth control and disease</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>149</i></span>,  <span class="NLM_fpage">274</span>– <span class="NLM_lpage">293</span>, <span class="refDoi"> DOI: 10.1016/j.cell.2012.03.017</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01262&amp;key=10.1016%2Fj.cell.2012.03.017" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01262&amp;key=22500797" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01262&amp;key=1%3ACAS%3A528%3ADC%252BC38Xls1eguro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=149&publication_year=2012&pages=274-293&author=M.+Laplanteauthor=D.+M.+Sabatini&title=mTOR+signaling+in+growth+control+and+disease&doi=10.1016%2Fj.cell.2012.03.017"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">mTOR signaling in growth control and disease</span></div><div class="casAuthors">Laplante, Mathieu; Sabatini, David M.</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">149</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">274-293</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">A review.  The mechanistic target of rapamycin (mTOR) signaling pathway senses and integrates a variety of environmental cues to regulate organismal growth and homeostasis.  The pathway regulates many major cellular processes and is implicated in an increasing no. of pathol. conditions, including cancer, obesity, type 2 diabetes, and neurodegeneration.  Here, we review recent advances in our understanding of the mTOR pathway and its role in health, disease, and aging.  We further discuss pharmacol. approaches to treat human pathologies linked to mTOR deregulation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqjbKBX-sScfrVg90H21EOLACvtfcHk0lgT5Cy4w9-KGA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xls1eguro%253D&md5=d1adac8ec64da63358e0af26a17ceb4e</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2012.03.017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2012.03.017%26sid%3Dliteratum%253Aachs%26aulast%3DLaplante%26aufirst%3DM.%26aulast%3DSabatini%26aufirst%3DD.%2BM.%26atitle%3DmTOR%2520signaling%2520in%2520growth%2520control%2520and%2520disease%26jtitle%3DCell%26date%3D2012%26volume%3D149%26spage%3D274%26epage%3D293%26doi%3D10.1016%2Fj.cell.2012.03.017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sarbassov, D. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guertin, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ali, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sabatini, D. M.</span></span> <span> </span><span class="NLM_article-title">Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>307</i></span>,  <span class="NLM_fpage">1098</span>– <span class="NLM_lpage">1101</span>, <span class="refDoi"> DOI: 10.1126/science.1106148</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01262&amp;key=10.1126%2Fscience.1106148" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01262&amp;key=15718470" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01262&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtlSrtbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=307&publication_year=2005&pages=1098-1101&author=D.+D.+Sarbassovauthor=D.+A.+Guertinauthor=S.+M.+Aliauthor=D.+M.+Sabatini&title=Phosphorylation+and+regulation+of+Akt%2FPKB+by+the+rictor-mTOR+complex&doi=10.1126%2Fscience.1106148"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Phosphorylation and Regulation of Akt/PKB by the Rictor-mTOR Complex</span></div><div class="casAuthors">Sarbassov, Dos D.; Guertin, David A.; Ali, Siraj M.; Sabatini, David M.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">307</span>
        (<span class="NLM_cas:issue">5712</span>),
    <span class="NLM_cas:pages">1098-1101</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Deregulation of Akt/protein kinase B (PKB) is implicated in the pathogenesis of cancer and diabetes.  Akt/PKB activation requires the phosphorylation of Thr308 in the activation loop by the phosphoinositide-dependent kinase 1 (PDK1) and Ser473 within the carboxyl-terminal hydrophobic motif by an unknown kinase.  We show that in Drosophila and human cells the target of rapamycin (TOR) kinase and its assocd. protein rictor are necessary for Ser473 phosphorylation and that a redn. in rictor or mammalian TOR (mTOR) expression inhibited an Akt/PKB effector.  The rictor-mTOR complex directly phosphorylated Akt/PKB on Ser473 in vitro and facilitated Thr308 phosphorylation by PDK1.  Rictor-mTOR may serve as a drug target in tumors that have lost the expression of PTEN, a tumor suppressor that opposes Akt/PKB activation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqfO1KyVE3glrVg90H21EOLACvtfcHk0lgT5Cy4w9-KGA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtlSrtbY%253D&md5=de758fd8128561e34301e67a42ae13a6</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1126%2Fscience.1106148&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1106148%26sid%3Dliteratum%253Aachs%26aulast%3DSarbassov%26aufirst%3DD.%2BD.%26aulast%3DGuertin%26aufirst%3DD.%2BA.%26aulast%3DAli%26aufirst%3DS.%2BM.%26aulast%3DSabatini%26aufirst%3DD.%2BM.%26atitle%3DPhosphorylation%2520and%2520regulation%2520of%2520Akt%252FPKB%2520by%2520the%2520rictor-mTOR%2520complex%26jtitle%3DScience%26date%3D2005%26volume%3D307%26spage%3D1098%26epage%3D1101%26doi%3D10.1126%2Fscience.1106148" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gan, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chin, Y. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ogura, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blenis, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cantley, L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toker, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, W.</span></span> <span> </span><span class="NLM_article-title">PtdIns(3,4,5)P3-dependent activation of the mTORC2 kinase complex</span>. <i>Cancer Discovery</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">1194</span>– <span class="NLM_lpage">1209</span>, <span class="refDoi"> DOI: 10.1158/2159-8290.CD-15-0460</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01262&amp;key=10.1158%2F2159-8290.CD-15-0460" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2015&pages=1194-1209&author=P.+Liuauthor=W.+Ganauthor=Y.+R.+Chinauthor=K.+Oguraauthor=J.+Guoauthor=J.+Zhangauthor=B.+Wangauthor=J.+Blenisauthor=L.+C.+Cantleyauthor=A.+Tokerauthor=B.+Suauthor=W.+Wei&title=PtdIns%283%2C4%2C5%29P3-dependent+activation+of+the+mTORC2+kinase+complex&doi=10.1158%2F2159-8290.CD-15-0460"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1158%2F2159-8290.CD-15-0460&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2159-8290.CD-15-0460%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DP.%26aulast%3DGan%26aufirst%3DW.%26aulast%3DChin%26aufirst%3DY.%2BR.%26aulast%3DOgura%26aufirst%3DK.%26aulast%3DGuo%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DB.%26aulast%3DBlenis%26aufirst%3DJ.%26aulast%3DCantley%26aufirst%3DL.%2BC.%26aulast%3DToker%26aufirst%3DA.%26aulast%3DSu%26aufirst%3DB.%26aulast%3DWei%26aufirst%3DW.%26atitle%3DPtdIns%25283%252C4%252C5%2529P3-dependent%2520activation%2520of%2520the%2520mTORC2%2520kinase%2520complex%26jtitle%3DCancer%2520Discovery%26date%3D2015%26volume%3D5%26spage%3D1194%26epage%3D1209%26doi%3D10.1158%2F2159-8290.CD-15-0460" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Benjamin, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colombi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moroni, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hall, M. N.</span></span> <span> </span><span class="NLM_article-title">Rapamycin passes the torch: a new generation of mTOR inhibitors</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">868</span>– <span class="NLM_lpage">880</span>, <span class="refDoi"> DOI: 10.1038/nrd3531</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01262&amp;key=10.1038%2Fnrd3531" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01262&amp;key=22037041" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01262&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtlyis7vI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2011&pages=868-880&author=D.+Benjaminauthor=M.+Colombiauthor=C.+Moroniauthor=M.+N.+Hall&title=Rapamycin+passes+the+torch%3A+a+new+generation+of+mTOR+inhibitors&doi=10.1038%2Fnrd3531"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Rapamycin passes the torch: a new generation of mTOR inhibitors</span></div><div class="casAuthors">Benjamin, Don; Colombi, Marco; Moroni, Christoph; Hall, Michael N.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">868-880</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Mammalian target of rapamycin (mTOR) is an atypical protein kinase that controls growth and metab. in response to nutrients, growth factors and cellular energy levels, and it is frequently dysregulated in cancer and metabolic disorders.  Rapamycin is an allosteric inhibitor of mTOR, and was approved as an immuno-suppressant in 1999.  In recent years, interest has focused on its potential as an anticancer drug.  However, the performance of rapamycin and its analogs (rapalogues) has been undistinguished despite isolated successes in subsets of cancer, suggesting that the full therapeutic potential of targeting mTOR has yet to be exploited.  A new generation of ATP-competitive inhibitors that directly target the mTOR catalytic site display potent and comprehensive mTOR inhibition and are in early clin. trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqTizwX9wDprrVg90H21EOLACvtfcHk0lg46QUmSCZ3rw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtlyis7vI&md5=a909649a82f3a2ce11c6b8fee78fa69e</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1038%2Fnrd3531&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd3531%26sid%3Dliteratum%253Aachs%26aulast%3DBenjamin%26aufirst%3DD.%26aulast%3DColombi%26aufirst%3DM.%26aulast%3DMoroni%26aufirst%3DC.%26aulast%3DHall%26aufirst%3DM.%2BN.%26atitle%3DRapamycin%2520passes%2520the%2520torch%253A%2520a%2520new%2520generation%2520of%2520mTOR%2520inhibitors%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2011%26volume%3D10%26spage%3D868%26epage%3D880%26doi%3D10.1038%2Fnrd3531" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Choi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schreiber, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clardy, J.</span></span> <span> </span><span class="NLM_article-title">Structure of the FKBP12-rapamycin complex interacting with the binding domain of human FRAP</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>273</i></span>,  <span class="NLM_fpage">239</span>– <span class="NLM_lpage">242</span>, <span class="refDoi"> DOI: 10.1126/science.273.5272.239</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01262&amp;key=10.1126%2Fscience.273.5272.239" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01262&amp;key=8662507" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01262&amp;key=1%3ACAS%3A528%3ADyaK28Xkt1Crs7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=273&publication_year=1996&pages=239-242&author=J.+Choiauthor=J.+Chenauthor=S.+L.+Schreiberauthor=J.+Clardy&title=Structure+of+the+FKBP12-rapamycin+complex+interacting+with+the+binding+domain+of+human+FRAP&doi=10.1126%2Fscience.273.5272.239"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Structure of the FKBP12-rapamycin complex interacting with the binding domain of human FRAP</span></div><div class="casAuthors">Choi, Jungwon; Chen, Jie; Schreiber, Stuart L.; Clardy, Jon</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, D. C.)</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">273</span>
        (<span class="NLM_cas:issue">5272</span>),
    <span class="NLM_cas:pages">239-242</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Rapamycin, a potent immunosuppressive agent, binds two proteins: the FK506-binding protein (FKBP12) and the FKBP-rapamycin-assocd. protein (FRAP).  A crystal structure of the ternary complex of human FKBP12, rapamycin, and the FKBP12-rapamycin-binding (FRB) domain of human FRAP at a resoln. of 2.7 angstroms revealed the two proteins bound together as a result of the ability of rapamycin to occupy two different hydrophobic binding pockets simultaneously.  The structure shows extensive interactions between rapamycin and both proteins, but fewer interactions between the proteins.  The structure of the FRB domain of FRAP clarifies both rapamycin-independent and -dependent effects obsd. for mutants of FRAP and its homologs in the family of proteins related to the ataxia-telangiectasis mutant gene product, and it illustrates how a small cell-permeable mol. can mediate protein dimerization.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqwBLM2PsItYLVg90H21EOLACvtfcHk0lj5FIGsPc0K5A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28Xkt1Crs7k%253D&md5=c72a82e14c09d9a705215b4ac0525336</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1126%2Fscience.273.5272.239&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.273.5272.239%26sid%3Dliteratum%253Aachs%26aulast%3DChoi%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DSchreiber%26aufirst%3DS.%2BL.%26aulast%3DClardy%26aufirst%3DJ.%26atitle%3DStructure%2520of%2520the%2520FKBP12-rapamycin%2520complex%2520interacting%2520with%2520the%2520binding%2520domain%2520of%2520human%2520FRAP%26jtitle%3DScience%26date%3D1996%26volume%3D273%26spage%3D239%26epage%3D242%26doi%3D10.1126%2Fscience.273.5272.239" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7a"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Eisen, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tuzcu, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dorent, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kobashigawa, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mancini, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valantine-von Kaeppler, H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Starling, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sorensen, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hummel, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lind, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abeywickrama, K. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bernhardt, P.</span></span> <span> </span><span class="NLM_article-title">Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>349</i></span>,  <span class="NLM_fpage">847</span>– <span class="NLM_lpage">858</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa022171</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01262&amp;key=10.1056%2FNEJMoa022171" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01262&amp;key=12944570" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01262&amp;key=1%3ACAS%3A528%3ADC%252BD3sXmvVSntrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=349&publication_year=2003&pages=847-858&author=H.+J.+Eisenauthor=E.+M.+Tuzcuauthor=R.+Dorentauthor=J.+Kobashigawaauthor=D.+Manciniauthor=H.+A.+Valantine-von+Kaepplerauthor=R.+C.+Starlingauthor=K.+Sorensenauthor=M.+Hummelauthor=J.+M.+Lindauthor=K.+H.+Abeywickramaauthor=P.+Bernhardt&title=Everolimus+for+the+prevention+of+allograft+rejection+and+vasculopathy+in+cardiac-transplant+recipients&doi=10.1056%2FNEJMoa022171"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7aR"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients</span></div><div class="casAuthors">Eisen, Howard J.; Tuzcu, E. Murat; Dorent, Richard; Kobashigawa, Jon; Mancini, Donna; Valantine-von Kaeppler, Hannah A.; Starling, Randall C.; Sorensen, Keld; Hummel, Manfred; Lind, Joan M.; Abeywickrama, Kamal H.; Bernhardt, Peter; Bernhardt, P.; Abeywickrama, K. H.; Lind, J.; Cretin, N.; Le Breton, S.; Kabir, J.; Murphy, J.; Laupacis, A.; Wells, G. A.; Mills, R.; Parry, G.; Tuzcu, E. M.; Nissen, S. E.; Schoenhagen, P.; Crowe, T.; Magyar, W.; Caughlin, J.; Shalling, P.; Werle, C.; Carrier, M.; Normandin, D.; Vezina, J.; Masters, R.; Davies, R.; Ross, H.; Cardella, C.; Delgado, D.; O'Grady, C.; Haddad, H.; Howlett, J.; Hirsch, G.; Kells, C.; O'Neill, B. J.; Giddens, K.; Perrone, S. V.; Favaloro, L.; Favaloro, R.; Kapplinsky, E.; Natello, A.; Grimm, M.; Laufer, G.; Wieselthaler, G.; Zuckermann, A.; Deviatko, E.; Vanhaecke, J.; Van Cleemput, J.; Droogne, W.; Strijckmans, A.; Goenen, M.; Timmermans, T.; Wellens, F.; Goethals, M.; Tack, W.; Kiowski, W.; Oechslin, E.; Brunner, H.; Schindler, R.; Haverich, A.; Pethig, K.; Bara, C.; Scheibner, I.; Hetzer, R.; Hummel, M.; Kapell, S.; Wenzel, E.; Soerensen, K.; Moelgaard, H.; Egeblad, H.; Nielsen-Kudsk, J. E.; Eiskjaer, H.; Tram, E.-M.; Arizon, J. M.; Concha, M.; Valles, F.; Granados, A. L.; Crespo, M. G.; Paniangua-Martin, M. J.; Tabuyo, T.; Juffe, A.; Rodriguez, J. A.; Pulpon, L. A.; Segovia, J.; Gandjbakhch, I.; Dorent, R.; Leger, P.; Levasseur, J.-P.; Vaissier, E.; De Lentdecker, P.; Dreyfus, G.; Dureau, G.; Boissonat, P.; Sebbag, L.; Roussouliere, A.; Parameshwar, J.; Schofield, P.; Steel, L.; Beresford, V.; Yonan, N.; Martyszczuk, R.; Reader, J.; Frigerio, M.; Masciocco, G.; Grassi, M.; Garbellini, M.; Oliva, F.; Vigano, M.; Pellegrini, C.; Rinaldi, M.; D'Armini, A. M.; Casarotto, D.; Cambino, A.; Luca, T.; Feltrin, G.; Gerosa, G.; Fiocchi, R.; Gamba, A.; Mammana, C.; Iamele, L.; Guagliomi, G.; Faggian, G.; Mazzucco, A.; Forni, A.; Simonsen, S.; Geiran, O.; Relbo, A.; Grov, I.; Garlicki, M.; Kao, W.; Downer, C.; Eisen, H. J.; Furukawa, S.; Rubin, S.; Berman, G. O.; Margulies, K. B.; Mather, P.; Wald, J.; Garcia, J.; Levelle, L.; Wong, J.; Hill, J.; Aranda, J.; Leach, D.; Ebling, A.; Kobashigawa, J.; Chait, J.; Wang, E.; Cole, B.; Patel, J.; Moriguchi, J.; Laks, H.; Tobis, J.; Espejo, M.; Mancini, D.; Cordisco, M. E.; Donchez, L.; Frazier, O. H.; Connelly, J. H.; Thomas, C. D.; Renlund, D.; Moore, S. A.; Taylor, D.; Kfoury, A. G.; Campbell, B.; Eidson, M.; Smith, A.; Book, W.; Snell, G.; Valantine-von Kaeppler, H. A.; Woodman, K.; Kari, K.; Majem, R.; Parekh, H.; Weishaar, D.; Trammell, J.; Smart, F.; Bowers, S.; Starling, R. C.; Gus, B.; Young, J. B.; McCarthy, P.; James, K.; McCurry, K.; Zaldonis, D.; Benza, R.; Rayburn, B.; Bourge, R.; Aaronson, K.; Pagani, F. D.; Koelling, T. M.; Dyke, D. B.; Baliga, R.; McLean, D.; Hauptman, P. J.; Rawlings, M.; Jarcho, J.; Symko, B.; Miller, L. W.; Schaefer, K. K.; Hare, J.; Kasper, E.; Lindenfeld, J.; Clegg, L.; Love, R. B.; Jacobs, L.; Davis, S. F.; Thole, P. A.; Goldberg, L. R.; Chambers, S.; Twomey, C.; Dec, G. W.; Cocca-Spoffard, D.; Camuso, J.; Hosenpud, J.; Tector, A. J.; Courch, J.; Hudson, D.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">349</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">847-858</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Background: Everolimus, a novel proliferation inhibitor and immunosuppressive agent, may suppress cardiac-allograft vasculopathy.  We conducted a randomized, double-blind, clin. trial comparing everolimus with azathioprine in recipients of a first heart transplant.  Methods: A total of 634 patients were randomly assigned to receive 1.5 mg of everolimus per day (209 patients), 3.0 mg of everolimus per day (211 patients), or 1.0 to 3.0 mg of azathioprine per kg of body wt. per day (214 patients), in combination with cyclosporine, corticosteroids, and statins.  The primary efficacy end point was a composite of death, graft loss or retransplantation, loss to follow-up, biopsy-proved acute rejection of grade 3A, or rejection with hemodynamic compromise.  Results: At six months, the percentage of patients who had reached the primary efficacy end point was significantly smaller in the group given 3.0 mg of everolimus (27.0 %, P<0.001) and the group given 1.5 mg of everolimus (36.4 %, P=0.03) than in the azathioprine group (46.7 %).  Intravascular ultrasonog. showed that the av. increase in maximal intimal thickness 12 mo after transplantation was significantly smaller in the two everolimus groups than in the azathioprine group.  The incidence of vasculopathy was also significantly lower in the 1.5-mg group (35.7 %, P=0.045) and the 3.0-mg group (30.4 %, P=0.01) than in the azathioprine group (52.8 %).  The rates of cytomegalovirus infection were significantly lower in the 1.5-mg group (7.7 %, P<0.001) and the 3.0-mg group (7.6 %, P<0.001) than in the azathioprine group (21.5 %).  Rates of bacterial infection were significantly higher in the 3.0-mg group than in the azathioprine group.  Serum creatinine levels were also significantly higher in the two everolimus groups than in the azathioprine group.  Conclusions: Everolimus was more efficacious than azathioprine in reducing the severity and incidence of cardiac-allograft vasculopathy, suggesting that everolimus therapy may alleviate this serious problem.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrvK3FiFj8DlrVg90H21EOLACvtfcHk0lj5FIGsPc0K5A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXmvVSntrc%253D&md5=f8f5cec33d3070c8806cdd2cfd3b7ede</span></div><a href="/servlet/linkout?suffix=cit7a&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa022171&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa022171%26sid%3Dliteratum%253Aachs%26aulast%3DEisen%26aufirst%3DH.%2BJ.%26aulast%3DTuzcu%26aufirst%3DE.%2BM.%26aulast%3DDorent%26aufirst%3DR.%26aulast%3DKobashigawa%26aufirst%3DJ.%26aulast%3DMancini%26aufirst%3DD.%26aulast%3DValantine-von%2BKaeppler%26aufirst%3DH.%2BA.%26aulast%3DStarling%26aufirst%3DR.%2BC.%26aulast%3DSorensen%26aufirst%3DK.%26aulast%3DHummel%26aufirst%3DM.%26aulast%3DLind%26aufirst%3DJ.%2BM.%26aulast%3DAbeywickrama%26aufirst%3DK.%2BH.%26aulast%3DBernhardt%26aufirst%3DP.%26atitle%3DEverolimus%2520for%2520the%2520prevention%2520of%2520allograft%2520rejection%2520and%2520vasculopathy%2520in%2520cardiac-transplant%2520recipients%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2003%26volume%3D349%26spage%3D847%26epage%3D858%26doi%3D10.1056%2FNEJMoa022171" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit7b"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jacob, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nair, A. B.</span></span> <span> </span><span class="NLM_article-title">A review on therapeutic drug monitoring of the mTOR class of immunosuppressants: everolimus and sirolimus</span>. <i>Drugs Ther Perspect</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>33</i></span>,  <span class="NLM_fpage">290</span>– <span class="NLM_lpage">301</span>, <span class="refDoi"> DOI: 10.1007/s40267-017-0403-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01262&amp;key=10.1007%2Fs40267-017-0403-0" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2017&pages=290-301&author=S.+Jacobauthor=A.+B.+Nair&title=A+review+on+therapeutic+drug+monitoring+of+the+mTOR+class+of+immunosuppressants%3A+everolimus+and+sirolimus&doi=10.1007%2Fs40267-017-0403-0"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit7b&amp;dbid=16384&amp;doi=10.1007%2Fs40267-017-0403-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40267-017-0403-0%26sid%3Dliteratum%253Aachs%26aulast%3DJacob%26aufirst%3DS.%26aulast%3DNair%26aufirst%3DA.%2BB.%26atitle%3DA%2520review%2520on%2520therapeutic%2520drug%2520monitoring%2520of%2520the%2520mTOR%2520class%2520of%2520immunosuppressants%253A%2520everolimus%2520and%2520sirolimus%26jtitle%3DDrugs%2520Ther%2520Perspect%26date%3D2017%26volume%3D33%26spage%3D290%26epage%3D301%26doi%3D10.1007%2Fs40267-017-0403-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit7c"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Alalawi, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Halawa, A.</span></span> <span> </span><span class="NLM_article-title">mTOR Inhibitors in the current practice</span>. <i>J. Clin. Exp. Nephrol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>1</i></span>,  <span class="NLM_fpage">26</span>, <span class="refDoi"> DOI: 10.21767/2472-5056.100026</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01262&amp;key=10.21767%2F2472-5056.100026" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2017&pages=26&author=F.+Alalawiauthor=A.+Sharmaauthor=A.+Halawa&title=mTOR+Inhibitors+in+the+current+practice&doi=10.21767%2F2472-5056.100026"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit7c&amp;dbid=16384&amp;doi=10.21767%2F2472-5056.100026&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.21767%252F2472-5056.100026%26sid%3Dliteratum%253Aachs%26aulast%3DAlalawi%26aufirst%3DF.%26aulast%3DSharma%26aufirst%3DA.%26aulast%3DHalawa%26aufirst%3DA.%26atitle%3DmTOR%2520Inhibitors%2520in%2520the%2520current%2520practice%26jtitle%3DJ.%2520Clin.%2520Exp.%2520Nephrol.%26date%3D2017%26volume%3D1%26spage%3D26%26doi%3D10.21767%2F2472-5056.100026" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Costa, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simon, D. I.</span></span> <span> </span><span class="NLM_article-title">Molecular basis of restenosis and drug-eluting stents</span>. <i>Circulation</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>111</i></span>,  <span class="NLM_fpage">2257</span>– <span class="NLM_lpage">2273</span>, <span class="refDoi"> DOI: 10.1161/01.CIR.0000163587.36485.A7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01262&amp;key=10.1161%2F01.CIR.0000163587.36485.A7" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=111&publication_year=2005&pages=2257-2273&author=M.+A.+Costaauthor=D.+I.+Simon&title=Molecular+basis+of+restenosis+and+drug-eluting+stents&doi=10.1161%2F01.CIR.0000163587.36485.A7"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1161%2F01.CIR.0000163587.36485.A7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1161%252F01.CIR.0000163587.36485.A7%26sid%3Dliteratum%253Aachs%26aulast%3DCosta%26aufirst%3DM.%2BA.%26aulast%3DSimon%26aufirst%3DD.%2BI.%26atitle%3DMolecular%2520basis%2520of%2520restenosis%2520and%2520drug-eluting%2520stents%26jtitle%3DCirculation%26date%3D2005%26volume%3D111%26spage%3D2257%26epage%3D2273%26doi%3D10.1161%2F01.CIR.0000163587.36485.A7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Motzer, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Escudier, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oudard, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hutson, T. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Porta, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bracarda, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grunwald, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thompson, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Figlin, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hollaender, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Urbanowitz, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berg, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kay, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lebwohl, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ravaud, A.</span></span> <span> </span><span class="NLM_article-title">Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial</span>. <i>Lancet</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>372</i></span>,  <span class="NLM_fpage">449</span>– <span class="NLM_lpage">456</span>, <span class="refDoi"> DOI: 10.1016/S0140-6736(08)61039-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01262&amp;key=10.1016%2FS0140-6736%2808%2961039-9" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=372&publication_year=2008&pages=449-456&author=R.+J.+Motzerauthor=B.+Escudierauthor=S.+Oudardauthor=T.+E.+Hutsonauthor=C.+Portaauthor=S.+Bracardaauthor=V.+Grunwaldauthor=J.+A.+Thompsonauthor=R.+A.+Figlinauthor=N.+Hollaenderauthor=G.+Urbanowitzauthor=W.+J.+Bergauthor=A.+Kayauthor=D.+Lebwohlauthor=A.+Ravaud&title=Efficacy+of+everolimus+in+advanced+renal+cell+carcinoma%3A+a+double-blind%2C+randomised%2C+placebo-controlled+phase+III+trial&doi=10.1016%2FS0140-6736%2808%2961039-9"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2808%2961039-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252808%252961039-9%26sid%3Dliteratum%253Aachs%26aulast%3DMotzer%26aufirst%3DR.%2BJ.%26aulast%3DEscudier%26aufirst%3DB.%26aulast%3DOudard%26aufirst%3DS.%26aulast%3DHutson%26aufirst%3DT.%2BE.%26aulast%3DPorta%26aufirst%3DC.%26aulast%3DBracarda%26aufirst%3DS.%26aulast%3DGrunwald%26aufirst%3DV.%26aulast%3DThompson%26aufirst%3DJ.%2BA.%26aulast%3DFiglin%26aufirst%3DR.%2BA.%26aulast%3DHollaender%26aufirst%3DN.%26aulast%3DUrbanowitz%26aufirst%3DG.%26aulast%3DBerg%26aufirst%3DW.%2BJ.%26aulast%3DKay%26aufirst%3DA.%26aulast%3DLebwohl%26aufirst%3DD.%26aulast%3DRavaud%26aufirst%3DA.%26atitle%3DEfficacy%2520of%2520everolimus%2520in%2520advanced%2520renal%2520cell%2520carcinoma%253A%2520a%2520double-blind%252C%2520randomised%252C%2520placebo-controlled%2520phase%2520III%2520trial%26jtitle%3DLancet%26date%3D2008%26volume%3D372%26spage%3D449%26epage%3D456%26doi%3D10.1016%2FS0140-6736%2808%2961039-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jerusalem, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rorive, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collignon, J.</span></span> <span> </span><span class="NLM_article-title">Use of mTOR inhibitors in the treatment of breast cancer: an evaluation of factors that influence patient outcomes</span>. <i>Breast Cancer: Targets Ther.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">43</span>– <span class="NLM_lpage">57</span>, <span class="refDoi"> DOI: 10.2147/BCTT.S38679</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01262&amp;key=10.2147%2FBCTT.S38679" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01262&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhs12gsrjE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2014&pages=43-57&author=G.+Jerusalemauthor=A.+Roriveauthor=J.+Collignon&title=Use+of+mTOR+inhibitors+in+the+treatment+of+breast+cancer%3A+an+evaluation+of+factors+that+influence+patient+outcomes&doi=10.2147%2FBCTT.S38679"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Use of mTOR inhibitors in the treatment of breast cancer: an evaluation of factors that influence patient outcomes</span></div><div class="casAuthors">Jerusalem, Guy; Rorive, Andree; Collignon, Joelle</div><div class="citationInfo"><span class="NLM_cas:title">Breast Cancer: Targets and Therapy</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">43-57, 15</span>CODEN:
                <span class="NLM_cas:coden">BCTTA9</span>;
        ISSN:<span class="NLM_cas:issn">1179-1314</span>.
    
            (<span class="NLM_cas:orgname">Dove Medical Press Ltd.</span>)
        </div><div class="casAbstract">A review.  Many systemic treatment options are available for advanced breast cancer, including endocrine therapy, chemotherapy, anti-human epidermal growth factor receptor 2 (HER2) therapy, and other targeted agents.  Recently, everolimus, a mammalian target of rapamycin (mTOR) inhibitor, combined with exemestane, an aromatase inhibitor, has been approved in Europe and the USA for patients suffering from estrogen receptor-pos., HER2-neg. advanced breast cancer previously treated by a nonsteroidal aromatase inhibitor, based on the results of BOLERO-2 (Breast cancer trials of OraL EveROlimus).  This study showed a statistically significant and clin. meaningful improvement in median progression-free survival.  Results concerning the impact on overall survival are expected in the near future.  This clin. oriented review focuses on the use of mTOR inhibitors in breast cancer.  Results reported with first-generation mTOR inhibitors (ridaforolimus, temsirolimus, everolimus) are discussed.  The current and potential role of mTOR inhibitors is reported according to breast cancer subtype (estrogen receptor-pos. HER2-neg., triple-neg., and HER2-pos. ER-pos./neg. disease).  Everolimus is currently being evaluated in the adjuvant setting in high-risk estrogen receptor-pos., HER2-neg. early breast cancer.  Continuing mTOR inhibition or alternatively administering other drugs targeting the phosphatidylinositol-3-kinase/protein kinase B-mTOR pathway after progression on treatments including an mTOR inhibitor is under evaluation.  Potential biomarkers to select patients showing a more pronounced benefit are reviewed, but we are not currently using these biomarkers in routine practice.  Subgroup anal. of BOLERO 2 has shown that the benefit is consistent in all subgroups and that it is impossible to select patients not benefiting from addn. of everolimus to exemestane.  Side effects and impact on quality of life are other important issues discussed in this review.  Second-generation mTOR inhibitors and dual mTOR-phosphatidylinositol-3-kinase inhibitors are currently being evaluated in clin. trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqXjFYIcn4ct7Vg90H21EOLACvtfcHk0li6cldTPas2mg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhs12gsrjE&md5=9a12c70c7c917baa41d282bc135b12af</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.2147%2FBCTT.S38679&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2147%252FBCTT.S38679%26sid%3Dliteratum%253Aachs%26aulast%3DJerusalem%26aufirst%3DG.%26aulast%3DRorive%26aufirst%3DA.%26aulast%3DCollignon%26aufirst%3DJ.%26atitle%3DUse%2520of%2520mTOR%2520inhibitors%2520in%2520the%2520treatment%2520of%2520breast%2520cancer%253A%2520an%2520evaluation%2520of%2520factors%2520that%2520influence%2520patient%2520outcomes%26jtitle%3DBreast%2520Cancer%253A%2520Targets%2520Ther.%26date%3D2014%26volume%3D6%26spage%3D43%26epage%3D57%26doi%3D10.2147%2FBCTT.S38679" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Arachchige
Don, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, X. F. S.</span></span> <span> </span><span class="NLM_article-title">Recent clinical trials of mTOR-targeted cancer therapies</span>. <i>Rev. Recent Clin. Trials</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">24</span>– <span class="NLM_lpage">35</span>, <span class="refDoi"> DOI: 10.2174/157488711793980147</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01262&amp;key=10.2174%2F157488711793980147" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01262&amp;key=20868343" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01262&amp;key=1%3ACAS%3A528%3ADC%252BC3MXlvFWntL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2011&pages=24-35&author=A.+S.+Arachchige%0ADonauthor=X.+F.+S.+Zheng&title=Recent+clinical+trials+of+mTOR-targeted+cancer+therapies&doi=10.2174%2F157488711793980147"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Recent clinical trials of mTOR-targeted cancer therapies</span></div><div class="casAuthors">Arachchige Don, Aruni S.; Zheng, X. F. Steven</div><div class="citationInfo"><span class="NLM_cas:title">Reviews on Recent Clinical Trials</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">24-35</span>CODEN:
                <span class="NLM_cas:coden">RRCTB2</span>;
        ISSN:<span class="NLM_cas:issn">1574-8871</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  The mammalian target of rapamycin (mTOR) is a central component within a complex intracellular signaling network that regulates various processes including cell growth, proliferation, metab., and angiogenesis.  A hyperactive PI3k/Akt/mTOR signaling pathway is found in many human cancers and alterations in this pathway are assocd. with the development and progression of cancer.  Drugs that target and inhibit mTOR activity are therefore expected to provide therapeutic value in a no. of cancer types.  Several classes of mTOR-targeted therapeutics are currently being evaluated in cancer clin. trials, including the rapamycins, dual PI3K-mTOR inhibitors, and ATP-competitive mTORC1/2 inhibitors.  This review summarizes important findings from recently completed trials of mTOR inhibitors and also discusses preliminary data from ongoing trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoX3gLMv9DD_bVg90H21EOLACvtfcHk0ljV6Rd0POxmvQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXlvFWntL0%253D&md5=fe90e00863d466ccdacc9caba00b249e</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.2174%2F157488711793980147&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F157488711793980147%26sid%3Dliteratum%253Aachs%26aulast%3DArachchige%2BDon%26aufirst%3DA.%2BS.%26aulast%3DZheng%26aufirst%3DX.%2BF.%2BS.%26atitle%3DRecent%2520clinical%2520trials%2520of%2520mTOR-targeted%2520cancer%2520therapies%26jtitle%3DRev.%2520Recent%2520Clin.%2520Trials%26date%3D2011%26volume%3D6%26spage%3D24%26epage%3D35%26doi%3D10.2174%2F157488711793980147" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shor, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gibbons, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abraham, R. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, K.</span></span> <span> </span><span class="NLM_article-title">Targeting mTOR globally in cancer: thinking beyond rapamycin</span>. <i>Cell Cycle</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">3831</span>– <span class="NLM_lpage">3837</span>, <span class="refDoi"> DOI: 10.4161/cc.8.23.10070</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01262&amp;key=10.4161%2Fcc.8.23.10070" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01262&amp;key=19901542" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01262&amp;key=1%3ACAS%3A528%3ADC%252BC3cXotlWrtL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2009&pages=3831-3837&author=B.+Shorauthor=J.+J.+Gibbonsauthor=R.+T.+Abrahamauthor=K.+Yu&title=Targeting+mTOR+globally+in+cancer%3A+thinking+beyond+rapamycin&doi=10.4161%2Fcc.8.23.10070"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting mTOR globally in cancer: thinking beyond rapamycin</span></div><div class="casAuthors">Shor, Boris; Gibbons, James J.; Abraham, Robert T.; Yu, Ker</div><div class="citationInfo"><span class="NLM_cas:title">Cell Cycle</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">3831-3837</span>CODEN:
                <span class="NLM_cas:coden">CCEYAS</span>;
        ISSN:<span class="NLM_cas:issn">1538-4101</span>.
    
            (<span class="NLM_cas:orgname">Landes Bioscience</span>)
        </div><div class="casAbstract">A review.  The mammalian target of rapamycin (mTOR) is centrally involved in growth, survival and metab.  In cancer, mTOR is frequently hyperactivated and is a clin. validated target for drug development.  Until recently, we have relied largely on the use of rapamycin to study mTOR function and its anticancer potential.  Recent insights now indicate that rapamycin is a partial inhibitor of mTOR through allosteric inhibition of mTOR complex-1 (mTORC1) but not mTOR complex-2 (mTORC2).  Both the mechanism of action and the cellular response to mTORC1 inhibition by rapamycin and related drugs may limit the effectiveness of these compds. as antitumor agents.  We and others have recently reported the discovery of second-generation ATP-competitive mTOR kinase inhibitors (TKIs) that bind to the active sites of mTORC1 and mTORC2, thereby targeting mTOR signaling function globally (reviewed in refs. 1-4).  The discovery of specific, active-site mTOR inhibitors has opened a new chapter in the 40-plus year old odyssey that began with the discovery of rapamycin from a soil sample collected on Easter Island.  Here, we discuss recent studies that highlight the emergence of rapamycin-resistant mTOR function in protein synthesis, cell growth, survival and metab.  It is shown that these rapamycin-resistant mTOR functions are profoundly inhibited by TKIs.  A more complete suppression of mTOR global signaling network by the new inhibitors is expected to yield a deeper and broader antitumor response in the clinic.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoy9EP_1DwoGrVg90H21EOLACvtfcHk0ljV6Rd0POxmvQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXotlWrtL4%253D&md5=4dab0a66742fadd9087aa2c439704f27</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.4161%2Fcc.8.23.10070&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4161%252Fcc.8.23.10070%26sid%3Dliteratum%253Aachs%26aulast%3DShor%26aufirst%3DB.%26aulast%3DGibbons%26aufirst%3DJ.%2BJ.%26aulast%3DAbraham%26aufirst%3DR.%2BT.%26aulast%3DYu%26aufirst%3DK.%26atitle%3DTargeting%2520mTOR%2520globally%2520in%2520cancer%253A%2520thinking%2520beyond%2520rapamycin%26jtitle%3DCell%2520Cycle%26date%3D2009%26volume%3D8%26spage%3D3831%26epage%3D3837%26doi%3D10.4161%2Fcc.8.23.10070" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13a"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Slotkin, E. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patwardhan, P. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vasudeva, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Stanchina, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tap, W. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwartz, G. K.</span></span> <span> </span><span class="NLM_article-title">MLN0128, an ATP-competitive mTOR kinase inhibitor with potent in vitro and in vivo antitumor activity, as potential therapy for bone and soft-tissue sarcoma</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">395</span>– <span class="NLM_lpage">406</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-14-0711</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01262&amp;key=10.1158%2F1535-7163.MCT-14-0711" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01262&amp;key=25519700" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01262&amp;key=1%3ACAS%3A528%3ADC%252BC2MXitlOjsbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2015&pages=395-406&author=E.+K.+Slotkinauthor=P.+P.+Patwardhanauthor=S.+D.+Vasudevaauthor=E.+de+Stanchinaauthor=W.+D.+Tapauthor=G.+K.+Schwartz&title=MLN0128%2C+an+ATP-competitive+mTOR+kinase+inhibitor+with+potent+in+vitro+and+in+vivo+antitumor+activity%2C+as+potential+therapy+for+bone+and+soft-tissue+sarcoma&doi=10.1158%2F1535-7163.MCT-14-0711"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13aR"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">MLN0128, an ATP-Competitive mTOR Kinase Inhibitor with Potent In Vitro and In Vivo Antitumor Activity, as Potential Therapy for Bone and Soft-Tissue Sarcoma</span></div><div class="casAuthors">Slotkin, Emily K.; Patwardhan, Parag P.; Vasudeva, Shyamprasad D.; de Stanchina, Elisa; Tap, William D.; Schwartz, Gary K.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">395-406</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The mammalian target of rapamycin (mTOR) is a serine/threonine protein kinase that exists in two complexes (mTORC1 and mTORC2) and integrates extracellular and intracellular signals to act as a master regulator of cell growth, survival, and metab.  The PI3K/AKT/mTOR prosurvival pathway is often dysregulated in multiple sarcoma subtypes.  First-generation allosteric inhibitors of mTORC1 (rapalogues) have been extensively tested with great preclin. promise, but have had limited clin. utility.  Here, we report that MLN0128, a second-generation, ATP-competitive, pan-mTOR kinase inhibitor, acts on both mTORC1 and mTORC2 and has potent in vitro and in vivo antitumor activity in multiple sarcoma subtypes.  In vitro, MLN0128 inhibits mTORC1/2 targets in a concn.-dependent fashion and shows striking antiproliferative effect in rhabdomyosarcoma (RMS), Ewing sarcoma, malignant peripheral nerve sheath tumor, synovial sarcoma, osteosarcoma, and liposarcoma.  Unlike rapamycin, MLN0128 inhibits phosphorylation of 4EBP1 and NDRG1 as well as prevents the reactivation of pAKT that occurs via neg. feedback release with mTORC1 inhibition alone.  In xenograft models, MLN0128 treatment results in suppression of tumor growth with two dosing schedules (1 mg/kg daily and 3 mg/kg b.i.d. t.i.w.).  At the 3 mg/kg dosing schedule, MLN0128 treatment results in significantly better tumor growth suppression than rapamycin in RMS and Ewing sarcoma models.  In addn., MLN0128 induces apoptosis in models of RMS both in vitro and in vivo.  Results from our study strongly suggest that MLN0128 treatment should be explored further as potential therapy for sarcoma.  Mol Cancer Ther; 14(2); 395-406. ©2014 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq2RbwSW4yjmLVg90H21EOLACvtfcHk0lhAs2Y16vvxGA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXitlOjsbo%253D&md5=7c1d867aae6e5ca99c63b554295a539a</span></div><a href="/servlet/linkout?suffix=cit13a&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-14-0711&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-14-0711%26sid%3Dliteratum%253Aachs%26aulast%3DSlotkin%26aufirst%3DE.%2BK.%26aulast%3DPatwardhan%26aufirst%3DP.%2BP.%26aulast%3DVasudeva%26aufirst%3DS.%2BD.%26aulast%3Dde%2BStanchina%26aufirst%3DE.%26aulast%3DTap%26aufirst%3DW.%2BD.%26aulast%3DSchwartz%26aufirst%3DG.%2BK.%26atitle%3DMLN0128%252C%2520an%2520ATP-competitive%2520mTOR%2520kinase%2520inhibitor%2520with%2520potent%2520in%2520vitro%2520and%2520in%2520vivo%2520antitumor%2520activity%252C%2520as%2520potential%2520therapy%2520for%2520bone%2520and%2520soft-tissue%2520sarcoma%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2015%26volume%3D14%26spage%3D395%26epage%3D406%26doi%3D10.1158%2F1535-7163.MCT-14-0711" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit13b"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hsieh, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edlind, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ingolia, N. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janes, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sher, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, E. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stumpf, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christensen, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonham, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ren, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jessen, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feldman, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weissman, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shokat, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rommel, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruggero, D.</span></span> <span> </span><span class="NLM_article-title">The translational landscape of mTOR signalling steers cancer initiation and metastasis</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>485</i></span>,  <span class="NLM_fpage">55</span>– <span class="NLM_lpage">61</span>, <span class="refDoi"> DOI: 10.1038/nature10912</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01262&amp;key=10.1038%2Fnature10912" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01262&amp;key=22367541" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01262&amp;key=1%3ACAS%3A528%3ADC%252BC38Xislynsbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=485&publication_year=2012&pages=55-61&author=A.+C.+Hsiehauthor=Y.+Liuauthor=M.+P.+Edlindauthor=N.+T.+Ingoliaauthor=M.+R.+Janesauthor=A.+Sherauthor=E.+Y.+Shiauthor=C.+R.+Stumpfauthor=C.+Christensenauthor=M.+J.+Bonhamauthor=S.+Wangauthor=P.+Renauthor=M.+Martinauthor=K.+Jessenauthor=M.+E.+Feldmanauthor=J.+S.+Weissmanauthor=K.+M.+Shokatauthor=C.+Rommelauthor=D.+Ruggero&title=The+translational+landscape+of+mTOR+signalling+steers+cancer+initiation+and+metastasis&doi=10.1038%2Fnature10912"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13bR"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">The translational landscape of mTOR signaling steers cancer initiation and metastasis</span></div><div class="casAuthors">Hsieh, Andrew C.; Liu, Yi; Edlind, Merritt P.; Ingolia, Nicholas T.; Janes, Matthew R.; Sher, Annie; Shi, Evan Y.; Stumpf, Craig R.; Christensen, Carly; Bonham, Michael J.; Wang, Shunyou; Ren, Pingda; Martin, Michael; Jessen, Katti; Feldman, Morris E.; Weissman, Jonathan S.; Shokat, Kevan M.; Rommel, Christian; Ruggero, Davide</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">485</span>
        (<span class="NLM_cas:issue">7396</span>),
    <span class="NLM_cas:pages">55-61</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The mammalian target of rapamycin (mTOR) kinase is a master regulator of protein synthesis that couples nutrient sensing to cell growth and cancer.  However, the downstream translationally regulated nodes of gene expression that may direct cancer development are poorly characterized.  Using ribosome profiling, we uncover specialized translation of the prostate cancer genome by oncogenic mTOR signaling, revealing a remarkably specific repertoire of genes involved in cell proliferation, metab. and invasion.  We extend these findings by functionally characterizing a class of translationally controlled pro-invasion mRNAs that we show direct prostate cancer invasion and metastasis downstream of oncogenic mTOR signaling.  Furthermore, we develop a clin. relevant ATP site inhibitor of mTOR, INK128, which reprograms this gene expression signature with therapeutic benefit for prostate cancer metastasis, for which there is presently no cure.  Together, these findings extend our understanding of how the cancerous' translation machinery steers specific cancer cell behaviors, including metastasis, and may be therapeutically targeted.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGps08bxDEwvObVg90H21EOLACvtfcHk0lhAs2Y16vvxGA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xislynsbw%253D&md5=37bf86fb8f86317ec13acf8f355e7ba8</span></div><a href="/servlet/linkout?suffix=cit13b&amp;dbid=16384&amp;doi=10.1038%2Fnature10912&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature10912%26sid%3Dliteratum%253Aachs%26aulast%3DHsieh%26aufirst%3DA.%2BC.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DEdlind%26aufirst%3DM.%2BP.%26aulast%3DIngolia%26aufirst%3DN.%2BT.%26aulast%3DJanes%26aufirst%3DM.%2BR.%26aulast%3DSher%26aufirst%3DA.%26aulast%3DShi%26aufirst%3DE.%2BY.%26aulast%3DStumpf%26aufirst%3DC.%2BR.%26aulast%3DChristensen%26aufirst%3DC.%26aulast%3DBonham%26aufirst%3DM.%2BJ.%26aulast%3DWang%26aufirst%3DS.%26aulast%3DRen%26aufirst%3DP.%26aulast%3DMartin%26aufirst%3DM.%26aulast%3DJessen%26aufirst%3DK.%26aulast%3DFeldman%26aufirst%3DM.%2BE.%26aulast%3DWeissman%26aufirst%3DJ.%2BS.%26aulast%3DShokat%26aufirst%3DK.%2BM.%26aulast%3DRommel%26aufirst%3DC.%26aulast%3DRuggero%26aufirst%3DD.%26atitle%3DThe%2520translational%2520landscape%2520of%2520mTOR%2520signalling%2520steers%2520cancer%2520initiation%2520and%2520metastasis%26jtitle%3DNature%26date%3D2012%26volume%3D485%26spage%3D55%26epage%3D61%26doi%3D10.1038%2Fnature10912" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14a"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mortensen, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fultz, K. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Packard, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khambatta, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gamez, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leisten, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Apuy, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghoreishi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hickman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Narla, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bissonette, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richardson, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peng, S. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perrin-Ninkovic, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tran, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, W. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tong, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cathers, B. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moghaddam, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Canan, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Worland, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sankar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raymon, H. K.</span></span> <span> </span><span class="NLM_article-title">CC-223, a potent and selective inhibitor of mTOR kinase: in vitro and in vivo characterization</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">1295</span>– <span class="NLM_lpage">1305</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-14-1052</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01262&amp;key=10.1158%2F1535-7163.MCT-14-1052" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01262&amp;key=25855786" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01262&amp;key=1%3ACAS%3A528%3ADC%252BC2MXpsFOgurk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2015&pages=1295-1305&author=D.+S.+Mortensenauthor=K.+E.+Fultzauthor=S.+Xuauthor=W.+Xuauthor=G.+Packardauthor=G.+Khambattaauthor=J.+C.+Gamezauthor=J.+Leistenauthor=J.+Zhaoauthor=J.+Apuyauthor=K.+Ghoreishiauthor=M.+Hickmanauthor=R.+K.+Narlaauthor=R.+Bissonetteauthor=S.+Richardsonauthor=S.+X.+Pengauthor=S.+Perrin-Ninkovicauthor=T.+Tranauthor=T.+Shiauthor=W.+Q.+Yangauthor=Z.+Tongauthor=B.+E.+Cathersauthor=M.+F.+Moghaddamauthor=S.+S.+Cananauthor=P.+Worlandauthor=S.+Sankarauthor=H.+K.+Raymon&title=CC-223%2C+a+potent+and+selective+inhibitor+of+mTOR+kinase%3A+in+vitro+and+in+vivo+characterization&doi=10.1158%2F1535-7163.MCT-14-1052"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14aR"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">CC-223, a Potent and Selective Inhibitor of mTOR Kinase: In Vitro and In Vivo Characterization</span></div><div class="casAuthors">Mortensen, Deborah S.; Fultz, Kimberly E.; Xu, Shuichan; Xu, Weiming; Packard, Garrick; Khambatta, Godrej; Gamez, James C.; Leisten, Jim; Zhao, Jingjing; Apuy, Julius; Ghoreishi, Kamran; Hickman, Matt; Narla, Rama Krishna; Bissonette, Rene; Richardson, Samantha; Peng, Sophie X.; Perrin-Ninkovic, Sophie; Tran, Tam; Shi, Tao; Yang, Wen Qing; Tong, Zeen; Cathers, Brian E.; Moghaddam, Mehran F.; Canan, Stacie S.; Worland, Peter; Sankar, Sabita; Raymon, Heather K.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1295-1305</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">MTOR is a serine/threonine kinase that regulates cell growth, metab., proliferation, and survival. mTOR complex-1 (mTORC1) and mTOR complex-2 (mTORC2) are crit. mediators of the PI3K-AKT pathway, which is frequently mutated in many cancers, leading to hyperactivation of mTOR signaling.  Although rapamycin analogs, allosteric inhibitors that target only the mTORC1 complex, have shown some clin. activity, it is hypothesized that mTOR kinase inhibitors, blocking both mTORC1 and mTORC2 signaling, will have expanded therapeutic potential.  Here, we describe the preclin. characterization of CC-223.  CC-223 is a potent, selective, and orally bioavailable inhibitor of mTOR kinase, demonstrating inhibition of mTORC1 (pS6RP and p4EBP1) and mTORC2 [pAKT(S473)] in cellular systems.  Growth inhibitory activity was demonstrated in hematol. and solid tumor cell lines. mTOR kinase inhibition in cells, by CC-223, resulted in more complete inhibition of the mTOR pathway biomarkers and improved antiproliferative activity as compared with rapamycin.  Growth inhibitory activity and apoptosis was demonstrated in a panel of hematol. cancer cell lines.  Correlative anal. revealed that IRF4 expression level assocs. with resistance, whereas mTOR pathway activation seems to assoc. with sensitivity.  Treatment with CC-223 afforded in vivo tumor biomarker inhibition in tumor-bearing mice, after a single oral dose.  CC-223 exhibited dose-dependent tumor growth inhibition in multiple solid tumor xenografts.  Significant inhibition of mTOR pathway markers pS6RP and pAKT in CC-223-treated tumors suggests that the obsd. antitumor activity of CC-223 was mediated through inhibition of both mTORC1 and mTORC2.  CC-223 is currently in phase I clin. trials.  Mol Cancer Ther; 14(6); 1295-305. ©2015 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrDt9130-L0z7Vg90H21EOLACvtfcHk0ljtBN819L-7xA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXpsFOgurk%253D&md5=f33b21dc89dedaf14fab54a819afb917</span></div><a href="/servlet/linkout?suffix=cit14a&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-14-1052&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-14-1052%26sid%3Dliteratum%253Aachs%26aulast%3DMortensen%26aufirst%3DD.%2BS.%26aulast%3DFultz%26aufirst%3DK.%2BE.%26aulast%3DXu%26aufirst%3DS.%26aulast%3DXu%26aufirst%3DW.%26aulast%3DPackard%26aufirst%3DG.%26aulast%3DKhambatta%26aufirst%3DG.%26aulast%3DGamez%26aufirst%3DJ.%2BC.%26aulast%3DLeisten%26aufirst%3DJ.%26aulast%3DZhao%26aufirst%3DJ.%26aulast%3DApuy%26aufirst%3DJ.%26aulast%3DGhoreishi%26aufirst%3DK.%26aulast%3DHickman%26aufirst%3DM.%26aulast%3DNarla%26aufirst%3DR.%2BK.%26aulast%3DBissonette%26aufirst%3DR.%26aulast%3DRichardson%26aufirst%3DS.%26aulast%3DPeng%26aufirst%3DS.%2BX.%26aulast%3DPerrin-Ninkovic%26aufirst%3DS.%26aulast%3DTran%26aufirst%3DT.%26aulast%3DShi%26aufirst%3DT.%26aulast%3DYang%26aufirst%3DW.%2BQ.%26aulast%3DTong%26aufirst%3DZ.%26aulast%3DCathers%26aufirst%3DB.%2BE.%26aulast%3DMoghaddam%26aufirst%3DM.%2BF.%26aulast%3DCanan%26aufirst%3DS.%2BS.%26aulast%3DWorland%26aufirst%3DP.%26aulast%3DSankar%26aufirst%3DS.%26aulast%3DRaymon%26aufirst%3DH.%2BK.%26atitle%3DCC-223%252C%2520a%2520potent%2520and%2520selective%2520inhibitor%2520of%2520mTOR%2520kinase%253A%2520in%2520vitro%2520and%2520in%2520vivo%2520characterization%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2015%26volume%3D14%26spage%3D1295%26epage%3D1305%26doi%3D10.1158%2F1535-7163.MCT-14-1052" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit14b"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jin, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, A.</span></span> <span> </span><span class="NLM_article-title">Preclinical study of CC223 as a potential anti-ovarian cancer agent</span>. <i>Oncotarget</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">58469</span>– <span class="NLM_lpage">58479</span>, <span class="refDoi"> DOI: 10.18632/oncotarget.17753</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01262&amp;key=10.18632%2Foncotarget.17753" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01262&amp;key=28938571" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01262&amp;key=1%3ACAS%3A280%3ADC%252BC1M%252FhtlOjuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=58469-58479&author=Z.+Jinauthor=H.+Niuauthor=X.+Wangauthor=L.+Zhangauthor=Q.+Wangauthor=A.+Yang&title=Preclinical+study+of+CC223+as+a+potential+anti-ovarian+cancer+agent&doi=10.18632%2Foncotarget.17753"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14bR"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Preclinical study of CC223 as a potential anti-ovarian cancer agent</span></div><div class="casAuthors">Jin Zhenzhen; Niu Huanfu; Wang Xuenan; Wang Qin; Yang Aijun; Zhang Lei</div><div class="citationInfo"><span class="NLM_cas:title">Oncotarget</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">35</span>),
    <span class="NLM_cas:pages">58469-58479</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Aberrant activation of mTOR contributes to ovarian cancer progression.  CC223 is a novel and potent mTOR kinase inhibitor.  The current study tested its activity against human ovarian cancer cells.  We showed that CC223, at nM concentrations, inhibited survival and proliferation of established/primary human ovarian cancer cells.  Further, significant apoptosis activation was observed in CC223-treated ovarian cancer cells.  CC223 disrupted assembly of mTOR complex 1 (mTORC1) and mTORC2 in SKOV3 cells.  Meanwhile, activation of mTORC1 and mTORC2 was almost completely blocked by CC223.  Intriguingly, restoring mTOR activation by introduction of a constitutively-active Akt1 only partially inhibited CC223-induced cytotoxicity in SKOV3 cells.  Further studies showed that CC223 inhibited sphingosine kinase 1 (SphK1) activity and induced reactive oxygen species (ROS) production in SKOV3 cells.  At last, oral administration of CC223 potently inhibited SKOV3 xenografted tumor growth in nude mice.  The results of this study imply that CC223 could be further studied as a potential anti-ovarian cancer agent.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRcU4AE24nN2t1QT_1O5WBYfW6udTcc2ebsCTxpLAH5dLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1M%252FhtlOjuw%253D%253D&md5=091fdb75cec2ddb9018ba74c124041e8</span></div><a href="/servlet/linkout?suffix=cit14b&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.17753&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.17753%26sid%3Dliteratum%253Aachs%26aulast%3DJin%26aufirst%3DZ.%26aulast%3DNiu%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DQ.%26aulast%3DYang%26aufirst%3DA.%26atitle%3DPreclinical%2520study%2520of%2520CC223%2520as%2520a%2520potential%2520anti-ovarian%2520cancer%2520agent%26jtitle%3DOncotarget%26date%3D2017%26volume%3D8%26spage%3D58469%26epage%3D58479%26doi%3D10.18632%2Foncotarget.17753" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pike, K. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malagu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hummersone, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Menear, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duggan, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gomez, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, N. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruston, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pass, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pass, M.</span></span> <span> </span><span class="NLM_article-title">Optimization of potent and selective dual mTORC1 and mTORC2 inhibitors: the discovery of AZD8055 and AZD2014</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">1212</span>– <span class="NLM_lpage">1216</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2013.01.019</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01262&amp;key=10.1016%2Fj.bmcl.2013.01.019" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01262&amp;key=23375793" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01262&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvFajs7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2013&pages=1212-1216&author=K.+G.+Pikeauthor=K.+Malaguauthor=M.+G.+Hummersoneauthor=K.+A.+Menearauthor=H.+M.+Dugganauthor=S.+Gomezauthor=N.+M.+Martinauthor=L.+Rustonauthor=S.+L.+Passauthor=M.+Pass&title=Optimization+of+potent+and+selective+dual+mTORC1+and+mTORC2+inhibitors%3A+the+discovery+of+AZD8055+and+AZD2014&doi=10.1016%2Fj.bmcl.2013.01.019"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Optimization of potent and selective dual mTORC1 and mTORC2 inhibitors: The discovery of AZD8055 and AZD2014</span></div><div class="casAuthors">Pike, Kurt G.; Malagu, Karine; Hummersone, Marc G.; Menear, Keith A.; Duggan, Heather M. E.; Gomez, Sylvie; Martin, Niall M. B.; Ruston, Linette; Pass, Sarah L.; Pass, Martin</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1212-1216</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The optimization of a potent and highly selective series of dual mTORC1 and mTORC2 inhibitors is described.  An initial focus on improving cellular potency while maintaining or improving other key parameters, such as aq. soly. and margins over hERG IC50, led to the discovery of the clin. candidate AZD8055.  Further optimization, particularly aimed at reducing the rate of metab. in human hepatocyte incubations, resulted in the discovery of the clin. candidate AZD2014.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo07emMEKp9mrVg90H21EOLACvtfcHk0lgnVFFthg_3hw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvFajs7c%253D&md5=325cb45f84bb4357005315ab3b27c0aa</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2013.01.019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2013.01.019%26sid%3Dliteratum%253Aachs%26aulast%3DPike%26aufirst%3DK.%2BG.%26aulast%3DMalagu%26aufirst%3DK.%26aulast%3DHummersone%26aufirst%3DM.%2BG.%26aulast%3DMenear%26aufirst%3DK.%2BA.%26aulast%3DDuggan%26aufirst%3DH.%2BM.%26aulast%3DGomez%26aufirst%3DS.%26aulast%3DMartin%26aufirst%3DN.%2BM.%26aulast%3DRuston%26aufirst%3DL.%26aulast%3DPass%26aufirst%3DS.%2BL.%26aulast%3DPass%26aufirst%3DM.%26atitle%3DOptimization%2520of%2520potent%2520and%2520selective%2520dual%2520mTORC1%2520and%2520mTORC2%2520inhibitors%253A%2520the%2520discovery%2520of%2520AZD8055%2520and%2520AZD2014%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2013%26volume%3D23%26spage%3D1212%26epage%3D1216%26doi%3D10.1016%2Fj.bmcl.2013.01.019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Crino, P. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nathanson, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Henske, E. P.</span></span> <span> </span><span class="NLM_article-title">The tuberous sclerosis complex</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>355</i></span>,  <span class="NLM_fpage">1345</span>– <span class="NLM_lpage">1356</span>, <span class="refDoi"> DOI: 10.1056/NEJMra055323</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01262&amp;key=10.1056%2FNEJMra055323" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01262&amp;key=17005952" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01262&amp;key=1%3ACAS%3A528%3ADC%252BD2sXisVGit7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=355&publication_year=2006&pages=1345-1356&author=P.+B.+Crinoauthor=K.+L.+Nathansonauthor=E.+P.+Henske&title=The+tuberous+sclerosis+complex&doi=10.1056%2FNEJMra055323"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">The tuberous sclerosis complex</span></div><div class="casAuthors">Crino, Peter B.; Nathanson, Katherine L.; Henske, Elizabeth Petri</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">355</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">1345-1356</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGreefc8lvD2Q7Vg90H21EOLACvtfcHk0lgnVFFthg_3hw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXisVGit7c%253D&md5=1cbf19b05ac03452756cf07e2d518e95</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1056%2FNEJMra055323&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMra055323%26sid%3Dliteratum%253Aachs%26aulast%3DCrino%26aufirst%3DP.%2BB.%26aulast%3DNathanson%26aufirst%3DK.%2BL.%26aulast%3DHenske%26aufirst%3DE.%2BP.%26atitle%3DThe%2520tuberous%2520sclerosis%2520complex%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2006%26volume%3D355%26spage%3D1345%26epage%3D1356%26doi%3D10.1056%2FNEJMra055323" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Meikle, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pollizzi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Egnor, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kramvis, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lane, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sahin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwiatkowski, D. J.</span></span> <span> </span><span class="NLM_article-title">Response of a neuronal model of tuberous sclerosis to mammalian target of rapamycin (mTOR) inhibitors: effects on mTORC1 and Akt signaling lead to improved survival and function</span>. <i>J. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>28</i></span>,  <span class="NLM_fpage">5422</span>– <span class="NLM_lpage">5432</span>, <span class="refDoi"> DOI: 10.1523/JNEUROSCI.0955-08.2008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01262&amp;key=10.1523%2FJNEUROSCI.0955-08.2008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01262&amp;key=18495876" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01262&amp;key=1%3ACAS%3A528%3ADC%252BD1cXmslWisbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2008&pages=5422-5432&author=L.+Meikleauthor=K.+Pollizziauthor=A.+Egnorauthor=I.+Kramvisauthor=H.+Laneauthor=M.+Sahinauthor=D.+J.+Kwiatkowski&title=Response+of+a+neuronal+model+of+tuberous+sclerosis+to+mammalian+target+of+rapamycin+%28mTOR%29+inhibitors%3A+effects+on+mTORC1+and+Akt+signaling+lead+to+improved+survival+and+function&doi=10.1523%2FJNEUROSCI.0955-08.2008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Response of a neuronal model of tuberous sclerosis to mammalian target of rapamycin (mTOR) inhibitors: effects on mTORC1 and Akt signaling lead to improved survival and function</span></div><div class="casAuthors">Meikle, Lynsey; Pollizzi, Kristen; Egnor, Anna; Kramvis, Ioannis; Lane, Heidi; Sahin, Mustafa; Kwiatkowski, David J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neuroscience</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">5422-5432</span>CODEN:
                <span class="NLM_cas:coden">JNRSDS</span>;
        ISSN:<span class="NLM_cas:issn">0270-6474</span>.
    
            (<span class="NLM_cas:orgname">Society for Neuroscience</span>)
        </div><div class="casAbstract">Tuberous sclerosis (TSC) is a hamartoma syndrome attributable to mutations in either TSC1 or TSC2 in which brain involvement causes epilepsy, mental retardation, and autism.  We have reported recently a mouse neuronal model of TSC in which Tsc1 is ablated in most neurons during cortical development.  We have tested rapamycin and RAD001 [40-O-(2-hydroxyethyl)-rapamycin], both mammalian target of rapamycin mTORC1 inhibitors, as potential therapeutic agents in this model.  Median survival is improved from 33 d to more than 100 d; behavior, phenotype, and wt. gain are all also markedly improved.  There is brain penetration of both drugs, with accumulation over time with repetitive treatment, and effective redn. of levels of phospho-S6, a downstream target of mTORC1.  In addn., there is restoration of phospho-Akt and phospho-glycogen synthase kinase 3 levels in the treated mice, consistent with restoration of Akt function.  Neurofilament abnormalities, myelination, and cell enlargement are all improved by the treatment.  However, dysplastic neuronal features persist, and there are only modest changes in dendritic spine d. and length.  Strikingly, mice treated with rapamycin or RAD001 for 23 d only (postnatal days 7-30) displayed a persistent improvement in phenotype, with median survival of 78 d.  In summary, rapamycin/RAD001 are highly effective therapies for this neuronal model of TSC, with benefit apparently attributable to effects on mTORC1 and Akt signaling and, consequently, cell size and myelination.  Although caution is appropriate, the results suggest the possibility that rapamycin/RAD001 may have benefit in the treatment of TSC brain disease, including infantile spasms.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp7NYIU5vQOo7Vg90H21EOLACvtfcHk0lgnVFFthg_3hw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXmslWisbY%253D&md5=213ca3d5a365d9fc0bddf139fd97a278</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1523%2FJNEUROSCI.0955-08.2008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1523%252FJNEUROSCI.0955-08.2008%26sid%3Dliteratum%253Aachs%26aulast%3DMeikle%26aufirst%3DL.%26aulast%3DPollizzi%26aufirst%3DK.%26aulast%3DEgnor%26aufirst%3DA.%26aulast%3DKramvis%26aufirst%3DI.%26aulast%3DLane%26aufirst%3DH.%26aulast%3DSahin%26aufirst%3DM.%26aulast%3DKwiatkowski%26aufirst%3DD.%2BJ.%26atitle%3DResponse%2520of%2520a%2520neuronal%2520model%2520of%2520tuberous%2520sclerosis%2520to%2520mammalian%2520target%2520of%2520rapamycin%2520%2528mTOR%2529%2520inhibitors%253A%2520effects%2520on%2520mTORC1%2520and%2520Akt%2520signaling%2520lead%2520to%2520improved%2520survival%2520and%2520function%26jtitle%3DJ.%2520Neurosci.%26date%3D2008%26volume%3D28%26spage%3D5422%26epage%3D5432%26doi%3D10.1523%2FJNEUROSCI.0955-08.2008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Krueger, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilfong, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mays, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Talley, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Agricola, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tudor, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Capal, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holland-Bouley, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Franz, D. N.</span></span> <span> </span><span class="NLM_article-title">Long-term treatment of epilepsy with everolimus in tuberous sclerosis</span>. <i>Neurology</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>87</i></span>,  <span class="NLM_fpage">2408</span>– <span class="NLM_lpage">2415</span>, <span class="refDoi"> DOI: 10.1212/WNL.0000000000003400</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01262&amp;key=10.1212%2FWNL.0000000000003400" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=87&publication_year=2016&pages=2408-2415&author=D.+A.+Kruegerauthor=A.+A.+Wilfongauthor=M.+Maysauthor=C.+M.+Talleyauthor=K.+Agricolaauthor=C.+Tudorauthor=J.+Capalauthor=K.+Holland-Bouleyauthor=D.+N.+Franz&title=Long-term+treatment+of+epilepsy+with+everolimus+in+tuberous+sclerosis&doi=10.1212%2FWNL.0000000000003400"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1212%2FWNL.0000000000003400&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1212%252FWNL.0000000000003400%26sid%3Dliteratum%253Aachs%26aulast%3DKrueger%26aufirst%3DD.%2BA.%26aulast%3DWilfong%26aufirst%3DA.%2BA.%26aulast%3DMays%26aufirst%3DM.%26aulast%3DTalley%26aufirst%3DC.%2BM.%26aulast%3DAgricola%26aufirst%3DK.%26aulast%3DTudor%26aufirst%3DC.%26aulast%3DCapal%26aufirst%3DJ.%26aulast%3DHolland-Bouley%26aufirst%3DK.%26aulast%3DFranz%26aufirst%3DD.%2BN.%26atitle%3DLong-term%2520treatment%2520of%2520epilepsy%2520with%2520everolimus%2520in%2520tuberous%2520sclerosis%26jtitle%3DNeurology%26date%3D2016%26volume%3D87%26spage%3D2408%26epage%3D2415%26doi%3D10.1212%2FWNL.0000000000003400" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">MacKeigan, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krueger, D. A.</span></span> <span> </span><span class="NLM_article-title">Differentiating the mTOR inhibitors everolimus and sirolimus in the treatment of tuberous sclerosis complex</span>. <i>Neuro Oncol</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">1550</span>– <span class="NLM_lpage">1559</span>, <span class="refDoi"> DOI: 10.1093/neuonc/nov152</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01262&amp;key=10.1093%2Fneuonc%2Fnov152" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01262&amp;key=26289591" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01262&amp;key=1%3ACAS%3A528%3ADC%252BC28XitVCntbfO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2015&pages=1550-1559&author=J.+P.+MacKeiganauthor=D.+A.+Krueger&title=Differentiating+the+mTOR+inhibitors+everolimus+and+sirolimus+in+the+treatment+of+tuberous+sclerosis+complex&doi=10.1093%2Fneuonc%2Fnov152"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Differentiating the mTOR inhibitors everolimus and sirolimus in the treatment of tuberous sclerosis complex</span></div><div class="casAuthors">MacKeigan, Jeffrey P.; Krueger, Darcy A.</div><div class="citationInfo"><span class="NLM_cas:title">Neuro-Oncology (Cary, NC, United States)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1550-1559</span>CODEN:
                <span class="NLM_cas:coden">NEURJR</span>;
        ISSN:<span class="NLM_cas:issn">1522-8517</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Tuberous sclerosis complex (TSC) is a genetic autosomal dominant disorder characterized by benign tumor-like lesions, called hamartomas, in multiple organ systems, including the brain, skin, heart, kidneys, and lung.  These hamartomas cause a diverse set of clin. problems based on their location and often result in epilepsy, learning difficulties, and behavioral problems.  TSC is caused by mutations within the TSC1 or TSC2 genes that inactivate the genes' tumor-suppressive function and drive hamartomatous cell growth.  In normal cells, TSC1 and TSC2 integrate growth signals and nutrient inputs to down regulate signaling to mammalian target of rapamycin (mTOR), an evolutionarily conserved serine-threonine kinase that controls cell growth and cell survival.  The mol. connection between TSC and mTOR led to the clin. use of allosteric mTOR inhibitors (sirolimus and everolimus) for the treatment of TSC.  Everolimus is approved for subependymal giant cell astrocytomas and renal angiomyolipomas in patients with TSC.  Sirolimus, though not approved for TSC, has undergone considerable investigation to treat various aspects of the disease.  Everolimus and sirolimus selectively inhibit mTOR signaling with similar mol. mechanisms, but with distinct clin. profiles.  This review differentiates mTOR inhibitors in TSC while describing the mol. mechanisms, pathogenic mutations, and clin. trial outcomes for managing TSC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoCumDeMj3tErVg90H21EOLACvtfcHk0liVzhw3VNVVkA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XitVCntbfO&md5=0d400bd50e7edfd9abcf1492573a7378</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1093%2Fneuonc%2Fnov152&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fneuonc%252Fnov152%26sid%3Dliteratum%253Aachs%26aulast%3DMacKeigan%26aufirst%3DJ.%2BP.%26aulast%3DKrueger%26aufirst%3DD.%2BA.%26atitle%3DDifferentiating%2520the%2520mTOR%2520inhibitors%2520everolimus%2520and%2520sirolimus%2520in%2520the%2520treatment%2520of%2520tuberous%2520sclerosis%2520complex%26jtitle%3DNeuro%2520Oncol%26date%3D2015%26volume%3D17%26spage%3D1550%26epage%3D1559%26doi%3D10.1093%2Fneuonc%2Fnov152" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">McCormack, F. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Inoue, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moss, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singer, L. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strange, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakata, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barker, A. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chapman, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brantly, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stocks, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, K. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lynch, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldberg, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, L. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kinder, B. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Downey, G. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sullivan, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colby, T. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McKay, R. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cohen, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Korbee, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taveira-DaSilva, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krischer, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trapnell, B. C.</span></span>; <span class="NLM_contrib-group">National Institutes of Health Rare Lung Diseases Consortium</span>; <span class="NLM_contrib-group">MILES Trial Group</span> <span> </span><span class="NLM_article-title">Efficacy and safety of sirolimus in lymphangioleiomyomatosis</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>364</i></span>,  <span class="NLM_fpage">1595</span>– <span class="NLM_lpage">1606</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1100391</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01262&amp;key=10.1056%2FNEJMoa1100391" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01262&amp;key=21410393" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01262&amp;key=1%3ACAS%3A528%3ADC%252BC3MXlsFegtr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=364&publication_year=2011&pages=1595-1606&author=F.+X.+McCormackauthor=Y.+Inoueauthor=J.+Mossauthor=L.+G.+Singerauthor=C.+Strangeauthor=K.+Nakataauthor=A.+F.+Barkerauthor=J.+T.+Chapmanauthor=M.+L.+Brantlyauthor=J.+M.+Stocksauthor=K.+K.+Brownauthor=J.+P.+Lynchauthor=H.+J.+Goldbergauthor=L.+R.+Youngauthor=B.+W.+Kinderauthor=G.+P.+Downeyauthor=E.+J.+Sullivanauthor=T.+V.+Colbyauthor=R.+T.+McKayauthor=M.+M.+Cohenauthor=L.+Korbeeauthor=A.+M.+Taveira-DaSilvaauthor=H.+S.+Leeauthor=J.+P.+Krischerauthor=B.+C.+Trapnellauthor=National+Institutes+of+Health+Rare+Lung+Diseases+Consortiumauthor=MILES+Trial+Group&title=Efficacy+and+safety+of+sirolimus+in+lymphangioleiomyomatosis&doi=10.1056%2FNEJMoa1100391"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Efficacy and safety of sirolimus in lymphangioleiomyomatosis</span></div><div class="casAuthors">McCormack, Francis X.; Inoue, Yoshikazu; Moss, Joel; Singer, Lianne G.; Strange, Charlie; Nakata, Koh; Barker, Alan F.; Chapman, Jeffrey T.; Brantly, Mark L.; Stocks, James M.; Brown, Kevin K.; Lynch, Joseph P., III; Goldberg, Hilary J.; Young, Lisa R.; Kinder, Brent W.; Downey, Gregory P.; Sullivan, Eugene J.; Colby, Thomas V.; McKay, Roy T.; Cohen, Marsha M.; Korbee, Leslie; Taveira-Dasilva, Angelo M.; Lee, Hye-Seung; Krischer, Jeffrey P.; Trapnell, Bruce C.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">364</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">1595-1606</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Lymphangioleiomyomatosis (LAM) is a progressive, cystic lung disease in women; it is assocd. with inappropriate activation of mammalian target of rapamycin (mTOR) signaling, which regulates cellular growth and lymphangiogenesis.  Sirolimus (also called rapamycin) inhibits mTOR and has shown promise in phase 1-2 trials involving patients with LAM.  METHODS: We conducted a two-stage trial of sirolimus involving 89 patients with LAM who had moderate lung impairment - a 12-mo randomized, double-blind comparison of sirolimus with placebo, followed by a 12-mo observation period.  The primary end point was the difference between the groups in the rate of change (slope) in forced expiratory vol. in 1 s (FEV1).  RESULTS: During the treatment period, the FEV, slope was -12 ± 2 mL per mo in the placebo group (43 patients) and 12 mL per mo in the sirolimus group (46 patients) (P < 0.001).  The abs. between-group difference in the mean change in FEV, during the treatment period was 153 mL, or approx. 11% of the mean FEV1 at enrollment.  As compared with the placebo group, the sirolimus group had improvement from baseline to 12 mo in measures of forced vital capacity, functional residual capacity, serum vascular endothelial growth factor D (VEGF-D), and quality of life and functional performance.  There was no significant between-group difference in this interval in the change in 6-min walk distance or diffusing capacity of the lung for carbon monoxide.  After discontinuation of sirolimus, the decline in lung function resumed in the sirolimus group and paralleled that in the placebo group.  Adverse events were more common with sirolimus, but the frequency of serious adverse events did not differ significantly between the groups.  CONCLUSIONS: In patients with LAM, sirolimus stabilized lung function, reduced serum VEGF-D levels, and was assocd. with a redn. in symptoms and improvement in quality of life.  Therapy with sirolimus may be useful in selected patients with LAM.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGreoHXYwZz-c7Vg90H21EOLACvtfcHk0liVzhw3VNVVkA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXlsFegtr0%253D&md5=46799ffecf19fb0e039f4e6ae35e9c32</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1100391&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1100391%26sid%3Dliteratum%253Aachs%26aulast%3DMcCormack%26aufirst%3DF.%2BX.%26aulast%3DInoue%26aufirst%3DY.%26aulast%3DMoss%26aufirst%3DJ.%26aulast%3DSinger%26aufirst%3DL.%2BG.%26aulast%3DStrange%26aufirst%3DC.%26aulast%3DNakata%26aufirst%3DK.%26aulast%3DBarker%26aufirst%3DA.%2BF.%26aulast%3DChapman%26aufirst%3DJ.%2BT.%26aulast%3DBrantly%26aufirst%3DM.%2BL.%26aulast%3DStocks%26aufirst%3DJ.%2BM.%26aulast%3DBrown%26aufirst%3DK.%2BK.%26aulast%3DLynch%26aufirst%3DJ.%2BP.%26aulast%3DGoldberg%26aufirst%3DH.%2BJ.%26aulast%3DYoung%26aufirst%3DL.%2BR.%26aulast%3DKinder%26aufirst%3DB.%2BW.%26aulast%3DDowney%26aufirst%3DG.%2BP.%26aulast%3DSullivan%26aufirst%3DE.%2BJ.%26aulast%3DColby%26aufirst%3DT.%2BV.%26aulast%3DMcKay%26aufirst%3DR.%2BT.%26aulast%3DCohen%26aufirst%3DM.%2BM.%26aulast%3DKorbee%26aufirst%3DL.%26aulast%3DTaveira-DaSilva%26aufirst%3DA.%2BM.%26aulast%3DLee%26aufirst%3DH.%2BS.%26aulast%3DKrischer%26aufirst%3DJ.%2BP.%26aulast%3DTrapnell%26aufirst%3DB.%2BC.%26aulast%3D%26aulast%3D%26atitle%3DEfficacy%2520and%2520safety%2520of%2520sirolimus%2520in%2520lymphangioleiomyomatosis%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2011%26volume%3D364%26spage%3D1595%26epage%3D1606%26doi%3D10.1056%2FNEJMoa1100391" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Talboom, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Velazquez, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oddo, S.</span></span> <span> </span><span class="NLM_article-title">The mammalian target of rapamycin at the crossroad between cognitive aging and Alzheimer’s disease</span>. <i>NPJ. Aging Mech. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>1</i></span>,  <span class="NLM_fpage">15008</span>, <span class="refDoi"> DOI: 10.1038/npjamd.2015.8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01262&amp;key=10.1038%2Fnpjamd.2015.8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01262&amp;key=28721257" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01262&amp;key=1%3ACAS%3A280%3ADC%252BC1cjovFaisg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2015&pages=15008&author=J.+S.+Talboomauthor=R.+Velazquezauthor=S.+Oddo&title=The+mammalian+target+of+rapamycin+at+the+crossroad+between+cognitive+aging+and+Alzheimer%E2%80%99s+disease&doi=10.1038%2Fnpjamd.2015.8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">The mammalian target of rapamycin at the crossroad between cognitive aging and Alzheimer's disease</span></div><div class="casAuthors">Talboom Joshua S; Velazquez Ramon; Oddo Salvatore; Oddo Salvatore</div><div class="citationInfo"><span class="NLM_cas:title">NPJ aging and mechanisms of disease</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">15008</span>
        ISSN:<span class="NLM_cas:issn">2056-3973</span>.
    </div><div class="casAbstract">Age-dependent cognitive decline is a major debilitating event affecting even individuals who are otherwise healthy.  Understanding the molecular basis underlying these changes may increase the healthspan of the elderly population.  It may also reveal insights into the pathogenesis of numerous neurodegenerative disorders characterized by cognitive deficits, as aging is the major risk factor for most of these disorders.  Alzheimer's disease (AD), the most common neurodegenerative disorder, first manifests itself as deficits in encoding new memories.  As AD progresses, these deficits spread to other cognitive domains that further debilitate the person before contributing to their demise.  Suppression of the mammalian target of rapamycin (mTOR) increases healthspan and lifespan in several organisms.  Numerous reports have linked alterations in mTOR signaling to age-dependent cognitive decline and the pathogenesis of AD.  This review will discuss recent work highlighting the complex role of mTOR in cognitive aging and in the pathogenesis of AD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSA0TQF8zU3rf69nzq6467DfW6udTcc2eYcJxv4oS3HgLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1cjovFaisg%253D%253D&md5=3a98d9e1b3facf63a929fa6d5d35667c</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1038%2Fnpjamd.2015.8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnpjamd.2015.8%26sid%3Dliteratum%253Aachs%26aulast%3DTalboom%26aufirst%3DJ.%2BS.%26aulast%3DVelazquez%26aufirst%3DR.%26aulast%3DOddo%26aufirst%3DS.%26atitle%3DThe%2520mammalian%2520target%2520of%2520rapamycin%2520at%2520the%2520crossroad%2520between%2520cognitive%2520aging%2520and%2520Alzheimer%25E2%2580%2599s%2520disease%26jtitle%3DNPJ.%2520Aging%2520Mech.%2520Dis.%26date%3D2015%26volume%3D1%26spage%3D15008%26doi%3D10.1038%2Fnpjamd.2015.8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22a"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ravikumar, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vacher, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berger, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davies, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oroz, L. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scaravilli, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Easton, D. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duden, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Kane, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rubinsztein, D. C.</span></span> <span> </span><span class="NLM_article-title">Inhibition of mTOR induces autophagy and reduces toxicity of polyglutamine expansions in fly and mouse models of Huntington disease</span>. <i>Nat. Genet.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>36</i></span>,  <span class="NLM_fpage">585</span>– <span class="NLM_lpage">595</span>, <span class="refDoi"> DOI: 10.1038/ng1362</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01262&amp;key=10.1038%2Fng1362" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01262&amp;key=15146184" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01262&amp;key=1%3ACAS%3A528%3ADC%252BD2cXksVajt7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2004&pages=585-595&author=B.+Ravikumarauthor=C.+Vacherauthor=Z.+Bergerauthor=J.+E.+Daviesauthor=S.+Luoauthor=L.+G.+Orozauthor=F.+Scaravilliauthor=D.+F.+Eastonauthor=R.+Dudenauthor=C.+J.+O%E2%80%99Kaneauthor=D.+C.+Rubinsztein&title=Inhibition+of+mTOR+induces+autophagy+and+reduces+toxicity+of+polyglutamine+expansions+in+fly+and+mouse+models+of+Huntington+disease&doi=10.1038%2Fng1362"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22aR"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of mTOR induces autophagy and reduces toxicity of polyglutamine expansions in fly and mouse models of Huntington disease</span></div><div class="casAuthors">Ravikumar, Brinda; Vacher, Coralie; Berger, Zdenek; Davies, Janet E.; Luo, Shouqing; Oroz, Lourdes G.; Scaravilli, Francesco; Easton, Douglas F.; Duden, Rainer; O'Kane, Cahir J.; Rubinsztein, David C.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Genetics</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">585-595</span>CODEN:
                <span class="NLM_cas:coden">NGENEC</span>;
        ISSN:<span class="NLM_cas:issn">1061-4036</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Huntington disease is one of nine inherited neurodegenerative disorders caused by a polyglutamine tract expansion.  Expanded polyglutamine proteins accumulate abnormally in intracellular aggregates.  Here we show that mammalian target of rapamycin (mTOR) is sequestered in polyglutamine aggregates in cell models, transgenic mice and human brains.  Sequestration of mTOR impairs its kinase activity and induces autophagy, a key clearance pathway for mutant huntingtin fragments.  This protects against polyglutamine toxicity, as the specific mTOR inhibitor rapamycin attenuates huntingtin accumulation and cell death in cell models of Huntington disease, and inhibition of autophagy has the converse effects.  Furthermore, rapamycin protects against neurodegeneration in a fly model of Huntington disease, and the rapamycin analog CCI-779 improved performance on four different behavioral tasks and decreased aggregate formation in a mouse model of Huntington disease.  Our data provide proof-of-principle for the potential of inducing autophagy to treat Huntington disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpe6pwZ9IPbhLVg90H21EOLACvtfcHk0ljf3BkQnWDPYA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXksVajt7s%253D&md5=39f48bebe54daa65eb21715819b703c4</span></div><a href="/servlet/linkout?suffix=cit22a&amp;dbid=16384&amp;doi=10.1038%2Fng1362&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fng1362%26sid%3Dliteratum%253Aachs%26aulast%3DRavikumar%26aufirst%3DB.%26aulast%3DVacher%26aufirst%3DC.%26aulast%3DBerger%26aufirst%3DZ.%26aulast%3DDavies%26aufirst%3DJ.%2BE.%26aulast%3DLuo%26aufirst%3DS.%26aulast%3DOroz%26aufirst%3DL.%2BG.%26aulast%3DScaravilli%26aufirst%3DF.%26aulast%3DEaston%26aufirst%3DD.%2BF.%26aulast%3DDuden%26aufirst%3DR.%26aulast%3DO%25E2%2580%2599Kane%26aufirst%3DC.%2BJ.%26aulast%3DRubinsztein%26aufirst%3DD.%2BC.%26atitle%3DInhibition%2520of%2520mTOR%2520induces%2520autophagy%2520and%2520reduces%2520toxicity%2520of%2520polyglutamine%2520expansions%2520in%2520fly%2520and%2520mouse%2520models%2520of%2520Huntington%2520disease%26jtitle%3DNat.%2520Genet.%26date%3D2004%26volume%3D36%26spage%3D585%26epage%3D595%26doi%3D10.1038%2Fng1362" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit22b"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Floto, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sarkar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perlstein, E. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kampmann, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schreiber, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rubinsztein, D. C.</span></span> <span> </span><span class="NLM_article-title">Small molecule enhancers of rapamycin-induced TOR inhibition promote autophagy, reduce toxicity in Huntington’s disease models and enhance killing of mycobacteria by macrophages</span>. <i>Autophagy</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">620</span>– <span class="NLM_lpage">622</span>, <span class="refDoi"> DOI: 10.4161/auto.4898</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01262&amp;key=10.4161%2Fauto.4898" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2007&pages=620-622&author=R.+A.+Flotoauthor=S.+Sarkarauthor=E.+O.+Perlsteinauthor=B.+Kampmannauthor=S.+L.+Schreiberauthor=D.+C.+Rubinsztein&title=Small+molecule+enhancers+of+rapamycin-induced+TOR+inhibition+promote+autophagy%2C+reduce+toxicity+in+Huntington%E2%80%99s+disease+models+and+enhance+killing+of+mycobacteria+by+macrophages&doi=10.4161%2Fauto.4898"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit22b&amp;dbid=16384&amp;doi=10.4161%2Fauto.4898&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4161%252Fauto.4898%26sid%3Dliteratum%253Aachs%26aulast%3DFloto%26aufirst%3DR.%2BA.%26aulast%3DSarkar%26aufirst%3DS.%26aulast%3DPerlstein%26aufirst%3DE.%2BO.%26aulast%3DKampmann%26aufirst%3DB.%26aulast%3DSchreiber%26aufirst%3DS.%2BL.%26aulast%3DRubinsztein%26aufirst%3DD.%2BC.%26atitle%3DSmall%2520molecule%2520enhancers%2520of%2520rapamycin-induced%2520TOR%2520inhibition%2520promote%2520autophagy%252C%2520reduce%2520toxicity%2520in%2520Huntington%25E2%2580%2599s%2520disease%2520models%2520and%2520enhance%2520killing%2520of%2520mycobacteria%2520by%2520macrophages%26jtitle%3DAutophagy%26date%3D2007%26volume%3D3%26spage%3D620%26epage%3D622%26doi%3D10.4161%2Fauto.4898" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Beaufils, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cmiljanovic, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cmiljanovic, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bohnacker, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Melone, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marone, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jackson, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sele, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borsari, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mestan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hebeisen, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hillmann, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giese, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zvelebil, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fabbro, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rageot, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wymann, M. P.</span></span> <span> </span><span class="NLM_article-title">5-(4,6-dimorpholino-1,3,5-triazin-2-yl)-4-(trifluoromethyl)pyridin-2-amine (PQR309), a potent, brain-penetrant, orally bioavailable, pan-class I PI3K/mTOR inhibitor as clinical candidate in oncology</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">7524</span>– <span class="NLM_lpage">7538</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b00930</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b00930" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01262&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtlKhurrP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=7524-7538&author=F.+Beaufilsauthor=N.+Cmiljanovicauthor=V.+Cmiljanovicauthor=T.+Bohnackerauthor=A.+Meloneauthor=R.+Maroneauthor=E.+Jacksonauthor=X.+Zhangauthor=A.+Seleauthor=C.+Borsariauthor=J.+Mestanauthor=P.+Hebeisenauthor=P.+Hillmannauthor=B.+Gieseauthor=M.+Zvelebilauthor=D.+Fabbroauthor=R.+L.+Williamsauthor=D.+Rageotauthor=M.+P.+Wymann&title=5-%284%2C6-dimorpholino-1%2C3%2C5-triazin-2-yl%29-4-%28trifluoromethyl%29pyridin-2-amine+%28PQR309%29%2C+a+potent%2C+brain-penetrant%2C+orally+bioavailable%2C+pan-class+I+PI3K%2FmTOR+inhibitor+as+clinical+candidate+in+oncology&doi=10.1021%2Facs.jmedchem.7b00930"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">5-(4,6-Dimorpholino-1,3,5-triazin-2-yl)-4-(trifluoromethyl)pyridin-2-amine (PQR309), a Potent, Brain-Penetrant, Orally Bioavailable, Pan-Class I PI3K/mTOR Inhibitor as Clinical Candidate in Oncology</span></div><div class="casAuthors">Beaufils, Florent; Cmiljanovic, Natasa; Cmiljanovic, Vladimir; Bohnacker, Thomas; Melone, Anna; Marone, Romina; Jackson, Eileen; Zhang, Xuxiao; Sele, Alexander; Borsari, Chiara; Mestan, Jurgen; Hebeisen, Paul; Hillmann, Petra; Giese, Bernd; Zvelebil, Marketa; Fabbro, Doriano; Williams, Roger L.; Rageot, Denise; Wymann, Matthias P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">7524-7538</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Phosphoinositide 3-kinase (PI3K) is deregulated in a wide variety of human tumors and triggers activation of protein kinase B (PKB/Akt) and mammalian target of rapamycin (mTOR).  Here we describe the preclin. characterization of compd. 1 (PQR309, bimiralisib), a potent 4,6-dimorpholino-1,3,5-triazine-based pan-class I PI3K inhibitor, which targets mTOR kinase in a balanced fashion at higher concns.  No off-target interactions were detected for 1 in a wide panel of protein kinase, enzyme, and receptor ligand assays.  Moreover, 1 did not bind tubulin, which was obsd. for the structurally related 4 (BKM120, buparlisib).  Compd. 1 is orally available, crosses the blood-brain barrier, and displayed favorable pharmacokinetic parameters in mice, rats, and dogs.  Compd. 1 demonstrated efficiency in inhibiting proliferation in tumor cell lines and a rat xenograft model.  This, together with the compd.'s safety profile, identifies 1 as a clin. candidate with a broad application range in oncol., including treatment of brain tumors or CNS metastasis.  Compd. 1 is currently in phase II clin. trials for advanced solid tumors and refractory lymphoma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqtvYAarVqsarVg90H21EOLACvtfcHk0lhg8yx6fmhQ0g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtlKhurrP&md5=54d4db75f6a8bda3f12eaf1d196352fd</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b00930&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b00930%26sid%3Dliteratum%253Aachs%26aulast%3DBeaufils%26aufirst%3DF.%26aulast%3DCmiljanovic%26aufirst%3DN.%26aulast%3DCmiljanovic%26aufirst%3DV.%26aulast%3DBohnacker%26aufirst%3DT.%26aulast%3DMelone%26aufirst%3DA.%26aulast%3DMarone%26aufirst%3DR.%26aulast%3DJackson%26aufirst%3DE.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DSele%26aufirst%3DA.%26aulast%3DBorsari%26aufirst%3DC.%26aulast%3DMestan%26aufirst%3DJ.%26aulast%3DHebeisen%26aufirst%3DP.%26aulast%3DHillmann%26aufirst%3DP.%26aulast%3DGiese%26aufirst%3DB.%26aulast%3DZvelebil%26aufirst%3DM.%26aulast%3DFabbro%26aufirst%3DD.%26aulast%3DWilliams%26aufirst%3DR.%2BL.%26aulast%3DRageot%26aufirst%3DD.%26aulast%3DWymann%26aufirst%3DM.%2BP.%26atitle%3D5-%25284%252C6-dimorpholino-1%252C3%252C5-triazin-2-yl%2529-4-%2528trifluoromethyl%2529pyridin-2-amine%2520%2528PQR309%2529%252C%2520a%2520potent%252C%2520brain-penetrant%252C%2520orally%2520bioavailable%252C%2520pan-class%2520I%2520PI3K%252FmTOR%2520inhibitor%2520as%2520clinical%2520candidate%2520in%2520oncology%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D7524%26epage%3D7538%26doi%3D10.1021%2Facs.jmedchem.7b00930" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bohnacker, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prota, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beaufils, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burke, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Melone, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Inglis, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rageot, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sele, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cmiljanovic, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cmiljanovic, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bargsten, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aher, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Akhmanova, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Díaz, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fabbro, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zvelebil, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steinmetz, M. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wymann, M. P.</span></span> <span> </span><span class="NLM_article-title">Deconvolution of Buparlisib’s mechanism of action defines specific PI3K and tubulin inhibitors for therapeutic intervention</span>. <i>Nat. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">14683</span>, <span class="refDoi"> DOI: 10.1038/ncomms14683</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01262&amp;key=10.1038%2Fncomms14683" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01262&amp;key=28276440" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01262&amp;key=1%3ACAS%3A280%3ADC%252BC1czksV2ruw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=14683&author=T.+Bohnackerauthor=A.+E.+Protaauthor=F.+Beaufilsauthor=J.+E.+Burkeauthor=A.+Meloneauthor=A.+J.+Inglisauthor=D.+Rageotauthor=A.+M.+Seleauthor=V.+Cmiljanovicauthor=N.+Cmiljanovicauthor=K.+Bargstenauthor=A.+Aherauthor=A.+Akhmanovaauthor=J.+F.+D%C3%ADazauthor=D.+Fabbroauthor=M.+Zvelebilauthor=R.+L.+Williamsauthor=M.+O.+Steinmetzauthor=M.+P.+Wymann&title=Deconvolution+of+Buparlisib%E2%80%99s+mechanism+of+action+defines+specific+PI3K+and+tubulin+inhibitors+for+therapeutic+intervention&doi=10.1038%2Fncomms14683"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Deconvolution of Buparlisib's mechanism of action defines specific PI3K and tubulin inhibitors for therapeutic intervention</span></div><div class="casAuthors">Bohnacker Thomas; Beaufils Florent; Melone Anna; Rageot Denise; Sele Alexander M; Cmiljanovic Vladimir; Cmiljanovic Natasa; Wymann Matthias P; Prota Andrea E; Bargsten Katja; Steinmetz Michel O; Burke John E; Inglis Alison J; Williams Roger L; Aher Amol; Akhmanova Anna; Diaz J Fernando; Fabbro Doriano; Zvelebil Marketa</div><div class="citationInfo"><span class="NLM_cas:title">Nature communications</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">14683</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BKM120 (Buparlisib) is one of the most advanced phosphoinositide 3-kinase (PI3K) inhibitors for the treatment of cancer, but it interferes as an off-target effect with microtubule polymerization.  Here, we developed two chemical derivatives that differ from BKM120 by only one atom.  We show that these minute changes separate the dual activity of BKM120 into discrete PI3K and tubulin inhibitors.  Analysis of the compounds cellular growth arrest phenotypes and microtubule dynamics suggest that the antiproliferative activity of BKM120 is mainly due to microtubule-dependent cytotoxicity rather than through inhibition of PI3K.  Crystal structures of BKM120 and derivatives in complex with tubulin and PI3K provide insights into the selective mode of action of this class of drugs.  Our results raise concerns over BKM120's generally accepted mode of action, and provide a unique mechanistic basis for next-generation PI3K inhibitors with improved safety profiles and flexibility for use in combination therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRzPPj8gFbG6HWEEzDrymxmfW6udTcc2ebE-RcW7TD0W7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1czksV2ruw%253D%253D&md5=97d27a7d83bf6ab6094a587565f82bf6</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1038%2Fncomms14683&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fncomms14683%26sid%3Dliteratum%253Aachs%26aulast%3DBohnacker%26aufirst%3DT.%26aulast%3DProta%26aufirst%3DA.%2BE.%26aulast%3DBeaufils%26aufirst%3DF.%26aulast%3DBurke%26aufirst%3DJ.%2BE.%26aulast%3DMelone%26aufirst%3DA.%26aulast%3DInglis%26aufirst%3DA.%2BJ.%26aulast%3DRageot%26aufirst%3DD.%26aulast%3DSele%26aufirst%3DA.%2BM.%26aulast%3DCmiljanovic%26aufirst%3DV.%26aulast%3DCmiljanovic%26aufirst%3DN.%26aulast%3DBargsten%26aufirst%3DK.%26aulast%3DAher%26aufirst%3DA.%26aulast%3DAkhmanova%26aufirst%3DA.%26aulast%3DD%25C3%25ADaz%26aufirst%3DJ.%2BF.%26aulast%3DFabbro%26aufirst%3DD.%26aulast%3DZvelebil%26aufirst%3DM.%26aulast%3DWilliams%26aufirst%3DR.%2BL.%26aulast%3DSteinmetz%26aufirst%3DM.%2BO.%26aulast%3DWymann%26aufirst%3DM.%2BP.%26atitle%3DDeconvolution%2520of%2520Buparlisib%25E2%2580%2599s%2520mechanism%2520of%2520action%2520defines%2520specific%2520PI3K%2520and%2520tubulin%2520inhibitors%2520for%2520therapeutic%2520intervention%26jtitle%3DNat.%2520Commun.%26date%3D2017%26volume%3D8%26spage%3D14683%26doi%3D10.1038%2Fncomms14683" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25a"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sessler, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rahm, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Becker, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldberg, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lippard, S. J.</span></span> <span> </span><span class="NLM_article-title">CF<sub>2</sub>H, a Hydrogen Bond Donor</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>139</i></span>,  <span class="NLM_fpage">9325</span>– <span class="NLM_lpage">9332</span>, <span class="refDoi"> DOI: 10.1021/jacs.7b04457</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jacs.7b04457" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref25/cit25a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01262&amp;key=1%3ACAS%3A528%3ADC%252BC2sXpt1Kgtbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=139&publication_year=2017&pages=9325-9332&author=C.+D.+Sesslerauthor=M.+Rahmauthor=S.+Beckerauthor=J.+M.+Goldbergauthor=F.+Wangauthor=S.+J.+Lippard&title=CF2H%2C+a+Hydrogen+Bond+Donor&doi=10.1021%2Fjacs.7b04457"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25aR"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">CF2H, a Hydrogen Bond Donor</span></div><div class="casAuthors">Sessler, Chanan D.; Rahm, Martin; Becker, Sabine; Goldberg, Jacob M.; Wang, Fang; Lippard, Stephen J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">139</span>
        (<span class="NLM_cas:issue">27</span>),
    <span class="NLM_cas:pages">9325-9332</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The CF2H group, a potential surrogate for the OH group, can act as an unusual hydrogen bond donor, as confirmed ty crystallog., spectroscopic, and computational methods.  Here, we demonstrate the bioisosterism of the OH and CF2H groups and the important roles of CF2-H···O hydrogen bonds in influencing intermol. interactions and conformational preferences.  Exptl. evidence, corroborated by theory, reveals the distinctive nature of CF2H hydrogen bonding interactions relative to their normal OH hydrogen bonding counterparts.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrOs-3evXpSKbVg90H21EOLACvtfcHk0lj1p10S4AoSAQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXpt1Kgtbo%253D&md5=f2345db11c3f695f3056c3c8cdad746c</span></div><a href="/servlet/linkout?suffix=cit25a&amp;dbid=16384&amp;doi=10.1021%2Fjacs.7b04457&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjacs.7b04457%26sid%3Dliteratum%253Aachs%26aulast%3DSessler%26aufirst%3DC.%2BD.%26aulast%3DRahm%26aufirst%3DM.%26aulast%3DBecker%26aufirst%3DS.%26aulast%3DGoldberg%26aufirst%3DJ.%2BM.%26aulast%3DWang%26aufirst%3DF.%26aulast%3DLippard%26aufirst%3DS.%2BJ.%26atitle%3DCF2H%252C%2520a%2520Hydrogen%2520Bond%2520Donor%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2017%26volume%3D139%26spage%3D9325%26epage%3D9332%26doi%3D10.1021%2Fjacs.7b04457" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit25b"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zafrani, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yeffet, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sod-Moriah, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berliner, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amir, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marciano, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gershonov, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saphier, S.</span></span> <span> </span><span class="NLM_article-title">Difluoromethyl Bioisostere: examining the “lipophilic hydrogen bond donor” concept</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">797</span>– <span class="NLM_lpage">804</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b01691</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b01691" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref25/cit25b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01262&amp;key=1%3ACAS%3A528%3ADC%252BC2sXis12jtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=797-804&author=Y.+Zafraniauthor=D.+Yeffetauthor=G.+Sod-Moriahauthor=A.+Berlinerauthor=D.+Amirauthor=D.+Marcianoauthor=E.+Gershonovauthor=S.+Saphier&title=Difluoromethyl+Bioisostere%3A+examining+the+%E2%80%9Clipophilic+hydrogen+bond+donor%E2%80%9D+concept&doi=10.1021%2Facs.jmedchem.6b01691"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25bR"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Difluoromethyl Bioisostere: Examining the "Lipophilic Hydrogen Bond Donor" Concept</span></div><div class="casAuthors">Zafrani, Yossi; Yeffet, Dina; Sod-Moriah, Gali; Berliner, Anat; Amir, Dafna; Marciano, Daniele; Gershonov, Eytan; Saphier, Sigal</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">797-804</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">There is a growing interest in org. compds. contg. the difluoromethyl group, as it is considered a lipophilic hydrogen bond donor that may act as a bioisostere of hydroxyl, thiol, or amine groups.  A series of difluoromethyl anisoles and thioanisoles was prepd. and their drug-like properties, hydrogen bonding, and lipophilicity were studied.  The hydrogen bond acidity parameters A (0.085-0.126) were detd. using Abraham's solute 1H NMR anal.  The difluoromethyl group acts as a hydrogen bond donor on a scale similar to that of thiophenol, aniline, and amine groups but not as that of hydroxyl.  Although difluoromethyl is considered a lipophilicity enhancing group, the range of the exptl. Δlog P(water-octanol) values (log P(XCF2H) - log P(XCH3)) spanned from -0.1 to +0.4.  For both parameters, a linear correlation was found between the measured values and Hammett σ consts.  These results may aid in the rational design of drugs contg. the difluoromethyl moiety.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrJEzcH0xPatbVg90H21EOLACvtfcHk0lj1p10S4AoSAQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXis12jtw%253D%253D&md5=36159f57b99aa812693f32ff38e88406</span></div><a href="/servlet/linkout?suffix=cit25b&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b01691&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b01691%26sid%3Dliteratum%253Aachs%26aulast%3DZafrani%26aufirst%3DY.%26aulast%3DYeffet%26aufirst%3DD.%26aulast%3DSod-Moriah%26aufirst%3DG.%26aulast%3DBerliner%26aufirst%3DA.%26aulast%3DAmir%26aufirst%3DD.%26aulast%3DMarciano%26aufirst%3DD.%26aulast%3DGershonov%26aufirst%3DE.%26aulast%3DSaphier%26aufirst%3DS.%26atitle%3DDifluoromethyl%2520Bioisostere%253A%2520examining%2520the%2520%25E2%2580%259Clipophilic%2520hydrogen%2520bond%2520donor%25E2%2580%259D%2520concept%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D797%26epage%3D804%26doi%3D10.1021%2Facs.jmedchem.6b01691" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zask, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaplan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verheijen, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richard, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Curran, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brooijmans, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bennett, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toral-Barza, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hollander, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ayral-Kaloustian, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, K.</span></span> <span> </span><span class="NLM_article-title">Morpholine derivatives greatly enhance the selectivity of mammalian target of rapamycin (mTOR) inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>52</i></span>,  <span class="NLM_fpage">7942</span>– <span class="NLM_lpage">7945</span>, <span class="refDoi"> DOI: 10.1021/jm901415x</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm901415x" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01262&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsVWrtb3J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=7942-7945&author=A.+Zaskauthor=J.+Kaplanauthor=J.+C.+Verheijenauthor=D.+J.+Richardauthor=K.+Curranauthor=N.+Brooijmansauthor=E.+M.+Bennettauthor=L.+Toral-Barzaauthor=I.+Hollanderauthor=S.+Ayral-Kaloustianauthor=K.+Yu&title=Morpholine+derivatives+greatly+enhance+the+selectivity+of+mammalian+target+of+rapamycin+%28mTOR%29+inhibitors&doi=10.1021%2Fjm901415x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Morpholine Derivatives Greatly Enhance the Selectivity of Mammalian Target of Rapamycin (mTOR) Inhibitors</span></div><div class="casAuthors">Zask, Arie; Kaplan, Joshua; Verheijen, Jeroen C.; Richard, David J.; Curran, Kevin; Brooijmans, Natasja; Bennett, Eric M.; Toral-Barza, Lourdes; Hollander, Irwin; Ayral-Kaloustian, Semiramis; Yu, Ker</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">7942-7945</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Dramatic improvements in mTOR-targeting selectivity were achieved by replacing morpholine in pyrazolopyrimidine inhibitors with bridged morpholines.  Analogs I [R1 = (R)- or (S)-3-methyl-4-morpholinyl, 2-methyl-4-morpholinyl, 8-oxa-3-azabicyclo[3.2.1]octan-3-yl, etc.; R2 = Me, Et, cyclopropyl, FCH2CH2, 3-pyridyl, 4-pyridyl; R3 = F3CCH2, 1-methoxycarbonyl-4-piperidinyl, 1-ethoxycarbonyl-4-piperidinyl, 3-pyridylmethyl] with subnanomolar mTOR IC50 values and up to 26000-fold selectivity vs. PI3Kα were prepd.  Chiral morpholines gave inhibitors whose enantiomers had different selectivity and potency profiles.  Mol. modeling suggests that a single amino acid difference between PI3K and mTOR (Phe961Leu) accounts for the profound selectivity seen by creating a deeper pocket in mTOR that can accommodate bridged morpholines.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpK2HnMHqTHqbVg90H21EOLACvtfcHk0liWJu1Rv0a1AA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsVWrtb3J&md5=5ef1eee5aa79531970049d3d26b46eb2</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1021%2Fjm901415x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm901415x%26sid%3Dliteratum%253Aachs%26aulast%3DZask%26aufirst%3DA.%26aulast%3DKaplan%26aufirst%3DJ.%26aulast%3DVerheijen%26aufirst%3DJ.%2BC.%26aulast%3DRichard%26aufirst%3DD.%2BJ.%26aulast%3DCurran%26aufirst%3DK.%26aulast%3DBrooijmans%26aufirst%3DN.%26aulast%3DBennett%26aufirst%3DE.%2BM.%26aulast%3DToral-Barza%26aufirst%3DL.%26aulast%3DHollander%26aufirst%3DI.%26aulast%3DAyral-Kaloustian%26aufirst%3DS.%26aulast%3DYu%26aufirst%3DK.%26atitle%3DMorpholine%2520derivatives%2520greatly%2520enhance%2520the%2520selectivity%2520of%2520mammalian%2520target%2520of%2520rapamycin%2520%2528mTOR%2529%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D7942%26epage%3D7945%26doi%3D10.1021%2Fjm901415x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Walker, E. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pacold, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perisic, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stephens, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hawkins, P. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wymann, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, R. L.</span></span> <span> </span><span class="NLM_article-title">Structural determinants of phosphoinositide 3-kinase inhibition by wortmannin, LY294002, quercetin, myricetin, and staurosporine</span>. <i>Mol. Cell</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">909</span>– <span class="NLM_lpage">919</span>, <span class="refDoi"> DOI: 10.1016/S1097-2765(05)00089-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01262&amp;key=10.1016%2FS1097-2765%2805%2900089-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01262&amp;key=11090628" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01262&amp;key=1%3ACAS%3A528%3ADC%252BD3cXnvVegurY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2000&pages=909-919&author=E.+H.+Walkerauthor=M.+E.+Pacoldauthor=O.+Perisicauthor=L.+Stephensauthor=P.+T.+Hawkinsauthor=M.+P.+Wymannauthor=R.+L.+Williams&title=Structural+determinants+of+phosphoinositide+3-kinase+inhibition+by+wortmannin%2C+LY294002%2C+quercetin%2C+myricetin%2C+and+staurosporine&doi=10.1016%2FS1097-2765%2805%2900089-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Structural determinants of phosphoinositide 3-kinase inhibition by wortmannin, LY294002, quercetin, myricetin, and staurosporine</span></div><div class="casAuthors">Walker, Edward H.; Pacold, Michael E.; Perisic, Olga; Stephens, Len; Hawkins, Philip T.; Wymann, Matthias P.; Williams, Roger L.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cell</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">909-919</span>CODEN:
                <span class="NLM_cas:coden">MOCEFL</span>;
        ISSN:<span class="NLM_cas:issn">1097-2765</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">The specific phosphoinositide 3-kinase (P13K) inhibitors wortmannin and LY294002 have been invaluable tools for elucidating the roles of these enzymes in signal transduction pathways.  The X-ray crystallog. structures of P13K bound to these lipid kinase inhibitors and to the broad-spectrum protein kinase inhibitors quercetin, myricetin, and staurosporine reveal how these compds. fit into the ATP binding pocket.  With a nanomolar IC50, wortmannin most closely fits and fills the active site and induces a conformational change in the catalytic domain.  Surprisingly, LY294002 and the lead compd. on which it was designed, quercetin, as well as the closely related flavonoid myricetin bind P13K in remarkably different orientations that are related to each other by 1800 rotations.  Staurosporine/P13K interactions are reminiscent of low-affinity protein kinase/staurosporine complexes.  These results provide a rich basis for development of isoform-specific P13K inhibitors with therapeutic potential.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpgIbTky2xQmbVg90H21EOLACvtfcHk0liWJu1Rv0a1AA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXnvVegurY%253D&md5=5dd92f9b48c437e43c0023fdff10c1ac</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1016%2FS1097-2765%2805%2900089-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1097-2765%252805%252900089-4%26sid%3Dliteratum%253Aachs%26aulast%3DWalker%26aufirst%3DE.%2BH.%26aulast%3DPacold%26aufirst%3DM.%2BE.%26aulast%3DPerisic%26aufirst%3DO.%26aulast%3DStephens%26aufirst%3DL.%26aulast%3DHawkins%26aufirst%3DP.%2BT.%26aulast%3DWymann%26aufirst%3DM.%2BP.%26aulast%3DWilliams%26aufirst%3DR.%2BL.%26atitle%3DStructural%2520determinants%2520of%2520phosphoinositide%25203-kinase%2520inhibition%2520by%2520wortmannin%252C%2520LY294002%252C%2520quercetin%252C%2520myricetin%252C%2520and%2520staurosporine%26jtitle%3DMol.%2520Cell%26date%3D2000%26volume%3D6%26spage%3D909%26epage%3D919%26doi%3D10.1016%2FS1097-2765%2805%2900089-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Davis, M. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hunt, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herrgard, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ciceri, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wodicka, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pallares, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hocker, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Treiber, D. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zarrinkar, P. P.</span></span> <span> </span><span class="NLM_article-title">Comprehensive analysis of kinase inhibitor selectivity</span>. <i>Nat. Biotechnol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>29</i></span>,  <span class="NLM_fpage">1046</span>– <span class="NLM_lpage">1051</span>, <span class="refDoi"> DOI: 10.1038/nbt.1990</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01262&amp;key=10.1038%2Fnbt.1990" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01262&amp;key=22037378" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01262&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtlyisrrK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2011&pages=1046-1051&author=M.+I.+Davisauthor=J.+P.+Huntauthor=S.+Herrgardauthor=P.+Ciceriauthor=L.+M.+Wodickaauthor=G.+Pallaresauthor=M.+Hockerauthor=D.+K.+Treiberauthor=P.+P.+Zarrinkar&title=Comprehensive+analysis+of+kinase+inhibitor+selectivity&doi=10.1038%2Fnbt.1990"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Comprehensive analysis of kinase inhibitor selectivity</span></div><div class="casAuthors">Davis, Mindy I.; Hunt, Jeremy P.; Herrgard, Sanna; Ciceri, Pietro; Wodicka, Lisa M.; Pallares, Gabriel; Hocker, Michael; Treiber, Daniel K.; Zarrinkar, Patrick P.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Biotechnology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1046-1051</span>CODEN:
                <span class="NLM_cas:coden">NABIF9</span>;
        ISSN:<span class="NLM_cas:issn">1087-0156</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">We tested the interaction of 72 kinase inhibitors with 442 kinases covering >80% of the human catalytic protein kinome.  Our data show that, as a class, type II inhibitors are more selective than type I inhibitors, but that there are important exceptions to this trend.  The data further illustrate that selective inhibitors have been developed against the majority of kinases targeted by the compds. tested.  Anal. of the interaction patterns reveals a class of 'group-selective' inhibitors broadly active against a single subfamily of kinases, but selective outside that subfamily.  The data set suggests compds. to use as tools to study kinases for which no dedicated inhibitors exist.  It also provides a foundation for further exploring kinase inhibitor biol. and toxicity, as well as for studying the structural basis of the obsd. interaction patterns.  Our findings will help to realize the direct enabling potential of genomics for drug development and basic research about cellular signaling.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoEZnKVs6Xt5rVg90H21EOLACvtfcHk0licvy2rLQDwPA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtlyisrrK&md5=67639f702cb48ffb2c60e9a250f0df5e</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1038%2Fnbt.1990&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnbt.1990%26sid%3Dliteratum%253Aachs%26aulast%3DDavis%26aufirst%3DM.%2BI.%26aulast%3DHunt%26aufirst%3DJ.%2BP.%26aulast%3DHerrgard%26aufirst%3DS.%26aulast%3DCiceri%26aufirst%3DP.%26aulast%3DWodicka%26aufirst%3DL.%2BM.%26aulast%3DPallares%26aufirst%3DG.%26aulast%3DHocker%26aufirst%3DM.%26aulast%3DTreiber%26aufirst%3DD.%2BK.%26aulast%3DZarrinkar%26aufirst%3DP.%2BP.%26atitle%3DComprehensive%2520analysis%2520of%2520kinase%2520inhibitor%2520selectivity%26jtitle%3DNat.%2520Biotechnol.%26date%3D2011%26volume%3D29%26spage%3D1046%26epage%3D1051%26doi%3D10.1038%2Fnbt.1990" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Brandt, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hillmann, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Noack, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Römermann, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Öhler, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rageot, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beaufils, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Melone, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sele, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wymann, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fabbro, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Löscher, W.</span></span> <span> </span><span class="NLM_article-title">The novel, catalytic mTORC1/2 inhibitor PQR620 and the PI3K/mTORC1/2 inhibitor PQR530 effectively cross the blood-brain barrier and increase seizure threshold in a mouse model of chronic epilepsy</span>. <i>Neuropharmacology</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>140</i></span>,  <span class="NLM_fpage">107</span>– <span class="NLM_lpage">120</span>, <span class="refDoi"> DOI: 10.1016/j.neuropharm.2018.08.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01262&amp;key=10.1016%2Fj.neuropharm.2018.08.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01262&amp;key=30081001" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01262&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsVGhtbjJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=140&publication_year=2018&pages=107-120&author=C.+Brandtauthor=P.+Hillmannauthor=A.+Noackauthor=K.+R%C3%B6mermannauthor=L.+A.+%C3%96hlerauthor=D.+Rageotauthor=F.+Beaufilsauthor=A.+Meloneauthor=A.+M.+Seleauthor=M.+P.+Wymannauthor=D.+Fabbroauthor=W.+L%C3%B6scher&title=The+novel%2C+catalytic+mTORC1%2F2+inhibitor+PQR620+and+the+PI3K%2FmTORC1%2F2+inhibitor+PQR530+effectively+cross+the+blood-brain+barrier+and+increase+seizure+threshold+in+a+mouse+model+of+chronic+epilepsy&doi=10.1016%2Fj.neuropharm.2018.08.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">The novel, catalytic mTORC1/2 inhibitor PQR620 and the PI3K/mTORC1/2 inhibitor PQR530 effectively cross the blood-brain barrier and increase seizure threshold in a mouse model of chronic epilepsy</span></div><div class="casAuthors">Brandt, Claudia; Hillmann, Petra; Noack, Andreas; Roemermann, Kerstin; Oehler, Leon A.; Rageot, Denise; Beaufils, Florent; Melone, Anna; Sele, Alexander M.; Wymann, Matthias P.; Fabbro, Doriano; Loescher, Wolfgang</div><div class="citationInfo"><span class="NLM_cas:title">Neuropharmacology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">140</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">107-120</span>CODEN:
                <span class="NLM_cas:coden">NEPHBW</span>;
        ISSN:<span class="NLM_cas:issn">0028-3908</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The mTOR signaling pathway has emerged as a possible therapeutic target for epilepsy.  Clin. trials have shown that mTOR inhibitors such as everolimus reduce seizures in tuberous sclerosis complex patients with intractable epilepsy.  Furthermore, accumulating preclin. data suggest that mTOR inhibitors may have anti-seizure or anti-epileptogenic actions in other types of epilepsy.  However, the chronic use of rapalogs such as everolimus is limited by poor tolerability, particularly by immunosuppression, poor brain penetration and induction of feedback loops which might contribute to their limited therapeutic efficacy.  Here we describe two novel, brain-permeable and well tolerated small mol. 1,3,5-triazine derivs., the catalytic mTORC1/C2 inhibitor PQR620 and the dual pan-PI3K/mTOR inhibitor PQR530.  These derivs. were compared with the mTORC1 inhibitors rapamycin and everolimus as well as the anti-seizure drugs phenobarbital and levetiracetam.  The anti-seizure potential of these compds. was detd. by evaluating the electroconvulsive seizure threshold in normal and epileptic mice.  Rapamycin and everolimus only poorly penetrated into the brain (brain:plasma ratio 0.0057 for rapamycin and 0.016 for everolimus).  In contrast, the novel compds. rapidly entered the brain, reaching brain:plasma ratios of ∼1.6.  Furthermore, they significantly decreased phosphorylation of S6 ribosomal protein in the hippocampus of normal and epileptic mice, demonstrating effective mTOR inhibition.  PQR620 and PQR530 significantly increased seizure threshold at tolerable doses.  The effect of PQR620 was more marked in epileptic vs. nonepileptic mice, matching the efficacy of levetiracetam.  Overall, the novel compds. described here have the potential to overcome the disadvantages of rapalogs for treatment of epilepsy and mTORopathies directly connected to mutations in the mTOR signaling cascade.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqvQmF8jJglOLVg90H21EOLACvtfcHk0licvy2rLQDwPA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsVGhtbjJ&md5=38f76201f9fb8c4643e59979b2bb4121</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1016%2Fj.neuropharm.2018.08.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.neuropharm.2018.08.002%26sid%3Dliteratum%253Aachs%26aulast%3DBrandt%26aufirst%3DC.%26aulast%3DHillmann%26aufirst%3DP.%26aulast%3DNoack%26aufirst%3DA.%26aulast%3DR%25C3%25B6mermann%26aufirst%3DK.%26aulast%3D%25C3%2596hler%26aufirst%3DL.%2BA.%26aulast%3DRageot%26aufirst%3DD.%26aulast%3DBeaufils%26aufirst%3DF.%26aulast%3DMelone%26aufirst%3DA.%26aulast%3DSele%26aufirst%3DA.%2BM.%26aulast%3DWymann%26aufirst%3DM.%2BP.%26aulast%3DFabbro%26aufirst%3DD.%26aulast%3DL%25C3%25B6scher%26aufirst%3DW.%26atitle%3DThe%2520novel%252C%2520catalytic%2520mTORC1%252F2%2520inhibitor%2520PQR620%2520and%2520the%2520PI3K%252FmTORC1%252F2%2520inhibitor%2520PQR530%2520effectively%2520cross%2520the%2520blood-brain%2520barrier%2520and%2520increase%2520seizure%2520threshold%2520in%2520a%2520mouse%2520model%2520of%2520chronic%2520epilepsy%26jtitle%3DNeuropharmacology%26date%3D2018%26volume%3D140%26spage%3D107%26epage%3D120%26doi%3D10.1016%2Fj.neuropharm.2018.08.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Marone, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Erhart, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mertz, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bohnacker, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schnell, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cmiljanovic, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stauffer, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia-Echeverria, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giese, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maira, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wymann, M. P.</span></span> <span> </span><span class="NLM_article-title">Targeting melanoma with dual phosphoinositide 3-kinase/mammalian target of rapamycin inhibitors</span>. <i>Mol. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">601</span>– <span class="NLM_lpage">613</span>, <span class="refDoi"> DOI: 10.1158/1541-7786.MCR-08-0366</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01262&amp;key=10.1158%2F1541-7786.MCR-08-0366" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01262&amp;key=19372588" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01262&amp;key=1%3ACAS%3A528%3ADC%252BD1MXks1anur8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2009&pages=601-613&author=R.+Maroneauthor=D.+Erhartauthor=A.+C.+Mertzauthor=T.+Bohnackerauthor=C.+Schnellauthor=V.+Cmiljanovicauthor=F.+Staufferauthor=C.+Garcia-Echeverriaauthor=B.+Gieseauthor=S.+M.+Mairaauthor=M.+P.+Wymann&title=Targeting+melanoma+with+dual+phosphoinositide+3-kinase%2Fmammalian+target+of+rapamycin+inhibitors&doi=10.1158%2F1541-7786.MCR-08-0366"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting Melanoma with Dual Phosphoinositide 3-Kinase/Mammalian Target of Rapamycin Inhibitors</span></div><div class="casAuthors">Marone, Romina; Erhart, Dominik; Mertz, Ann C.; Bohnacker, Thomas; Schnell, Christian; Cmiljanovic, Vladimir; Stauffer, Frederic; Garcia-Echeverria, Carlos; Giese, Bernd; Maira, Sauveur-Michel; Wymann, Matthias P.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Research</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">601-613</span>CODEN:
                <span class="NLM_cas:coden">MCROC5</span>;
        ISSN:<span class="NLM_cas:issn">1541-7786</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Phosphoinositide 3-kinase (PI3K)/protein kinase B/Akt and Ras/mitogen-activated protein kinase pathways are often constitutively activated in melanoma and have thus been considered as promising drug targets.  Exposure of melanoma cells to NVP-BAG956, NVP-BBD130, and NVP-BEZ235, a series of novel, potent, and stable dual PI3K/mammalian target of rapamycin (mTOR) inhibitors, resulted in complete G1 growth arrest, redn. of cyclin D1, and increased levels of p27KIP1, but negligible apoptosis.  In contrast, treatment of melanoma with the pan-class I PI3K inhibitor ZSTK474 or the mTORC1 inhibitor rapamycin resulted only in minor redn. of cell proliferation.  In a syngeneic B16 mouse melanoma tumor model, orally administered NVP-BBD130 and NVP-BEZ235 efficiently attenuated tumor growth at primary and lymph node metastatic sites with no obvious toxicity.  Metastatic melanoma in inhibitor-treated mice displayed reduced nos. of proliferating and significantly smaller tumor cells.  In addn., neovascularization was blocked and tumoral necrosis increased when compared with vehicle-treated mice.  In conclusion, compds. targeting PI3K and mTOR simultaneously were advantageous to attenuate melanoma growth and they develop their potential by targeting tumor growth directly, and indirectly via their interference with angiogenesis.  Based on the above results, NVP-BEZ235, which has entered phase I/II clin. trials in patients with advanced solid tumors, has a potential in metastatic melanoma therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo75H1e5k7uxrVg90H21EOLACvtfcHk0lhpafh4GHHFRQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXks1anur8%253D&md5=1098c3d2f8e0c169550adb0409fff1e2</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1158%2F1541-7786.MCR-08-0366&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1541-7786.MCR-08-0366%26sid%3Dliteratum%253Aachs%26aulast%3DMarone%26aufirst%3DR.%26aulast%3DErhart%26aufirst%3DD.%26aulast%3DMertz%26aufirst%3DA.%2BC.%26aulast%3DBohnacker%26aufirst%3DT.%26aulast%3DSchnell%26aufirst%3DC.%26aulast%3DCmiljanovic%26aufirst%3DV.%26aulast%3DStauffer%26aufirst%3DF.%26aulast%3DGarcia-Echeverria%26aufirst%3DC.%26aulast%3DGiese%26aufirst%3DB.%26aulast%3DMaira%26aufirst%3DS.%2BM.%26aulast%3DWymann%26aufirst%3DM.%2BP.%26atitle%3DTargeting%2520melanoma%2520with%2520dual%2520phosphoinositide%25203-kinase%252Fmammalian%2520target%2520of%2520rapamycin%2520inhibitors%26jtitle%3DMol.%2520Cancer%2520Res.%26date%3D2009%26volume%3D7%26spage%3D601%26epage%3D613%26doi%3D10.1158%2F1541-7786.MCR-08-0366" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">O’Reilly, K. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rojo, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">She, Q. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Solit, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mills, G. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lane, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hofmann, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hicklin, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ludwig, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baselga, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosen, N.</span></span> <span> </span><span class="NLM_article-title">mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>66</i></span>,  <span class="NLM_fpage">1500</span>– <span class="NLM_lpage">1508</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-05-2925</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01262&amp;key=10.1158%2F0008-5472.CAN-05-2925" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01262&amp;key=16452206" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01262&amp;key=1%3ACAS%3A528%3ADC%252BD28XpsVegtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2006&pages=1500-1508&author=K.+E.+O%E2%80%99Reillyauthor=F.+Rojoauthor=Q.+B.+Sheauthor=D.+Solitauthor=G.+B.+Millsauthor=D.+Smithauthor=H.+Laneauthor=F.+Hofmannauthor=D.+J.+Hicklinauthor=D.+L.+Ludwigauthor=J.+Baselgaauthor=N.+Rosen&title=mTOR+inhibition+induces+upstream+receptor+tyrosine+kinase+signaling+and+activates+Akt&doi=10.1158%2F0008-5472.CAN-05-2925"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">mTOR Inhibition Induces Upstream Receptor Tyrosine Kinase Signaling and Activates Akt</span></div><div class="casAuthors">O'Reilly, Kathryn E.; Rojo, Fredi; She, Qing-Bai; Solit, David; Mills, Gordon B.; Smith, Debra; Lane, Heidi; Hofmann, Francesco; Hicklin, Daniel J.; Ludwig, Dale L.; Baselga, Jose; Rosen, Neal</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">66</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1500-1508</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Stimulation of the insulin and insulin-like growth factor I (IGF-I) receptor activates the phosphoinositide-3-kinase/Akt/mTOR pathway causing pleiotropic cellular effects including an mTOR-dependent loss in insulin receptor substrate-1 expression leading to feedback down-regulation of signaling through the pathway.  In model systems, tumors exhibiting mutational activation of phosphoinositide-3-kinase/Akt kinase, a common event in cancers, are hypersensitive to mTOR inhibitors, including rapamycin.  Despite the activity in model systems, in patients, mTOR inhibitors exhibit more modest antitumor activity.  We now show that mTOR inhibition induces insulin receptor substrate-1 expression and abrogates feedback inhibition of the pathway, resulting in Akt activation both in cancer cell lines and in patient tumors treated with the rapamycin deriv., RAD001.  IGF-I receptor inhibition prevents rapamycin-induced Akt activation and sensitizes tumor cells to inhibition of mTOR.  In contrast, IGF-I reverses the antiproliferative effects of rapamycin in serum-free medium.  The data suggest that feedback down-regulation of receptor tyrosine kinase signaling is a frequent event in tumor cells with constitutive mTOR activation.  Reversal of this feedback loop by rapamycin may attenuate its therapeutic effects, whereas combination therapy that ablates mTOR function and prevents Akt activation may have improved antitumor activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpIDQUdQ-jbi7Vg90H21EOLACvtfcHk0lhpafh4GHHFRQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XpsVegtg%253D%253D&md5=758cd9999dc156bf498edf32174fc2e7</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-05-2925&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-05-2925%26sid%3Dliteratum%253Aachs%26aulast%3DO%25E2%2580%2599Reilly%26aufirst%3DK.%2BE.%26aulast%3DRojo%26aufirst%3DF.%26aulast%3DShe%26aufirst%3DQ.%2BB.%26aulast%3DSolit%26aufirst%3DD.%26aulast%3DMills%26aufirst%3DG.%2BB.%26aulast%3DSmith%26aufirst%3DD.%26aulast%3DLane%26aufirst%3DH.%26aulast%3DHofmann%26aufirst%3DF.%26aulast%3DHicklin%26aufirst%3DD.%2BJ.%26aulast%3DLudwig%26aufirst%3DD.%2BL.%26aulast%3DBaselga%26aufirst%3DJ.%26aulast%3DRosen%26aufirst%3DN.%26atitle%3DmTOR%2520inhibition%2520induces%2520upstream%2520receptor%2520tyrosine%2520kinase%2520signaling%2520and%2520activates%2520Akt%26jtitle%3DCancer%2520Res.%26date%3D2006%26volume%3D66%26spage%3D1500%26epage%3D1508%26doi%3D10.1158%2F0008-5472.CAN-05-2925" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kleinert, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sylow, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fazakerley, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krycer, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oxbøll, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jordy, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jensen, T. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schjerling, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kiens, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">James, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruegg, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richter, E. A.</span></span> <span> </span><span class="NLM_article-title">Acute mTOR inhibition induces insulin resistance and alters substrate utilization in vivo</span>. <i>Mol. Metab.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">630</span>– <span class="NLM_lpage">641</span>, <span class="refDoi"> DOI: 10.1016/j.molmet.2014.06.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01262&amp;key=10.1016%2Fj.molmet.2014.06.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01262&amp;key=25161886" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01262&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtFyjtLzK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2014&pages=630-641&author=M.+Kleinertauthor=L.+Sylowauthor=D.+J.+Fazakerleyauthor=J.+R.+Krycerauthor=K.+C.+Thomasauthor=A.+J.+Oxb%C3%B8llauthor=A.+B.+Jordyauthor=T.+E.+Jensenauthor=G.+Yangauthor=P.+Schjerlingauthor=B.+Kiensauthor=D.+E.+Jamesauthor=M.+A.+Rueggauthor=E.+A.+Richter&title=Acute+mTOR+inhibition+induces+insulin+resistance+and+alters+substrate+utilization+in+vivo&doi=10.1016%2Fj.molmet.2014.06.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Acute mTOR inhibition induces insulin resistance and alters substrate utilization in vivo</span></div><div class="casAuthors">Kleinert, Maximilian; Sylow, Lykke; Fazakerley, Daniel J.; Krycer, James R.; Thomas, Kristen C.; Oxboell, Anne-Julie; Jordy, Andreas B.; Jensen, Thomas E.; Yang, Guang; Schjerling, Peter; Kiens, Bente; James, David E.; Ruegg, Markus A.; Richter, Erik A.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Metabolism</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">630-641</span>CODEN:
                <span class="NLM_cas:coden">MMOEAS</span>;
        ISSN:<span class="NLM_cas:issn">2212-8778</span>.
    
            (<span class="NLM_cas:orgname">Elsevier GmbH</span>)
        </div><div class="casAbstract">The effect of acute inhibition of both mTORC1 and mTORC2 on metab. is unknown.  A single injection of the mTOR kinase inhibitor, AZD8055, induced a transient, yet marked increase in fat oxidn. and insulin resistance in mice, whereas the mTORC1 inhibitor rapamycin had no effect.  AZD8055, but not rapamycin reduced insulin-stimulated glucose uptake into incubated muscles, despite normal GLUT4 translocation in muscle cells.  AZD8055 inhibited glycolysis in MEF cells.  Abrogation of mTORC2 activity by SIN1 deletion impaired glycolysis and AZD8055 had no effect in SIN1 KO MEFs.  Re-expression of wildtype SIN1 rescued glycolysis.  Glucose intolerance following AZD8055 administration was absent in mice lacking the mTORC2 subunit Rictor in muscle, and in vivo glucose uptake into Rictor-deficient muscle was reduced despite normal Akt activity.  Taken together, acute mTOR inhibition is detrimental to glucose homeostasis in part by blocking muscle mTORC2, indicating its importance in muscle metab. in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGouv-4unEc1lbVg90H21EOLACvtfcHk0lgHrBE0IUs0HQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtFyjtLzK&md5=963cffe34095e3c60fe38d2393e733b6</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1016%2Fj.molmet.2014.06.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.molmet.2014.06.004%26sid%3Dliteratum%253Aachs%26aulast%3DKleinert%26aufirst%3DM.%26aulast%3DSylow%26aufirst%3DL.%26aulast%3DFazakerley%26aufirst%3DD.%2BJ.%26aulast%3DKrycer%26aufirst%3DJ.%2BR.%26aulast%3DThomas%26aufirst%3DK.%2BC.%26aulast%3DOxb%25C3%25B8ll%26aufirst%3DA.%2BJ.%26aulast%3DJordy%26aufirst%3DA.%2BB.%26aulast%3DJensen%26aufirst%3DT.%2BE.%26aulast%3DYang%26aufirst%3DG.%26aulast%3DSchjerling%26aufirst%3DP.%26aulast%3DKiens%26aufirst%3DB.%26aulast%3DJames%26aufirst%3DD.%2BE.%26aulast%3DRuegg%26aufirst%3DM.%2BA.%26aulast%3DRichter%26aufirst%3DE.%2BA.%26atitle%3DAcute%2520mTOR%2520inhibition%2520induces%2520insulin%2520resistance%2520and%2520alters%2520substrate%2520utilization%2520in%2520vivo%26jtitle%3DMol.%2520Metab.%26date%3D2014%26volume%3D3%26spage%3D630%26epage%3D641%26doi%3D10.1016%2Fj.molmet.2014.06.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zeng, L. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gutmann, D. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, M.</span></span> <span> </span><span class="NLM_article-title">Rapamycin prevents epilepsy in a mouse model of tuberous sclerosis complex</span>. <i>Ann. Neurol.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">444</span>– <span class="NLM_lpage">453</span>, <span class="refDoi"> DOI: 10.1002/ana.21331</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01262&amp;key=10.1002%2Fana.21331" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01262&amp;key=18389497" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01262&amp;key=1%3ACAS%3A528%3ADC%252BD1cXmsFGqt7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2008&pages=444-453&author=L.+H.+Zengauthor=L.+Xuauthor=D.+H.+Gutmannauthor=M.+Wong&title=Rapamycin+prevents+epilepsy+in+a+mouse+model+of+tuberous+sclerosis+complex&doi=10.1002%2Fana.21331"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Rapamycin prevents epilepsy in a mouse model of tuberous sclerosis complex</span></div><div class="casAuthors">Zeng, Ling-Hui; Xu, Lin; Gutmann, David H.; Wong, Michael</div><div class="citationInfo"><span class="NLM_cas:title">Annals of Neurology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">444-453</span>CODEN:
                <span class="NLM_cas:coden">ANNED3</span>;
        ISSN:<span class="NLM_cas:issn">0364-5134</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">Objective: Tuberous sclerosis complex (TSC) represents one of the most common genetic causes of epilepsy.  TSC gene inactivation leads to hyperactivation of the mammalian target of rapamycin signaling pathway, raising the intriguing possibility that mammalian target of rapamycin inhibitors might be effective in preventing or treating epilepsy in patients with TSC.  Mice with conditional inactivation of the Tsc1 gene primarily in glia (Tsc1GFAPCKO mice) develop glial proliferation, progressive epilepsy, and premature death.  Here, we tested whether rapamycin could prevent or reverse epilepsy, as well as other cellular and mol. brain abnormalities in Tsc1GFAPCKO mice.  Methods: Tsc1GFAPCKO mice and littermate control animals were treated with rapamycin or vehicle starting at postnatal day 14 (early treatment) or 6 wk of age (late treatment), corresponding to times before and after onset of neurol. abnormalities in Tsc1GFAPCKO mice.  Mice were monitored for seizures by serial video-EEG and for long-term survival.  Brains were examd. histol. for astrogliosis and neuronal organization.  Expression of phospho-S6 and other mol. markers correlating with epileptogenesis was measured by Western blotting.  Results: Early treatment with rapamycin prevented the development of epilepsy and premature death obsd. in vehicle-treated Tsc1GFAPCKO mice.  Late treatment with rapamycin suppressed seizures and prolonged survival in Tsc1GFAPCKO mice that had already developed epilepsy.  Correspondingly, rapamycin inhibited the abnormal activation of the mammalian target of rapamycin pathway, astrogliosis, and neuronal disorganization, and increased brain size in Tsc1GFAPCKO mice.  Interpretation: Rapamycin has strong efficacy for preventing seizures and prolonging survival in Tsc1GFAPCKO mice.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoDrvRnEyf-tLVg90H21EOLACvtfcHk0lgHrBE0IUs0HQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXmsFGqt7c%253D&md5=e4dbf8b71250ec0594029fed56c0d8c2</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1002%2Fana.21331&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fana.21331%26sid%3Dliteratum%253Aachs%26aulast%3DZeng%26aufirst%3DL.%2BH.%26aulast%3DXu%26aufirst%3DL.%26aulast%3DGutmann%26aufirst%3DD.%2BH.%26aulast%3DWong%26aufirst%3DM.%26atitle%3DRapamycin%2520prevents%2520epilepsy%2520in%2520a%2520mouse%2520model%2520of%2520tuberous%2520sclerosis%2520complex%26jtitle%3DAnn.%2520Neurol.%26date%3D2008%26volume%3D63%26spage%3D444%26epage%3D453%26doi%3D10.1002%2Fana.21331" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Burger, M.
T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pecchi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wagman, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ni, Z. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knapp, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hendrickson, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Atallah, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pfister, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bartulis, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frazier, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ng, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verhagen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haznedar, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huh, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iwanowicz, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xin, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Menezes, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Merritt, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiesmann, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaufman, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crawford, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bussiere, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shoemaker, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zaror, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maira, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Voliva, C. F.</span></span> <span> </span><span class="NLM_article-title">Identification of NVP-BKM120 as a potent, selective, orally bioavailable class I PI3 kinase inhibitor for treating cancer</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">774</span>– <span class="NLM_lpage">779</span>, <span class="refDoi"> DOI: 10.1021/ml200156t</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml200156t" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01262&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtVOktrrI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2011&pages=774-779&author=M.%0AT.+Burgerauthor=S.+Pecchiauthor=A.+Wagmanauthor=Z.+J.+Niauthor=M.+Knappauthor=T.+Hendricksonauthor=G.+Atallahauthor=K.+Pfisterauthor=Y.+Zhangauthor=S.+Bartulisauthor=K.+Frazierauthor=S.+Ngauthor=A.+Smithauthor=J.+Verhagenauthor=J.+Haznedarauthor=K.+Huhauthor=E.+Iwanowiczauthor=X.+Xinauthor=D.+Menezesauthor=H.+Merrittauthor=I.+Leeauthor=M.+Wiesmannauthor=S.+Kaufmanauthor=K.+Crawfordauthor=M.+Chinauthor=D.+Bussiereauthor=K.+Shoemakerauthor=I.+Zarorauthor=S.+M.+Mairaauthor=C.+F.+Voliva&title=Identification+of+NVP-BKM120+as+a+potent%2C+selective%2C+orally+bioavailable+class+I+PI3+kinase+inhibitor+for+treating+cancer&doi=10.1021%2Fml200156t"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of NVP-BKM120 as a Potent, Selective, Orally Bioavailable Class I PI3 Kinase Inhibitor for Treating Cancer</span></div><div class="casAuthors">Burger, Matthew T.; Pecchi, Sabina; Wagman, Allan; Ni, Zhi-Jie; Knapp, Mark; Hendrickson, Thomas; Atallah, Gordana; Pfister, Keith; Zhang, Yanchen; Bartulis, Sarah; Frazier, Kelly; Ng, Simon; Smith, Aaron; Verhagen, Joelle; Haznedar, Joshua; Huh, Kay; Iwanowicz, Ed; Xin, Xiaohua; Menezes, Daniel; Merritt, Hanne; Lee, Isabelle; Wiesmann, Marion; Kaufman, Susan; Crawford, Kenneth; Chin, Michael; Bussiere, Dirksen; Shoemaker, Kevin; Zaror, Isabel; Maira, Sauveur-Michel; Voliva, Charles F.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">774-779</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Phosphoinositide-3-kinases (PI3Ks) are important oncol. targets due to the deregulation of this signaling pathway in a wide variety of human cancers.  Herein we describe the structure guided optimization of a series of 2-morpholino, 4-substituted, 6-heterocyclic pyrimidines where the pharmacokinetic properties were improved by modulating the electronics of the 6-position heterocycle, and the overall druglike properties were fine-tuned further by modification of the 4-position substituent.  The resulting 2,4-bismorpholino 6-heterocyclic pyrimidines are potent class I PI3K inhibitors showing mechanism modulation in PI3K dependent cell lines and in vivo efficacy in tumor xenograft models with PI3K pathway deregulation (A2780 ovarian and U87MG glioma).  These efforts culminated in the discovery of 15 (NVP-BKM120), currently in Phase II clin. trials for the treatment of cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpzJ68B9pPbMbVg90H21EOLACvtfcHk0lgYQx6bK1sEtA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtVOktrrI&md5=5d00d73dda1fc0d8f0f07d12900282ed</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1021%2Fml200156t&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml200156t%26sid%3Dliteratum%253Aachs%26aulast%3DBurger%26aufirst%3DM.%2BT.%26aulast%3DPecchi%26aufirst%3DS.%26aulast%3DWagman%26aufirst%3DA.%26aulast%3DNi%26aufirst%3DZ.%2BJ.%26aulast%3DKnapp%26aufirst%3DM.%26aulast%3DHendrickson%26aufirst%3DT.%26aulast%3DAtallah%26aufirst%3DG.%26aulast%3DPfister%26aufirst%3DK.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DBartulis%26aufirst%3DS.%26aulast%3DFrazier%26aufirst%3DK.%26aulast%3DNg%26aufirst%3DS.%26aulast%3DSmith%26aufirst%3DA.%26aulast%3DVerhagen%26aufirst%3DJ.%26aulast%3DHaznedar%26aufirst%3DJ.%26aulast%3DHuh%26aufirst%3DK.%26aulast%3DIwanowicz%26aufirst%3DE.%26aulast%3DXin%26aufirst%3DX.%26aulast%3DMenezes%26aufirst%3DD.%26aulast%3DMerritt%26aufirst%3DH.%26aulast%3DLee%26aufirst%3DI.%26aulast%3DWiesmann%26aufirst%3DM.%26aulast%3DKaufman%26aufirst%3DS.%26aulast%3DCrawford%26aufirst%3DK.%26aulast%3DChin%26aufirst%3DM.%26aulast%3DBussiere%26aufirst%3DD.%26aulast%3DShoemaker%26aufirst%3DK.%26aulast%3DZaror%26aufirst%3DI.%26aulast%3DMaira%26aufirst%3DS.%2BM.%26aulast%3DVoliva%26aufirst%3DC.%2BF.%26atitle%3DIdentification%2520of%2520NVP-BKM120%2520as%2520a%2520potent%252C%2520selective%252C%2520orally%2520bioavailable%2520class%2520I%2520PI3%2520kinase%2520inhibitor%2520for%2520treating%2520cancer%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2011%26volume%3D2%26spage%3D774%26epage%3D779%26doi%3D10.1021%2Fml200156t" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fabian, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Biggs, W. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Treiber, D. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Atteridge, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Azimioara, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benedetti, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carter, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ciceri, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edeen, P. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Floyd, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ford, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galvin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gerlach, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grotzfeld, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herrgard, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Insko, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Insko, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lélias, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mehta, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Milanov, Z. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Velasco, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wodicka, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, H. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zarrinkar, P. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lockhart, D. J.</span></span> <span> </span><span class="NLM_article-title">A small molecule-kinase interaction map for clinical kinase inhibitors</span>. <i>Nat. Biotechnol.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">329</span>– <span class="NLM_lpage">336</span>, <span class="refDoi"> DOI: 10.1038/nbt1068</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01262&amp;key=10.1038%2Fnbt1068" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01262&amp;key=15711537" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01262&amp;key=1%3ACAS%3A528%3ADC%252BD2MXitF2nt7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2005&pages=329-336&author=M.+A.+Fabianauthor=W.+H.+Biggsauthor=D.+K.+Treiberauthor=C.+E.+Atteridgeauthor=M.+D.+Azimioaraauthor=M.+G.+Benedettiauthor=T.+A.+Carterauthor=P.+Ciceriauthor=P.+T.+Edeenauthor=M.+Floydauthor=J.+M.+Fordauthor=M.+Galvinauthor=J.+L.+Gerlachauthor=R.+M.+Grotzfeldauthor=S.+Herrgardauthor=D.+E.+Inskoauthor=M.+A.+Inskoauthor=A.+G.+Laiauthor=J.+M.+L%C3%A9liasauthor=S.+A.+Mehtaauthor=Z.+V.+Milanovauthor=A.+M.+Velascoauthor=L.+M.+Wodickaauthor=H.+K.+Patelauthor=P.+P.+Zarrinkarauthor=D.+J.+Lockhart&title=A+small+molecule-kinase+interaction+map+for+clinical+kinase+inhibitors&doi=10.1038%2Fnbt1068"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">A small molecule-kinase interaction map for clinical kinase inhibitors</span></div><div class="casAuthors">Fabian, Miles A.; Biggs, William H.; Treiber, Daniel K.; Atteridge, Corey E.; Azimioara, Mihai D.; Benedetti, Michael G.; Carter, Todd A.; Ciceri, Pietro; Edeen, Philip T.; Floyd, Mark; Ford, Julia M.; Galvin, Margaret; Gerlach, Jay L.; Grotzfeld, Robert M.; Herrgard, Sanna; Insko, Darren E.; Insko, Michael A.; Lai, Andiliy G.; Lelias, Jean-Michel; Mehta, Shamal A.; Milanov, Zdravko V.; Velasco, Anne Marie; Wodicka, Lisa M.; Patel, Hitesh K.; Zarrinkar, Patrick P.; Lockhart, David J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Biotechnology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">329-336</span>CODEN:
                <span class="NLM_cas:coden">NABIF9</span>;
        ISSN:<span class="NLM_cas:issn">1087-0156</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Kinase inhibitors show great promise as a new class of therapeutics.  Here the authors describe an efficient way to det. kinase inhibitor specificity by measuring binding of small mols. to the ATP site of kinases.  The authors have profiled 20 kinase inhibitors, including 16 that are approved drugs or in clin. development, against a panel of 119 protein kinases.  The authors find that specificity varies widely and is not strongly correlated with chem. structure or the identity of the intended target.  Many novel interactions were identified, including tight binding of the p38 inhibitor BIRB-796 to an imatinib-resistant variant of the ABL kinase, and binding of imatinib to the SRC-family kinase LCK.  The authors also show that mutations in the epidermal growth factor receptor (EGFR) found in gefitinib-responsive patients do not affect the binding affinity of gefitinib or erlotinib.  Our results represent a systematic small mol.-protein interaction map for clin. compds. across a large no. of related proteins.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqA0vNmMOXrnrVg90H21EOLACvtfcHk0ljsDDcbqFKqLQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXitF2nt7w%253D&md5=6aedd5ceb8f77cd26ee50425dcec7bdf</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1038%2Fnbt1068&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnbt1068%26sid%3Dliteratum%253Aachs%26aulast%3DFabian%26aufirst%3DM.%2BA.%26aulast%3DBiggs%26aufirst%3DW.%2BH.%26aulast%3DTreiber%26aufirst%3DD.%2BK.%26aulast%3DAtteridge%26aufirst%3DC.%2BE.%26aulast%3DAzimioara%26aufirst%3DM.%2BD.%26aulast%3DBenedetti%26aufirst%3DM.%2BG.%26aulast%3DCarter%26aufirst%3DT.%2BA.%26aulast%3DCiceri%26aufirst%3DP.%26aulast%3DEdeen%26aufirst%3DP.%2BT.%26aulast%3DFloyd%26aufirst%3DM.%26aulast%3DFord%26aufirst%3DJ.%2BM.%26aulast%3DGalvin%26aufirst%3DM.%26aulast%3DGerlach%26aufirst%3DJ.%2BL.%26aulast%3DGrotzfeld%26aufirst%3DR.%2BM.%26aulast%3DHerrgard%26aufirst%3DS.%26aulast%3DInsko%26aufirst%3DD.%2BE.%26aulast%3DInsko%26aufirst%3DM.%2BA.%26aulast%3DLai%26aufirst%3DA.%2BG.%26aulast%3DL%25C3%25A9lias%26aufirst%3DJ.%2BM.%26aulast%3DMehta%26aufirst%3DS.%2BA.%26aulast%3DMilanov%26aufirst%3DZ.%2BV.%26aulast%3DVelasco%26aufirst%3DA.%2BM.%26aulast%3DWodicka%26aufirst%3DL.%2BM.%26aulast%3DPatel%26aufirst%3DH.%2BK.%26aulast%3DZarrinkar%26aufirst%3DP.%2BP.%26aulast%3DLockhart%26aufirst%3DD.%2BJ.%26atitle%3DA%2520small%2520molecule-kinase%2520interaction%2520map%2520for%2520clinical%2520kinase%2520inhibitors%26jtitle%3DNat.%2520Biotechnol.%26date%3D2005%26volume%3D23%26spage%3D329%26epage%3D336%26doi%3D10.1038%2Fnbt1068" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5OQ4" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5OQ4','PDB','5OQ4'); return false;">PDB: 5OQ4</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4JT6" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4JT6','PDB','4JT6'); return false;">PDB: 4JT6</a></li></ul></div></div><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes-2"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i116"><a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.8b01262">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_28504"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a class="ext-link" href="/">ACS Publications website</a> at DOI: <a class="ext-link" href="/doi/abs/10.1021/acs.jmedchem.8b01262">10.1021/acs.jmedchem.8b01262</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">Information on amino acid conservation of PI3K/mTOR structural elements influencing the −CHF<sub>2</sub> dipole and structural elements of PI3K/mTOR close to morpholine bridge; a docking model of mTOR kinase with bound PQR620 (<b>3</b>); SD errors of mTOR and lipid kinase binding; a TREEspot data visualization of KINOMEScan interactions (of PQR620 (<b>3</b>), INK128 (<b>73</b>), SB2602 (<b>74</b>), and PP242 (<b>75</b>), selectivity profile analyses, and the raw date of kinase interactions (KINOMEscan of PQR620 (<b>3</b>)); in vitro pharmacology, enzyme and uptake assays, cancer cell line panel for compound PQR620 (<b>3</b>); quantification of cell cycle distribution of A2058 and SKOV3 cells after exposure to PQR620 (<b>3</b>), INK128 (<b>73</b>), PP242 (<b>75</b>), SB2602 (<b>74</b>), rapamycin, and GDC0941 (<b>76</b>) and phosphoprotein levels in A2058 and SKOV3 cells after drug exposure; correlation of cancer mutations and sensitivity to PQR620 (<b>3</b>) in cancer cell line panel; mouse PK data; unspecific rat brain tissue binding values for PQR620 (<b>3</b>); MDCK permeability data and P-gp dependence; collection of compound activity data, clogP and PSA; compound structures overview; <sup>1</sup>H NMR spectra; <sup>13</sup>C{<sup>1</sup>} NMR spectra; MALDI-MS spectra. ESI-HRMS spectra; and HPLC chromatograms (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.8b01262/suppl_file/jm8b01262_si_001.pdf">PDF</a>)</p></li><li><p class="inline">Molecular formula strings and selected data (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.8b01262/suppl_file/jm8b01262_si_002.csv">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.8b01262/suppl_file/jm8b01262_si_001.pdf">jm8b01262_si_001.pdf (21.44 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.8b01262/suppl_file/jm8b01262_si_002.csv">jm8b01262_si_002.csv (4.57 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.8b01262/suppl_file/jm8b01262_si_003.xlsx">jm8b01262_si_003.xlsx (41.91 kb)</a></li></ul></div></div><span class="author-information-subsection-header">Accession Codes</span><p class="last">PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5OQ4">5OQ4</a> was used for docking of compound PQR620 (<b>3</b>) into PI3Kγ. PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4JT6">4JT6</a> was used for docking of compound PQR620 (<b>3</b>) into mTOR kinase.</p><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.8b01262&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2018.61.issue-22%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.8b01262%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.8b01262" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                4MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"67997e394e443d2a","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
